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Abstract 
 
Aim 
Fifty percent of patients with squamous cell carcinoma of the Head and Neck 
develop loco regional recurrence after treatment. Factors leading to this failure 
are most likely altered intra tumoural glucose metabolism and increased hypoxia. 
Tissue glucose utilisation and the degree of hypoxia can be visualised by CT 
PET imaging with 
18FDG and hypoxic radio nuclides.  
 
This thesis has investigated 
18FDG CT PET guided target volume delineation 
methods and attempted to validate 
64Cu ATSM as a hypoxic radio nuclide in 
patients with squamous cell carcinoma of the Head and Neck. 
 
Materials and Methods 
Eight patients with locally advanced disease underwent 
18FDG CT PET imaging 
before and during curative radiotherapy or chemo radiotherapy. Fixed (SUV cut 
off  and  percentage  threshold  of  the  SUVmax)  and  adaptive  thresholds  were 
investigated. The functional volumes automatically delineated by these methods 
and SUVmax were compared at each point, and between thresholds. 
 
Four patients with locally advanced disease, two to seven days prior to surgery, 
underwent 3D dynamic CT PET imaging immediately after injection of 
64Cu 
ATSM.  Two  patients  were  also  imaged  18  hours  after  injection,  and  two 
underwent a dynamic contrast enhanced CT to evaluate intra tumoural perfusion. 
All patients received pimonidazole before surgery. The pimonidazole, GLUT1, 
CAIX,  and  HIF1a  immuno histochemical  hypoxic  fractions  were  defined. 
Staining  was  correlated  with  the  retention  pattern  of 
64Cu ATSM  at  3  time 
points. Hypoxic target volumes were delineated according to tumour to muscle, 
blood and background ratios.   
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Results 
18FDG  primary  and  lymph  node  target  volumes  significantly  reduced  with 
radiation dose by the SUV cut off method and correlated with the reduction in 
the  SUVmax  within  the  volume.  Volume  reduction  was  also  found  between 
thresholds by the same delineation method. The volumes delineated by the other 
methods  were  not  significantly  reduced  (except  the  lymph  node  functional 
volume when defined by the adaptive threshold).  
 
64Cu ATSM correlated with hypoxic immuno histochemical staining but not with 
blood flow. Tumour ratios increased with time after injection, which influenced 
the delineated hypoxic target volume. 
 
Conclusion 
Dose escalated image guided radiotherapy strategies using these CT PET guided 
functional  volumes  have  the  potential  to  improve  loco regional  control  in 
patients with squamous cell carcinoma of the Head and Neck. 
 
CT PET 
18FDG  volume  delineation  is  intricately  linked  to  the  method  and 
threshold of delineation and the timing of the imaging.  
 
64Cu ATSM  is  promising  as  a  hypoxic  radio nuclide  and  warrants  further 
investigation.   24
Chapter 1   
 
Squamous Cell Carcinoma of the Head and  eck 
 
1.1 Incidence of Head and  eck Cancer 
 
In  2004,  in  the  United  Kingdom  (UK),  284,560  people  were  diagnosed  with 
cancer. The four commonest sites included: breast (16%), lung (13%), colorectal 
(13%), and prostate (12%) [1 3]. 
 
Carcinoma of the Head and Neck (HN) is relatively rare. In 2004, 6,963 people 
were diagnosed with HN cancer (larynx, oral cavity, oropharynx, hypopharynx, 
and  para nasal  sinuses,  excluding  nasopharynx)  equalling  2.8%  of  all  cancer 
diagnoses in 0.014% of the total adult population [4]. The commonest sites were: 
the  larynx  (31.5%),  oral  cavity  (21.6%),  tongue  (20.1%),  and  pharynx 
(oropharynx  and  hypopharynx  19.2%).    Table  1.1  shows  the  number  of  new 
cases by site in the UK in 2004. 
 
Table 1.1  ew Cases of Head and  eck Cancer in the United Kingdom in 2004 
Site  Male    (%)  Female   (%) 
Larynx  1800    (25.8)  394         (5.7) 
Oral Cavity  904      (13.0)  601         (8.6) 
Tongue  889      (12.8)  513         (7.4) 
Oropharynx  649      (9.3)  242         (3.5) 
Hypopharynx  348      (5.0)  100         (1.4) 
Lip  193      (2.8)  91           (1.3) 
Other sites  166      (2.4)  73           (1.0) 
TOTAL  4949    (71.07)  2014      (28.93) 
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Eighty six percent of HN cancers are diagnosed in patients over 50 years of age 
[1 3].  The incidence has doubled in younger adults over the past 30 years (3.6 to 
8.8 per 100,000 men aged 40 to 49; and 11.5 to 24.9 per 100,000 men aged 50 to 
59) [5,6]. Figure 1.1 illustrates the age specific incidence rates for HN in men 
and women in the UK in 2005. The rate was 52 to 56 per 100,000 population in 
men, and 10 to 24 per 100,000 women aged 50 to 85. 
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Figure 1.1: Age specific incidence rates for men and women with Head and  eck cancer per 
100,000 population in the United Kingdom in 2005 
 
1.2 Aetiology 
 
1.2.1 Tobacco 
Approximately  28%  of  the  adult  population  in  the  UK  smoke  [7]  (mainly 
cigarettes).  Smoking  and  alcohol  consumption  are  the  commonest  factors 
implicated in the aetiology of Squamous Cell Carcinoma of the HN (SCCHN). 
There  is  a  dose  response  and  synergistic  effect  [8].  Patients  have  a  35  fold 
increased risk when more than 4 alcoholic drinks are consumed with 20 to 40 
cigarettes smoked per day.  
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The risk  associated with smoking depends on  the tobacco type and mode of 
inhalation of the smoke. Betel nut (oriental palm seed) chewing increases the risk 
of developing oral cavity cancer, especially in patients from Bangladesh. This is 
dependent on the amount chewed and the duration of use or exposure [9]. 
 
Smoking cessation significantly reduces the risk of developing SCCHN by 50% 
3 to 5 years after stopping [10]. Ten years later, the risk equals that of non 
smokers [11].  
 
1.2.2 Alcohol 
The risk of SCCHN increases with the amount, and type of alcohol consumed, 
especially beer and spirits [8]. Alcohol consumption has nearly doubled in the 
UK over the past century, especially among 16 to 24 year olds. In 2002, 18% of 
adult men and 30% of women exceeded the recommended weekly intake (21 
units in men, and 18 units in women), compared to 10% and 26% respectively in 
1988 [12].  
 
Alcohol intake has increased in young adults aged 16 to 24 in the UK.  In 1996 
35%  of  men,  and  21%  of  women  in  this  age  group  drank  more  than  the 
Government’s weekly recommended alcohol intake [13]. This increased to 37% 
of men and 26% of women in 2003.  
 
In the 11 to 15 year old group, 47% of boys and 36% of girls in England drank 
alcohol on a weekly basis [14], and this was typically binge drinking. In young 
non smokers, more than 3.75 units of alcohol per day was the most important 
risk factor for SCCHN [15], and was associated with a linear increase in risk.  
 
1.2.3 Diet and  utrition 
A  low  intake  of  fruit  and  vegetables  has  been  associated  with  an  increased 
incidence of SCCHN [16]. There is an inverse association between total intake of 
fruit and vegetables, and development of this cancer [17]. Deficiency in vitamins 
A and C, as well as iron, selenium and folate are all associated with an increased 
risk [18,19].   
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Heavy alcohol consumption and malnutrition are linked lifestyle factors.  A low 
body mass index (BMI) has been associated with an increased risk of squamous 
cell carcinomas (SCC) of the larynx [20] and was highest in men. Poor survival 
following treatment was especially associated with a BMI less than 22.8 kg/m
2 
[21].  
 
1.2.4 Viral 
Human papilloma virus (HPV) has been implicated in the pathogenesis of SCC’s 
of the oropharynx, and to a lesser extent oral cavity. HPV 16 is the commonest 
serotype,  and  the  tonsil  the  commonest  site  associated  with  HPV  positive 
SCCHN. HPV positive patients are less likely to be heavy smokers, drinkers, or 
have p53 mutations. A positive HPV 16 serotype is associated with an improved 
disease specific survival [22].  
 
The  largest  review  from  the  Surveillance,  Epidemiology  and  End  Results 
database reported the incidence rate increased each year by 3% between 1998 
and 2003. The rate of HPV positive SCCHN was 43.6% for the tonsil, and 38.4% 
for the posterior third of tongue sites [23].  
 
1.2.5 Immuno Suppression 
Immuno suppression may be either primary or acquired. The most commonly 
acquired forms are due to viral disease, and drugs. There have been reports of 
oral SCC following allogenic haemopoietic bone marrow transplantation [24], on 
a background of chronic graft versus host disease, suggesting a mechanism of 
persistent, prolonged inflammation.  
 
Human  Immunodeficiency  Virus  (HIV)  is  increasing  in  incidence,  and  33.2 
million people worldwide were infected in 2007 [25]. The risk of HN cancer is 
increased  in  patients  with  HIV.  Only  Kaposi’s  Sarcoma  is  classified  as  an 
Acquired Immune Deficiency Syndrome defining disease.  Hodgkin’s Disease 
was associated with a 11.5 fold greater risk, oropharyngeal SCC 6 fold greater, 
SCC’s of the oral cavity and pharynx 2.7 fold greater, and SCC of the larynx 2.8 
greater risk [26] compared to the non HIV positive population.  
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1.2.8 Pre malignant Conditions (Leucoplakia and Erythroplakia) 
Oral leucoplakia is the commonest pre malignant condition leading to SCCHN. 
The incidence in the UK is between 0.2 and 11.7% [27], and depends on the 
minimum degree of whiteness of the mucosa taken to define the lesion. The 
annual rate of malignant transformation is 4.4 to 17.5% [28,29].  
 
Erythroplakia  is  less  common  with  an  incidence  of  0.09%,  and  the  rate  of 
malignant  transformation  is  less  than  1%  [30].  Oral  submucosal  fibrosis  and 
lichen  planus  are  less  common,  and  associated  with  an  even  lower  rate  of 
transformation. 
 
1.2.3 Marijuana 
There are a number of conflicting reports in the literature of the association with 
SCCHN. These include a dose response relationship in patients under the age of 
55 with the amount and duration of marijuana  smoked per day [31]. Further 
studies  are  required  to  confirm  or  refute  an  association  of  marijuana  and 
SCCHN. 
 
1.3 Development of Second Primary Cancers 
 
Second  primary  cancers  in  patients  with  SCCHN  are  either  synchronous,  or 
metachronous, and develop at a median interval of 2  years after the primary 
diagnosis. 
 
Synchronous cancers are geographically distinct, separated from the first primary 
lesion by more than or equal to 2cm of normal (squamous) epithelium. These are 
diagnosed at the same time or within 6 months of the first cancer. Metachronous 
cancers are diagnosed at least 6 months after the first cancer.  
 
The cumulative risk has been reported as 26% at 10 years, and 47% at 20 years 
[32]. The overall rate of development was 17.6%, and lung was the commonest 
second site. Up to 40% of these are synchronous, and 60% metachronous [33].   
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1.4 Anatomical Sites of the Head and  eck  
 
The extra cranial HN extends from the base of skull to the thoracic inlet, and 
includes the oral cavity, oropharynx, nasopharynx, larynx, and hypopharynx, as 
well  as  the  nasal  vestibule,  nasal  cavity  and  para nasal  sinuses.  Other  sites 
include  the  orbit  and  orbital  contents,  salivary  and  thyroid  gland.  Figure  1.2 
illustrates  the  main  anatomical  sites  within  the  HN.  These  sites  are  divided 
according to the International Union against Cancer/American Joint Committee 
on Cancer (UICC/AJCC) 2002 staging system [34], and have been detailed and 
illustrated by Henry Gray [35] as shown in the figures 1.2 to 1.4. 
 
 
Figure 1.2: Sagital view of the anatomical Head and  eck   30
1.4.1 Oral Cavity 
The oral cavity extends anteriorly from the vermillion border of the lips to the 
junction of the hard and soft palate postero superiorly, and the  circumvallate 
papillae  postero inferiorly.  The  structures  within  this  site  include:  the  buccal 
musoca, upper and lower alveolus and gingivae, hard palate, the anterior two 
thirds of the tongue, and the floor of mouth. Figure 1.3 illustrates the anterior 
view of the oral cavity. 
 
 
Figure 1.3: Anterior view of the oral cavity 
  
1.4.2 Oropharynx 
The  oropharynx  extends  from  the  anterior  tonsillar  pillar  and  circumvallate 
papillae anteriorly to the pharyngeal wall posteriorly. The superior border is the 
level of the hard palate, and the inferior border is the hyoid bone. The lateral wall 
consists of the anterior and posterior tonsillar pillars, and the pharyngeal palatine 
tonsil. At the level of the hyoid, the oropharynx becomes the hypopharynx.  The 
structures contained within the oropharynx include: the posterior one third of the 
tongue, vallecalue, lingual surface of the epiglottis, posterior pharyngeal wall, 
and soft palate.    31
1.4.3 Hypopharynx 
The hypopharynx starts superiorly at the level of the hyoid and epiglottis, and 
extends  inferiorly  to  the  lower  border  of  the  cricoid  cartilage.  The  larynx  is 
anterior to the hypopharynx and indents its lateral aspect forming the potential 
pyriform  fossa  spaces.  The  hypopharynx  is  divided  into  three  sub sites:  the 
pyriform fossae, post cricoid, and the posterior pharyngeal wall.  
 
1.4.4 Larynx 
The larynx consists of three sub sites: the supraglottis, glottis, and subglottis. The 
supraglottis  is  divided  into  the  epiglottis,  false  vocal  cords,  ventricles, 
aryepiglottic folds and arytenoids. The glottis contains the true vocal cords, along 
with the anterior and posterior commissure. Figure 1.4 illustrates the anterior 
view of the larynx. 
 
 
  Figure 1.4: Anterior view of the larynx 
 
1.4.5  asopharynx 
The  nasopharynx  is  the  most  superior  portion  of  the  pharynx  and  is  in 
continuation with the oropharynx at the superior surface of the soft palate. The 
superior border is the body of the sphenoid bone, and the basillar part of the 
occipital bone. The anterior wall is the posterior nasal choanae. The posterior   32
wall is the clivus, 1
st and 2
nd cervical vertebrae, and the posterior wall of the 
pharynx.  
 
1.4.6 Rare Sites of Squamous Cell Carcinoma Development   
These  include  the:  nasal  cavity  and  para nasal  sinuses,  ear,  and  the  salivary 
glands. 
 
1.5 Lymphatic Drainage 
 
Within the HN, anatomical sites drain to regional lymph nodes (LN), which in 
turn drain into the thoracic duct. LN enlargement may be due to a variety of 
benign and malignant causes.  
 
Benign causes commonly include: bacterial, viral, fungal infections for example 
β haemolytic streptococcal tonsillar infections. Malignant causes include primary 
cancers: such as Non Hodgkin’s lymphoma, Hodgkin’s disease, leukaemias, or 
metastatic disease.  
 
Primary  SCCHN  can  develop  loco regional  metastatic  cervical 
lymphadenopathy, but supra clavicular nodal involvement is rare. 
 
1.5.1 Lymph  ode Disease in Primary Squamous Cell Cancers of the Head 
and  eck 
Microscopic  and  macroscopic  cervical  LN  metastases  develop  due  to  loco 
regional spread from the primary site. Surgery, external beam radiotherapy (RT) 
or chemo radiotherapy (CRT), and post operative indications for RT and CRT 
for the eradication of microscopic and macroscopic LN disease are all tailored to 
this  level  of  risk.  The  neck  traditionally  has  been  divided  into  anterior  and 
posterior  triangles  separated  by  the  sternocleidomastoid  muscle  (SCM).  Six 
major anatomical groups exist shown in Table 1.2, and levels II to V further are 
subdivided by imaging.  
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Table 1.2: Anatomical boundaries of the lymph node groups within the neck 
Level  Anatomical Region 
I  a) Submental  
b) Submandibular triangles 
II  Upper jugular chain  
Nodes lie deep to the upper third of the 
sternocleidomastoid  muscle.  Extend 
from base of skull to hyoid. 
III  Middle jugular chain  
Nodes  lie  deep  to  the  middle  third  of 
sternocleidomastoid. Extend from hyoid 
to cricoid. 
IV  Lower jugular chain  
Nodes  lie  deep  to  the  lower  third  of 
sternocleidomastoid.  Extends  from 
omohyoid muscle to clavicle. 
V  Posterior triangle 
Behind  the  posterior  border  of  the 
sternocleidomastoid muscle. 
VI  Anterior compartment 
Around the midline visceral structures 
of the neck from the hyoid bone to the 
suprasternal notch. 
 
 
The risk of LN spread is dependent on: primary site, lateralisation, size, and 
histology (lympho vascular invasion, peri neural invasion, and grade). The first 
LN’s  to  be  infiltrated  by  metastatic  SCC  receive  venous  tributaries  from  the 
adjacent organ (primary site), as well as organs in other areas. 
 
Lindberg [36] reported the topographical distribution, and incidence of cervical 
LN disease in patients with SCCHN, and this was consolidated by computed 
tomography (CT), and magnetic resonance imaging (MRI) [37,38] definition of   34
LN  sites.  Figure  1.5  shows  the  regional  cervical  LN  groups  relative  to  the 
anatomical structures of the HN. 
 
Figure 1.5:  odal classification of cervical lymph node groups defined according to CT and 
MRI modalities (left anterior neck position) [38] 
 
For  early  T1  SCCs  the  risk  of  LN  metastases  is  low.  Similarly,  glottic  and 
subglottic  laryngeal  SCCs  have  a  low  risk  because  these  sites  are  relatively 
avascular. 
 
The incidence of LN disease is highest for oropharyngeal primary SCCs. For 
example: the incidence of LN involvement on imaging was 39% in those with a 
clinical LN negative neck, and 61% in those with clinical LN positive disease.  
The  incidence  of  a  particular  LN  level  being  positive  for  metastatic 
oropharyngeal SCC was for example 55% for level II ipsi lateral LNs, and 13% 
for the contra lateral level. The incidence of LN disease has been defined [39 
42], and increased rates are also associated with midline lesions.  
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1.6 Staging  
 
HN cancers are staged according to the TNM (Tumour Node Metastasis)/AJCC 
2002  6
th  Edition  [34].  The  staging  is  clinical,  pathological,  and  primary  site 
dependent.  The LN stage is identical for all primary sites except nasopharynx 
and thyroid. Table 1.3 shows an example of the TNM staging for cancers of the 
pharynx, and 1.4 the overall stage grouping. 
 
Table  1.3:  Generic  T M/AJCC  2002  6
th  Edition  Classification  for  oropharyngeal  and 
hypopharyngeal cancers 
Tumour (T)   ode ( )  Metastasis (M) 
T(is)  
Carcinoma in situ 
   
T1  
<2cm 
 1 
Ipsi lateral single < 3 cm 
M1  
Presence  of  metastatic 
disease 
T2 
2 to 4cm 
 2a  
Ipsi lateral single > 3 to 
6 cm 
 
 2b 
Ipsi lateral  multiple  <  6 
cm 
 
 2c 
Bilateral, contra lateral  
< 6 cm  
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T3   
>4 cm 
 3 > 6 cm   
T4  
Invasion into 
surrounding structures 
a. Superficial 
b. Deep structures  
   
 
 
Table 1.4: T M (2002) 6
th Edition Overall Stage Grouping for Head and  eck cancer 
Stage  T M 
0  Tis        N0          M0 
I  T1         N0          M0 
II  T2         N0          M0 
III  T3         N0          M0 
T1 3      N1          M0 
IVA  T4a        N0 1      M0 
T1 4a     N2         M0 
IVB  Any T    N3          M0 
T4b       Any N     M0 
IVC  Any T   Any N     M1 
 
 
1.7 Pathology 
 
1.7.1 Squamous Epithelium 
Squamous epithelium lines the mucosal surfaces of the HN. It consists of layers 
of either keratinising or non keratinising squamous cells depending on location 
and function. For example: keratinising epithelium is found on the hard palate, 
lateral  anterior  two  thirds  of  the  tongue  and  the  external  lips,  and  prevents 
cellular  dehydration.  Squamous  cells  are  irregular,  flat  and  scale  like,  and   37
constitute simple or stratified epithelium [43]. Figure 1.6 shows the haematoxylin 
and eosin (H+E) stained section of normal pharyngeal mucosa. 
 
 
Figure 1.6: Haematoxylin and eosin stained section (magnification x 20) of non dysplastic  
pharyngeal  squamous mucosa 
 
1.7.2 Squamous Cell Carcinomas 
SCCs  are  the  commonest  carcinomas  of  the  HN  in  over  90%  of  cases  [44]. 
Variants  include:  papillary,  verrucous,  basaloid,  undifferentiated,  lympho 
epithelial, adenosquamous, spindle cell and anaplastic types. SCCs arise within 
normal squamous epithelium, or glandular epithelium with squamous metaplasia.  
 
Non SCCs  include:  lymphoma  (Non Hodgkin’s),  sarcoma,  small  cell 
(neuroendocrine), melanoma, adenocarcinomas, and merkel cell carcinomas.  
 
1.7.3 Pathological Assessment 
 
1.7.3.1 Cytology 
Specimens are obtained either by fine needle aspiration (FNA) of a palpable or 
ultrasound  (USS)  detected  LN,  or  by  lavage,  or  brushings  for  example.  The 
cytological appearance following FNA from a cervical LN is illustrated in figure 
1.7. Cytological diagnosis is operator dependent.  
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Figure 1.7: Cytological appearance of squamous cell carcinoma from a cervical lymph node 
 
Keratinising  SCCs  are  discohesive,  dense  cell  populations.  Cells  features 
include:  polygonal  shape,  varying  size,  hyper chromatic  nuclei  and  epithelial 
pearls. 
 
Well differentiated  SCCs  are  mature  squamous  cells with  irregular  or  hyper 
chromatic nuclei. Moderately or poorly differentiated SCCs have large nuclei, 
clumped chromatin, and prominent nucleoli. 
 
1.7.3.2 Macroscopic Pathology 
SCCs are ulcerative with raised, rolled margins, and an indurated base. With 
time, lesions infiltrate deeply, become nodular, and develop central necrosis. 
 
After fixation in 10% neutral buffered formalin features include: cut white, or 
pale grey surfaces, with irregular margins, and central gelatinous necrosis. 
 
1.7.3.3 Microscopic Pathology 
SCCs  are  histologically  invasive.  Cells  breach  the  basement  membrane,  and 
invade along tissue planes.  
 
The characteristic features on H+E staining include: inter cellular bridges, and 
keratin pearls (kerato hyaline granules).  Prickle cells are keratinocytes, and are 
artefacts  of  processing.  Squamous  cancer  cells  are  atypical,  with  cellular 
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pleomorphism,  increased  mitoses,  and  hyper chromatic  nuclei.  Figure  1.8 
illustrates an H+E stained SCC of the oral cavity. 
 
 
Figure 1.8: Squamous cell carcinoma of the oral cavity 
 
H+E  histological  specimens  are  graded  into  well,  moderately  and  poorly 
differentiated  cancers.  Well differentiated  SCCs  closely  resemble  normal 
keratinising  squamous  cells.  Moderately  differentiated  SCCs,  have  a  reduced 
amount of keratin present, increased nuclear pleomorphism, mitosis and cellular 
atypia.  Poorly  differentiated  cancers  have  non cohesive  inter cellular  bridges, 
and either no or small amounts of keratin within the specimen [43]. 
 
1.8 Presentation 
 
Patients may present in a number of different ways. Asymptomatic patients are 
rare and often diagnosed incidentally either following a dental consultation, or 
the discovery of a painless neck mass.  
 
Symptoms depend on the primary site and stage of disease.  The commonest 
symptoms include: change in voice quality for more than 6 weeks, oral pain or 
ulceration for more than 3 weeks, neck mass, mass within the oral cavity, and 
dysphagia  or  pain  on  swallowing  for  more  than  3  weeks.  Others  symptoms 
include:    new  or  persistent  pain  within  the  extra cranial  HN,  unilateral  nasal 
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obstruction with nasal discharge, and mobile teeth without co existent peri dontal 
disease.  
 
Patients with locally advanced or metastatic disease may experience lethargy, 
weight loss, shortness of breath and stridor, cough, or symptoms associated with 
tumour fungation and secondary infection.  
 
1.9 Clinical Examination and Investigations  
 
Following a full patient history to elicit the presenting symptoms and associated 
aetiological risk  factors, a  full HN examination is undertaken.  The  aim is to 
assess each anatomical site, and determine the extent of any visible or palpable 
disease, and associated metastases to regional LNs. This includes a fibre optic 
nasendoscopy to allow direct visualisation of the post nasal space, pharynx and 
larynx,  examination  of  the  oral  cavity  and  oropharynx,  and  palpation  of  all 
cervical and supra clavicular LN groups.  
 
Initial  investigations  include  baseline  haematological  (full  blood  count)  and 
biochemical (renal and liver function, and bone profile) blood tests. Examination 
under anaesthesia is usually undertaken, allowing visualisation and bi manual 
palpation of all possible disease sites. Histological confirmation through USS 
guided FNA or biopsy will increase the likelihood of obtaining positive histology 
and corroborate the clinical signs. 
 
1.10 Imaging  
 
Imaging provides anatomical delineation of disease sites and associated invasion 
into surrounding structures. USS, contrast enhanced CT, and MRI of the HN 
allows the patient to be effectively staged for loco regional disease. A CT chest 
will  detect  metastatic  disease  outside  the  extra cranial  HN.  This  information 
guides prognosis and treatment decisions. Functional imaging using combined 
Computed  Tomography Positron  Emission  Tomography  (CT PET)  is 
increasingly used to stage patients.   41
1.10.1 Ultrasound Imaging 
USS is a simple, highly operator dependent procedure. High frequency (7 to 
15MHz) sound waves are emitted in a pulse, generated from a transducer through 
the application of an alternating current across piezoelectric crystals. The wave 
attenuation is detected by the transducer, and characterises the tissue. Doppler 
studies allow the assessment of vascularity within the region.  
 
1.10.1.2 Indications for Ultrasound use in Head and  eck Cancer 
USS  may  characterise  benign  or  malignant  tissue  in combination  with  FNA, 
either  at  the  time  of  diagnosis,  during  the  follow  up  for  recurrence,  or  less 
commonly in combination with endoscopy for endo luminal assessment. 
 
1.10.2 Computed Tomography 
CT  was  first  reported  by  Hounsfield  in  1973  [45].  This  uses  x ray  beam 
transmission, and the subsequent attenuation of that beam as it passes through the 
patient to provide anatomical information. Multi slice CT imagers are currently 
used in clinical practice. 
 
The x ray beam is generated from x ray tubes rotated across the field of view. X 
ray attenuation can then be measured at any distance from the centre of rotation. 
Multi slice CT utilises multiple banks of detectors (8 to 64 rows). Within a single 
360  degree  rotation  as  the  patient  moves  on  the  couch  through  the  gantry, 
multiple image sets are acquired for example 4, 16, 32, and 64 slices. An x ray 
cone  beam  is  used  in  multi slice  CT  imagers,  and  the  attenuation  data 
corresponds  to  the  detection  of  x rays  between  the  volumes  of  two  adjacent 
cones.  
 
Helical CT imagers use fan beam x rays, and data is acquired as the couch moves 
at a steady speed through the gantry as the x ray tube and detectors rotate around 
the  patient.  The  images  obtained  are  in  the  form  of  a  continuous  ribbon  of 
contiguous slices angulated through the path of the spiral or helix [46]. 
 
The transmitted attenuated x ray  beam is converted into a current signal and 
reconstructed into an image. The CT slice is divided into a matrix containing 3D   42
3 dimensional) voxels (in the x, y, and z directions) or 2D (two dimensional) 
pixels (x and y directions). The matrix has 512 x 512 voxels per slice, each voxel 
measuring 0.5mm x 0.5mm. The attenuation within each voxel is reconstructed 
by  filtered  back  projection  to  the  point  of  origin.  The  attenuation  values  are 
represented  as  grayscale  on  the  2D  image,  and  these  are  then  converted  to 
Houndsfield  units  (HU).  This  incorporates  a  linear attenuation  co efficient  of 
tissue  and  water.  For  example,  the  HU  for  water  is  0,  soft  tissues  0  to  100 
(depending on the water content), fat 100, and bone 1000. The operator is able to 
alter the window level and window width, to adjust the brightness and contrast 
and view structures accordingly for example, bone, soft tissue, and lung [47]. 
 
1.10.2.1 Indications for Computed Tomography in Head and  eck Cancer 
CT allows the accurate diagnosis and staging (bone/cartilage invasion and soft 
tissue extension, and detection of lung parenchymal metastases), post treatment 
follow up, and detection of suspected recurrence of SCCHN.  
 
1.10.2.2 Computed Tomography and Radiotherapy Planning 
CT data and images guide RT (IGRT) planning, and are required for treatment 
planning  systems  (TPS).  This  allows  target  volume  (TV)  delineation  without 
distortion  from  surrounding  structures,  and  provides  information  on  electron 
density for the TPS algorithms to calculate the radiation dose. In oropharyngeal 
and oral cavity cancers, the presence of dental amalgam, or metal prostheses is 
associated with artefacts affecting the image quality, and ability to delineate the 
TV from normal tissue. 
 
1.10.3 MRI 
MRI is based on the application of an external magnetic field and pulsed radio 
waves. Free and attached protons in water and fat re align either parallel or anti 
parallel to the field and precess at the same frequency as the magnetic field. A 
radio frequency pulse (less than 1millisecond) is applied at 90 degrees to the 
magnetic field, and alternates with it. This causes the protons to precess in phase 
with  each  other  rather  than  independently.  This  proton  deflection  signal  is 
proportional  to  the  strength  of  the  radio frequency  pulse.  Once  the  pulse  is   43
removed the protons re align in the direction of the external magnetic field (T1 
recovery) and precession continues un synchronised (T2 decay).  
 
The signal alternation is detected by the receiving coils within the MRI unit, and 
processed to produce a pixel intensity map and the grayscale image. The signal 
intensity depends on the number of protons within each voxel, the strength of the 
applied magnetic field, and the direction of alignment of the protons around the 
axis following application of the magnetic field.  
 
1.10.3.1 Indications for MRI of the Head and  eck 
MRI is principally used to assess soft tissue and bony extension of SCCHN at 
diagnosis, and the extent of local recurrence. MRI has the advantage of improved 
diagnostic accuracy compared to CT imaging, especially for nasopharyngeal and 
oropharyngeal carcinomas. Improved detection of: extension of carcinomas into 
the  musculature  of  the  tongue  base,  cranial  nerves,  peri neural  invasion  and 
spread, and the detection of either early bone marrow involvement or focal bone 
erosions is possible [48].    
 
1.10.4 Computed Tomography Positron Emission Tomography 
The  use  of  CT PET  is  increasingly  common  in  the  investigative  process  for 
SCCHN.  The  commonest  radio nuclide  used  in  clinical  practice  is 
18Fluro 2 
deoxyglucose (
18FDG). Chapter 2 describes the principles of PET imaging and 
18FDG in detail. 
 
1.10.5.1 Carcinoma of Unknown Primary 
The incidence of carcinoma of unknown primary in cervical LN metastases is 
between 1 to 2% of all HN cancer diagnoses [49]. 
18FDG CT PET is indicated 
when  no  primary  site  is  detected  after  MRI  or  CT  imaging,  but  before  pan 
endoscopy and biopsy. Functional imaging up to 6 weeks after biopsy may lead 
to a false positive result. 
18FDG CT PET can detect the primary site in up to 25% 
of patients, as well as distant metastases in a further 11%, and loco regional 
metastases in 16% [50]. When undertaken prior to pan endoscopy, the detection 
rate was further increased to 45.2% [51].  
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In up to 16% of patients with a negative CT PET, panendoscopy and biopsy of 
the post nasal space, base of tongue, bilateral tonsils, and pyriform fossae, will 
histologically confirm the primary site [49]. Detection of primary cancers within 
the supraglottis and Waldeyer’s ring can be difficult, because the primary may be 
small or superficial, normal lymphoid tissue may be adjacent to the primary site, 
and 
18FDG is secreted in saliva accumulating in the valleculae and pyriform fossa 
[52]. 
 
1.10.5.2 Lymph  ode Metastases 
The  detection  of  metastatic  disease  within  LNs  can  be  difficult  because  the 
primary tumour may be adjacent to a LN producing an overlap of 
18FDG avidity, 
or the node is small.  Correlation with pathology may improve this [53].  
 
1.10.5.3  Extra Cranial  Metastases  and  Pulmonary   odules  of  Unknown 
Significance 
The incidence of second primaries and extra cranial HN metastases detected by 
CT PET imaging is up to 20% [49].   
 
1.10.5.4 Recurrent Disease 
Following treatment, recurrent disease can be difficult to detect by conventional 
imaging because of resolving tissue inflammation, anatomical changes, and scar 
formation, producing soft tissue distortion.  
 
The optimal time to assess residual disease after RT or CRT is 3 to 4 months.  
From 3 months post treatment, the accuracy of recurrence detection increases up 
to 94% [54,55]. One month after treatment up to 28% of patients with negative 
scans have persistent or recurrent disease. Eighty six percent of patients with 
positive PET scans have histological confirmation of recurrence [56].  
 
1.10.5.5 The Use of
 18FDG PET to Aid Radiotherapy Planning of the Head and 
 eck 
CT data sets are used to delineate TVs in patients with SCCHN. The use of PET 
information in this process is becoming increasingly important but not common. 
The use of 
18FDG CT PET data is well established in planning radical RT for   45
non small cell lung cancer (NSCLC), and has been associated with a smaller 
delineated  gross  tumour  volume  (GTV),  and  reduced  volumes  of  normal 
irradiated lung.  
 
Optimisation  of  TV  delineation  is  vital  for  intensity  modulated  RT  (IMRT) 
planning and delivery, because steep dose gradients at the volume edge, lead to 
rapid  dose  fall off.  Inaccurate  TV  delineation  due  to  imaging,  or  observer 
variation, may reduce the dose to the high risk TV. This translates into reduced 
local control and overall survival and may increase late morbidity to organs at 
risk. Information from PET can alter either the planned treatment by 29% [57], 
radiation field arrangement by 14 to 53%, or prescribed dose by 11% [58,59] in 
patients with SCCHN.  
 
1.11 Guidance to Improve Outcomes in Head and  eck Cancer 
 
The National Institute of Clinical Excellence (NICE) [60] has issued guidelines 
aimed at improving the diagnosis, treatment and outcome of patients with HN 
cancer. A number of core standards have been recommended within England to 
achieve  these  improvements.  They  include  for  example:  urgent  referral,  and 
suggestions  of  investigative  pathways  and  service  provision  (including  multi 
disciplinary approaches). 
 
1.12 Management Options 
 
Curative treatment in all cases depends on RT, CRT, or surgery. These are often 
combined to improve outcome.  Such aggressive treatment can be at the cost of 
long term  morbidity  affecting  the  patient’s  quality  of  life.  Speech  and 
swallowing difficulties are significant with any treatment option.  
 
1.12.1 Surgery 
Surgical  excision  of  the  primary  tumour  and  any  suspected  or  actual  LN 
metastatic disease depends on a number of factors including: site, staging, and   46
long term  morbidity  (verbalisation,  and  swallowing),  with  the  aim  of  disease 
control and functional preservation.  
 
Surgery has advantages such as reduced treatment time and avoidance of the 
short and long term side effects of RT. The loco regional control is improved 
with the addition of adjuvant RT or CRT.  
 
Surgical resection options of the primary  cancer range  from: trans oral laser, 
wide  local  excision,  and  excision  en bloc  with  adjacent  structures. 
Reconstruction will be required if a significant defect has been created by the 
surgical  procedure.  Reconstruction  methods  include  for  example  an  arterio 
venous  anastomosis  of  a  latissimus  dorsi,  or  a  radial  forearm  free  flap. 
Reconstruction may be immediate at the time of surgery or delayed to allow for 
tissue recovery. 
 
Neck  dissections  (ND)  are  undertaken  either  as  primary  treatment  with  or 
without resection of the primary cancer, alone if no known primary is found, as a 
staged procedure following CRT or radical RT, or as salvage at the time of loco 
regional  recurrence.  The  ND  procedures  may  be  extended  radical,  radical, 
modified,  or  selective  (postero lateral,  lateral,  anterior,  supra omohyoid).  The 
recurrence rates are similar for radical, modified and selective NDs [61 63], and 
depend  on  the  pathological  presence  of  extra capsular  spread,  the  number  of 
positive LNs, and the addition of adjuvant RT/CRT. 
 
1.12.2 External Beam Radiotherapy 
RT is the curative treatment modality in SCCHN, and this is dependent on the 
total dose and the overall treatment time. Treatment is delivered to encompass 
the macroscopic primary and LN disease, along with adjacent areas at highest 
risk  of  recurrence.  The  regional  ipsi lateral  or  bilateral  LNs  may  be 
prophylactically treated depending on the risk of metastases associated with the 
primary cancer. 
 
RT is delivered commonly as 3D conformal RT (3DCRT) via a linear accelerator 
(LINAC) at mega voltage (MV) energies as photons and electrons.     47
Prior to treatment, dental assessment and percutaneous gastrostomy placement 
may be undertaken to optimise nutrition and hydration. Following this, speech, 
language and dietetic assessment continue to promote the normal laryngeal and 
pharyngeal function. 
 
The  acute  side  effects  of  RT  include:  skin  erythema,  dry  and  moist 
desquamation, increased oral secretions (due to radiation induced mucositis), dry 
mouth (reduced salivary gland secretions), pain, and rarely secondary bacterial 
infection (due to poor oral hygiene and compliance with treatment advice during 
RT). Late effects (from 6 months post completion of treatment) include: skin 
fibrosis,  telangectasia,  and  oedema,  dry  mouth,  accelerated  dental  caries  can 
significantly add to the morbidity experienced and so reduce the quality of life 
experienced. 
 
Treatment volumes (GTV, clinical TV [CTV], and planning TV [PTV]) have 
been described by the International Commission of Radiation Units (ICRU) [64].   
 
GTV:   
Visible or palpable macroscopic disease on clinical examination, and imaging.  
 
CTV:      
Encompasses  the  microscopic  spread  not  visible  on  imaging  or  clinical 
examination.  
 
PTV:   
This takes into account daily geographical variation caused by internal organ 
motion or inaccuracies in the treatment field position (systematic and random 
errors), to ensure the PTV has received 95 to 107% of the prescribed dose.  
 
Each of these volumes creates a margin (which may be limited by barriers of 
spread or around organs at risk) to ensure both macro and microscopic disease is 
within the radiation field. Irradiation of microscopic disease reduces the risk of 
loco regional  recurrence.  These  LN  CTVs  are  delineated  according  to  the 
Radiation Therapy Oncology Group (RTOG) Collaboration guidelines [65].   48
The treatment technique and delivered dose minimise toxicity to organs at risk 
and  ensure  that  the  tolerance  doses  for  individual  organs  are  not  exceeded. 
Radiation dose is delivered per fraction in Gray (Gy). The size of each fraction 
depends on the treatment schedule for example: conventional fractionation 2Gy 
per fraction Monday to Friday, one fraction per day. Typically a two phased 
technique is employed (Phase 1 macroscopic and microscopic sites [primary and 
nodal], and Phase 2 macroscopic disease only) to a total dose of 66 to 70Gy, 
Monday to Friday over 6.5 to 7 weeks with MV photons. 
 
1.12.2.1 Prophylactic Lymph  ode Irradiation in  ode  egative  eck 
Irradiation is usually undertaken when the risk of occult LN disease is more than 
20%  [39,63,66].  In  conventionally  fractionated  RT,  doses  are  between  44  to 
50Gy. 
 
1.12.2.2  ode Positive  eck 
The risk of loco regional recurrence is directly related to the development of 
extra capsular LN extension, in patients with clinical or radiological evidence of 
LN disease. This risk is positively correlated to the size of the LN [67].  For 
example in LNs less than 1cm the risk of extra capsular spread is 17 to 43%, 1 to 
3cm the risk is 53 to 83%, and greater than 3cm the risk of extra capsular spread 
is 74 to 95% [68 70]. 
 
The treatment options include: RT alone, CRT, or a ND followed by adjuvant 
treatment, or a planned ND 6 weeks following the completion of primary RT or 
CRT.  The  decision  is  dependent  on  the  size  of  the  involved  LNs  and  the 
relationship to surrounding structures. 
 
1.12.3 Brachytherapy 
Brachytherapy is the use of a radioactive source (
192Iridium) directly placed into 
the cancer either manually (low dose rate), or via a remote after loading system 
(high dose rate, fractionated regime). It may be a sole modality of treatment for 
T1 to T2 lateral tongue and floor of mouth carcinomas, or as a boost to these 
sites following RT. The Head and Neck European Group of Curietherapy linked 
to the European Society of Therapeutic Radiology and Oncology has published   49
recommendations for brachytherapy use is SCCHN [71]. The delivered dose is 
60 to 66Gy. 
 
1.12.4  eo Adjuvant Chemo Radiotherapy 
The  initial  outcomes  for  oral  cavity,  laryngeal,  oropharyngeal  and 
hypopharyngeal  SCC  treatments  reported  an  8%  5 year  overall  survival 
advantage  when  concomitant  platinum  based  CRT  was  used  to  treat  locally 
advanced disease. The absolute survival benefit was 4.4% at 5 years with the 
addition  of  chemotherapy,  taking  the  5 year  overall  survival  from  31.6%  to 
36.0%. The benefit of both concomitant chemotherapy and altered fractionation 
RT reduced with increasing age, and was no longer of benefit over the age of 71 
[72,73].  
 
1.12.5  eoadjuvant/Induction Chemotherapy 
The use of neoadjuvant chemotherapy has previously been restricted to patients 
with nasopharyngeal carcinoma [74], or when there was a significant delay in 
starting RT treatment which may potentially allow the disease to progress.   
 
Platinum based neoadjuvant chemotherapy in the treatment of SCCHN either 
alone or in combination with 5 fluorouracil has not shown a significant benefit 
compared to local treatment alone [72,73]. 
 
Docetaxel (75mg/m
2) has been added to cisplatin and 5 fluorouracil schedules, 
and shown to significantly improve the median progression free survival, reduce 
the risk of disease related death, and improve the 3 year overall survival by 10 to 
14%. However the loco regional failure rate was still 57 to 65%, and the toxicity 
related death doubled to 5.5% [75,76].  
 
1.12.6 Post Operative Radiotherapy 
Indications for PORT depend on factors that predict the risk of local recurrence. 
The  most  important  are  positive  resection  margins,  and  extra capsular  LN 
extension.  Either  of  these  are  an  indication  for  adjuvant  RT.  PORT  is  also 
recommended  when  two  or  more  of  the  following  factors  are  present:  close 
margins of less than 5mm, soft tissue invasion, two or more positive LNs, more   50
than 1 LN group involved, any LN more than 3cm, multi centric primary cancer, 
peri neural invasion, lympho vascular invasion, poorly differentiated histology, 
T3 or 4 disease, oral cavity primary site, carcinoma in situ or dysplasia at the 
edge of the resection margin, and uncertain surgical or pathological findings. 
 
RT  according  to  the  ICRU  guidelines  [64,77]  is  delivered  to  encompass  the 
surgical bed (CTV), to include any possible microscopic contamination within 
the surgical field. Accordingly, the ipsi lateral (IL), or contra lateral (CL) naïve 
or operated neck may be included in the treatment volume depending on risk. LN 
delineation of the CTV in the post operative, and node positive neck has been 
described [78]. The RT dose delivered is 60Gy in 30 fractions (2Gy per fraction). 
High risk disease (positive margins, extra capsular nodal spread) will receive a 
total dose of 64Gy in 32 fractions. 
 
1.12.7 Post Operative Chemo Radiotherapy 
Higher  rates  of  local  recurrence  (27  to  61%)  are  associated  with  certain 
pathological features including: extra capsular spread, positive mucosal resection 
margins, and two or more LNs. The presence of any of these features will reduce 
the 5 year overall survival to 27 to 34% [79]. 
 
Initial  studies  compared  PORT  alone,  or  in  combination  with  3  cycles  of 
cisplatin and 5 fluorouracil following surgery [80]. The rate of local recurrence 
was 30%, distant relapse rate 23%, and the over all survival was 40% at 5 years 
in those treated with PORT alone.  
 
Combined  modality  treatment  for  SCCHN  in  the  post operative  setting  has 
proved to be beneficial in high risk individuals (pT3 to 4, two
 or more regional 
LNs, extra capsular extension of LN
 disease, positive resection margins, or two 
or more indications of PORT).  Cisplatin based post operative CRT (cisplatin at 
100 milligram per meter squared [mg/m
2], 60 to 66Gy of RT) is associated with a 
2 year loco regional control rate of 82% in those who received post operative 
CRT, compared with 72% in the PORT alone group.
 The 5 year loco regional 
relapse was 42% greater for PORT alone. The 5 year overall survival was up to   51
13% greater in those who received chemotherapy. There was no difference in the 
late toxicity with the addition of chemotherapy [81,82]. 
 
1.12.8 IMRT 
IMRT is the delivery of radiation via a number of small beamlets through the use 
of multi leaf collimators, either as a dynamic or step and shoot LINAC based 
treatment, or helical tomotherapy. This allows the radiation beam to be shaped, 
improving conformity, and allows for dose escalation by sparing organs at risk. 
This technique may be administered in the primary or adjuvant setting. 
 
1.12.9 Biological Agents 
The epidermal growth factor receptors (EGFR) are linked to a tyrosine kinase 
(TK) residue, and expressed at increased levels of 90 to 100% in SCCHN [83].  
Ligand  binding  to  the  receptor  activates  TK,  and  down  stream  signal 
transduction. 
 
Cetuximab is a humanised murine monoclonal antibody (MAB) to the receptor 
extra cellular domain, inhibiting the activation of the TK. In patients with locally 
advanced  SCC  of  the  oropharynx,  larynx,  and  hypopharynx,  cetuximab 
(400mg/m
2 1 week prior to the start of RT, followed by 250mg/m
2 weekly during 
RT) significantly improved the 3 year overall survival by 10% compared to RT 
alone, and loco regional control by 32% [84]. Cetuximab is indicated for patients 
with stage III or IV SCCHN who would have been treated with platinum based 
CRT, but are unable to receive the chemotherapy due to other medical problems 
[85]. 
 
The acneiform rash side effect following EGFR inhibition positively correlates 
with clinical outcome, and is evident within three weeks of starting therapy. The 
overall survival is improved in those who experience increased severity of this 
cutaneous side effect.  
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1.13 Metastatic Disease  
 
The management of advanced SCCHN is focused on symptom control and the 
maintenance  of  quality  of  life.  Palliative  chemotherapy  and  RT,  analgesia, 
nutritional and psychological support are  components of this supportive care. 
Outcome is poor, with a median survival of 6 to 9 months.  The 1 year survival is 
between 20 to 40% if patients receive palliative chemotherapy [86].  
 
In the UK, the commonest first line agents are combination cisplatin (75mg/m
2, 
day 1)  and infusional 5 fluorouracil (750 to 1000mg/m
2 days 1 to 4). Single 
agent taxanes are used second line. Palliative RT may be a single fraction (8Gy) 
or hypo fractionated (27Gy in 6 fractions, 39Gy in 13 fractions).  
 
1.14 Survival and Outcome 
 
The 5 year survival of patients with SCCHN is dependent on early diagnosis, 
stage and primary site, and remains at 35%. In the UK, 2,496 deaths (35.84%) 
from HN cancer were recorded in 2006 [87]. The number of deaths increased 
sharply after the age of 60. Over the past 30 to 40 years there has been minimal 
change in the European age standardised mortality rate [88], which is illustrated 
in figure 1.9. 
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Figure 1.9: European age standardised mortality rates in men and women with Head and 
 eck cancer between 1971 and 2006 
 
1.15 Thesis Aims 
 
Treatment  failure  in  patients  with  SCCHN  is  principally  due  to  poor  local 
control. Fifty percent fail in this region, and only 20% will go on to develop 
metastases outside the HN.  
 
Local failure is due to the extent of disease at presentation and tumour biology 
(hypoxic  radio resistance,  and  increased  metabolism).  Failure  after  treatment 
results in disease that is difficult to treat and is a major cause of death despite 
changes in surgical, chemotherapeutic, and radiation treatment.  
 
RT dose escalation to regions at risk of local failure has the potential to improve 
control and so outcome.  
 
CT PET imaging can identify TVs that reflect the underlying tumour biology.  A 
number  of  radio nuclides  have  been  used  for  example 
18FDG  (glucose 
metabolism), 
64Cu ATSM  (
64Cu  (II)  diacetyl bis(N
4methylthiosemicarbazone))   54
and 
18Fluoro misonidazole (hypoxia), 3' deoxy 3' 
18fluorothymidine3' deoxy 3' 
fluorothymidine (proliferation/DNA synthesis). The incorporation of biological 
imaging in the patient’s investigative and treatment pathway can depend on the 
physical  isotope  properties  and  radio chemistry  for  production,  and  most 
importantly the ability to define and treat the representative biological volumes. 
 
This  thesis  is  focused  on  the  application  of  two  radio nuclides  in  CT PET 
imaging of SCCHN to delineate intra tumoural metabolic and hypoxic TVs that 
may be dose escalated with RT, to reduce the rate of local failure.  
 
Firstly, 
18FDG has the potential to make the greatest clinical impact, and be the 
most widely applicable to IGRT because it images metabolically active tumour, 
which may result in failure to cure with RT. There is no agreed method of TV 
delineation.  Three  separate  methods  (two  fixed  and one  adaptive)  have  been 
directly compared before and during RT in patients undergoing RT or CRT for 
locally advanced SCCHN. This evaluated differences in the defined TV, factors 
that  may  influence  any  volume  change,  and  gave  guidance  as  to  the  most 
appropriate  method  for  RT  planning.  PETVCAR  software  was  used  to 
automatically  delineate  volumes  at  each  imaging  point  by  4  SUV  cut  off 
thresholds, 5 thresholds of the percentage of the SUVmax, and an individualised 
adaptive threshold. The volumes defined during RT were directly compared with 
those  before  the  start  of  treatment.  The  SUVmax  was  assessed  within  these 
volumes, as well as the background uptake of 
18FDG.  
 
Secondly 
64Cu ATSM has been suggested as a novel hypoxic radio nuclide in 
SCCs. The retention pattern at 5 to 20, 40 to 60 minutes and 18 hours following 
injection has been investigated in patients with locally advanced disease who 
were due to be treated with primary surgery. The TVs were defined by tumour to 
muscle, blood and background ratios at these time points. The exogenous and 
endogenous hypoxic fraction was calculated by immuno histochemical methods 
on the surgical specimen, and correlated with the intra tumoural distribution of 
64Cu ATSM. Perfusion parameters were evaluated to map blood flow with the 
retention of 
64Cu ATSM. 
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Chapter 2   
 
18Fluoro 2 deoxyglucose  CT PET  Functional 
Imaging  and  Target  Volume  Delineation  in 
Squamous Cell Cancer of the Head and  eck 
 
MRI  and  CT PET  are  the  two  main  functional  imaging  modalities.  Intra 
tumoural homeostatic pathways may be assessed such as: glucose metabolism, 
and hypoxia (Chapter 3), as well as perfusion parameters. Perfusion imaging will 
be discussed in Chapter 3 section 3.7. 
 
2.1 Positron Emission Tomography 
 
Emitted neutron radiation from 
10Boron was first imaged by Javid et al in 1952 
[1] and then in 1956 with positrons in the assessment of intra cranial lesions [2].  
CT  and  MRI  localise  and  visualise  abnormal  tissue  in  relation  to  normal 
anatomical  structures.  The  combination  of  CT  and  PET  provides  additional 
information  of  physiological  processes  related  to  the  anatomical  region.  For 
example:  glucose  metabolism,  hypoxia,  and  deoxyribonucleic  acid  (DNA) 
synthesis.  The  automatic  co registration  of  these  data  sets  through  hybrid 
combination CT PET machines has improved the interpretation of PET images 
compared to PET alone. 
 
2.1.1 Emission and Detection of Positrons 
Unstable radio active isotopes return to the stable state by positron (positively 
charged electrons/anti matter) emission, or capture of an orbiting electron.  
 
These radio nuclides may be produced by the addition of a proton to the parent 
nucleus, or neutron ejection from the nucleus in a nuclear reactor. An example of 
these reactions is shown. 
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Proton Addition
  18O + Proton → 
18F  
 
 eutron Ejection 
62 Zn → 
62Cu + Neutron 
 
The energy emitted by the positrons is proportional to the number of protons 
within the nucleus. These positrons interact with electrons in the surrounding 
environment  over  a  short  distance.  The  final  interaction  is  an  annihilation 
reaction (converting mass to energy), to generate two co incident photons, each 
with an emitted energy of 511KeV (Kilo electron Volt). The photons travel in 
opposite directions to each other at 180 degrees. Residual kinetic energy from the 
annihilation reaction may deflect the positrons by up to 0.5 degrees from this 
path [3]. 
 
Annihilation co incidence photons are detected by multiple 3D rings of crystals 
(photo diodes)  in  blocks,  which  rotate  around  the  couch  within  the  positron 
emission tomography (PET) scanner. The photons are converted to light, and 
software algorithms are used to reconstruct the image.  
 
These photons are detected as random or true events following the annihilation 
reaction. The true events occur when the co incidence photons travel along their 
projected path when the two photons reach the detectors within 20 nano seconds, 
at 180 degrees to each other. Random co incidence events occur when a single 
photon is detected, or when two random photons are detected at the same time. 
Random events increase the background activity and reduce the image quality.  
 
The  sensitivity  of  the  scanner  is  dependent  on:  the  thickness  of  the  detector 
crystal (50% reduction in the thickness will reduce the sensitivity by a factor of 
four), the number of detectors, their size and position from the region of interest 
(ROI), and the photo diode material. 
 
2.1.2 Detector Crystals 
The  commonest  detector  crystals  are  lutetium  oxyorthosilicate,  and  bismuth 
germanium oxide [4]. The properties of the crystal include: density, generated 
light pulse width, light output, and the scintillator light wavelength. Lutetium   67
oxyorthosilicate is the most efficient at photon detection because it produces a 
lower number of scattered and random co incidence events. Table 2.1 shows the 
attributes of each of the commonest detector crystals. 
 
Table 2.1: The physical properties of Lutetium Oxyorthosilicate and Bismuth Germanium 
Oxide 
  Density 
(g/cm
3) 
Maximum 
Wavelength 
(nm) 
Photon 
(MeV) 
Decay 
Time  
(ns) 
Lutetium 
Oxyorthosilicate  
7.4  420  30,000  40 
Bismuth 
Germanium 
Oxide  
7.13  480  8,200  60,300 
 
 
2.1.3 Spatial Resolution 
The camera resolution is defined as the full width half maximum. This is the 
minimum distance that the detectors are able to register the emitted annihilation 
photons as two separate events. The resolution depends most importantly on the 
crystal  width,  range  and  non linear  deflection  of  the  photons,  along  with  the 
software used to reconstruct the images. The resolution of combined scanners is 
between 4 to 6mm. 
 
2.1.4 Scatter 
Scatter occurs when the annihilation photons are deviated from their true path. 
The scatter increases the signal to background ratio of the scanner, affecting the 
image quality, blurring the ROI on the reconstructed image. The Monte Carlo 
calculation is the optimal method to reduce scatter, based on the Klein Nishina 
formula [3]. This utilises the attenuation map from the CT data, and the first 
image  reconstruction  to  calculate  the  expected  background  scatter.  Other 
methods include: shielding in the form of projections between the photo diode 
blocks (small septa improve photon detection from adjacent planes, but increase 
scatter),  time  of  flight  projections  to  enhance  image  reconstruction  [5],   68
deconvolution of the scatter projections, and review of the PET matrix depending 
on the detected activity outside the ROI. 
 
2.1.5 Attenuation and Dead Time 
Annihilation  photons  may  be  attenuated  along  their  projected  path  by 
surrounding tissue. This attenuation can be corrected using the HU from the CT 
data set.  
 
The detector system may not register each individual detection event (dead time) 
if it occurs within a short time period from another event. This occurs when the 
radio nuclide emits high annihilation photon counts per second, for example 
15O 
and 
13N. A time elapse is required to allow the detection of each photon event 
(2µs). The dead time is dependent on the rate of decay of light within the photo 
diode block, and the photo multiplier tube. 
 
2.1.6 CT Contrast Agents in Combination with CT PET 
The administration of intra venous iodinated contrast during CT PET imaging 
allows  improved  detection  and  characterisation  of  pathological  lesions,  and 
surrounding anatomical structures. The evaluation and detection of regional LN 
groups is an example of this. Contrast is contra indicated in patients with iodine 
allergies, significant renal impairment, and hyperthyroidism [6]. It also allows a 
dynamic contrast enhanced CT (DCE CT) to be undertaken with the patient in 
the same position as the CT PET scan. 
 
Oral contrast agents define the intestinal tract with either positive or negative 
attenuation.  
 
Artefacts may occur during the co registration of the CT and PET image sets in 
high contrast attenuation regions or near dental amalgam. Artefacts appear as 
regions of high 
18FDG uptake [7], and are usually only present in the attenuation 
corrected (AC) PET images. 
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2.1.7 Patient Position 
Imaging  takes  between  20  to  60  minutes  depending  on  the  extent  of  the 
anatomical region to be visualised. Arm position is dependent on site of imaging, 
beam hardening and streak artefacts can occur on the CT data set [8] depending 
on position.  
 
When CT PET images are used to plan RT in SCCHN, arms flexed above the 
head will produce beam hardening, and potentially attenuate the radiation beam 
during dosimetry calculations. Patients are therefore imaged with their arms by 
their sides, both for treatment planning scans, and ideally for diagnostic imaging 
as well. Conversely, the arms are raised, and elbows flexed when the abdomen is 
imaged. 
 
2.1.8 Image Reconstruction and Algorithms for the Fusion of CT and PET 
Image reconstruction defines the spatial distribution of the radio nuclide within 
the body, accounts for random scatter, and the photon emission rate. 
 
The lines of projection of the annihilation photons are grouped and ordered into a 
sinogram,  to  identify  the  spatial  distribution  of  the  radio nuclide  within  each 
individual PET image. This data is then smoothed and filtered to reduce the noise 
and deblur the image, inversely transformed, and filter back projected (along the 
line of projection of the emitted photon) to the point of annihilation. 
 
The  PET  and  CT  images  generated  can  then  be  fused  automatically  using 
integrated  software  or  manually  to  achieve  the  final  image.  The  CT  data  is 
acquired  first  in  full  expiration,  followed  by  the  PET  during  shallow  tidal 
breathing from combined CT PET machines. Movement artefact can lead to mis 
registration of the image sets. This is less within the HN region compared to 
thorax but may be improved by the use of immobilisation devices such as the 
thermoplastic HN shell for RT planning scans. 
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2.2 Radio Pharmaceutical Properties of 
18Fluorine  
 
18FDG is the commonest radio nuclide in clinical use, and its structure is shown 
in figure 2.1 with the 
18Fluorine linked to the carbon atom at position two of the 
ring structure.  
 
 
Figure 2.1: The structure of 
18Fluoro 2 deoxyglucose  
 
18FDG can be produced by two methods: either by the addition of elemental 
fluorine  (directly  or  indirectly)  to  deoxyglucose,  or  most  commonly  by  a 
nucleophilic  substitution  reaction  in  a  cyclotron.  In  this  reaction, 
18Oxygen 
incorporated  into  water,  is  bombarded  with  high  energy  (less  than  15MeV) 
protons within the target of the cyclotron [9]. 
18FDG is produced through robotic 
automated methods to improve purity, sterility, and reduce the radiation exposure 
to production staff. 
 
The imaging properties of 
18Fluorine correspond to the emitted photon energies. 
More than 96% of positrons are emitted by 
+β decay, and the energy of these is 
635KeV. The average tissue range is 0.64 millimeters (mm) with a maximum 
path length of 2.4mm, and this improves the image resolution [10]. The half life 
(t1/2) of 
18Fluorine is 110 minutes. This facilitates the incorporation of 
18FDG into 
the intra cellular glucose metabolic pathway. 
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2.3 
18Fluoro 2 deoxyglucose 
 
2.3.1 Glucose Metabolism and Transport 
Glucose is transported by facilitated diffusion via GLUT (Glucose Transporter) 
trans membrane  channels  from  the  extra cellular  space  to  the  intra cellular 
cytoplasm regulated by insulin secretion.  
 
Initially,  intra cellular  glucose  is  converted  to  glucose 6 phosphate  by 
hexokinase (rate limiting), and then by a multi enzyme step into pyruvate with 
the production of NADH (nicotine adenine dinucleotide – reduced form) and 
adenosine tri phosphate (ATP) illustrated in figure 2.2. Hexokinase is inhibited 
by increased concentrations of glucose 6 phosphate (negative feedback).  
 
 
Figure 2.2: The transport of glucose from the extra cellular to intra cellular environment, 
and its intra cellular metabolic pathway 
 
 
Under  aerobic  conditions,  pyruvate  is  transported  from  the  cytoplasm  to  the 
mitochondria, and converted to acetylCoA. This is incorporated into the Krebs 
cycle by conversion to citric acid and oxaloacetate. Electrons are transported 
along the electron transport chain within the mitochondrial membrane through 
the reduction of NAD (nicotine adenine dinucleotide) to NADH. Oxygen is the 
final electron acceptor, leading to the production of carbon dioxide and water.   72
ATP is generated during this oxidative phosphorylation. Pyruvate is retained in 
the cytoplasm in anaerobic conditions, and converted to lactic acid, generating 
ATP.  Electron  transport  occurs  with  the  final  electron  acceptance  by  carbon 
dioxide. 
 
The hallmarks of cancer include self sustaining growth, lack of effect of growth 
inhibitory  factors/cytokines,  evasion  of  apoptosis,  unlimited  replication, 
angiogenesis, cell migration, invasion, and metastasis formation [11]. The up 
regulation  of  glucose  metabolism  in  cancer  cells  is  due  to  this  increased 
metabolic  demand.    These  all  require  ATP  from  glucose  metabolism,  and 
contribute to the generation of 
18FDG CT PET images.  
 
2.3.2 GLUT Trans Membrane Transporters 
The  GLUT  family  consists  of  7  glycosylated  trans membrane  transporter 
proteins.  Glucose  transportation  is  facilitated  by  a  conformational  change 
following glucose binding to their extra cellular domain. GLUT1 is located on 
red blood cells for example. 
 
The up regulation of glucose metabolism in cancer cells was initially reported by 
Warburg [12]. Glycolysis and the production of lactic acid are greatest in cancer 
cells compared to normal cells under aerobic conditions. The rate of metabolism 
is dependent on up regulated glucose transport [13], hexokinase and glucose 6 
phoshate  concentration.  There  is  increased  expression  of  the  genes  encoding 
hexokinase (bound to the mitochondrial membrane in cancer cells), GLUT1 and 
3, and mRNA (messenger ribo nucleic acid) transcription [14] in cancer cells. 
These up regulated events are all absent from physiologically normal cells [15].  
 
2.3.3 Intra cellular trapping of 
18Fluoro 2 deoxyglucose  
The 
18FDG enters the cells via GLUT and is phosphorylated by hexokinase to 
18Fluoro 2 deoxyglucose 6 phosphate.  This  is  metabolically  inactive,  and 
trapped  within  the  cell  by  the  fluorine  ion  at  the  second  carbon  position, 
preventing its conversion to pyruvate. Within the cell, low levels of glucose 6 
phosphatase prevent dephosphorylation, further increasing the concentration of   73
18FDG. The accumulation of 
18FDG is proportional to the rate of intra cellular 
glucose metabolism [10]. 
 
Increased transcription of GLUT1 and 3 in cancer cells leads to faster uptake of 
18FDG compared to normal cells [16]. Figure 2.3 illustrates the transport and 
metabolism of 
18FDG. 
 
 
Figure  2.3:  The  transport  of 
18FDG  from  the  extra cellular  to  the  intra  cellular 
environment, and its intra cellular metabolic pathway 
 
 
18FDG is therefore  a surrogate marker of  glucose metabolism, and is  rapidly 
distributed in plasma, extra cellular and intra cellular compartments.  
 
2.4 Radio nuclide Quantification  
 
The  uptake  of 
18FDG  is  quantified  by:  visual  interpretation,  the  standardised 
uptake value (SUV), and kinetic modelling. Each method was reviewed by the 
National  Institute  of  Health  in  2006,  and  Consenus  Recommendations  [17] 
published. Other methods include the Patlak Gjedde analysis, and total lesion 
glycolysis (TLG). 
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2.4.1 Visual Interpretation 
Visual interpretation is the simplest method to assess 
18FDG uptake, and can be 
used regardless of blood samples, the length of image acquisition, and the type of 
imaging. However this method is subjective, dependent on the interpretation of 
background uptake, and static imaging does not account for changes in uptake 
with  time.  This  method  is  dependent  on  the  time  period  from  injection  to 
imaging, the blood glucose concentration, and effects from partial voluming [17]. 
 
2.4.2 Standard Uptake Value 
The SUV is the most commonly used semi quantitative tool to quantify 
18FDG 
uptake at a specific time point. The concentration of radio nuclide is normalised 
to the injected dose, and the patient’s body weight (bw) [18]. This has previously 
been reported as the Dose Uptake Ratio [19], Differential Absorption Ratio [20], 
or Differential Uptake Ratio [21]. The term SUV has now replaced these. The 
equation for the calculation of the SUV is shown below. 
 
 
SUV (MBq/g/ml) =    Tissue Uptake of Radio nuclide (MBq/ml) 
Injected  Radio nuclide  Dose  (MBq)  /  (body  weight  (kg)  x 
1000) 
 
(MBq/g/ml – MegaBequerel per gram per millilitre) 
 
 
The SUVmax indicates the maximum SUV detected within the ROI, whereas the 
SUVmean is the mean or average SUV within the ROI. 
 
The uptake and concentration of 
18FDG and other radio nuclides is dependent on 
a number of factors [22], which are shown in table 2.2. 
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Table 2.2: The parameters affecting radio nuclide uptake 
Parameters Affecting Radio nuclide Uptake 
Quantity of radio nuclide administered 
Route of administration 
Pharmaco kinetics and pharmaco dynamics of radio nuclide 
Competition by endogenous substrate for target site 
Non specific interactions within the surrounding environment 
Biochemistry of ligand 
Vascular volume of the tissue 
Time of uptake after administration 
 
 
The SUV method can be used with static and whole body imaging, provides 
semi quantitative interpretation, and no requirement for blood samples. Small 
changes  in  the  SUV  are  more  difficult  to  detect  if  the  calculation  is  not 
normalised [17]. 
 
The calculation of the SUV can be influenced by a number of factors [23,24], 
shown in table 2.3. 
 
Table 2.3: Factors affecting the SUV calculation 
Factor  Affect on SUV 
Time  Period  from  Injection  to 
Imaging 
Final SUV (often use injection to mid 
image acquisition time point [19]) 
Attenuation Correction  Always  required,  accounts  for  noise, 
counts  obtained,  gamma  energy  of 
radio nuclide,  the  use  of  intra venous 
contrast agent 
Region of Interest Shape  Averaged  volume  of  pixels  or  voxels 
within defined boundary 
Partial Volume  Dependent on reconstruction algorithm 
and average pixel/voxel intensity   76
Hardware  Calibration,  recovery  co efficients 
effect noise and image resolution 
Software  Reconstruction  algorithm  influences 
noise and image resolution 
Co registration   Depends  on  accuracy  of  registration 
and correlation of ROI in time and final 
SUV  
Body Size/Weight 
 
 
Lean Body Mass/Body Surface Area 
Whole body imaging does not take into 
account uptake in fatty tissue.  
 
Account  for  changes  in  weight  in 
whole  body  imaging,  and  correct  for 
sex 
 
 
These  factors  can  often  be  corrected  by  normalisation  and  calibration 
calculations.  
 
The SUV will peak and then plateau in malignant lesions up to 90 minutes after 
injection [25,26], or later in some cases. Imaging usually commences 90 minutes 
after 
18FDG injection to aid the differentiation of benign and malignant lesions. 
The time point of imaging is especially important when comparing ROI within 
serial CT PET images. The peak and plateau of 
18FDG concentration within the 
ROI is dynamic, and unless serial scans are imaged at the same time point after 
injection, then time differences will lead to variations in the calculated SUV. In 
practise this can be difficult because the number of patients to be imaged and the 
time of injection of 
18FDG relative to the time of imaging. 
 
2.4.2.1  ormalisation to Body Weight, Lean Body Mass, and Body Surface 
Area 
Currently,  the  most  widely  accepted  normalisation  is  to  the  patient’s  body 
weight.  
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Other SUV normalisation methods include: lean body mass (lbm) [27], or body 
surface  area  (BSA)  [28].  These  values  account  for  weight  loss.  All  the 
normalised  SUVs  (body  weight,  lbm,  and  BSA)  positively  correlate  with  the 
absolute metabolic rate [17]. The equations below illustrate the SUV normalised 
to the lbm and BSA.  
 
 
SUVlbm or BSA  =   Tissue Uptake of Radio nuclide (MBq/ml) 
    Injected Dose of Radio nucilde (MBq) x lbm (kg) or BSA (m
2) 
 
Female lbm = (1.07 x body weight kg)   148 [body weight (kg) / height (cm)]
 2  
 
Male lbm = (1.1 x body weight kg)   120 [body weight (kg) / height (cm)]
 2 
 
BSA =  0.007184 x body weight (kg)
 0.425 x height (cm)
 0.725 
 
2.4.2.2  ormalisation to Blood Glucose 
The SUV can also be normalised to the patient’s blood glucose (SUVgluc) as 
shown. 
 
SUVgluc =  SUV x Glucose value (mmol/l)   
5.5mmol/l 
 
Glucose normalised SUVs in patients with SCCHN were used to assess local 
recurrence  after  radical  RT.  The  mean  SUVgluc  pre treatment  was  2.25  to 
28.5g/ml compared to 7.2g/ml in those patients without local recurrence. While 
at  1  month  post  RT  on 
18FDG  PET  imaging,  the  mean  SUVgluc  was  1.8  to 
9.97g/ml in those with local recurrence and 3.74g/ml in those patients without 
local  recurrence  [29].  When  patients  were  imaged  after  fasting,  and  then 
following an oral glucose tolerance test (250ml water and 50g oral glucose), the 
fasting SUVs ranged from 4.1 to 10.9g/ml, and SUV reduced significantly by 2.2 
to 5.9g/ml after the oral glucose tolerance test. This may suggest the sensitivity 
of 
18FDG  blood  glucose  concentration.  However,  these  results  should  be 
interpreted with caution as patients were imaged 1 month after RT, which may   78
elevate  the  values,  and  image  quality  can  be  impaired  after  a  glucose  load 
because of increased muscle uptake of 
18FDG [30]. 
 
2.4.3 Kinetic Modelling 
Data is acquired dynamically in kinetic modelling. Arterial blood samples are 
used  to  calculate  the  rate  constants  and  compartmental  model  under 
investigation. The derivation of these constants is complex as they reflect the 
differences in radio nuclide transport, and metabolism. For example, the lump 
constant  reflects  differences  in  transport  between 
18FDG  and  glucose, 
phosphorylation by hexokinase and dephosporylation [22,31].  
 
This method is a research tool, and has limited use in everyday clinical imaging 
due to patient compliance with arterial blood samples, and complexity of the 
procedure. The model is highly dependent on the quality of data and samples 
collected as well as partial volume effects [17]. 
 
2.4.4 Patlak Gjedde Analysis 
The Patlak Gjedde analysis quantifies radio nuclides that are irreversibly trapped 
within cells, such as 
18FDG. The influx rate constant can be determined. The data 
is acquired dynamically, and time activity curves calculated [32]. This method 
accounts for the distribution of the radio nuclide within the whole body, although 
patient movement can produce errors in the curve [25]. 
 
2.4.5 Total Lesion Glycolysis  
The TLG is a non invasive estimate of the glycolytic rate within the ROI. The 
change in the TLG can be calculated either directly or as the Larson Ginsberg 
Index [33] which is shown in the equation below. 
 
TLG =   Delineated Volume of ROI x SUVmean 
 
Larson Ginsberg Index =    
[SUVmean pre treatment x (pre treatment volume   SUVmean post treatment) x 
volume post treatment] 
[(SUVmean pre treatment x pre treatment volume)]   79
The  calculation  of  absolute  glucose  utilisation  rates  requires  complex  kinetic 
modelling and rate constant determination [22]. 
 
2.5 Physiological Uptake of 
18Fluoro 2 deoxyglucose  
 
Physiological  uptake  of 
18FDG  can  influence  the  interpretation  of  CT PET 
images. Uptake can be increased within the myocardium, skeletal muscle, brown 
fat, gastro intestinal tract, lymphatic tissue (tonsil, adenoids, thymus, and bone 
marrow),  urinary  tract,  and  low grade  uptake  within  the  breast,  ovaries  and 
uterus.  Fasting prior to imaging reduces the circulating insulin levels, and so the 
uptake of 
18FDG uptake into muscle and fat. Ensuring that patients are kept warm 
prior to and during their scan has a similar effect. 
 
Increased  bone  marrow  uptake  is  particularly  prominent  following 
chemotherapy, and in those patients who require granulocyte colony stimulating 
factor injections for the treatment of chemotherapy induced neutropenia. These 
all potentially reduce the scan sensitivity. 
 
False positive interpretations of 
18FDG CT PET may be secondary to: prolonged 
wound healing (especially in the presence of activated macrophages), infection, 
seromas,  RT  induced  inflammation,  granulomatous  diseases  (tuberculosis, 
sarcoidosis and histoplasmosis), and endocrine disorders (Paget’s and Grave’s 
disease).  Conversely,  reduced  uptake  (false  negative)  may  occur  in  areas  of 
necrosis. 
 
2.5.1 Physiological Uptake within the Head and  eck 
18FDG  avidity  may  occur  in  dental  implants,  periodontal  infections,  normal 
musculature of the HN, and the Waldeyer’s ring. 
 
Dental implants produce stripe artefacts that appear as areas of increased 
18FDG 
uptake on AC images. Reduced uptake is due to increased absorption of emitted 
photons by the metallic implant. Periodontal and dental space disease associated 
with an inflammatory reaction will locally increase the uptake of 
18FDG.    80
Anterior floor of mouth, masticator muscles, anterior tip of the tongue, muscles 
of the face, neck, and larynx [34] all physiologically take up 
18FDG. These are 
more prominent in nervous patients or those who talk after 
18FDG administration.  
 
Lymphoid  tissue  within  the  Waldeyer’s  ring  also  produces  low grade  uptake 
(tonsil and posterior third of tongue). 
 
Small amounts of glucose are present in the saliva and correspond to low grade 
uptake within the salivary  glands. Post operatively, uptake  within granulation 
tissue around the tracheal stoma may be present in patients who have undergone 
a laryngectomy. 
 
2.6  Methods  to  Delineate 
18Fluoro 2 deoxyglucose  CT PET 
Guided Target Volumes for Radiotherapy Planning 
 
The method of delineation of metabolically active TVs is vitally important, as 
this will impact RT planning, dosimetry, and the final dose deliverable in dose 
escalation strategies aimed at improving local control. Threshold methods for TV 
delineation in SCCHN have been extrapolated from those used in NSCLC, and 
may  be  fixed  or  adaptive.  The  majority  of  published  studies  have  not  used 
combined  CT PET  machines,  and  the  CT  and  PET  datasets  were  acquired 
separately and often at different time points.  
 
Software available for delineation can be commercial or generated by a computer 
team  within  an  institution  limiting  the  reproducibility  of  data.  Automatic 
segmentation  allows  the  software  user  to  define  either  a  fixed  or  adaptive 
threshold. The edge of the volume is then automatically defined. Clinician choice 
therefore depends on resource availability. 
 
2.6.1 Visual Interpretation  
The  individual  clinician  can  adjust  the  threshold  depending  on  contouring 
preference,  without  taking  into  account  information  from  the  CT  data set,  to 
define the 
18FDG TV.    81
There is considerable inter observer variation in 
18FDG PET TV delineation by 
this method. This is reduced when protocols incorporate settings for window 
width and level, and inclusion of CT criteria to define disease [35].  In NSCLC, 
the information from PET defined TVs changed the RT field size by 25 to 34% 
[36,37]. This was also true for the two studies reported in SCCHN. The TVs 
corresponded in 90% of cases on CT, MRI and 
18FDG PET imaging [38]. The 
TV delineation and normal tissue sparing  were improved when CT and PET 
images were fused. The GTV reduced by at least 25% in 33% of patients, and in 
46% the PTV was increased or decreased by 20% [39].  
 
Figure 2.4 a, b, and c illustrates this in SCCHN. The higher the threshold, the 
more 
18FDG background uptake is excluded, and the smaller the volume as in 
figure 2.4 c. 
 
 
 
 
 
 
 
 
 
Figure 2.4: Clinician thresholded CT PET images by visual interpretation 
 
 
The use of visual interpretation within centres should be clearly defined, and will 
be  improved  when  used  with  criteria  for  inclusion  of  disease  extension  (CT 
criteria for soft tissue enhancement) into the functional volume (FV). 
 
2.6.2 Fixed Thresholds 
The  SUV  Cut  Off  (SUVCO)  is  an  absolute  fixed  threshold.  The  threshold 
excludes any 
18FDG positive regions that are below the pre determined level, and 
includes regions that are equal to or greater than it.  
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The percentage threshold of the SUVmax (PTSUVmax) defines the delineating 
edge according to a pre determined percentage of the SUVmax. For example a 
40% threshold to define a ROI with a SUVmax of 10g/ml will use a 4.0g/ml 
SUV threshold.  
 
The main disadvantage of both methods is neither the background uptake nor the 
individual SUV within the ROI are taken into consideration. Both methods do 
not require information from the CT data set. 
 
2.6.2.1 SUV Cut Off 
The use of an SUVCO threshold of 2.5g/ml has been reported to differentiate 
normal and tumour tissue [40] in NSCLC. When compared to the CT defined 
volume, the 
18FDG avid TV was on average 12.64% smaller for the SUVCO 
threshold of 2.5g/ml, and 61.66% smaller when contoured by the 40% of the 
SUVmax threshold. When the SUV was assessed according to the delineated 
volume,  there  was  improved  correlation  at  higher  absolute  thresholds  greater 
than 6 and 7g/ml compared to the percentage threshold method.  Smaller fixed 
absolute SUVCO thresholds of 4 to 6g/ml corresponded to tumour volumes less 
than 10.0 centimetres cubed (cm
3) when compared to the CT volume [41]. This 
threshold was recommended for tumour delineation in NSCLC.  
 
Other studies have used this 2.5g/ml cut off to differentiate tumour from normal 
tissue, and then applied a percentage SUVmax threshold to define the TV [42]. 
PET  aided  tumour  delineation  from  surrounding  atelectasis  in  NSCLC.  The 
surrounding  low grade 
18FDG  uptake  in  areas  of  atelectasis  significantly 
influenced the PET defined volume in more than 50% of patients [43] resulting 
in treatment modification.  
 
Similarly, an SUVCO threshold of 3 to 4g/ml used to manually delineate the PET 
based TV was evaluated in patients undergoing radical RT for SCCHN [44]. 
Unlike  other  studies  this  reported  increased  observer  variation  when  PET 
imaging was used to plan RT. However this study was biased as clinicians were 
not blinded, and each clinician arbitrarily set the SUV threshold to contour the 
volumes in line with visual interpretation.   83
2.6.2.2 Percentage threshold of the SUVmax 
The 36 to 50% threshold of the SUVmax has been used to define the 
18FDG PET 
TV in patients with SCCHN and NSCLC.  
 
The 40% of the SUVmax reduced the volume of irradiated lung by 22.8% in 12 
NSCLC  patients  who  underwent  curative  RT  [45].    However,  the  tumour 
SUVmax was defined as the largest region of highest uniform 
18FDG uptake 
rather  than  the  maximum  SUV  within  an  individual  PET  voxel.  Similar 
differences in PET guided TV delineation and irradiated lung volumes have also 
been reported by this method [46,47]. 
 
In  75%  of  patients  with  SCCHN,  PET  TVs  delineated  by  the  50%  of  the 
SUVmax threshold were smaller than those derived from CT data alone [48]. 
However 25% of this group had the high risk macroscopic disease under treated 
when IMRT was planned on the CT data set only. 
 
Following this, Daisne initially reported automatic segmentation of PET volumes 
using signal to background information calculated from a lucite phantom [49].  
Further  studies  by  this  group  validated  CT,  MRI  and  PET  imaging  with 
macroscopic  pathological  specimens  from  patients  who  underwent 
laryngectomies. The gold standard laryngeal GTV was the pathological volume 
in 2mm laryngeal axial sections delineated by an experienced Pathologist. There 
was no significant difference in the TVs delineated by CT and MRI. The PET 
volume was 28 to 37% smaller than those delineated by CT and MRI, and the 
pathological volume was a further 46% smaller than the PET volume [50]. Some 
of  the  pathological  volumes  were  up  to  107%  larger  than  the  PET  defined 
volumes due to partial volume effects, and the inability of PET to adequately 
detect extra laryngeal extension. CT over estimated the pathological volume in 
65% and MRI in 89% of cases. 
 
2.6.3 Adaptive Thresholds 
Adaptive thresholds use information from parameters within the ROI such as the 
SUVmax to calculate an individual threshold to define the edge for each TV. The 
background uptake is taken into account during this process to aid the distinction   84
of pathological and normal tissue uptake. The threshold is usually then generated 
by an algorithm written into the software 
 
Phantom studies using glass spheres filled with various amounts of 
18FDG have 
been used to create such an algorithm in patients with NSCLC. The results were 
then  applied  to  RT  planning.  This  suggested  that  the  SUVCO  threshold  of 
2.5g/ml reflected TVs that were up to 23% smaller compared to the true phantom 
volume. The SUV was linearly related to the defined volume. Similar volumes at 
42% of the SUVmax were defined with a difference of 67% between the true 
phantom volume and the SUVCO volume [51]. These differences were due to 
tumour heterogeneity, as they were not present within the phantom model. A 
signal to background algorithm was then proposed from this linear relationship to 
define the TV ([0.307 x mean target SUV]+0.588). This provided the adaptive 
threshold for each individual ROI/FV. The inherent difficulty with this method is 
the SUVmean within the ROI is dependent on the volume size.  
 
In SCCHN, Geets et al confirmed that PET TVs were smaller than anatomically 
delineated volumes [52]. This group reported 18 patients with SCCHN (stage II 
to IV) who where due to receive 70Gy in 7 weeks of radical CRT, or accelerated 
RT (70Gy in 6 weeks). All patients underwent CT, MRI and 
18FDG PET imaging 
prior to treatment and after a mean dose of 46Gy. The PET guided TVs were 
automatically delineated by software developed within the institution, and were 
up to 38% smaller than those based on CT and MRI. There was no difference 
between CT and MRI delineated volumes.  
 
The volume change significantly corresponded to an 8% reduction in the mean 
IL parotid dose and 3% reduction in the mean CL parotid dose. The volume 
reduction  corresponded  to  a  smaller  PTV,  improving  the  dose  distribution. 
Imaging  during  treatment  resulted  in  significantly smaller  delineated  TVs  by 
57% for MRI and 42% for CT when compared to the pre treatment planning CT.  
 
Gradient based threshold methods have also been developed to improve 
18FDG 
PET  guided  TV  delineation.  This  process  involves  denoising  (attenuates 
statistical noise), deblurring and then deconvoluting (compensates for the effects   85
of scatter point spread function, and ensures the image is independent from the 
PET camera) the image. Finally vector gradients are estimated across each voxel. 
In phantom studies, the gradient based method under estimated the volume of 
each sphere by 10 to 20% [53]. On review of the work by Daisne et al [50] 
neither the threshold, nor gradient based methods of 
18FDG PET TV delineation 
completely encompassed the macroscopic pathological volume. 
 
The  threshold  methods  reported  all  have  the  disadvantage  of  not  being 
transferable between institutions, and over estimate the true volume by  up to 
68%  [50].  The  relation  of  the  threshold  to  the  signal  to  background  ratio  is 
dependant  on  the  cameras  calibration  curve  and  acquisition  parameters.  The 
parameters  involved  include  the  radio nuclide  administered,  emitted  gamma 
count rate, camera resolution, image reconstruction algorithms, and the use of 
smoothing kernels. These require a different calibration in individual cameras. 
The phantom used to gain this information during calibration (size, shape) will 
affect the parameter obtained. 
 
2.6.4 Halo Edge Detection 
This was initially used in NSCLC [54], and then applied to SCCHN [55]. The 
halo is defined by its specific colour, thin wall, low SUV, and location around 
maximal metabolic activity within the TV. An SUV Cut Off of 2.5g/ml was used 
to define pathological uptake within the nodal and primary sites from normal 
background activity. The halo had an SUV of 2.19g/ml, and in 68% of cases this 
resulted in modification of the final TV. 
 
2.6.5 Comparison of Delineation Methods  
Four different segmentation methods in NSCLC have been directly compared 
(visual interpretation, SUVCO threshold of 2.5g/ml, 40% of the SUVmax, and a 
signal to background ratio based adaptive algorithm). The volume defined by the 
percentage maximum did not encompass all the disease outlined on CT. There 
was a positive correlation between the PET guided TV defined by the SUVCO 
threshold,  signal  to  background  ratio,  and  visual  interpretation  methods 
(p=<0.02,  correlation  co efficient  0.96  to  0.98).  The  SUVmax,  and  tumour 
volume positively correlated (p<0.01) when the 
18FDG PET TV was defined by   86
the  SUVCO  threshold  method  [56].  The  SUVCO  threshold  needed  to  be 
increased in patients with a higher background uptake of 
18FDG to ensure clear 
delineation, because the background uptake varied due to inflammation [57]. 
 
Two studies in SCCHN have compared TV delineation by SUVCO threshold of 
2.5g/ml, PTSUVmax 50%, and an adaptive threshold [58,59] prior to the start of 
RT, and are discussed in section 4.4 of chapter 4.  
 
2.7  Aims  of 
18Fluoro 2 deoxyglucose  CT PET  Guided  Target 
Volume Delineation Study 
 
The method of 
18FDG CT PET guided volume delineation is intricately related to 
the ability to dose escalate and reduce local failure. With no consensus, published 
studies are small and often difficult to replicate due to differences in software. 
The availability of commercial software to automatically delineate volumes will 
increase the need for consensus on volume definition especially if collaborative 
dose escalation studies are to be developed. 
 
Three  methods  of 
18FDG  CT PET  guided  TV  delineation  have  been  directly 
compared  to  assess  the  impact  on  the  delineated  volume  using  an  automatic 
delineation software package by GE Healthcare before and at three time points 
during curative RT or CRT in patients with SCCHN. 
 
These  methods  were:  SUVCO,  PTSUVmax,  and  an  individualised  adaptive 
threshold  (IAT).  Within  each  method  different  thresholds  were  used  (4 
thresholds  for  the  SUVCO,  5  thresholds  for  the  PTSUVmax,  and  1  IAT)  to 
further evaluate the effect of the threshold on volume change. The relationship 
between  dose  and  volume,  and  dose  and  SUVmax  was  assessed  by  the  co 
registration of the individual CT PET data sets at 8 to 18Gy, 36 to 50Gy, and 
66Gy  with  the  pre treatment  CT PET.  The  influence  of  the  SUVmax  on  the 
volume was also evaluated, as well as the background uptake of 
18FDG within 
the CL SCM. Other parameters were analysed included the SUV mean, TLG,   87
and glucose normalised values but these have not been reported in this thesis due 
to space constraints.  
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Chapter 3 
 
Hypoxia  and  Hypoxic  Functional  Imaging  using 
64Cu ATSM in Squamous Cell Carcinoma of the 
Head and  eck  
 
3.1 Radiation Induced Cell Death 
 
3.1.1 Oxygen and Radiation Induced Cell Death 
Orbiting  electrons  within  atoms  are  ionised  by  free  electrons  from  radiation, 
producing a cascade of ionisations.  
 
Ionised electrons interact with water to produce hydrated electrons, and ionised 
water  molecules  (radio-lysis).  The  positively  charged,  unstable,  and  highly 
reactive ionised water breaks down into a hydroxide free radical and hydrogen 
ion.   
 
Single and double-stranded DNA breaks, base changes, protein cross-links with 
DNA and intra-cellular macromolecules are produced by radiation-induced free 
radical damage. Double-strand DNA breaks are lethal to the cell. Repair of the 
damage  may  produce  chromosomal  aberrations  and  altered  gene  expression 
resulting in apoptosis, or mutations that promote cell survival.  
 
Oxygen (O2) is critical to radiation-induced cell death, to fix free radical DNA 
damage, which generates further free radical products. O2 modifies the radiation 
dose to achieve cell kill, quantified by the Oxygen Enhancement Ratio (OER). 
The OER exponentially increases from 1.0 when the oxygen tension is between 0 
to  20  millimetres  of  mercury  (mmHg),  indicating  hypoxic  radio-resistance. 
Under hypoxic conditions three times the radiation dose is needed to achieve the 
same level of cell kill as in normoxia (OER = 1.0) [1].  
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3.2 Hypoxia 
 
3.2.2 Types of Hypoxia 
Hypoxia  is  dynamic  within  the  tumour,  and  develops  when  oxygen  demand 
exceeds supply. The partial pressure of O2 (pO2) of 0.5 to 20mmHg predicts the 
response to fractionated RT [2]. 
 
Acute hypoxia is perfusion related. For example: vessel occlusion or collapse due 
to  trapping  of  red  blood  cells,  high  intra-tumoural  tissue  pressure,  and 
disorganised  neo-vasculature  secondary  to  angiogenesis.  Anaemia,  and 
hypoxaemia contributes to this.   
 
Chronic  hypoxia  occurs  when  cells  are  more  than  70micrometers  ( m),  and 
typically  100  to  200 m  from  the  afferent  capillary,  and  in  the  presence  of 
counter-current blood flow. As cancer cells proliferate, mature cells are displaced 
further  away  from the  vessel, creating an oxygen diffusion  gradient. Chronic 
hypoxia develops as the diffusion distance of oxygen increases, causing radio-
resistance.  
 
3.3 Intra cellular Effects of Hypoxia 
 
Acidosis develops due to the loss of ion gradients, membrane depolarisation, and 
influx of extra-cellular chloride and calcium. At pO2 levels less than 10mmHg 
intra-cellular ATP levels reduce. Mitochondrial function fails as oxygen tensions 
fall below 1mmHg, uncoupling oxidative phosphorylation [3]. 
 
Post-transcriptional  changes  of  hypoxia-regulated  genes  alter  downstream 
signalling of hypoxia-inducible factors.  This promotes cellular differentiation, 
cell cycle arrest, apoptosis and reduced growth or dormancy until improved intra-
cellular conditions (re-oxygenation) develop, and accelerated growth begins. For 
example,  the  G1  to  S  phase  transition  requires  retinoblastoma  protein 
phosphorylation  by  specific  cyclin-dependent  kinase.  In  hypoxia,  cyclin-  98
dependent kinase inhibitor (p27) is induced, preventing cell cycle progression 
into S phase by retinoblastoma protein hypophosphorylation [4]. 
 
Point  mutations,  gene  amplifications,  and  chromosomal  re-arrangements 
immortalise  the  cell,  reducing  apoptosis,  and  promoting  angiogenesis.  This 
increases the stem cell population, further increasing intra-cellular hypoxia. Post-
transcriptional  and  translational  modifications  occur  when  the  pO2  is  1  to 
2mmHg, and gene mutations less than 1mmHg [3].  
 
3.3.1 Hypoxia and Chemo Sensitivity 
Disordered  angiogenesis,  and  increasing  cell  distance  from  the  vasculature 
reduce the access of chemotherapeutic drugs. Hypoxia induced cell cycle arrest 
reduces chemo-sensitivity, accumulating cells in the G2 phase, with a reduced S-
phase fraction [4].  
 
3.4 Detection and Quantification of Hypoxia  
 
3.4.1 Polarographic Oxygen Electrodes 
Polarographic electrodes are the gold standard method for hypoxia detection. A 
negative current applied between the anode and the cathode reduces tissue O2 at 
the cathode tip. The measured pO2 is proportional to the current. Real time in-
vivo acute and chronic hypoxia can be measured.  
 
Electrodes are invasive, and require an accessible superficial ROI. The electrode 
path  distorts  tissue  architecture,  reducing  histological  information.  Abnormal 
readings can occur in regions of fibrosis and necrosis. 
 
Normal tissue has a pO2 of 40 to 60mmHg. Less than 10% of solid tumours are 
in this range, 60% have a pO2 of less than 2.5mmHg, with the median less than 
10mmHg [3].  
 
The electrodes have been used to correlate prognosis and hypoxia in SCCHN. 
Hypoxia  less  than  2.5mmHg  is  the  most  significant  factor  to  affect  patient   99
survival. The 3-year overall survival was 28% when the tumour hypoxic fraction 
was  less  than  5mmHg,  and  36%  if  greater  than  5mmHg.  The  5-year  overall 
survival was 0 to 20% with a greater fraction less than 5mmHg [5].  
 
Hypoxia within LN metastases from SCCHN significantly reduces local control. 
A  LN  pO2  less  than  2.5mmHg  is  an  independent  prognostic  factor  of  local 
control and response to RT [6].  
 
3.4.2 Optical Sensors 
Sensors are based on pO2 dependent changes in the excitation half-life of the 
luminophore within the tip of a fibre-optic probe. Compared to the polarographic 
electrode, pO2 less than 2.5mmHg is difficult to detect, and the probe is static. 
Photo-luminescence  has  been  correlated  with  pimonidazole  (immuno-
histochemistry) IHC in a xenograft SCC laryngeal model [7]. 
 
3.4.3 Immuno Histochemistry 
IHC detects exogenous or endogenous antigens of interest retrieved from fixed 
wax embedded tissue by a multi-step process.  
 
Tissue  is  preserved  prior  to  staining  in  neutral  buffered  formalin  or  other 
formaldehyde based fixative. Formalin produces hydroxymethylene cross-linked 
bridges with intra-cellular amino acids, proteins, or between proteins and nucleic 
acids. Fixation takes at least 24 to 48 hours. Distortion of tissue morphology, 
artefact  formation,  and  masking  of  the  antigen  of  interest  are  minimal. 
Deformation depends on how the tissue is placed in formalin. Large specimens 
require fixation in excess of 48 hours, altering the protein structure, and tissue 
architecture.  
 
The  formalin  fixed  tissue  specimens  are  preserved  by  dehydration  through 
graded alcohols, and then infiltrated with paraffin wax. The wax blocks can then 
be  microtome  sectioned,  histo-pathologically  reviewed  after  H+E  staining  or 
further investigated by IHC methods. 
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The  embedded  tissue  is  dewaxed  and  rehydrated  to  restore  antigen  immuno-
reactivity.  Antigen  specific  high-affinity  antibody  use  ensures  minimal  non-
specific  background  binding.  The  antibody  is  incubated  at  room  temperature 
(time  dependent  on  the  antibody,  antigen  under  investigation,  and  is  usually 
between 10 to 60 minutes) with the rehydrated tissue.  
 
The antibody may be detected by: direct, two step indirect, three step indirect, or 
soluble enzyme immune complex methods. Horseradish peroxidase (HRP) is a 
colourless  substrate  with  an  iron  containing  heme  group  at  its  active  site. 
Exposure  to  hydrogen  peroxide  oxidises  it  to  a  brown  pigment  leading  to 
visualisation of the antibody-bound antigen.  
 
3.4.3.1 Pimonidazole 
Pimonidazole  is  a  2-nitroimidazole.  It  can  be  administered  intra-venously  a 
minimum of 16 hours prior to tissue extraction (to allow for adduct fixation) and 
detected by IHC. It is irreversibly reduced by a 2 step electron reduction when 
the pO2 is less than or equal to 10mmHg, and covalently bound to tissue. Initial 
studies in dogs reported a mean labelled fraction of 72% 24 hours after injection. 
The t1/2 in solid tumours was greater than 3 days [8]. 
 
Pimonidazole  is  reduced  through  a  nitro-radical  anion  intermediate  to 
pimonidazole adducts that bind to intra-cellular sulphydrl containing molecules 
such as glutathione. NADH and NADPH donate electrons in the first step of 
reductive activation to form the nitro-radical anion. The rate of pimonidazole 
oxidative  metabolism  is  controlled  by  the  redox  state  of  NADPH.  Anoxia 
associated  with  mitochondrial  inhibition,  and  the  uncoupling  of  oxidative 
phosphorylation will block NADPH and inhibit pimonidazole adduct formation 
[9].  
 
Figure  3.1  illustrates  the  reduction  of  pimonidazole  in  the  intra-cellular 
environment. 
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Figure 3.1: The reduction of pimonidazole in the intra cellular environment 
 
Normal tissue including: liver, oesophagus, kidney, skin, salivary glands (intra-
lobular ducts), bone marrow and thymus positively stain for pimonidazole [10].  
 
The  kidneys  excrete  69%  of  pimonidazole  within  72  hours  of  injection.  The 
central nervous system toxicity is dose-limiting. The commonest side effects are 
lethargy, flushing, and disorientation. These were reported when pimonidazole 
was  used  as  a  radio-sensitiser,  and  500mg/m
2  was  the  highest  tolerated  dose 
without toxicity [11]. 
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Pre-clinical and clinical studies have validated pimonidazole as a gold standard 
IHC surrogate marker of hypoxia.  
 
Pimonidazole adduct detection in murine xenograft models, correlated with pO2 
polarographic oxygen electrode measurements [12], and areas of poorly perfused 
but  viable  tumour,  which  predicted  radio-sensitivity  [13].  There  was  no 
pimonidazole staining in areas of necrosis. 
 
Clinical studies in patients with SCCHN have used 0.5g/m
2 of pimonidazole. 
Cytoplasmic  adduct  formation  increased  with  increasing  distance  from  blood 
vessels and increasing hypoxia [14].  Keratinisation in SCCs can over-estimate 
binding by up to 30% when co-localised [15]. Studies in SCC cervix [16,17], and 
SCCHN  [18,19]  have  found  pimonidazole  positive  hypoxic  fractions  of  0  to 
79%.  The  2-year  local  control  was  48%  for  hypoxic  tumours  defined  by 
pimonidazole adducts, and 87% for oxic ones. This hypoxic fraction positively 
correlated  with  polarographic  electrode  measurements.  The  pimonidazole 
hypoxic  fraction  was  0.3  to  17.2%  [20].    Loco-regional  recurrence  was 
associated with an average pO2 of 4.1mmHg. Hypoxia reduced the disease-free 
survival by 50% [21]. 
 
3.4.3.2 GLUT1 
GLUT1 expression is mediated by hypoxia inducible factor 1 alpha (HIF1a), and 
reduced  oxidative  phosphorylation.  GLUT1  and  GLUT3  are  up-regulated  in 
cancers, especially SCCHN.  
 
GLUT1  is  detected  within  the  cell  membrane  and  cytoplasm,  with  increased 
intensity surrounding necrotic regions. Staining is absent in connective tissue and 
necrosis.  GLUT1  expression  is  an  independent  predictor  of  metastasis-free 
survival.  There  is  a  weak  correlation  between  GLUT1  staining  and  pO2 
measurements by polarographic electrodes especially at O2 concentrations less 
than  2.5mmHg  [22].  GLUT1  positively  correlated  with  pimonidazole  and 
carbonic anhydrase IX (CAIX) [23].  
   103
In  SCCHN,  the  pattern  of  GLUT1  staining  was  dependent  on  the  degree  of 
differentiation.  In  poorly-differentiated  tumour  regions,  central,  peri-necrotic 
staining was present, in a hypoxia-inducible pattern. Positive staining was within 
the periphery of the tumour in well-differentiated areas. The pattern of GLUT1 
staining was distinguishable from normal epithelium [24]. GLUT1 staining is 
diffuse over the entire tumour in almost all tumours, and this is correlated with 
an  increased  risk  of  distant  metastases,  and  a  poor  5-year  overall  survival 
[25,26]. 
 
3.4.3.3 Carbonic Anhydrase IX 
Carbonic anhydrase maintains intra-cellular pH by catalysing the conversion of 
carbon dioxide to carbonic acid, and is up-regulated in hypoxic conditions.  
 
CAIX is a alpha isoenzyme of this 3 gene family, a transmembrane glycoprotein, 
normally expressed in gastro-intestinal mucosa, and the hepato-biliary system. 
Over  expression  occurs  in  SCCHN,  SCC  cervix,  colo-rectal  cancer,  bladder 
cancer and NSCLC, in peri-necrotic regions, within the cell membrane [27].  
 
In biopsies from patients with SCCHN, the CAIX positive hypoxic fraction was 
between 0 to 39%, and was at smaller distances from the blood vessel at 80 m 
compared  to  pimonidazole  (greater  than  120 m)  [28].  High  expression  was 
associated with a significantly reduced complete response rate of 40% compared 
to 70.9% in patients who underwent CRT. Expression was not related to the 
primary site or stage. Positive staining occurred in areas of low micro-vessel 
density, and was absent within normal HN mucosa [29].  
 
3.4.3.4 Hypoxia Inducible Factor 1a 
HIF  is  an  endogenous  transcription  factor.  It  translocates  to  the  nucleus  in 
hypoxic conditions, and binds to the hypoxia response element. For example: 
GLUT1, CAIX, erythropoietin, and vascular endothelial growth factor to form a 
heterodimer. The beta subunit is constitutively expressed.  
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In hypoxic conditions there is no post-translational ubiquitination of the alpha 
subunit, regulated by propyl hydroxylase. This activates the hypoxia response 
elements on genes. In normoxia, HIF1a is bound to Von Hippel Lindau (VHL) 
protein,  and  endonuclease  1  maintains  the  subunit  in  a  reduced  state.  Up-
regulation of HIF1a mediates adaptive downstream signalling on target genes 
modulating angiogenesis, glycolysis, invasion and metastasis formation. HIF1a 
and  CAIX  expression  are  positively  correlated  because  the  CAIX  promoter 
region is adjacent to the hypoxia response element [30].  
 
In patients with SCCHN treated with RT, HIF1a was over expressed in 94%. 
Expression was focal in 65%, diffuse in 35%, weak in 57%, and negative in 6%. 
HIF1a expression inversely correlated with a complete response to treatment, and 
the  local  failure-free  survival  [31].  Both  HIF1a  and  CAIX  are  independent 
prognostic factors for loco-regional control and survival, with an additive effect 
when co-localised [32]. 
 
3.4.4 Single Gel Electrophoresis 
The COMET assay detects hypoxia within single cells. The single strand DNA 
breaks produced by radiation are detected within the tail of the comet. The length 
of the tail correlates with the single strand DNA breakage and so hypoxia. The 
assay has been correlated with pimonidazole staining [33].  
 
3.4.5 Osteopontin 
Osteopontin is secreted by a calcium binding glycophosphoprotein, and inversely 
associated  with  VHL  activity.  Levels  greater  than  450ng/ml  in  patients  with 
SCCHN were associated with a 50% reduction in loco-regional control, and a 
75% reduction in the 2.5-year overall survival [34].  
 
3.4.6 Gene Analysis 
DNA micro-arrays utilise DNA oligo-nucleotides, containing specific sequences 
detected  by  hybridised  clonal  DNA.  The  micro-array  signal  is  quantified  by 
fluorophore  luminescence.  In  patients  with  SCCHN,  hypoxia  meta-gene 
sequences  clustered  around  hypoxia  regulating  gene  elements  had  increased   105
expression  of  CAIX  and  HIF1a  genes.  The  median  gene  expression  was  an 
independent predictor of recurrence-free survival [35].  
 
3.4.7 Hypoxia Functional Imaging 
This is discussed in detail in section 3.8. 
 
3.5 Hypoxia and Outcome in Squamous Cell Carcinoma of the 
Head and  eck 
 
Hypoxia  is  present  in  50%  of  solid  tumours  negatively  impacting  clinical 
outcome irrespective of tumour size or histology. The pre-treatment pO2 is lower 
in the tumour than normal tissue regardless of stage and patient demographics, 
with significant variability between,  compared to within tumours. Regions of 
local recurrences have a greater hypoxic fraction.  Hypoxia is an independent 
prognostic factor for local control and overall survival in patients with SCCHN 
[3].  
 
3.6 Methods to Overcome the Effects of Hypoxia  
 
3.6.1 Hyper Baric Oxygen 
The  O2  at  100%  concentration,  pressurised  to  101.3kPa  is  delivered  via  a 
compression chamber. Patients are pre-treated for 30 minutes prior to RT.  
 
The  Cochrane  Collaboration  reported  an  absolute  reduction  in  the  5-year 
mortality  from  SCCHN  by  9.2%,  and  improved  local  control.  However  the 
treatment  sensitises  both  tumour  and  normal  tissue and  increased  the  risk  of 
severe  radiation  necrosis  2.3  fold.  This  and  the  increased  rate  of  fits  during 
compression and patient compliance reduced the use of hyperbaric O2 [36]. 
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3.6.2 Radiotherapy with Hypoxic Modifiers 
 
3.6.2.3 Radio Sensitisers 
Nitro-imidazoles have been extensively investigated as hypoxic radio-sensitisers.  
Like  pimonidazole  they  undergo  single  or  multi-step  electron  reductive  bio-
activation  in  hypoxic  conditions.  Radio-sensitisation  is  by  electron  migration 
along  the  DNA  producing  breaks,  or  by  direct  interaction  between  the  2-
nitroimidazole  and  free  radicals  in  DNA.  Significant  gastro-intestinal, 
irreversible peripheral neuropathy, and encephalopathy toxicity occurred initially 
with  metronidazole  and  misonidazole.  The  benefit  from  these  was  minimal 
during RT in SCCHN [37]. 
 
Loco-regional  control  and  overall  survival  significantly  improved  in  SCCHN 
when new generation nitro-imidazoles were added to the RT schedule [38].  
 
Nimorazole has the advantage of reversible peripheral neuropathy. The 1.2g/m
2 
of  nimorazole  daily  in  combination  with  62  to  68Gy  of  radical  RT  had  a 
significant improvement in the 5-year local control rate, which was dependent on 
T and N stage, and the pre-treatment haemoglobin level [39] in patients with 
SCCHN. Late neuro-toxicity was not increased by the addition nimorazole. 
 
3.6.2.1 Carbogen 
Carbogen is a combination of 95% O2 and 5% carbon dioxide, and correlated 
with higher pO2 measurements by polarographic electrodes [40]. The impact of 
chronic hypoxia was reduced by a five fold increase in the pO2 causing a shift to 
the right in the oxygen dissociation curve [41].  
 
Nicotinamide  (amide  derivative  of  Vitamin  B3)  reduces  the  transient  vessel 
occlusion, and improves perfusional related hypoxia [42].   
 
These have been combined with accelerated RT to counteract the effects of acute 
and chronic hypoxia, and repopulation by tumour stem cells. Accelerated RT to 
68Gy in 34 fractions was given to patients with SCCHN in conjunction with 
carbogen breathing prior to RT, and oral nicotinamide once a day, 90 minutes   107
prior  to  RT.  Nausea  and  vomiting  were  the  major  toxicities  in  68%,  and 
nicotinamide was reduced from 80 to 60mg/Kg
 in all patients. The 3-year local 
control rate was 69% [43].  
 
Continuous hyper-fractionated accelerated RT has been combined with carbogen 
and nicotinamide. Disease-free survival in patients with SCCHN improved, but 
gastro-intestinal toxicity was the limiting factor [44]. 
 
3.6.2.2 Tirapazamine 
Tirapazamine  is  a  benzotriazine  that  undergoes  1  step  electron  bio-activated 
reduction  in  hypoxia.  Cell  kill  is  additive  when  combined  with  RT,  and 
synergistic with cisplatin [45].  
 
Patients with SCCHN were treated with cisplatin based CRT and tirapazamine 
(290mg/m
2 1 hour prior to cisplatin weeks 1, 4 and 7, and then weeks 2, 3, 5 and 
6 as a single agent at 160mg/m
2 during RT). Acute radiation toxicity was not 
enhanced. The dose-limiting toxicity was grade 3 and 4 febrile neutropaenia. The 
median 3-year overall survival was 69% [46]. Hypoxia was improved when PET 
imaged with 
18Fluoro-misonidazole (
18FMISO) pre-treatment, and 5 weeks after 
CRT with tirapazamine [47]. 
 
3.6.5 Bio Reductive Drugs 
Quinone  derivatives  such  as  mitomycin  C  are  selectively  bio-activated  in 
hypoxic conditions. Such combinations with RT have been largely replaced by 
cisplatin. The use of mitomycin C continues in CRT for the treatment of SCC of 
the oesophagus and anus.  
 
3.6.1 Altered Fractionation Radiotherapy 
Altered fractionation RT may either be accelerated, hyper-fractionated, or both. 
Altered fractionation in SCCHN had a 3.4% survival benefit at 5 years, which 
reduced to 2% if the total RT dose was not reduced, and 1.7% if the dose was 
reduced. Local control improved by 6.4%, especially within the primary site, but 
reduced over the age of 50. The survival benefit was 8% at 5 years for hyper-
fractionated regimes [48].   108
3.6.3 Haemoglobin Modification 
The haemoglobin concentration is an independent prognostic factor for treatment 
outcome, along with T and N stage, performance status, age, and total radiation 
dose  to  the  primary  site.  The  estimated  5-year  survival  in  patients  with  a 
haemoglobin  less  than  14.5g/dl  in  men,  and  13g/dl  in  women  with  SCCHN 
undergoing curative RT was 21.7% compared to 35.7%. However, loco-regional 
failure increased by 16.2%, and the late grade 3 radiation-induced toxicity by 
19.8% compared to 7.1% at 5 years in anaemic patients [49].  
 
Blood  transfusion  and  recombinant  human  erythropoietin  use  to  improve 
anaemia  in  patients  undergoing  radical  RT  or  CRT  has  been  controversial. 
Recombinant  erythropoietin  has  been  associated  with  poorer  loco-regional 
control  and  overall  survival  in  anaemic  patients  with  SCCHN  [50].  Blood 
transfusions may reduce outcome in patients undergoing radical RT due to the 
presence of interleukins that act as pro-angiogenic tumour growth factors [51]. 
 
3.6.7 Vascular Disrupting Agents 
Vascular  disrupting  agents  such  as  combretastatin  disorganise  microtubule 
function  and  impair  endothelial  cell  adhesion.  Haemorrhagic  tumour  necrosis 
occurs, and response rates to combined treatment with chemotherapy such as 
paclitaxel and RT [52] are increased. Cardiac ischaemia and hypertension are 
significant toxicities. Their use may be limited in patients with SCCHN who 
have co-existent smoking related vascular disease. 
 
3.6.8 Hyperthermia 
Hyperthermia may be local to the tumour, or generalised to the whole body. 
Increasing the temperature when radiation is given simultaneously produces a 
thermal enhancement ratio, increasing tumour cell kill for the same radiation 
dose. Hypoxic cells are more sensitive to heat damage because of low intra-
cellular  pH,  and  reduced  blood  flow  to  the  tumour.  Five  studies  have  been 
published  in  patients  with  HN  cancer,  and  on  meta-analysis  the  combined 
treatment compared to RT alone improved loco-regional control by 18% [53].   109
3.6.9 Dose Escalation 
Detection  of  hypoxia  by  CT-PET  has  increased  interest  in  dose-escalation  to 
overcome hypoxic radio-resistance. Such strategies are possible using IMRT for 
example to spare normal tissue and target dose on the CT-PET defined area. This 
is further discussed in section 3.8.2. 
 
3.7 Perfusion Imaging  
 
Perfusion and hypoxia imaging are intricately linked because well-perfused areas 
may be hypoxic or oxic, and the delivery of the radio-nuclide to the ROI is 
perfusion dependent.  
 
3.7.1 MRI 
Hypoxia detection by MRI exploits the magnetic properties of haemoglobin, the 
use of intra-venous contrast, and nuclear proton concentrations [54]. 
 
For  example,  Blood  Oxygen  Level  Dependent  MRI  utilises  paramagnetic 
deoxyhaemoglobin  in  red  blood  cells  to  detect  acute  hypoxia,  because  the 
haemoglobin concentration within the vessel, and the delivery of red blood cells 
to the ROI are assumed to be proportional to the pO2. Whereas, intra-tumoural 
blood volume (BV), capillary permeability (CP), and tumour oxygenation are 
assessed by dynamic contrast enhanced MRI (DCE-MRI) by the intra-vascular 
retention pattern of micro and macro molecular intra-venous contrast agents.  
 
3.7.2 Dynamic Contrast Enhanced CT 
DCE-CT is used to quantify BV, blood flow (BF), CP, and mean transit time 
(MTT)  of  the  blood  within  a  defined  ROI,  and  has  mainly  been  studied  in 
patients with intra-cerebral vascular events or space occupying lesions. 
 
Perfusion is the BF through a tissue of interest per unit volume. The ROI is 
selected  prior  to  contrast  injection  and  imaging.  An  intra-venous  iodinated 
contrast  agent  is  dynamically  tracked  during  its  first  circulation  through  the 
capillary bed (dynamic first-pass approach). BF is calculated in HU 20 to 40   110
seconds  after  injection  when  a  plateau  is  reached.  The  method  assumes  the 
contrast agent is completely retained in the intra-vascular compartment, and not 
metabolised or absorbed.   
 
The BV can be calculated from the equation below.  
 
BV (ml/100g) =            Concentration of contrast in the tissue of interest 
Concentration of contrast in the artery 
 
Attenuation on CT images is directly related to the amount of contrast injected. 
The BV can then be calculated directly from the equation below. 
 
BV (ml/100g) =            Houndsfield Units in tissue 
Houndsfield Units in the artery 
 
Imaging of BF is better with DCE-CT compared to DCE-MRI because of the 
linear relationship between the BF and contrast within the ROI.  
 
Complex mathematical models have been developed (deconvolution and non-
deconvolution)  to  calculate  BV,  BF  and  MTT  from  DCE-CT  data.  Over-
estimation can occur without this because contrast leaks from the intra-vascular 
into  the  extra-cellular  space  due  to  the  vascular  endothelium  in  tumours  and 
inflammation [55]. 
 
3.7.2.1 Deconvolution Methods 
Parametric  or  non-parametric  deconvolution  is  used  to  calculate  BF.  The 
concentration of contrast after injection in each CT voxel is dependent on the 
impulse residual function and the arterial input function.  
 
The impulse residual function is the concentration of the contrast agent within 
the voxel of interest, at time (t) following the ideal immediate administration of 
the agent. The arterial input function is measured from one of the major arterial 
vessels,  for  example  within  the  HN:  common,  internal  or  external  carotid   111
arteries. The concentration of the contrast within that vessel which supplies the 
voxel of interest at time (t) can then be estimated [56].  
 
Deconvolution  removes  the  effect  of  the  arterial  input  function  on  the  tissue 
concentration curve. The impulse residual function is then only dependent on the 
haemo-dynamics within the voxel of interest. 
 
The MTT is the plateau of the impulse residual function after the increase in the 
concentration  of  the  contrast  within  the  voxel,  and  before  the  concentration 
reduces within the vessels. This is a measure of the time the contrast remains in 
the intra-vascular space within the ROI [55]. 
 
The calculation of BF from the parameters of BV and MTT has been described 
as the Central Volume Principle in the equation below [57]. 
 
BF (ml/100g/min) =    BV (ml/100g) 
   MTT (sec) 
 
The permeability surface area (PS) is a measure of the fractional vascular volume 
and outflux constant divided by the tissue density within the ROI. This may be 
calculated by two methods. 
 
PS (ml/100g/min) =     Outflux constant x fractional vascular volume 
    Tissue density 
 
or 
 
Fraction of extracted tracer = 1 – exp (-PS / Fractional vascular volume) 
 
3.7.2.2  on Deconvolution Methods 
The calculation of BF by this method requires high contrast velocity (10ml/s) 
within the regional vascular bed. BF is often only 7ml/sec, and so rarely used in 
clinical imaging [56].  
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3.7.2.3 Treatment Response  
The ROI must be defined prior to contrast injection and imaging. This is usually 
2 to 4cm, and is assumed to be representative  of the entire tumour.  In large 
necrotic SCCs under or over-estimation may occur. 
 
DCE-CT imaging was performed in patients with SCCHN before and 30 days 
after  completion  of  1  cycle  of  neoadjuvant  cisplatin  and  5-fluorouracil 
chemotherapy.  The  mean  BV,  BF  and  CP  reduced  by  20%,  and  the  MTT 
increased in patients with a clinical response to neoadjuvant chemotherapy [58]. 
Higher  pre-treatment  parameters  were  correlated  with  a  greater  response  to 
treatment.  The  degree  of  contrast  enhancement  within  the  tumour  was 
proportional to the level of neo-vascularisation. Local control reduced by 50% 2 
years after radical RT when the BF was less than the median [59].  
 
3.8 Hypoxia Imaging with CT PET 
 
A number of radio-nuclides have been reported as hypoxia imaging agents in 
CT-PET. The most widely studied is 
18FMISO, but copper bisthiosemicarbazone 
complexes (Cu-ATSM) are increasing in popularity. Others include: 
18Fluoro-
azomycin  arabinoside  (
18FAZA), 
18Fluoro-erythronitroimidazole  (
18FETNIM), 
18Fluoro-etanidazole (
18FETA), a tri-fluorinated etanidazole derivative (
18F-EF3), 
and a penta-fluorinated derivative (
18F-EF5).  
 
3.8.1 
18Fluoro 2 deoxyglucose 
18FDG as a hypoxic radio-nuclide in much debated with no clear consensus. 
 
In  human  SCCHN  cell  lines,  tritiated  fluoro-2-deoxyglucose  uptake  was 
increased by 46% to 120% after hypoxic incubation for 6 hours [60] from a basal 
uptake of 20%, which correlated with increased immuno-cytochemical GLUT1 
expression. In hepatoma xenograft models, the auto-radiographic distribution of 
18FDG  positively  correlated  with  the  IHC  distribution  of  GLUT1,  3  and 
hexokinase 2 expression [61].  
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Correlation  of 
18FDG  uptake  on  microPET  and  auto-radiography  with 
pimonidazole IHC staining has been inconclusive with reduced differentiation of 
uptake  between  hypoxic  and  oxic  regions.  The 
18FDG  uptake  in  a  hypoxic 
SCCVII  model  was  not  correlated  with  the  tumour  pO2  measured  by 
polarographic  electrodes  [62].  The  distribution  of 
18FDG  was  central  and 
homogeneous, compared to the peripheral and heterogeneous uptake of 
18FMISO 
[63] in dual tracer studies.  
 
The  majority  of  studies  in  patients  with  SCCHN  have  also  reported  no 
correlation  of 
18FDG  uptake  with  pO2  polarographic  electrode  measurements 
[64], or 
18FMISO uptake [65,66]. Correlation between 
18FMISO and 
18FDG in 
patients  with  SCCHN  may  indicate  an  aggressive  malignant  phenotype  with 
greater radio-resistance due to chronic hypoxia and high glucose metabolism.  
 
3.8.2 
18Fluoro Misonidazole 
18FMISO has been used to image chronic hypoxia, but it has limited widespread 
use because uptake changes with time and oxygen tension, and spatial resolution 
is poor compared to imaging with 
18FDG [54].
 
 
Similar  to  other  2-nitro-imidazoles, 
18FMISO  in  the  presence  of  hypoxia 
undergoes  a  multi-step  electron  reduction  by  nitro-reductases  in  viable 
mitochondria to an amine radical. This is retained within the cell. In the presence 
of oxygen, this
 radical is oxidised back to 
18FMISO, and diffuses out of the cell. 
18FMISO is lipophilic, and excreted via the kidneys and hepato-biliary system.  
 
Uptake correlates with hypoxia in SCCHN detected by polarographic electrodes 
[54]. In SCCHN, the 
18FMISO defined (tumour to blood ratio of greater than 1.2) 
hypoxic FV was an independent predictor of overall survival. Four hours after 
injection, the tumour to muscle ratio and accumulation of 
18FMISO positively 
correlated with local recurrence [65]. 
 
Hypoxic volumes were assessed with 
18FMISO and 
18FDG PET imaging pre-
treatment, and at week 4 and 8 of cisplatin based CRT with tirapazamine in 
SCCHN. No residual 
18FMISO uptake was seen at the site of 
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treatment, but increased uptake was noted in patients with advanced disease at 
presentation [67]. Studies reported 71% of primary and nodal sites had hypoxia 
defined by 
18FMISO. Loco-regional failure increased in patients with hypoxic 
volumes,  and  in  those  who  did  not  receive  tirapazamine  [68].  The  reduced 
18FMISO uptake may have been due to radio-sensitisation by tirapazamine, and 
re-oxygenation during treatment reducing the hypoxic volume. 
 
Serial 
18FMISO CT-PET hypoxic FVs imaged on day 1 and 4 of curative RT 
correlated  in  71%  of  patients  with  SCCHN  when  voxels  were  compared. 
However if a tumour to blood ratio of greater than or equal to 1.2 was used to 
delineate the volume this reduced to 46% [69] indicating the dynamic nature of 
hypoxia.  
 
Re-oxygenation during RT has been imaged in patients who underwent 
18FMISO 
and 
18FDG PET prior to IMRT with concurrent chemotherapy, and after 20Gy. 
The time-activity retention exhibited three distinct patterns within the hypoxic 
volume:  high  perfusion  and  good  oxygenation,  perfusion  with  hypoxia,  and 
severe hypoxia with reduced perfusion. It was suggested that 
18FMISO imaged 
re-oxygenation in those with less aggressive tumours [70]. 
 
The  retention  pattern  of 
18FMISO  predicted  outcome  to  RT  in  patients  with 
SCCHN. Classic hypoxia was associated with a poor outcome, with high radio-
nuclide retention and lower than average perfusion within the hypoxic volume, 
suggesting inadequate vasculature [71]. Conversely, no radio-nuclide retention 
and normal or greater than average perfusion suggested an efficient vasculature 
and no hypoxia, and so a good prognosis. The retention patterns during curative 
RT, suggested the pattern of 
18FMSIO at 30Gy was predictive of recurrence [72].  
 
Dose escalation to hypoxic volumes requires serial imaging with 
18FMISO, as 
single  pre-treatment  imaging  cannot  adequately  predict  the  time  to  re-
oxygenation following the start of RT in SCCHN. Also 
18FMISO uptake within 
the voxel does not accurately predict the true tumour hypoxia. The 
18FMISO 
hypoxic FV (40% of the SUVmax) defined in patients with SCCHN has been 
dose escalated using IMRT to 110% of the GTV dose (70Gy in 35 fractions) by a   115
uniform escalation across the volume or voxel based dose painting to a maximum 
to 2.4Gy per fraction. The escalated dose was calculated using a tumour control 
probability algorithm [71]. Other methods have used a tumour to blood ratio of 
1.2 to 1.4, and delivered a uniform dose escalation of 20% to a total dose 84Gy, 
but also delivered a 50% dose escalation to 105Gy in 1 patient [73].  
 
Dose escalation of 20 to 50% of 70Gy in 35 fractions significantly improved the 
tumour control probability within hypoxic FVs [74]. No increased normal tissue 
toxicity was noted in these studies. Voxel-based dose painting requires kinetic 
information  from  dynamic  CT-PET  imaging  to  calculate  the  dose  to  an 
individual voxel depending on the retention of the radio-nuclide within it.   
 
However,  as  hypoxia  is  dynamic,  with  changing  oxygen  tensions  within  the 
tumour micro-environment, sequential 
18FMISO imaging can lead not only to 
poor  correlation  of  temporally  distinct  scans  (due  to  mis-registration,  patient 
position and differences in noise) but also to reduced dose optimisation with the 
dose escalation process, as the hypoxic volume changes [75]. 
 
3.8.3
 18Fluoro azomycin arabinoside
 
18FAZA  is  a  lipophilic  nitro-imidazole  with  hypoxia  selectivity.  Uptake  is 
positively  correlated  with  the  immuno-fluorescence  of  pimonidazole  adducts 
[76]. 
18FAZA hypoxic volumes have also been dose escalated to 80.5Gy in 35 
fractions with IMRT in SCCHN patients [77]. 
 
3.8.4
 18Fluoro erythronitroimidazole 
18Fluoro-erythronitroimidazole (FETNIM) is a 2-nitroimidazole hypoxic radio-
nuclide. Uptake is spatially distinct compared to 
18FDG, and hypoxia selective. 
This radio-nuclide is more hydrophilic than 
18FMISO, with hypoxic tumour to 
blood ratios at 2 hours of 1.8 +/- 0.64. The delineated 
18FETNIM hypoxic FV in 
patients  with  SCCHN  negatively  correlated  with  intra-tumoural  pO2 
measurements [78]. 
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3.8.5
 18Fluoro etanidazole 
18Fluoro-etanidazole is 2-nitroimidazole radio-nuclide. Hypoxia selectivity peaks 
2 to 4 hours after injection [79]. Retention at 60 minutes was greater in tumours 
with a higher fraction of pO2 values less than 1mmHg. Retention 60 minutes 
after injection positively correlated with a pO2 less than 5mmHg [80]. Human 
studies are awaited. 
 
3.8.6
 18F EF3 
18F-EF3 is tri-fluorinated etanidazole. A small study in 10 patients with SCCHN 
reported  a  homogeneous  distribution  on  whole  body  static  2D  imaging,  30 
minutes after injection. The tumour to muscle ratio varied between of 1.42 to 
1.87 from 40 to 409 minutes [81]. 
 
 
3.8.7
 18F EF5 
18F-EF5  is  penta-fluorinated  etanidazole.  In  dynamically  acquired  CT-PET 
imaging over 60 minutes, and late static imaging at 2, 3 and 4 hours in patients 
with SCCHN the median tumour to muscle ratio was 1.38 3 hours after injection, 
and did not correlate with 
18FDG uptake [82].  
 
3.9 Copper bis(thiosemicarbazone)  
   
Copper (Cu) is a transitional metal. Bisthiosemicarbazones were first noted to 
have tumouricidal properties in Ehrlich ascites tumour cells. This cyto-toxicity 
was linked to the redox potential of Cu, and correlated with the inhibition of 
mitochondrial oxidative phosphorylation [83,84].  The potential for copper radio-
isotopes to be used as PET imaging agents has been further studied. 
 
3.9.1 Isotopes 
The  availability  of  copper  radio-nuclides  has  increased  for  CT-PET  imaging 
(
60,61,62,and 64Cu), and targeted radio-nuclide therapy (
64 and 67Cu) [85,86]. Table 3.1 
shows the available copper isotopes, and their radio-active properties. 
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Table 3.1: The radio active properties of copper isotopes 
Isotope  Half 
Life  
Emitted 
Radiation 
γ  Energy  of 
Penetrating 
Radiation  
(KeV) 
β+/ β  
 on 
Penetrating 
Radiation 
(KeV) 
Average  
Range of  on 
Penetrating 
Radiation in 
Tissue (mm) 
60Cu  20 
minutes 
β
+ (93%),
  
Electron  
Capture 
(7%) 
511  873  4.4 
61Cu  3.3 
hours 
β
+ (62%),  
Electron  
Capture 
(38%) 
511  527  2.6 
62Cu  9.74 
minutes 
β
+ (98%),  
Electron  
Capture 
(2%) 
511  1315  6.6 
64Cu  12.7  
hours 
β
+  (19%), 
Electron  
Capture 
(41%),  
β
-  (40%) 
511  278  1.4 
66Cu  5.1 
minutes 
β
- (100%)  -  1109  5.6 
67Cu  62 
hours 
β
- (100%)  93  121  0.61 
 
 
60, 61 and 62Cu are suitable for PET imaging due to their positron emission rates.  
 
64Cu  is  used  for  imaging  and  therapy  [87].    The  improved  spatial  resolution 
occurs because of the low initial positron emission rate (19%), but higher doses   118
are  therefore  also  required.  The  high  rate  of  electron  capture  increases  the 
radiation dose to the imaged patient, which has the potential to limit its use in 
clinical  imaging.  The  long  half-life  allows  off  site  production,  without 
measurable loss of activity at the point of administration.  
 
66 and 67Cu can be used for targeted therapies when linked to MABs [88]. 
 
The  appropriateness  of  these  isotopes  for  imaging  depends  on  the  spatial 
resolution, scatter fraction, and noise equivalent count rate. 
60  and  62Cu have a 
higher  sensitivity,  noise  equivalent  count  rate,  and  lower  spatial  resolution 
(6.3mm and 7.2mm respectively) and are used in studies with small molecules 
that have faster kinetics such as perfusion imaging. Conversely, 
61 and 64Cu have 
slower kinetics, associated with lower sensitivity but better spatial resolution of 
5.1mm  and  4.7mm  respectively,  which  compensates  for  the  loss  of  contrast 
within the image [89]. 
 
3.9.2 Copper Bisthiosemicarbazone 
Copper bisthiosemicarbazone complexes were investigated initially as perfusion 
agents  Cu(II)-pyruvaldehdye-bis(N
4methylthiosemicarbazone  (Cu-PTSM)  [90]. 
Cu-PTSM is highly lipophilic with a low molecular weight, and rapidly diffuses 
into cells. The distribution is proportional to BF [91].  
 
3.9.3 Structure 
The lipophilicity and redox potential of 13 
64Cu labelled complexes has been 
investigated in EMT6 mammalian cancer cells at time points up to 1 hour in oxic 
and hypoxic conditions, including re-oxygenation. Figure 3.2 shows the structure 
of Cu-ATSM.  
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Figure 3.2: The chemical structure of copper bis(thiosemicarbazone) 
 
Functional moieties attached to the R1 to 4 positions alter the structure-activity 
relationship, and lipophilicty. Alkylation at the terminal R3 and 4 amino position 
determines lipophilicity, but does not correlate with hypoxia selectivity [92]. 
 
The  total  number  of  alkyl  groups  along  the  diketone  backbone  at  R1  and  2 
positions determined the redox potential and hypoxia selectivity. The potential 
ranged from -0.42 to -0.59V [85,86].  
 
64Cu-ATSM was the most hypoxia selective, while other complexes depending 
on the di-amine backbone were selective in normoxia for example Cu-PTSM. 
Hypoxia selectivity of Cu-ATSM occurred with a reduction potential of less than 
-0.58V when compared to silver/silver chloride [86].  
 
3.9.4 Hypoxia Selectivity and Intra cellular Retention 
Cu-ATSM  was  first  documented  in  the  Langendorff  isolated  perfused  rat 
ischaemic heart model, after 
62Cu-ATSM was found to be selectively reduced by 
hypoxic  rather  than  normoxic  mitochondria  [93].  This  complex  had  a  redox 
potential of -0.297V and was lower than Cu-PTSM, and similar to NADH (-
0.315V).    Cu(II)  is  reduced  by  complex  I  mitochondrial  NADH-dependent 
reduction by NADPH cytochrome p450 reductase [94]. The reduction of 
62Cu-
ATSM was increased four-fold by electron transport inhibition. Eighty percent of 
62Cu-ATSM  was  retained  under  hypoxic  conditions  due  to  the  selectivity  of 
mitochondrial complex I, and the rapidity of cell entry.  
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The  cellular  retention  of  Cu-ATSM  has  been  debated,  and  three  patterns 
proposed.  
 
Firstly, the reduction of Cu(II) to Cu(I)  was thought to promote irreversible 
cellular retention when the ATSM ligand dissociated from the unstable Cu(I) ion 
[93,95,96].  
 
Secondly,  in  EMT6  cells,  Cu-ATSM  complexes  are  taken  up  and  reduced 
regardless of cellular pO2. Reduced Cu(I) was stable after dissociation from the 
ATSM ligand and retained within the cell. Oxygen has the potential to re-oxidise 
the Cu(I) back to Cu(II) which then diffuses out of the cell. Dissociation from the 
ligand  aids  cellular  retention  by  preventing  re-association  with  Cu(I).  This 
hypoxia selectivity of Cu-ATSM [97] depends on the alkyl R1 and R2 position.  
 
Thirdly,  Cu  metabolism  is  homeostatically  maintained  by  import  (Ctr  l)  and 
export  (Menkes  and  Wilsons  protein)  pumps. 
64Cu-ATSM  uptake  rapidly 
increased in anoxic and hypoxic FaDu cells during the first 30 to 60 minutes of 
incubation, and was 2 to 9 times greater in hypoxia compared to normoxia [98]. 
It was proposed that Cu-ATSM translocated across the cell membrane and was 
reduced to a charged Cu(I)-ATSM complex. This either dissociates to Cu(I) and 
ATSM, or is re-oxidised back to Cu(II)-ATSM in the presence of oxygen. The 
Cu(I) then becomes part of the intra-cellular pool of Cu, and is metabolised. The 
Cu pumps are up or down-regulated depending on the intra-cellular environment 
and cell line. Up-regulation increased the efflux of Cu(I) [99], reducing the intra-
cellular Cu(I) pool. Cu(II)-ATSM could then be translocated into the cell, and the 
reduction cycle continued. Chaperone proteins prevent the re-oxidation of Cu(I) 
in the presence of oxygen [100]. 
 
Cu(II)-ATSM may be washed out of cells due to its membrane permeability. 
Cellular  retention  and  washout  are  dependent  on  the  reduction  potential  and 
degree of hypoxia. The ATSM ligand is linked to Cu(I) in high affinity and does 
not  compete  with  the  intra-cellular  pool  of  Cu(I)  binding  proteins  Atx1  and 
Ctr1c. In the presence of these proteins, the ligand will irreversibly transfer the   121
Cu(I)  to  the  binding  protein.  This  suggests  the  preferential  reduction  of  Cu-
ATSM in the presence of intra-cellular hypoxia and anoxia [101]. 
 
3.9.5 Bio Distribution 
64Cu-ATSM and 
64Cu-PTSM in the EMT6 BALB/c mouse tumour model were 
rapidly  cleared  from the blood after 1 minute. A  greater proportion of 
64Cu-
ATSM was within the blood 40 minutes after injection compared to 
64Cu-PTSM. 
This then plateaued and remained up to imaging completion at 4 hours.  
 
Intra-cerebral uptake occurred early and retention was greater for 
64Cu-PTSM. A 
similar pattern was seen in the heart and lung. Cu radio-nuclides are excreted by 
the renal and hepato-biliary systems.  
 
Auto-radiography indicated 
64Cu-ATSM uptake was heterogeneous, and 
64Cu-
PTSM homogenous [102]. At 1 minutes after injection, 20% of the activity was 
bound to plasma proteins and remained stable over the next 60 minutes [103]. 
 
This  data  has  been  computationally  extrapolated  in  5  patients  with  NSCLC 
injected with 480MBq of 
60Cu-ATSM. Uptake was noted in the liver, kidneys 
spleen, and intestine.  It was suggested that 
64Cu-ATSM would remain in the 
blood pool for 1.25 hours (+/- 0.37hours) and the liver for 8.25 hours (+/- 0.17 
hours) after injection [104].  
 
3.9.6 Pre Clinical Studies 
18FMISO uptake
 was 90% less than that of 
64Cu-ATSM in EMT6 cells at 1 hour 
in any hypoxic
 condition [102]. At 2 hours, 
18FMISO uptake was dependent on 
the  oxygen  concentration.  Wash  out  studies  suggested  the  initial  oxygen 
concentration  determined  the  amount  of 
64Cu-ATSM  washed  out  from  the 
incubated cells. 
 
Xenografted mice with SCCVII tumours injected with 
64Cu-ATSM and 
18FMISO 
were PET imaged for 90 minutes while breathing air, and then carbogen. The 
hypoxic  fraction  was  compared  to  grayscale  pimonidazole  staining.  The 
pimonidazole positive fraction was 36.0% in hypoxia, and 7.9% during carbogen   122
breathing. 
18FMISO uptake was modulated depending on the inspired conditions 
but 
64Cu-ATSM was not, suggesting irreversible binding [105]. This confirmed 
the  suggestion  that  Cu(I)  was  retained  within  macromolecules  of  copper 
homeostatic mechanisms [98,106] 
 
In a rat anaplastic prostate tumour model, imaging of 
64Cu-ATSM at 16 to 20 
hours after injection corresponded to the distribution of 
18FMISO. The uptake of 
64Cu-ATSM positively correlated with pO2 at 16 to 20 hours but not at 30 to 120 
minutes after injection. Pimonidazole staining positively correlated with the late 
spatial  distribution  of 
64Cu-ATSM,  but  negatively  correlated  with  the  early 
distribution [107]. In FaDu tumour bearing rats there was no time dependent 
change  in 
64Cu-ATSM  distribution  suggesting  the  uptake  was  dependent  on 
differences  in  chaperone  proteins,  influx  and  efflux  copper  pumps  between 
models. 
 
A single study assessed the binding of 
64Cu-ATSM to serum albumin. In humans 
95%  of  available 
64Cu-ATSM  was  bound  to  this  protein.  Increased  binding 
improves the contrast between hypoxic and oxic tissue on imaging by reducing 
the cellular uptake of 
64Cu-ATSM in areas of high BF in normal tissue [108]. 
 
In  a  rat  9L  gliosarcoma  model  pO2, 
67Cu-ATSM  uptake  on  PET,  and  auto-
radiography were compared. The pO2 was 8mmHg lower in hypoxic conditions, 
which  significantly  increased  the  uptake  of 
67Cu-ATSM  by  37%.  In  100% 
oxygen,  uptake  was  reduced  by  48%.  The  auto-radiographic  distribution  of 
18FDG  was  compared  to 
67Cu-ATSM  and  was  distinctly  different  [106].  Cu-
ATSM  heterogeneously  accumulated  in  the  outer  rim  of  hypoxic  but  viable 
tumour, and not in necrotic regions, and 
18FDG was homogenously distributed in 
the inner rim. 
 
64Cu-ATSM auto-radiography and IHC staining of EF5, pimonidazole, CAIX, 
and Hoescht 33342 (vascular marker) were correlated in various rat xenograft 
(mammary adenocarcinoma, fibrosarcoma, and 9L glioma) models. 
64Cu-ATSM 
uptake was tumour dependent. Correlation suggested the uptake of 
64Cu-ATSM 
was perfusion related in the fibrosarcoma model, and hypoxia related in the other   123
models. [109]. Myocardial ischaemia models indicated Cu-ATSM uptake was 
increased in hypoxic but not necrotic regions. When compared with the perfusion 
(
11C-acetate), the uptake was highest in areas of low perfusion [110,111]. 
 
3.9.7 Clinical Studies  
 
3.9.7.1 Squamous Cell Cancer of the Cervix 
60Cu-ATSM  has  been  investigated  using  1-hour  dynamic  3D  PET  imaging 
immediately after injection in 38 patients in conjunction with an 
18FDG PET.  
 
The  mean  tumour  to  muscle  ratio  was  3.8  +/-  2.0  on  the  30  to  60  minutes 
summed images. The ratio above 3.5 was randomly selected to define hypoxia. 
Progression-free survival was 71% with a tumour to muscle ratio of less than or 
equal to 3.5 compared to 28% for a ratio greater than this. The cause-specific 
survival was 74% and 49% respectively after completion of CRT. 
18FDG uptake 
was  not  related  to  the  ratio  [112].  The  expression  of  CAIX  and  EGFR  was 
significantly increased in patients with a tumour to muscle ratio of greater than 
3.5 [113].  
 
3.9.7.2  on Small Cell Lung Cancer 
Similarly, 481MBq of 
60Cu-ATSM was intra-venously administered followed by 
an immediate 1 hour 3D dynamic PET (frame length:  30 x 2 seconds, 12 x 10 
seconds, 6 x 20 seconds, 5 x 60 seconds, and 10 x 300 seconds) in 19 patients 
with NSCLC. Tumour to muscle ratio of greater than 3.0 was used to define 
hypoxia on the summed 30 to 60 minute images. The mean ratio was 3.4, and 
was 1.5 times greater in patients who failed to respond to treatment [114]. 
 
62Cu-ATSM and 
62Cu-PTSM were investigated in two patients with lung nodules 
of  unknown  significance.  High  uptake  of  both  radio-nuclides  and 
18FDG 
occurred in regions of histologically confirmed SCC [115].  
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3.9.7.3 Squamous Cell Cancer of the Head and  eck 
Chao et al in 2001 [116] reported a patient with SCC of the right tonsil who 
received dose-escalated IMRT to a 
60Cu-ATSM guided FV defined as a tumour 
to muscle ratio twice that of the CL SCM muscle.  
 
The hypoxic FV received 80Gy in 35 fractions  (2.3Gy per fraction), and the CT 
guided  GTV  received  70Gy  in  35  fractions  (2Gy  per  fraction)  treated  by  a 
simultaneous integrated boost (SIB) technique.  
 
3.9.7.4 Rectal Carcinoma 
A single study has used 
60Cu-ATSM to predict response to neoadjuvant CRT. 
Seventeen  patients  with  locally  advanced  rectal  carcinoma  underwent  3D 
dynamic  PET  imaging  2  weeks  prior  to  45Gy  in  25  fractions  of  RT  with 
concurrent 5-fluorouracil. Surgery was performed 6 weeks after the completion 
of treatment.  
 
A tumour to muscle ratio greater than 2.6 was used to define the hypoxia. The 
overall and progression free survival was worse for those with hypoxic tumours. 
Those with a mean tumour to muscle ratio of 2.2 had their tumours down-staged 
on pathological review [117].  
 
3.10 Aims of 
64Cu ATSM CT PET Imaging 
 
18FMISO has a number of limitations in hypoxic CT-PET imaging, and 
64Cu-
ATSM has therefore been investigated as a potential hypoxic radio-nuclide. 
 
64Cu-ATSM uptake and retention was evaluated during CT-PET imaging in 4 
patients who underwent primary surgery for the treatment of locally advanced 
SCCHN. A minimum of 48 hours prior to surgery, 
64Cu-ATSM was injected 
followed by an immediate 1 hour 3D dynamic CT-PET. Further late 3D static 
CT-PET  imaging  was  undertaken  18  hours  after  injection.  To  assess  the 
relationship of 
64Cu-ATSM with perfusion, a DCE-CT was performed after the 
3D dynamic 1 hour CT-PET was completed.   125
The uptake and retention of 
64Cu-ATSM was assessed at 5 to 20 minutes, 40 to 
60 minutes and 18 hours after injection to evaluate the change in uptake with 
time. The resulting tumour to muscle, background, and blood ratios were used to 
define the hypoxic FV with the PETVCAR software.  
 
Eighteen hours prior to surgery, pimonidazole was administered. The patient then 
underwent  their  planned  surgical  procedure.  Photographs  were  taken  intra-
operatively  and  margins  were  inked  if  required  to  aided  orientation  of  the 
specimen. The surgical specimen was fixed in 10% neutral buffered formalin, 
diagnostically  reviewed  and  macroscopically  dissected  by  the  reviewing 
Pathologist.  The  formalin  fixed  cut  specimens  were  wax  embedded,  and 
microtomed sections IHC stained for pimonidazole, GLUT1, CAIX and HIF1a. 
The stained IHC antigen fraction was calculated by a grid and total area method. 
These stained fractions were correlated for co-localisation.  
 
The CT-PET images of 
64Cu-ATSM uptake were correlated at 5 to 20 minutes, 
40  to  60  minutes,  and  18  hours  after  injection  with  the  exogenous,  and 
endogenous  IHC  markers  of  hypoxia.  The  BF  was  correlated  within  a  4cm 
tumour region to the uptake of 
64Cu-ATSM at these time points 
 
This potential validation of 
64Cu-ATSM as a surrogate marker of hypoxia and 
assessment of uptake in relation to BF allows future dose escalation studies to be 
conducted to attempt to overcome hypoxia associated radio-resistance and loco-
regional failure in SCCHN.   126
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Chapter 4 
 
18Fluoro 2 deoxyglucose  CT PET  Guided  Target 
Volume Delineation Study 
 
4.1 Materials and Methods 
 
4.1.1 Trial Recruitment 
Between March 2006 and May 2008, 12 patients were recruited at University 
College Hospitals NHS Foundation Trust, London (UCLH).  
 
Fourteen patients where recruited at Mount Vernon Cancer Centre, Northwood, 
Middlesex  during  this  time  period.  Unfortunately,  because  of  software 
incompatibility issues for image analysis, only the UCLH patients were analysed 
and will be discussed.  
 
Patients due to undergo radical RT (conventional fractionation of 66Gy, 2Gy per 
fraction  treating  daily  Monday  to  Friday,  over  6.5  weeks)  or  CRT  with 
concurrent cisplatin were recruited according to the International Conference of 
Harmonisation Good Clinical Practice (GCP) guidelines. Patients were recruited 
after  eligibility  screening  by  Clinicians  in  the  local  multi disciplinary  team 
meeting.   
 
The eligibility criteria included: age greater than or equal to 50, histological or 
cytological  confirmation  of  SCCHN,  locally  advanced  disease,  Eastern  Co 
operative Oncology Group (ECOG) performance status 0 to 2, life expectancy 
greater than 12 weeks, and no major co morbidities.   
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Patients were excluded from the study if they had a serious inter current illness, 
diabetes mellitus, or psychiatric disorder. 
  
Treatment was planned according to the departmental Head and Neck protocol. 
Patients received concurrent cisplatin chemotherapy (if eligible) either at a dose 
of 75 to 100mg/m
2 day 1, 22 and 43, or 50mg/m
2 per day on day 1 + 2, and day 
29 + 30. The cisplatin dose was reduced if clinically required. 
  
Once recruited, patients could be withdrawn from the study at any point if there 
was: failure of compliance, disease progression, or the development of severe 
inter current illness. Similarly, patients were able to withdraw without reason or 
prejudice and continue their treatment. One patient died in the community from 
aspiration pneumonia prior to starting the protocol and another was withdrawn 
due to rapid disease progression, therefore ten patients underwent the imaging 
protocol. 
 
4.1.2 Investigations Prior to Trial Enrolment 
All patients underwent a full history and clinical examination, performance status 
assessment,  height,  weight,  screening  of  peripheral  blood  samples 
(haematological and biochemical), and assessment of the glomerular filtration 
rate (if concurrent chemotherapy was administered). 
 
4.1.3 Radiotherapy Planning Process 
In line with current practice, an immobilisation shell was made for each patient 
prior to the start of RT and the first CT PET scan. This ensured the accurate 
delivery of RT to the HN and image co registration. All imaging was performed 
with the patient in the shell replicating the treatment position. A flat couch top 
was used on the CT PET scanner and a Therapy Radiographer “Set Up” each 
patient at each scan time point. 
 
RT  was  planned  conventionally  (virtual  simulation  or  TV  delineation  for 
3DCRT)  with  or  without  intra venous  contrast  according  to  the  diagnostic 
imaging, biopsy result, and overall staging information.  
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4.1.4 
18FDG CT PET Examination 
Prior to each CT PET investigation, patients were fasted for 6 hours and their 
blood glucose noted prior to the intra venous administration of 
18FDG. Following 
injection, patients lay flat on a couch, in a warm darkened room for 1 hour, to 
ensure minimal 
18FDG uptake in skeletal muscle.  
 
4.1.5 Timing of Imaging 
Image acquisition was undertaken on a GE Healthcare Discovery (DST 16) CT 
PET scanner.  
 
All patients underwent whole body 3D 
18FDG CT PET imaging 72 hours prior to 
the  start  of  treatment  (0Gy).    Further  CT PET  imaging  of  the  HN  only  was 
planned at 10Gy, 44Gy and 66Gy (days 5, 32 and 47 of treatment). Following 
image acquisition the data was transferred to optical disk for storage within the 
Nuclear Medicine Department. 
 
4.1.6 Patient Characteristics and Clinical Information 
The patients’ notes were reviewed and information collected included:  age, 
gender,  TNM  staging,  primary  site,  presenting  symptoms,  co morbidities, 
prescribed medication, smoking and alcohol, concurrent chemotherapy (number 
of cycles prescribed and received), and radiation dose. 
 
4.1.7 
18FDG Delineation of Metabolically Active Functional Volumes 
In conjunction with Dr I Kayani, Nuclear Medicine Consultant at UCLH, the 
imaging was analysed between October 2008 and October 2009.  
 
4.1.8 PET Volume Computerised Assisted Reading 
The PETVCAR (PET Volume Computerised Assisted Reading) software (GE 
Healthcare Medical Systems, WI, USA) was used in conjunction with the GE 
Advantage Work Stations in the Nuclear Medicine Department at UCLH. The 
Advantage Work Stations are used to routinely report clinical CT PET scans.   
 
PETVCAR is based on the Volume Viewer 3.1 application of the reporting tool. 
It allows automatic image analysis of CT, PET and CT PET images for use either   145
diagnostically to assess disease, or to aid contouring of the ROI that can be used 
in RT planning. The software also allows the analysis of the ROI in the baseline 
scan with the single visit application, and sequential scans can be compared to 
the baseline scan with the multi visit application. Only one time point scan can 
be compared to another time point scan to allow response assessment.  
 
The software automatically highlights and generates the defined ROI from the 
PET  scan  based  on  the  threshold  levels  defined  by  the  user.  The  ROI  is 
automatically propagated when imaging sets are compared, allowing analysis of 
the selected FV. This software package can be used in conjunction with any PET 
radio nuclide  to  measure  the:  FV,  SUVmax  and  mean,  TLG,  and  glucose 
normalised values within each ROI. 
 
4.1.8.1 Retrieval of Patients Scans from Archive 
CT PET imaging was retrieved from the archived databases. Each central clinical 
and research database connected to the Advantage Workstation was selected and 
filtered. The patient was highlighted, along with all the image sets linked to that 
patient’s  identification  number,  and  then  copied  from  archive  to  the  clinical 
workstation.  
 
The  height,  weight  and  blood  glucose  (mmol/l)  were  corroborated  with  the 
written  records  to  ensure  the  correct  calculation  of  the  SUV  and  associated 
parameters. 
 
The AC CT HN, and PET AC data sets were selected for volume delineation 
with PETVCAR. CT and PET images were automatically co registered.   
 
Automatic co registration was reviewed both in relation to soft tissue and bony 
(inner  table  of  skull,  and  cervical  spinous  processes)  anatomy  in  the  axial, 
sagital, and coronal planes and manually adjusted if required. The fused CT PET 
images were represented as 50% CT and 50% PET content. 
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4.1.8.2 Definition of Primary and Lymph  ode Regions of Interest on the Pre 
Treatment Imaging 
The pre treatment image sets were loaded in to the single visit application. The 
ROI was defined on PET (grayscale), CT and fused CT PET imaging. When the 
extent was unclear, for example low grade uptake, imaging and histology reports 
where reviewed to corroborate the findings and adjust the ROI accordingly.  
 
A bookmark was placed over the ROI and reviewed in all planes. The bookmark 
contained a cube shaped boundary box that surrounded the ROI. The size of the 
boundary box was adjusted to avoid overlap with other structures and exclude 
normal tissue from the ROI. The 3D cube contained only the auto contoured and 
segmented ROI.  
 
This process was repeated until all the ROI had been selected and optimised. 
Each ROI was annotated. The exact anatomical location of each ROI was noted 
for reference at a later date. For example 1 = right level II medial node at the 
angle of the mandible. 
 
4.1.8.3 Background Uptake of 
18Fluoro 2 deoxyglucose 
A reference region was defined on each scan to calculate the background SUV. 
This  was  selected  within  SCM.  A  sphere  was  chosen,  resized  and  moved 
depending on the changes that occurred between the scans if appropriate. The 
boundary of the sphere did not extend outside the boundary of the muscle. 
 
4.1.8.4 Volume Definition on Multiple Image Sets 
Similarly, the pre treatment AC CT and PET data sets were selected, as well as 
the data sets at a single other study time point, and loaded into the multi visit 
application.  
 
The pre treatment and comparison scans was automatically co registered (rigid 
registration)  by  the  software,  based  on  the  CT  image  set.  The  minimal  CT 
resolution was 512 x 512 pixels. The computer mouse cursor was moved over the 
pedicles of the cervical vertebra to check the registration quality. The images sets 
were then adjusted in the x, y, and z directions and the co registration was reset.   147
This process was continued until the registration was optimal (within a 1mm 
tolerance) especially within the ROI. Figure 4.1 illustrates an exaggerated mis 
match in co registration a) prior to manual adjustment, and b) after adjustment. 
The pre treatment CT PET was represented in  grayscale, and the comparison 
CT PET in blue. 
 
   
Figure  4.1:  The  co registered  CT PET  data  sets,  a)  prior  to  correction,  and  b)  after 
correction of co registration 
 
The bookmarks with their accompanying boundary boxes defined in the single 
visit application on the pre treatment CT PET were automatically propagated to 
the co registered CT PET either at the time point of 10Gy, 44Gy, or 66Gy. On 
completion,  the  comparison  CT PET  data  set  had  inherited  the  bookmarks 
including:  boundary  box  size,  identification  of  each  ROI,  and  the  segmented 
algorithm used to threshold the ROI.  However, at the time of propagation, the 
software defaulted back to the original threshold factory settings, and therefore 
these required re defining for each ROI on each image set.  
 
This propagation application located the bookmark in the comparison scan to a 
position calculated during the co registration process. Depending on the response 
during treatment, and on review with the Consultant Radiologist, the size of the 
boundary  box,  and  the  location  was  adjusted  if  required  to  optimise 
segmentation. 
 
This process was repeated until each image set had been directly compared with 
the pre treatment imaging. 
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4.1.8.5 Thresholds Used to Define the Functional Volume 
Each  ROI  on  the  scan  was  defined  according  to  the  selected  threshold,  and 
delineation  method  on  the  single  visit  and  multi visit  application.  Table  4.1 
indicates the thresholds used to define each ROI/FV. The SUV was automatically 
normalised to body weight in grams per millilitre (bwg/ml). 
 
Table 4.1: The thresholds used to define each 
18FDG functional volume  
Threshold Method  Thresholds Investigated 
SUV Cut off   2.5, 3.0, 3.5, 4.0 (bwg/ml) 
Percentage of the SUVmax   30, 35, 40, 45, 50  
Individualised Adaptive Threshold  0.5 weighting factor 
 
 
The software defaulted to an SUVCO threshold of 2.0bwg/ml, and a PTSUVmax 
of 50%. The thresholds were therefore individually set for each ROI, at each 
imaging point. The SUV used to contour the volume for the PTSUVmax method 
was individually calculated. The SUVmax was noted within each ROI at each 
imaging  point.  The  percentage  threshold  was  then  calculated  and  the 
corresponding SUV manually entered into the software for each ROI on each 
scan in the single and multi visit application. 
 
4.1.8.6 Calculation of the Individualised Adaptive Threshold 
The IAT was based on the individual SUV within each ROI and the background 
SUV.  
 
An iterative algorithm was used to detect the threshold level that separated the 
ROI  from  the  background  tissue  by  weighting  the  SUVmax  and  SUVmean 
within the ROI with a weighting factor (0 ≤ ω ≤ 1, where 0=background and 
1=object of interest), represented as a Boolean variable. This weighting factor 
was automatically set at 0.5. Figure 4.2 graphically represents the process of FV 
delineation by this method as 4 steps. 
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Figure 4.2: Graphical representation of the individualised adaptive threshold functional 
volume definition 
 
 
Firstly, the intersection of the original PET volume, and the volume of the book 
marked boundary box was defined as volume A. The SUV threshold (t) was 
calculated by multiplying the weighting factor (ω) by the SUVmax, which is 
represented as the turquoise square in volume A. Next the voxels with an SUV 
greater than or equal to the threshold were defined (volume B). This volume was 
then grown by a dilatation morphological operation (d) to represent a halo around 
volume B and is represented as volume C (volume C = d[d(B)]/d(B)) in step 3. 
Next a new threshold was calculated (tnew= SUVmean[B] x ω + SUVmean[C] x 
(1  ω)), and the final volume B was the segmented ROI.  
 
Up to 3 iterations of step three were completed if the new threshold did not equal 
the threshold (t) in step 1. Lastly in step 4, the volume was post processed to 
achieve the final delineated volume (D). The resulting volume from the steps 1 to 
3 was volume C, and volume D therefore is the halo around volume C generated 
by the dilatation morphological operation (D= d[d(C)]/d(C)). 
 
4.1.9 Parameter Definition  
Table 4.2 indicates the parameters recorded for each CT PET scan. 
 
 
Boundary 
Box 
A
B
C
D
Step 
1 
Step 
2 
Step 
3 
Step 
4   150
Table 4.2: Definition of parameters used to assess the 
18FDG functional volume prior to and 
during treatment 
Parameter  Unit  Definition 
Functional Volume  cm
3  Total volume of the ROI 
SUVmax  bwg/ml  Maximum SUV detected within the ROI 
SUVmean  bwg/ml  Mean SUV (SUV in each voxel summed 
within the ROI, and then divided by the 
number of voxels within the ROI) 
Total Lesion Glycolysis   bwg  Volume x SUVmean 
 
 
The parameters of SUVmax, SUVmean, and TLG were also normalised to the 
patient’s blood glucose (mmol/l). 
 
Only the functional volume, SUVmax, and SUV within the background region 
will be discussed in this chapter. 
 
4.1.10 Radiotherapy Structure Sets 
RT Structure Sets (RTSS) were created for each ROI at a SUVCO threshold of 
3.0bwg/ml, and exported from the Advantage Work Station in the RT Planning 
Department at UCLH. 
 
4.2 Statistical Analysis 
 
Statistical advice was sought from the MRC Clinical Trials Centre, 5
th Floor, 90 
Tottenham  Court  Road,  London.  StatsDirect  (StatsDirect  Limited,  Cheshire, 
WA14 4QA , UK) statistical software package was used to analyse the data. The 
data was first assessed for normality using the Shapiro Wilks Test.  
 
The primary 
18FDG FVs were normally distributed, and analysed by the paired t 
test to compare the difference in the sample means either between thresholds, or 
imaging  points,  and  the  simple  linear  regression  (SLR)  model  to  assess  the 
relationship of the outcome variable. For example: FV, SUVmax, to that of the   151
predictor variable for example: dose. The mean, and standard error of the mean 
(SEM) are stated. 
 
The LN 
18FDG FVs were not normally distributed, and were analysed by the 
Wilcoxon Summed Rank Test (WCSRT) to compare two sample populations. 
This was the non parametric equivalent to the paired t test. The SLR model was 
also used. The median and inter quartile range (IQR) are stated. 
 
The  p values  quoted  correspond  to  the  95%  confidence  interval  (CI)  for  the 
sample,  and  one way  test  results  to  assess  for  a  reduction  in  values  with  an 
increase in the radiation dose. 
 
The results are stated according to the imaging time interval for example 0Gy 
(pre treatment imaging), 8 to 18Gy (imaging scheduled for 10Gy), 36 to 50Gy 
(imaging scheduled for 44Gy), and 66Gy, and the actual dose points were used 
for each imaging set for the SLR analysis. 
 
The SLR modelling used the equation:  y= bx + a  
 
y=  Outcome  
b=  Slope of the line of best fit 
x=  Predictor  
a=  Intercept of the line of best fit with the y axis 
 
This was calculated by the least squares method (minimisation of the sum of the 
squares of deviation from a straight line), and allowed a theoretical outcome (y) 
to be calculated from the data. For example radiation dose (x) required to reduce 
the FV to zero. This was used to indicate a potential theoretical dose that would 
be required to eradicate the functional volume during dose escalation studies. 
 
The values for the reference ROI were normally distributed and assessed by the 
parametric paired t test.  
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4.3 Results 
 
4.3.1 Patient Characteristics 
Table 4.3 illustrates the patient characteristics from all ten patients recruited into 
the study who underwent imaging. 
 
Table 4.3: The characteristics of study patients  
Patient  Age  Gender  Primary Site  T M Classification 
1  58  Male  Larynx – Glottis  T3  N0   M0 
2  55  Male  Nasal Cavity  T4  N0   M0 
3  60  Male  Posterior 1/3 of the Tongue  T4  N2c M0 
4  64  Male  Posterior Nasal Space  T3  N2a M0 
5  71  Male  Posterior 1/3 of the Tongue  T4  N0   M0 
6  75  Male  Larynx   Supraglottis  T2  N2c M0 
7  65  Male  Pyriform fossa  T3  N1   M0 
8  56  Female  Tonsil  T3  N2c M0 
9  54  Male  Larynx – Supraglottis  T2  N2b M0 
10  61  Male  Posterior 1/3 of the Tongue  T2  N2c M0 
 
 
Patients 4 and 8 could not be assessed because the CT PET baseline images were 
not optically stored and have been highlighted in blue.  
   
4.3.2 The Imaging Protocol 
All eight patients analysed were imaged within 72 hours of the start of their 
planned radical treatment, and at 66Gy on treatment completion.  
 
For the second imaging point, three patients were imaged at 10Gy according to 
the protocol, four patients were imaged 1 fraction earlier at 8Gy, and one patient 
was imaged 4 fractions later at 18Gy.  
 
No patients were imaged at 44Gy according to the protocol. Five patients were 
imaged 2 fractions earlier at 40Gy, one patient was imaged 3 fractions earlier at   153
38Gy, one patient was imaged 4 fractions earlier at 36Gy, and one patient was 
imaged 3 fractions later at 50Gy. 
 
4.3.3 
18Fluoro 2 deoxyglucose Delineated Functional Volume 
Eight primary and twenty LN 
18FDG positive regions were evaluated in these 
eight patients. 
 
4.3.3.1 Primary Functional Volumes   
 
4.3.3.1.1 SUV Cut Off  
The mean FV and SEM is indicated in table 4.4 for each threshold and expressed 
as a histogram in figure 4.3 with the SEM represented as error bars. 
 
Table 4.4: The mean and standard error of the mean for the delineated primary functional 
volumes by the SUV Cut Off method 
Functional Volume (cm
3)    SUV  Cut  Off 
Threshold 
(bwg/ml)  0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Mean  34.95  30.93  25.98  18.77  2.5 
  SEM  8.42   8.34  8.22  4.94 
Mean  28.31  23.85  18.24  10.36  3.0 
  SEM  7.26  6.70  5.94  2.61 
Mean  23.9  20.09  13.25  6.01  3.5 
SEM  6.64  5.82  4.35  1.70 
Mean  20.65  17.14  10.28  3.70  4.0 
SEM  6.16  5.06  3.38  1.30 
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Figure  4.3:  The  mean 
18FDG  primary  functional  volume  defined  by  the  SUV  Cut  Off 
thresholds 
 
 
There was a highly significant reduction in the FV at each imaging point between 
2.5 to 3.0bwg/ml, 2.5 to 3.5bwg/ml, and 2.5 to 4.0bwg/ml indicated in table 4.5. 
This  was  most  significant  at  0Gy,  and  8  to  18Gy.  The  percentage  reduction 
between  these  thresholds  is  also  shown,  and  was  greatest  between  2.5  and 
4.0bwg/ml thresholds.  
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Table 4.5: The mean percentage, actual reduction, p values, and 95% confidence intervals 
for the primary functional volume delineated by the SUV Cut Off method at each imaging 
point  
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Imaging  
Point 
(Gy) 
 
Mean 
Percentage 
Reduction 
 
Mean 
Reduction 
(cm
3) 
p value  95%  CI 
(cm
3) 
0  18.98  6.64  0.004  2.42   10.84 
  
8 to 18  22.88  7.08  0.004  2.48  11.67  
36 to 50  29.79  7.74  0.011  1.58  13.81 
2.5 to 3.0 
66  44.82  7.36  0.018  0.64   14.08  
0  31.62  11.05  0.002  4.80   17.30 
8 to 18  35.05  10.84  0.004  3.94   17.73  
36 to 50  48.99  12.73  0.01  2.72   22.72  
2.5 to 3.5 
66  67.96  11.16  0.015  1.15   20.90  
0  40.92  14.30  0.002  6.10    22.50  
8 to 18  44.58  3.78  0.005  4.65   22.92  
36 to 50  60.44  15.70  0.01  3.30   28.10  
2.5 to 4.0 
66  80.29  13.19  0.013  2.06   24.31  
 
 
 
Table 4.6 indicates the percentage and actual reduction in primary volume at 
each delineation threshold when the pre treatment volume was compared to: 8 to 
18Gy, 36 to 50Gy, and 66Gy. There was no significant reduction in the FV at 8 
to 18Gy compared to 0Gy at any SUVCO delineation threshold. However, there 
was a highly significant reduction at 66Gy and 36 to 50Gy compared to 0Gy at 
3.0, 3.5, and 4.0bwg/ml thresholds only. This was greatest at 66Gy, and most 
significant when all imaging points were compared at the 3.0bwg/ml threshold. 
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Table 4.6: The mean percentage, actual reduction, p values and 95% confidence intervals 
between the imaging points for the primary functional volume delineated at each SUV Cut 
Off threshold 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Compared 
Imaging  
Points 
(Gy) 
 
Mean 
Percentage 
Reduction 
 
Mean 
Reduction 
(cm
3) 
p value  95%  CI 
(cm
3) 
0 to  
8 18 
18.96  4.03  0.071   0.46 to 
+8.51 
0 to  
36 50 
28.98  8.98  0.067   18.78 to 
+0.83 
2.5 
0 to 66  53.22  18.19  0.004   30.11 to  
 6.26 
0 to  
8 18 
25.54  4.47  0.072   0.47 to 
+8.69 
0 to  
36 50 
38.29  10.08  0.013   18.60 to  
 1.54 
3.0 
0 to 66  63.68  18.98  0.007   32.86 to  
 5.08 
0 to  
8 18 
25.92  3.81  0.073   0.48 to 
+8.1 
0 to  
36 50 
44.23  10.65  0.01   19.07 to  
 2.22 
3.5 
0 to 66  67.97  18.64  0.009   32.86 to  
 4.41 
0 to  
8 18 
26.39  3.51  0.101   0.88 to 
+7.9 
0 to  
36 50 
46.23  10.38  0.011   18.76 to  
 1.98 
4.0 
0 to 66  67.05  17.41  0.01   31.22 to  
 3.61 
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Figure  4.4a  illustrates  the  pre treatment  volume
  delineated  by  the  SUVCO 
threshold of 2.5bwg/ml for patient 6 in green (t1) using the PETVCAR software. 
This volume is located inside the green boundary box. Also, the LN regions (t2 
to 4), and the reference region (Ref) for the background SUV are delineated in 
red. Figure 4.4b illustrates the corresponding coronal CT image. 
 
       
 
Figure 4.4a and b: The pre treatment primary functional volume defined by the SUV Cut 
Off threshold of 2.5bwg/ml for patient 6. a) Axial fused CT PET, and b) the coronal CT 
PET image  
 
 
The reduction in the primary FV during treatment is shown in figures 4.5a to d. 
Figure  4.5a  illustrates  the  pre treatment 
18FDG  primary  FV  delineated  at 
3.5bwg/ml on the CT PET axial image (primary volume delineated in green (t1) 
surrounded by a green boundary box) in patient 6. Similarly, the LN regions (t3 
4), and reference ROI (Ref) are delineated in red. Figure 4.5b, c, and d show this 
at 18Gy, 40Gy, and 66Gy respectively. There is also a reduction in the intensity 
of 
18FDG  uptake  in  the  defined  ROI  during  treatment  compared  to  the  pre 
treatment level. 
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Figure 4.5a to d: The CT PET  primary functional volume for patient 6 defined  by the 
3.5bwg/ml SUV Cut Off threshold at 0Gy a), 18Gy b), 40Gy c), and 66Gy  
 
 
This  reduction  in  the  primary  FV  was  confirmed  by  a  significant  negative 
correlation with the radiation dose for the SUVCO thresholds of 3.0, 3.5, and 
4.0bwg/ml.  This negative correlation was greatest for the primary FV defined by 
the  SUVCO  threshold  of  4.0bwg/ml  (p value  0.008,  correlation  co efficient   
0.468, 95% CI  0.71 to  0.14cm
3), and this has been illustrated as an example in 
figure 4.6. The line of best fit is in green. Each circle on the graph represents a 
separate primary FV at each imaging point. The significance values for the other 
thresholds are indicated in table 1 Appendix 1, as well as the graphs in Appendix 
2 (figure 1a to c). 
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Figure 4.6: The negative correlation between the radiation dose and the primary functional 
volume delineated by the 4.0bwg/ml SUV Cut Off threshold  
 
The theoretical radiation dose required to reduce the primary FV to zero was 
calculated from the slope of the line to potentially guide future dose escalation 
studies. The equation used for the primary FV defined by the SUVCO threshold 
of 4.0bwg/ml is indicated as an example. The equations for the other thresholds 
are documented in Appendix 3 (Equations 1 to 3). 
 
SUV Cut Off 4.0bwg/ml:  FV (cm
3) =   0.244Dose(Gy) + 20.056  
 
The calculated doses required for possible dose escalation studies from these 
equations would be: 152Gy for the primary FV delineated by the 2.5bwg/ml 
threshold, 110Gy for the 3.0bwg/ml, 92Gy for the 3.5bwg/ml, and 84Gy for the 
4.0bwg/ml thresholded primary FV. 
 
4.3.3.1.2 Percentage of the SUVmax   
The mean primary FV delineated by the PTSUVmax and the corresponding SEM 
is illustrated in table 4.7. Figure 4.7 illustrates these values as a histogram. Most 
strikingly, these delineated volumes increase, especially at 66Gy.  
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Table 4.7: The mean and standard error of the mean for the delineated primary functional 
volumes by the percentage threshold of the SUVmax method 
Functional Volume (cm
3)    Percentage 
Threshold  of 
the SUVmax 
(%) 
0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Mean  23.55  24.13  27.64  55.51  30 
  SEM  5.17  4.70  6.45  16.14 
Mean  19.16  20.15  20.93  44.74  35 
  SEM  4.26  4.07  4.95  13.07 
Mean  16.18  16.76  15.16  35.04  40 
SEM  3.51  3.47  3.00  10.00 
Mean  13.41  13.61  11.58  28.36  45 
SEM  2.85  2.75  2.07  8.32 
Mean  10.95  10.94  8.44  21.44  50 
SEM  2.49  2.20  1.54  6.17 
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Figure 4.7: The mean 
18FDG defined primary functional volume by the percentage of the 
SUVmax method   161
Table 4.8 indicates the highly significant reduction in the primary FV at each 
imaging point between 30 and 35%, 30 and 40%, 30 and 45%, and 30 and 50%. 
This was most significant at 0 and 36 to 50Gy. 
 
Table 4.8: The mean percentage, actual reduction, p values, and 95% confidence intervals 
for the primary functional volume delineated by the percentage of the SUVmax method at 
each imaging point  
Percentage 
Threshold  of 
the SUVmax 
(%) 
Imaging  
Point 
(Gy) 
 
Mean 
Percentage 
Reduction 
 
Mean 
Reduction 
(cm
3) 
p value  95%  CI 
(cm
3) 
0  18.63  4.39  0.001  1.97   6.86  
8 to 18  6.48  3.98  0.001  1.83   6.12  
36 to 50  24.24  6.70  0.008  1.70   11.70  
30 to 35 
66  9.89  9.50  0.029  0.45   19.45  
0  25.52  7.36  0.003   2.86   11.86  
8 to 18  26.05  7.36  0.002  3.12   11.61  
36 to 50  25.39  12.48  0.007  3.25   21.69  
30 to 40 
66  30.67  18.0  0.022  0.68   35.31  
0  40.08  10.14  0.003  3.92   1 6.34  
8 to 18  36.20  10.51  0.001  5.00   16.03  
36 to 50  35.20  16.06  0.006  4.88   27.24 
30 to 45 
66  39.75  23.87  0.017  2.27   45.48  
0  51.38  12.60  0.002  5.48   19.72 
8 to 18  46.53  13.19  0.001  6.52   19.86 
36 to 50  43.81  19.15  0.005  6.24   32.06  
30 to 50 
66  50.71  29.94  0.015  3.70   56.17 
 
 
Unlike  the  primary  FV  delineated  by  the  SUVCO  thresholds,  there  was  no 
significant  reduction  in  volume  at  8  to  18Gy,  36  to  50Gy  and  60Gy  when 
compared to the pre treatment volume, which is indicated in table 4.9.    162
There was an increase in the mean primary FV delineated by the 30 to 45% of 
the SUVmax threshold between 0 to 18Gy, and in all thresholds between 36 to 
50Gy and 66Gy when compared to the pre treatment FV. However, this increase 
was not significant. 
 
The largest increase was by 152.65% at the 50% of the SUVmax threshold. The 
increase between these two dose points was between 108.68% and 144.98% from 
30% to 45% of the SUVmax threshold. 
 
When the percentage change was reviewed throughout the entire radiation dose 
the  volume  increased  between  35.73%  and  133.49%.  The  increase  was  the 
greatest (133.49%) at the 35% of the SUVmax threshold. 
 
Table 4.9: The mean percentage, actual change, p values and 95% confidence intervals for 
the  primary  functional  volumes  delineated  by  the  percentage  of  the  SUVmax  threshold 
between each imaging point  
Percentage 
Threshold  of 
the SUVmax 
(%) 
Compared 
Imaging  
Points 
(Gy) 
 
Mean 
Percentage 
Change 
 
Mean 
Change 
(cm
3) 
p value  95%  CI 
(cm
3) 
0 to  
8 18 
+2.44  +0.58  0.414   6.67 to 
+5.52 
0 to  
36 50 
+17.35  +4.09  0.211   7.26 to 
+15.44 
30 
0 to 66  +35.73  +25.53  0.065   9.76 to 
+60.82 
0 to  
8 18 
+5.16  +0.99  0.355   7.06 to 
+5.08 
0 to  
36 50 
+9.26  +1.78  0.321   6.88 to 
+10.43 
35 
0 to 66  +133.49  +20.41  0.071   8.79 to 
+49.61   163
0 to  
8 18 
+3.54  +0.58  0.401   5.81 to 
+4.66 
0 to  
36 50 
 6.34   1.03  0.334   6.43 to 
+4.38 
40 
0 to 66  +116.48  +14.89  0.078   7.29 to 
+37.07 
0 to  
8 18 
+1.49  +0.20  0.453   4.05 to 
+3.65 
0 to  
36 50 
 13.70   1.837  0.165   6.00 to 
+2.33 
45 
0 to 66  +111.43  +11.79  0.091   7.01 to 
+30.58 
0 to  
8 18 
 0.12  +0.01  0.496   3.17 to 
+3.20 
0 to  
36 50 
 22.49   2.462  0.075   6.06 to 
+1.139 
50 
0 to 66  +95.82  +8.19  0.101   5.59 to 
21.96 
 
 
Figure  4.8  a  to  d  illustrates  the  primary  FV  in  patient  6  at  the  30%  of  the 
SUVmax threshold on the axial CT PET fused images. The FV is delineated in 
green (t1), and in figures b and c the green boundary box is visualised. The LN 
FVs (t3 and 4), and the reference region (Ref) are delineated in red. Figure 4.8a 
contours the primary FV at 0Gy, b) at 18Gy, c) at 40Gy, and d) at 66Gy.  
 
With  increasing  radiation  dose,  the  intensity  of  the 
18FDG  uptake  within  the 
primary region has reduced especially at 66Gy, but the defined volume is visibly 
larger  and  virtually  encompasses  the  entire  boundary  box.  This  is  especially 
evident when compared to the reduction in the primary FV delineated by the 
SUVCO method in figure 4.5a to d. 
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Figure  4.8a  to  d:  The 
18FDG  primary  functional  volume  delineated  by  the  30%  of  the 
SUVmax threshold in patient 6 at 0Gy a), 18Gy b), 40Gy c), and 66Gy d)  
 
 
The SLR model confirmed there was no correlation between the primary FV 
delineated by the SUVmax threshold and the radiation dose. The line of best fit 
suggested a trend towards a positive correlation, and this is illustrated for the 
30% threshold of the SUVmax in figure 4.9. Graphs for other thresholds are in 
figure 2a to d Appendix 2. 
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Figure 4.9: Simple linear regression between the radiation dose and the primary functional 
volume delineated by the 30% of the SUVmax threshold 
 
 
The theoretical dose required to reduce the delineated primary FV by this method 
has been calculated for each percentage of the SUVmax threshold. The equation 
used for the 30% threshold is shown. This illustrates the increase in the FV with 
each increase in radiation dose. For example, at 66Gy the FV delineated at this 
30% threshold of the SUVmax would be 44.01cm
3, and at 80Gy this volume 
would theoretically increase to 48.91cm
3, which equates to a 10.02% increase in 
volume. 
 
30% of the SUVmax:  FV (cm
3) =  0.350Dose(Gy) + 20.913 
 
However,  at  the  50%  of  the  SUVmax  threshold,  this  was  less  evident.  For 
example this theoretical FV would be 16.09cm
3 at 66Gy, and 17.50cm
3, and 
equals an 8.06% increase in volume. 
 
The equations for the other percentage of the SUVmax delineation thresholds are 
in Appendix 3 (Equations 4 to 7). 
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4.3.3.1.3 Individualised Adaptive Threshold 
The mean pre treatment FV was 23.82cm
3 (SE of mean 6.72cm
3). At 8 to 18Gy, 
this had reduced to 18.46cm
3 (SE of mean 5.73cm
3), and at 36 to 50Gy the 
volume had further  reduced to 14.63cm
3 (SE of mean 6.41cm
3). However  at 
66Gy this volume had increased to 20.52cm
3 (SE of mean 15.92cm
3). This is 
illustrated in the histogram in figure 4.10.  
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Figure 4.10: The mean 
18FDG primary functional volume delineated by the individualised 
adaptive threshold   
 
 
There was no significant difference in the primary FV delineated by the IAT 
method between 8 to 18Gy, 36 to 50Gy, and 66Gy when compared to the pre 
treatment volume.  
 
The mean absolute reduction was 5.35cm
3 at 8 to 18Gy, and the mean percentage 
reduction was 22.46% compared to the pre treatment volume. At 36 to 50Gy, the 
absolute  reduction  was  9.19cm
3,  and  the  percentage  reduction  was  38.58%. 
However at 66Gy the mean reduction was 5.86cm
3, and the mean percentage 
change was 22.83% when compared to the 0Gy volume, even though the data 
illustrates an increase in volume. This is due to the large volume changes across   167
data. The range of FVs at 0Gy was 4.4 to 60.2cm
3,
 compared to
 0 to 122.2cm
3 at 
66Gy. 
 
This was confirmed by no significant correlation between the delineated FV and 
radiation dose (p value 0.65, correlation co efficient  0.083, 95% CI for the co 
efficient  0.42 to 0.27cm
3), which is illustrated in figure 3 of Appendix 2. 
 
The theoretical dose required in escalation studies increased in a similar manner 
to that by the PTSUVmax. 
 
Individualised Adaptive Threshold:  
FV  =  0.0786Dose(Gy) + 21.108 
 
The theoretical FV at 66Gy was 26.29cm
3, and at 80Gy was 27.39 cm
3, and 
equalled a 4.01% increase between these dose points.  
 
 
4.3.3.2 Lymph  ode Functional Volumes   
 
4.3.3.2.1 SUV Cut Off 
The  median  LN  FV  and  the  corresponding  SEM  delineated  by  the  SUVCO 
method are illustrated in table 4.10.  
 
The box and whisker plot in figure 4.11 illustrates the median delineated LN FV 
by the 2.5bwg/ml SUVCO threshold. The box represents the 25
th to the 75
th 
centile. The colour change from teal to grey represents the median value of the 
data. The range of the data points is indicated by the error bars at either end of 
the box plot on the graph. 
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Table 4.10: The median and inter quartile range for the lymph node functional volumes 
delineated by the SUV Cut Off thresholds 
Functional Volume (cm
3)    SUV  Cut  Off 
Threshold 
(bwg/ml)  0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Median  2.65  1.15  0.40  0.00  2.5 
  IQR  9.00  7.50  4.40  0.70 
Median  1.70  0.40  0.05  0.00  3.0 
  IQR  7.60  5.70  3.00  0.10 
Median  1.20  0.10  0.00  0.00  3.5 
IQR  6.50  4.90  1.90  0.00 
Median  0.80  0.05  0.00  0.00  4.0 
IQR  5.60  4.30  1.10  0.00 
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Figure 4.11: The median 
18FDG lymph node functional volume delineated by the 2.5bwg/ml 
SUV Cut Off threshold 
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The  box  and  whisker  plots  for  the  LN  FV  delineated  by  the  3.0,  3.5  and 
4.0bwg/ml thresholds are illustrated in figures 4a to c of Appendix 2. 
 
Similar to the primary FV delineated by this method, there was a significant 
reduction  between  thresholds  at  each  imaging  point  when  compared  to  the 
volume defined by the 2.5bwg/ml threshold, and at 36 to 50Gy, and 66Gy when 
compared to the FV defined at 0Gy by each threshold. 
 
There  was  a  highly  significant  reduction  at  each  imaging  point  between  the 
SUVCO thresholds of 2.5 to 3.0bwg/ml, 2.5 to 3.5bwg/ml, and 2.5 to 4.0bwg/ml 
(p<0.0001 to 0.007, median reduction 0.20 to 1.90cm
3, 95% CI 0.00 to 3.90cm
3). 
At  66Gy,  the  percentage  reduction  could  not  be  calculated  between  the 
thresholds because the median FV was zero when delineated by the 2.5bwg/ml 
threshold. Table 3 in Appendix 1 indicates these results in full. 
 
There was no significant volume change between 0Gy and 8 to 18Gy for all the 
SUVCO  thresholds  investigated.  However  between  0Gy  and  36  to  50Gy 
(p<0.0001, median reduction 1.85 to 3.50cm
3, 95% CI 0.25 to 5.90cm
3) and 0Gy 
and  66Gy  (p<0.0002,  median  reduction  2.00  to  3.53cm
3,  95%  CI  0.25  to 
57.05cm
3) there was a highly significant reduction at each threshold. This was 
greatest at 66Gy for the 3.0bwg/ml SUVCO threshold. Table 4 in Appendix 1 
indicates these results in full. 
 
Figure  4.12a  to  d  shows  the  fused  CT PET  axial  images  of  patient  6  at  the 
SUVCO threshold of 3.5bwg/ml. The most representative slice of the second LN 
FV is delineated in green (t3). The reference region (Ref) and two other FVs 
present on these images (the primary (t1) and another LN (t4)) are delineated in 
red.  The images represent the FVs at the doses of 0Gy a), 18Gy b), 40Gy c), and 
66Gy  d).  The  reduction  in  volume  and 
18FDG  avidity  with  each  increase  in 
radiation dose is visualised and reflects that seen in the primary FV delineated by 
this method in figure 4.5 a to d. 
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Figure 4.12a to d: The 
18FDG lymph node functional volume delineated by the SUV Cut Off 
threshold of 3.5bwg/ml in patient 6 at 0Gy a), 10Gy b), 40Gy c), and 66Gy  
 
 
The FV reduction was confirmed by a significant negative correlation between 
the radiation dose and delineated LN volume at each SUVCO threshold. This 
was most significant for the SUVCO threshold of 3.0bwg/ml (p value  0.009, 
correlation  co efficient   0.291,  95%  CI   0.48  to   0.08cm
3).  However  the 
correlation co efficients were less than those for the primary FV delineated by 
the same thresholds. The correlation co efficient values for the other thresholds 
are in table 5 of Appendix 1, and graphs in figure 5a to d in Appendix 2. 
  
An example of the equation used to calculate the theoretical dose required to 
eradicate the LN FV delineated by each SUVCO threshold is shown. Equations 8 
to 10 in Appendix 3 illustrate the others. 
 
SUV Cut Off 3.0bwg/ml:  FV (cm
3) =   0.089Dose(Gy) + 5.473 
 
d  c 
b  a   171
The potential doses required for this are lower than those for the primary FV 
delineated by this method. These are 68Gy for the FV delineated by the SUVCO 
threshold of 2.5bwg/ml, 62Gy for 3.0bwg/ml, 60Gy for 3.5bwg/ml, and 58Gy for 
LN FVs delineated by the 4.0bwg/ml threshold.  
 
There was a 55.26% reduction in dose required to reduce the LN FV to zero 
compared to the primary FV to zero at the SUVCO threshold of 2.5bwg/ml. This 
reduction was 43.64%, 34.78%, and 30.95%, at the respective thresholds of 3.0, 
3.5, and 4.0bwg/ml. 
 
4.3.3.2.2 Percentage of the SUVmax   
The median LN FV delineated at each PTSUVmax, and the corresponding IQR 
are shown in table 4.11. These values increase for all delineation thresholds after 
36Gy.  This pattern was also exhibited by the primary FV delineated by this 
method. 
 
Table 4.11: The median and inter quartile range for the lymph node functional volumes 
delineated by the percentage thresholds of the SUVmax  
Functional Volume (cm
3)    Percentage 
Threshold  of 
the SUVmax 
(%) 
0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Median  4.25  4.40  4.50  4.50  30 
  IQR  5.90  4.80  6.40  4.30 
Median  4.20  3.60  4.45  4.50  35 
  IQR  4.70  4.30  4.10  4.30 
Median  3.80  3.25  4.00  4.40  40 
IQR  5.00  3.50  3.70  2.60 
Median  3.10  2.90  3.35  3.90  45 
IQR  4.70  2.90  2.90  2.20 
Median  2.70  2.60  3.00  3.40  50 
IQR  4.10  2.30  1.80  2.30 
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Figure 4.13 illustrates an example of the box and whisker plot for the LN FV 
delineated by the 45% of the SUVmax threshold. Figure 6a to d in Appendix 2 
illustrates these graphs for the remaining thresholds. 
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Figure  4.13:  The  median 
18FDG  lymph  node  functional  volume  delineated  by  the  45% 
threshold of the SUVmax 
 
There was no significant reduction in the FV at each imaging point between the 
30% and 35% threshold. However, there was a highly significant FV reduction at 
each imaging point between the 40%, 45%, and 50% when compared to the 
volume  defined  by  the  30%  of  the  SUVmax  threshold  (p<0.0001,  median 
reduction 0.40 to 2.63cm
3, 95% CI 0.50 to 5.70cm
3). Table 6 in Appendix 1 
indicates these results in full. 
 
There was no significant difference in the FV at 8 to 18Gy, 36 to 50Gy, and 
66Gy  compared  to  the  pre treatment  volume  at  each  threshold.  Table  7  in 
Appendix 1 indicates these results in full. 
 
Figure 4.14a to d illustrates the delineated LN at 30% of the SUVmax in green 
(t3). The primary site (t1) and the reference region (Ref) are delineated in red at 
0Gy a), 10Gy b), 40Gy c), and 66Gy d) for patient 6. The FV reduced in size   173
between 0Gy and 40Gy (Figures 4.14a to c). At 66Gy, although the intensity of 
18FDG uptake was reduced, the volume had increased compared to the 40Gy 
image. In this figure 4.14d this LN FV has been defined as the entire boundary 
box. This was similar to the change in the primary FV delineated by this method 
in figure 4.8 a to d, and different to the LN FV defined by the SUVCO threshold 
in figure 4.12 a to d. 
 
         
     
Figure 4.14a to d: The 
18FDG lymph node functional volume delineated by the 30% of the 
SUVmax threshold in patient 6 at 0Gy a), 10Gy b), 40Gy c), and 66Gy d)  
 
 
The lack of volume change with radiation dose was confirmed by no significant 
correlation on SLR modelling when the LN FV was defined by the PTSUVmax 
method. Table 8 in Appendix 1 documents the statistical results, with a trend 
towards  a  positive  correlation  co efficient.  Figure  7a  to  e  in  Appendix  2 
illustrates this in graphical form.  
 
a  b 
c  d   174
The theoretical LN FV calculated from this model increased with radiation dose. 
An  example  of  this  increase  is  shown  and  the  remaining  equations  are  in 
Appendix 3 (Equations 11 to14). 
 
30% of the SUVmax:  FV (cm
3) =  0.034Dose(Gy) + 9.046 
 
Similarly,  the  theoretical  FV  at  66Gy  was  11.29cm
3  and  at  80Gy  this  was 
11.76cm
3. This equalled a 3.99% increase between these points. The theoretical 
LN FV delineated by the 50% threshold of the SUVmax at 66Gy was 6.05cm
3, 
and at 80Gy this was 6.37cm
3. This equalled a 5.01% increase between these 
points 
 
4.3.3.2.3 Individualised Adaptive Threshold 
Figure 4.15 illustrates the median LN FV delineated by the IAT method as a box 
and whisker plot graph. At 0Gy the median volume was 2.50cm
3 (IQR 4.90cm
3). 
This reduced to 2.15cm
3 (IQR 3.20cm
3) at 8 to 18Gy, 0.95cm
3 (IQR 2.20cm
3) at 
36 to 50Gy, and 0.05cm
3 (IQR 1.90cm
3) at 66Gy. 
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Figure  4.15:  The  median 
18FDG  lymph  node  functional  volume  delineated  by  the 
individualised adaptive threshold   175
The absolute median difference at 8 to 18Gy compared to 0Gy was +1.23cm
3 (p 
value 0.996, 95% CI +0.35 to + 2.55cm
3), and the percentage difference was 
14%.  At 36 to 50Gy the LN FV significantly reduced by  2.15cm
3 (p value 
0.0005, 95% CI  3.95 to  1.05cm
3), which equalled a 62% reduction. Finally 
between 66Gy and 0Gy there was a further significant reduction of  3.40cm
3 (p 
value <0.0001, 95% CI  6.6 to  1.55cm
3), which equated to a 98% reduction in 
volume. 
 
Similar to the primary FV delineated by this method, there was no correlation 
between the defined LN FV and radiation dose (p value 0.501, correlation co 
efficient  0.076, 95% CI  0.291 to +0.145cm
3).  
 
The theoretical dose required to reduce the LN FV to 0cm
3 from the line of the 
slope was 128Gy.  
 
Individualised Adaptive Threshold: FV  =   0.179Dose(Gy) + 22.902 
 
 
4.3.4 The SUVmax within the Functional Volume 
 
4.3.4.1 SUVmax within the Primary Functional Volume 
 
4.3.4.1.1 SUV Cut Off 
Table 4.12 indicates the mean SUVmax and the SEM within the primary FV 
delineated by the SUVCO method. This is further illustrated by the histogram in 
figure  4.16.  The  pre treatment  SUVmax  was  identical  in  the  primary  FV 
delineated by all the SUVCO thresholds. 
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Table 4.12: The mean and standard error of the mean for the SUVmax within the primary 
functional volume delineated by the SUV Cut Off thresholds 
SUVmax (bwg/ml)    SUV  Cut  Off 
Threshold 
(bwg/ml)  0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Mean  12.38  10.57  7.71  5.75  2.5 
  SEM  2.33  2.13  1.19  0.94 
Mean  12.38  10.57  7.35  5.41  3.0 
  SEM  2.33  1.14  0.76  0.60 
Mean  12.38  10.18  7.35  5.41  3.5 
SEM  2.33  2.35  1.42  1.13 
Mean  12.38  9.71  7.35  4.93  4.0 
SEM  2.33  2.57  1.42  1.31 
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Figure 4.16: The SUVmax within the primary functional volume delineated by the SUV Cut 
Off thresholds 
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Table 4.13 shows the mean difference in the SUVmax within the primary FV 
delineated by the 3.0, 3.5, and 4.0bwg/ml compared to the 2.5bwg/ml threshold 
at each imaging point. The SUVmax reduced by 0.0 and 14.14% between the 
imaging points. The CI could not be calculated at 0Gy because there was no 
difference in the values and a star in the table indicates this.  
 
Table 4.13: The mean percentage, actual reduction, p values, and 95% confidence intervals 
for  the  SUVmax  within  the  primary  functional  volume  delineated  by  the  SUV  Cut  Off 
thresholds at each imaging point  
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Imaging  
Point 
(Gy) 
 
Mean 
Percentage 
Reduction 
 
Mean 
Reduction 
(bwg/ml) 
p value  95%  CI 
(bwg/ml) 
0  *  *  *  * 
8 to 18  0.00  +1.81  0.100   1.19 to 
+4.81 
36 to 50   4.37  +0.34  0.180   0.46 to 
+1.14 
2.5 to 3.0 
66   5.89  +0.34  0.180   0.46 to 
+1.14 
0  *  *  *  * 
8 to 18   3.67   2.68  0.061   1.19 to 
+4.81 
36 to 50   4.37   0.34  0.175   1.14 to  
+ 0.46 
2.5 to 3.5 
66   5.88   0.34  0.175   1.14 to  
+ 0.46 
2.5 to 4.0  0  *  *  *  *   178
8 to 18   8.13   2.68  0.190   9.43 to 
+4.08 
36 to 50   4.37   0.34  0.175   1.14 to  
+ 0.46 
 
66   14.14   0.34  0.175   1.14 to  
+ 0.46 
 
 
Table 4.14 indicates the percentage and absolute mean difference in the SUVmax 
within the primary FV at each SUVCO threshold between the imaging points of 
8 to 18Gy, 36 to 50Gy, and 66Gy compared to the pre treatment value.  
 
There was no significant reduction in the SUVmax at 8 to 18Gy compared to the 
pre treatment  value  at  any  threshold  investigated.  However  there  was  a 
significant reduction at 36 to 50Gy and 66Gy, compared to the pre treatment 
values at all SUVCO thresholds investigated. This was most significant at 36 to 
50Gy at the threshold of 3.0 and 3.5bwg/ml. 
 
Table 4.14: The mean percentage, actual reduction, p values and 95% confidence intervals 
for  the  SUVmax  within  the  primary  functional  volume  delineated  by  the  SUV  Cut  Off 
thresholds between the imaging points  
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Compared 
Imaging  
Points 
(Gy) 
 
Mean 
Percentage 
Change 
 
Mean 
change 
(bwg/ml) 
p value  95%  CI 
(bwg/ml) 
0 to  
8 18 
 11.97  +1.81  0.098   1.19 to 
+4.81 
0 to  
36 50 
 31.24   4.68  0.011   8.42 to  
 0.93 
2.5 
0 to 66   38.31   6.64  0.013   12.23 to  
 1.05   179
0 to  
8 18 
 11.97  +1.81  0.098   1.19 to 
+4.81 
0 to  
36 50 
 41.07   5.01  0.006   8.55 to  
 1.47 
3.0 
0 to 66   40.40   6.98  0.014   12.93 to  
 1.02 
0 to  
8 18 
 18.66  +2.20  0.075   1.02 to 
+5.42 
0 to  
36 50 
 41.07   5.01  0.006   8.55 to  
 1.47 
3.5 
0 to 66   40.40   7.54  0.007   13.03 to  
 2.05 
0 to  
8 18 
 32.23  +2.24  0.071   0.96 to 
+5.44 
0 to  
36 50 
 41.07   4.58  0.013   8.40 to  
 0.75 
4.0 
0 to 66   44.06   7.58  0.011   13.64 to  
 1.503 
 
 
This was confirmed by a significant negative correlation between the radiation 
dose and the SUVmax within the primary FV. This was most significant at the 
SUVCO threshold of 3.0bwg/ml (p value 0.006, correlation co efficient  0.483, 
95% CI  0.72 to  0.16bwg/ml), which is illustrated in figure 4.17. The graphs for 
the other thresholds are in figure 8a to c of Appendix 2, and the correlation co 
efficients in table 9 of Appendix 1. 
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Figure 4.17: Simple linear regression relationship between the SUVmax within the primary 
functional volume delineated at SUV Cut Off threshold of 3.0bwg/ml and the radiation dose 
   
The theoretical radiation dose required to reduce the SUVmax within the primary 
FV to zero was also calculated from the SLR model for each threshold. This is 
shown in the equation below for the SUVCO threshold of 3.0bwg/ml. The other 
equations are in Appendix 3 (Equations 15 to 17). 
 
SUV Cut Off 3.0bwg/ml:   
SUVmax (bwg/ml)   =   0.108Dose(Gy) + 11.952 
 
The radiation dose required was 128Gy at the 2.5bwg/ml threshold, and 112Gy, 
122Gy, and 120Gy at the 3.0, 3.5, and 4.0bwg/ml thresholds respectively. The 
dose to reduce the SUVmax within the primary FV to zero when delineated by 
the SUVCO threshold of 3.0bwg/ml was only 2Gy more than the dose required 
to reduce the FV itself to zero. 
 
4.3.4.1.2 Percentage Threshold of the SUVmax 
The mean SUVmax within the primary FV at 0Gy was identical to that within the 
FV defined by the SUVCO method at 12.38bwg/ml (SEM 2.33bwg/ml). At 8 to 
18Gy,  this  reduced  to  10.57bwg/ml  (SEM  2.13bwg/ml).  There  was  a  further   181
reduction  at  36  to  50Gy  to  7.71bwg/ml  (SEM  1.19bwg/ml),  and  finally  to 
5.75bwg/ml  (SEM  0.94bwg/ml)  at  66Gy.  A  single  SUVmax  value  only  was 
gained for the primary site in each patient, and this was used to calculate the 
PTSUVmax.  
 
The absolute mean SUVmax at 8 to 18Gy increased by +1.18bwg/ml (p value 
0.098,  95%  CI   1.12  to  +4.81).  At  36  to  50Gy  the  SUVmax  reduced  by   
5.68bwg/ml  (p value  0.014,  95%  CI   10.56  to   0.78),  and  at  66Gy  by   
6.64bwg/ml  (p value  0.013,  95%  CI   12.23  to   1.05)  compared  to  the  pre 
treatment value. The reduction in the SUVmax was only significant between at 
66Gy, and 36 to 50Gy when compared with the value at 0Gy. This equalled a 
mean increase of 9.54% at 8 to 18Gy, and a reduction of 45.88%, and 53.63% at 
36 to 50Gy, and 66Gy respectively. 
 
Similar  to  the  SUVmax  within  the  primary  FV  delineated  by  the  SUVCO 
thresholds,  there  was  a  significant  negative  correlation  between  the  SUVmax 
within the primary FV delineated by the PTSUVmax method and the radiation 
dose  (p value  0.007,  correlation  co efficient   0.467,  95%  CI   0.70  to   
0.14bwg/ml). 
  
The theoretical radiation dose required to reduce the SUVmax to zero within the 
primary FV delineated by the PTSUVMax thresholds was 128Gy. 
 
Percentage of the SUVmax:    
SUVmax (bwg/ml)=  0.094Dose(Gy) + 11.870 
 
This is in comparison to the increasing primary FV with increasing radiation 
dose when defined by this method. 
 
4.3.4.1.3 Individualised Adaptive Threshold 
The mean SUVmax within the pre treatment FV was the same as the other two 
methods  at  12.38bwg/ml  (SEM  2.33bwg/ml).  This  reduced  to  10.64bwg/ml 
(SEM 2.14bwg/ml) at 8 to 18Gy, 7.71bwg/ml (SEM 1.20bwg/ml) at 36 to 50Gy, 
and 4.66bwg/ml (SEM 1.35bwg/ml) at 66Gy, and is shown in figure 4.18.   182
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Figure  4.18:  The  SUVmax  within  the  primary  functional  volume  delineated  by  the 
individualised adaptive threshold  
 
The absolute mean difference was  1.75bwg/ml (p value 0.109, 95% CI  1.31 to 
+4.82bwg/ml) at 8 to 18Gy compared to the pre treatment value.  
 
Similar to the other delineation methods, the SUVmax significantly reduced at 36 
to 50Gy by  4.66bwg/ml (p value 0.011, 95% CI  8.42 to  0.94bwg/ml), and 
66Gy  by   7.73bwg/ml  (p value  0.015,  95%  CI   14.49  to   0.96bwg/ml).  This 
equated to a percentage reduction of 11.26% 8 to 18Gy, 31.43% 36 at 50Gy, and 
44.81% at 66Gy. The SUVmax values calculated by this method were less than 
those by the other two methods. 
 
A significant negative correlation was confirmed between the SUVmax within 
the primary FV and the radiation dose (p value 0.003, correlation co efficient  
0.508, 95% CI  0.73 to  0.19bwg/ml) shown in figure 4.19. This correlation was 
greatest compared to the other two delineation methods.  
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Figure 4.19: Simple linear regression relationship between the SUVmax within the primary 
functional volume delineated by the individualised adaptive threshold and the radiation 
dose 
 
The  theoretical  radiation  dose  required  to  reduce  the  SUVmax  within  these 
primary FVs to zero was 112Gy. 
 
Individualised Adaptive Threshold:  
SUVmax (bwg/ml)=   0.109Dose(Gy) + 12.049 
 
This is in comparison to the increasing primary FV with increasing radiation 
dose when defined by this method. 
 
4.3.4.2.2 SUVmax within the Lymph  ode Functional Volume  
 
4.3.4.2.2.1 SUV Cut Off 
The median pre treatment SUVmax was identical within the LN FV delineated 
by all thresholds of the SUVCO method and is shown in table 4.15. Figure 4.20 
illustrates this for the SUVmax within the LN FV delineated by the 3.0bwg/ml 
threshold as a box and whisker plot.    184
Table 4.15: The median and inter quartile range for the SUVmax within the lymph node 
functional volume delineated by the SUV Cut Off thresholds 
SUVmax (bwg/ml)    SUV  Cut  Off 
Threshold 
(bwg/ml)  0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Median  6.15  3.90  3.05  0.00  2.5 
  IQR  7.80  8.40  5.50  3.10 
Median  6.15  3.90  1.55  0.00  3.0 
  IQR  7.80  8.40  5.50  3.10 
Median  6.15  2.20  0.00  0.00  3.5 
IQR  11.11  8.40  5.50  3.10 
Median  6.15  2.20  0.00  0.00  4.0 
IQR  11.11  8.40  5.50  0.00 
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Figure  4.20:  The  SUVmax  within  the  lymph  node  functional  volume  delineated  by  the 
3.0bwg/ml SUV Cut Off threshold 
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Figures 9a to c of Appendix 2 illustrate the box and whisker plots for the other 
thresholds. 
 
There was no significant reduction in the SUVmax within the LN FV between 
the  SUVCO  of  2.5bwg/ml  and  3.0bwg/ml  at  any  imaging  point.  Unlike  the 
SUVmax  within  the  primary  FV,  there  was  a  significant  reduction  in  the 
SUVmax  within  this  LN  FV  at  all  imaging  points  between  the  SUVCO 
thresholds  of  2.5  to  3.5bwg/ml  and  2.5  to  4.0bwg/ml  (p<0.0001,  median 
reduction 0.65 to 1.55bwg/ml 95% CI 0.0 to 1.75bwg/ml). Table 10 in Appendix 
1 indicates these results in full.  
 
The median difference increased initially at 8 to 18Gy. The SUVmax like that 
within  the  primary  FV  then  significantly  reduced  at  36  to  50Gy  (p<0.0001, 
median reduction 3.60 to 4.05bwg/ml 95% CI 2.55 to 7.55bwg/ml), and 66Gy 
(p<0.0001, median reduction 5.45 to 5.68bwg/ml 95% CI 3.40 to 8.20bwg/ml) 
compared to the pre treatment value. Table 11 in Appendix 1 indicates these 
results in full.  
 
This was confirmed by a significant negative correlation between the SUVmax 
within  the  delineated  LN  FV  with  the  radiation  dose  at  all  SUV  Cut  Off 
thresholds.  The  correlation  co efficient  was  greatest  at  2.5bwg/ml  (p value 
<0.0001, correlation co efficient  0.537, 95% CI  0.64 to  0.36bwg/ml) and this 
is shown in figure 4.21. The results for the other thresholds are found in table 12 
of Appendix 1 and figures 10a to c of Appendix 2. 
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Figure 4.21: Simple linear regression relationship between the SUVmax within the lymph 
node functional volume delineated by the SUV Cut Off threshold of 2.5bwg/ml and the 
radiation dose 
 
The theoretical radiation dose required to reduce the SUVmax within the LN FV 
to zero was 80Gy, 74Gy, 70Gy, and 68Gy for the value at 2.5, 3.0, 3.5, and 
4.0bwg/ml respectively. The 2.5bwg/ml equation is indicated and the equations 
for the other thresholds are in Appendix 3 (Equations 18 to 20). 
 
SUV Cut Off 2.5bwg/ml:   
SUVmax (bwg/ml)  =   0.083Dose(Gy) + 6.621 
 
4.3.4.2.2.2 Percentage Threshold of the SUVmax 
The  median  pre treatment  SUVmax  within  the  LN  FV  delineated  by  the 
PTSUVmax method was also 6.15bwg/ml (IQR 7.80bwg/ml). This had reduced 
to 3.90bwg/ml (IQR 5.90bwg/ml) at 8 to 18Gy, 3.05bwg/ml (IQR 3.20bwg/ml) 
at 36 to 50Gy, and 2.30bwg/ml (IQR 1.20bwg/ml) at 66Gy. This is illustrated in 
figure 4.22. 
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Figure  4.22:  The  SUVmax  within  the  lymph  node  functional  volume  delineated  by  the 
percentage of the SUVmax method 
 
There was a significant reduction in the SUVmax at 36 to 50Gy, and 66Gy when 
compared to 0Gy. The median difference initially increased at 8 to 18Gy by 
+1.45bwg/ml (p value 0.999, 95% CI 0.70 to 2.35bwg/ml). This difference was 
then   3.15bwg/ml  (p value  <0.0001,  95%  CI   4.80  to   2.00bwg/ml)  at  36  to 
50Gy,  and   4.43bwg/ml  (p value  <0.0001,  95%  CI   6.85  to   2.60bwg/ml)  at 
66Gy. This equated to a 23.55% increase at 8 to 18Gy, and then a reduction of 
51.21% at 36 to 50Gy, and 72.03% at 66Gy compared to the 0Gy. 
 
The SUVmax within the LN FV delineated by the PTSUVmax method was also 
negatively  correlated  with  radiation  dose  (p value  <0.0001,  correlation  co 
efficient  0.508, 95% CI  0.65 to  0.32bwg/ml), and is shown in figure 11 of 
Appendix 2. 
    
The  theoretical  radiation  dose  required  to  reduce  the  SUVmax  within  this 
delineated volume to zero was higher at 100Gy. 
 
Percentage of the SUVmax:   
SUVmax (bwg/ml)=   0.068Dose(Gy) + 6.765   188
4.3.4.2.2.3 Individualised Adaptive Threshold 
The median pre treatment SUVmax within the LN FV delineated by the IAT was 
the same as that in the FVs delineated by the other methods at 6.15bwg/ml (IQR 
7.80bwg/ml).  This  reduced  to  3.90bwg/ml  (IQR  6.20bwg/ml)  at  8  to  18Gy, 
2.85bwg/ml  (IQR  3.70bwg/ml)  at  36  to  50Gy,  and  0.80bwg/ml  (IQR 
2.30bwg/ml) at 66Gy. This is illustrated in figure 12 of appendix 2. 
 
The median difference at 8 to 18Gy compared to 0Gy was +1.37bwg/ml (p value 
0.002, 95% CI  0.70 to 2.35bwg/ml). This difference was  3.63bwg/ml (p value 
<0.0001, 95% CI  5.45 to  2.15bwg/ml) at 36 to 50Gy, and  6.20bwg/ml (p value 
<0.0001, 95% CI  8.45 to  3.45bwg/ml) at 66Gy. This equated to a percentage 
change of +22.27% at 8 to 18Gy, 53.67% at 36 to 50Gy, and 86.99% at 66Gy. 
 
This negative correlation between the SUVmax within the LN FV delineated by 
the IAT method and the radiation dose (p value <0.0001, correlation co efficient 
 0.589, 95% CI  0.72 to  0.43bwg/ml) was confirmed, and is shown in figure 12 
of Appendix 2.  
 
The  theoretical  radiation  dose  required  to  reduce  the  SUVmax  within  these 
volumes to zero was calculated as 80Gy. 
 
Individualised Adaptive Threshold:  
SUVmax (bwg/ml)=   0.0878Dose(Gy) + 6.889 
 
 
4.3.5 The Background Uptake of 
18Fluoro 2 deoxyglucose  
 
4.3.5.1 SUV Cut Off and Percentage Threshold of the SUVmax 
The mean background uptake of 
18FDG was identical for the reference region 
defined by both the SUVCO and PTSUVmax, and is illustrated in figure 4.23. 
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Figure 4.23: The mean background SUV within the reference region delineated by the SUV 
Cut Off and percentage of the SUVmax methods 
 
The mean pre treatment SUV was 1.16bwg/ml (SEM 0.11 bwg/ml, range 0.60 
1.60bwg/ml). At 8 to 18Gy this was 1.11bwg/ml (SEM 0.10 bwg/ml, range 0.8 
1.40bwg/ml). At 36 to 50Gy the mean SUV was 1.29bwg/ml (SEM 0.15bwg/ml, 
range  0.70 2.10bwg/ml),  and  at  66Gy  the  mean  SUV  was  1.23bwg/ml 
(SEM0.14bwg/ml, range 0.60 1.70bwg/ml). 
 
There was no significant difference and no correlation between in the SUV at 
imaging points during treatment compared to the pre treatment value. 
 
4.3.5.2 Individualised Adaptive Threshold  
Figure 4.24 illustrates the mean background SUV when the reference ROI was 
delineated by the IAT method. 
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Figure  4.24:  The  mean  background  SUV  within  the  reference  region  delineated  by  the 
individualised adaptive threshold  
 
The mean background SUV within this reference ROI was 1.28bwg/ml (SEM 
0.17bwg/ml,  range  0.60 2.30bwg/ml)  at  0Gy,  1.28bwg/ml  (SEM  0.20bwg/ml, 
range 0.60 2.4bwg/ml) at 8 to 18Gy, 1.38bwg/ml (SEM 0.19bwg/ml, range 0.70 
2.40bwg/ml)  at  36  to  50Gy,  and  1.45bwg/ml  (SEM  0.27bwg/ml,  range  0.60 
2.90bwg/ml) at 66Gy. These values were higher than those delineated by the 
other methods. 
 
There was no significant difference or correlation in the background SUV within 
the reference ROI delineated by the IAT with the radiation dose. 
 
 
4.3.6 The Actual SUVmax Used to Define the Percentage Threshold of the 
SUVmax for the Functional Volume 
 
4.3.6.1 Mean SUV to Define the Primary Functional Volume 
The actual mean percentage values of the SUVmax used to define the edge of the 
primary FV at each percentage threshold of SUVmax are shown in figure 4.25. 
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At  each  imaging  point  there  was  a  reduction  in  the SUV  used  to  define  the 
volume, in keeping with the reduction of the SUVmax within the FV.   
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Figure 4.25: The actual SUV used to define the edge of the primary functional volume for 
each percentage of the SUVmax threshold 
 
 
The values for the mean, and SEM at each imaging point are illustrated in table 
13 of Appendix 1. Importantly, the mean SUV used to define the edge of the 
volume at 66Gy for the 30% threshold of the SUVmax was 1.73bwg/ml
 (SEM 
0.28bwg/ml, range 0.80 to 3.10bwg/ml), and at 50% this was 2.90bwg/ml
 (SEM 
0.46bwg/ml, range 1.90 to 5.1bwg/ml). This compared to the background uptake 
at this time point of 1.23bwg/ml (SEM 0.14bwg/ml, range 0.60 1.70bwg/ml). 
This indicates the background uptake was the same or equal to the SUV used to 
define the edge especially at the lower thresholds. 
 
There was a significant increase in the SUV used to define the edge of each 
primary FV at the 35%, 40%, 45%, and 50% threshold compared to the 30% 
threshold. This was most significant at 40%, 45%, and 50% of the SUVmax (p 
value 0.0002 to 0.001, mean increase in SUV 0.29 to 2.48bwg/ml 95% CI 0.29 to 
2.48bwg/ml). This increase was greatest at 0Gy and 8 to 18Gy. This is illustrated 
in table 14 in Appendix 1.   192
The SUV used to delineate the edge of the primary FV at each of the PTSUVmax 
has been compared with the background SUV at each imaging point. The SUV 
used to define the edge was significantly greater than the background SUV for all 
thresholds at all imaging points. The exception to this was the SUV used to 
define the 30% threshold FV at 66Gy. At 66Gy, the difference was between 0.5 
and 1.38bwg/ml depending on the threshold and is illustrated in table 4.16. 
 
Table 4.16: The mean difference, p values, and 95% confidence intervals for the SUV used 
to define the primary functional volume and the background SUV at each imaging time 
point by the percentage thresholds of the SUVmax  
Percentage 
Threshold  of  the 
SUVmax 
(%) 
Mean  Difference 
(bwg/ml) 
p value  95% CI (bwg/ml) 
0  2.56  0.004  0.95 to 4.16 
8 to 18  2.04  0.02  0.49 to 3.59 
36 to 50  1.04  0.017  0.25 to 1.83 
30  
66  0.50  0.051   0.13 to  +1.13 
0  3.18  0.003  1.31 to 5.05 
8 to 18  2.58  0.006  0.79 to 4.36 
36 to 50  1.40  0.005  0.46 to 2.34 
35 
66  0.79  0.041  0.04 to 1.53 
0  3.75  0.002  1.59 to 5.92 
8 to 18  3.13  0.004  1.07 to 5.18 
36 to 50  1.80  0.002  0.75 to 2.85 
40 
66  1.08  0.02  0.22 to 1.92 
0  4.39  0.002  1.95 to 6.82 
8 to 18  3.64  0.004  1.34 to 5.93 
36 to 50  2.16  0.002  0.97 to 3.36 
45 
66  1.38  0.001  0.45 to 2.30 
0  5.04  0.002  2.32 to 7.76 
8 to 18  4.91  0.003  1.65 to 6.74 
50 
36 to 50  2.60  0.001  1.27 to 3.93   193
  66  1.66  0.003  0.62 to 2.70 
 
 
4.3.6.1 Median SUV used  to Define the Lymph  ode Functional Volume 
The median SUV used to delineate the LN FV at each PTSUVmax is shown in 
table 4.17. These values reduced at each imaging point during treatment, and also 
increased depending on the threshold. 
 
Table 4.17: The median and inter quartile range for the SUV used to define the lymph node 
functional volume delineated by the percentage thresholds of the SUVmax  
SUV (bwg/ml)    Percentage 
Threshold  of 
the SUVmax 
(%) 
0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Median  1.85  1.15  0.90  0.65  30 
  IQR  1.50  0.10  0.10  0.10 
Median  2.15  1.35  1.10  0.80  35 
  IQR  1.70  1.30  0.10  0.10 
Median  2.45  1.60  1.20  0.95  40 
IQR  1.90  1.40  0.10  0.10 
Median  2.80  1.75  1.40  1.00  45 
IQR  1.90  1.60  0.10  0.10 
Median  3.10  1.95  1.55  1.10  50 
IQR  2.40  1.70  0.10  0.10 
 
 
Similar to the primary  FV, the SUV used to define the  LN FV significantly 
increased at each imaging point when the thresholds were compared to the SUV 
used  at  the  30%  threshold  (p<0.0001,  median  increase  in  SUV  0.10  to 
1.50bwg/ml 95% CI 0.10 to 1.55bwg/ml). Table 15 in Appendix 1 illustrates 
these values.  
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The SUV used to define the edge of the LN FV at each threshold and imaging 
point was compared to the background SUV within the reference ROI and is 
shown in table 4.18.  
 
Table 4.18: The median difference, p values, and 95% confidence intervals for the SUV 
used to define the lymph node functional volume and the background SUV at each imaging 
point by the percentage thresholds of the SUVmax  
Percentage 
Threshold  of  the 
SUVmax 
(%) 
Median 
Difference 
(bwg/ml) 
p value  95% CI (bwg/ml) 
0  +1.00  0.001  +0.35 to +1.80 
8 to 18  +0.60  0.064   0.05 to +1.35 
36 to 50  +0.13  0.297   0.30 to +0.55 
30  
66   0.40  0.001   0.60 to  0.20 
0  +1.30  0.0002  +0.60 to +2.30 
8 to 18  +0.93  0.009  +0.15 to +1.75 
36 to 50  +0.05  0.391   0.40 to +0.50 
35 
66   0.25  0.009   0.45 to  0.05 
0  +1.65  <0.0001  +0.80 to +2.75 
8 to 18  +1.15  0.0033  +0.35 to +2.10 
36 to 50  +0.20  0.226   0.30 to +0.75 
40 
66   0.10  0.403   0.37 to +0.10 
0  +1.98  <0.0001  +1.05 to +3.20 
8 to 18  +1.43  0.0004  +0.45 to +2.55 
36 to 50  +0.40  0.1564   0.15 to +0.95 
45 
66  0.00  0.932   0.25 to +0.20 
0  +2.38  <0.0001  +1.30 to +3.70 
8 to 18  +1.68  <0.0001  +0.60 to +2.90 
36 to 50  +0.60  0.024  0.00 to +1.15 
50 
66  +0.15  0.210   0.10 to +0.35 
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The  SUV  used  to  define  the  edge  of  the  FV  was  significantly  greater  at  all 
thresholds  than  the  background  SUV  at  0Gy,  8  to  18Gy,  and  36  to  50Gy. 
However,  at  66Gy  this  SUV  was  significantly  smaller  than  that  within  the 
background  for  the  30%,  and  35%  thresholds,  and  there  was  no  significant 
difference at the 40%, 45%, and 50% thresholds. 
 
4.3.7 The Relationship between the SUVmax within the Functional Volume 
and the Delineated Functional Volume 
 
4.3.7.1 Primary functional volume and the SUVmax 
When the PTSUVmax defined the primary FV, there was a trend towards an 
increase in the delineated FV and a reduction in the SUVmax within that FV, but 
this was not significant.  An example of this is shown in figure 4.26 for the 30% 
threshold. Similarly, there was no correlation with the FV defined by the IAT 
method. 
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Figure 4.26: Simple linear regression relationship between the SUVmax and the primary 
functional volume delineated by the 30% threshold of the SUVmax  
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However,  when  the  SUVmax  was  compared  with  the  FV  delineated  by  the 
SUVCO  thresholds,  there  was  a  highly  significant  positive  correlation.  An 
example of this is shown in figure 4.27 for the SUVCO threshold of 3.0bwg/ml 
(p value <0.0001, correlation co efficient 0.718, 95% CI 0.49 to 0.86bwg/ml). 
The remaining graphs for the other thresholds are in Appendix 2 figure 14 a to c, 
and statistics in table 16 of Appendix 1. 
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Figure 4.27: Simple linear regression relationship between the SUVmax and the primary 
functional volume delineated by the SUV Cut Off threshold of 3.0bwg/ml 
 
 
From  this  relationship,  the  theoretical  FV  was  calculated  according  to  the 
SUVmax. An example of this equation is shown for the 3.0bwg/ml threshold. 
The other equations are in Appendix 3 (Equations 21 to 23). 
 
SUV Cut Off threshold 3.0bwg/ml:  
FV (cm
3) =  2.212SUVmax(bwg/ml) + 0.424 
 
For  example: a SUVmax of 11.0bwg/ml would calculate a theoretical  FV of 
24.76cm
3. 
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4.3.7.2 Lymph  ode Functional Volume and the SUVmax 
There was no significant relationship between the delineated  LN FV and the 
SUVmax within the volume when defined by the all the percentage thresholds of 
the SUVmax. 
 
However, similarly there was a significant positive correlation between the LN 
FV delineated by the SUVCO thresholds and the SUVmax. This correlation was 
greatest at the SUVCO threshold of 3.0bwg/ml (p value <0.0001, correlation co 
efficient  0.631,  95%  CI  0.49  to  0.75bwg/ml).  Table  17  in  Appendix  1,  and 
figures 15 a to d in Appendix 2 illustrate the statistical and graphical values for 
the other thresholds. 
 
There was also a weak positive correlation when the LN FV was defined by the 
IAT  method  (p value  0.01,  correlation  co efficient  0.276,  95%  CI  0.06  to 
0.47bwg/ml) 
 
An  example  of  the  theoretical  LN  FV  calculated  from  these  SLR  models  is 
shown. The other equations are in Appendix 3 (Equations 24 to 26). 
 
SUV Cut Off 3.0bwg/ml:  FV (cm
3) =  1.176SUVmax(bwg/ml)  1.581 
 
For  example: a SUVmax of 11.0bwg/ml would calculate a theoretical  FV of 
11.35cm
3.   198
4.4 Discussion  
 
Three delineation methods were investigated: SUVCO, PTSUVmax, and IAT, 
with a combination of 10 thresholds. This study has shown that the defined FV 
before  and  during  RT  is  intricately  linked  to  the  delineation  method  and 
threshold.  
 
This volume change will impact on the potential dose that may be delivered 
through dose escalation strategies. Smaller FVs require a lower total dose to be 
reduced  to  zero.  This  volume  reduction  is  also  correlated  with  the  SUVmax 
reflecting intra tumoural glucose metabolism.  
 
4.4.1 Statistical Methods 
The difference in statistical normality of the volume distribution may have been 
due  to  the  small  number  of  patients  because  there  were  only  eight  primary, 
compared to 20 LN FVs.  
 
Patients may have more than one LN positive depending on the primary site, and 
this has the potential to lead to heterogeneity of 
18FDG uptake between LNs 
depending on the individual metastatic LN biology. Non parametric tests could 
have been used if the primary and LN volumes were analysed together, but this 
would have over represented the reduction in the primary volume and under 
represented the reduction in the LN volume during radiation treatment. This also 
indicated the differences in the uptake of 
18FDG in the LN and primary regions. 
Due to the small number of patients it was not possible to assess this change 
according to the individual LN levels within the neck. 
 
4.4.2 SUVmax within the Region of Interest 
The SUVmax most importantly defined the FV and therefore will be discussed 
first. 
 
In both the primary and LN FVs, the SUVmax was significantly reduced only at 
36 to 50Gy, and 66Gy compared to 0Gy at each SUVCO threshold. There was a   199
significant  reduction  in  the  SUVmax  within  the  LN  FV  for  the  delineating 
threshold at 8 to 18Gy when the 3.5 and 3.0bwg/ml thresholds were compared 
with 2.5bwg/ml, and when the 4.0, 3.5, and 3.0bwg/ml thresholds were directly 
compared with that at 2.5bwg/ml at each imaging point.   
 
The  pattern  of  reduction  of  the  SUVmax  within  the  primary  and  LN  FVs 
delineated by the PTSUVmax and IAT methods was also seen at 36 to50Gy and 
66Gy.  There  was  a  significant  negative  correlation  for  the  SUVmax  with 
radiation dose in volumes delineated by all methods. 
 
A theoretical SUVmax calculated from these values would be reduced to zero 
after 112 to 128Gy of RT within the primary, and at 68 to 80Gy within the LN 
FV  for  the  SUVCO  thresholds.    This  reduction  in  the  SUVmax  within  the 
primary FV would be at 128Gy, and 100Gy within the LN FV when defined by 
the PTSUVmax, and 122Gy within the primary, and 80Gy within the LN FV 
when delineated by the IAT. Since 
18FDG is a surrogate marker of increased 
glucose metabolism, it would suggest that at these radiation doses intra tumoural 
metabolism within the defined FV was reduced and cell growth prevented. 
 
The pre treatment SUVmax within the defined volumes was identical. This is an 
important point, as differences detected in the metabolic activity during RT are 
due to the delineation method and threshold used. This can be seen when the 
SUVmax  at  the  other  three  imaging  points  are  reviewed.  For  example,  the 
differences ranged from: 0.062 and 0.92bwg/ml at 8 to 18Gy, 0.0 to 0.36bwg/ml 
at 36 to 50Gy, and 0.82 to 1.088bwg/ml at 66Gy for the primary FV between the 
thresholds and methods.  
 
Increased 
18FDG uptake has been noted 1 day after the administration of cisplatin 
in  xenografted  mice  with  SCC,  and  in  a  moderately  differentiated  human 
SCCHN cell line. This slowly reduced as the number of viable cells declined, 
suggesting 
18FDG  uptake  can  initially  increase  prior  to  a  reduction  in  cell 
number. This may be cytokine mediated secondary to inflammation [1]. 
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The SUVmax can change during a course of treatment reflecting the differences 
in metabolic activity within the tumour as RT progresses. The reduction in SUV 
acts as a surrogate marker for the decline in glucose metabolism as the viable cell 
population reduces.  
 
This  is  not  always  the  case,  and  the  volume  delineated  (dependent  on  the 
delineation method) may or may not correlate with changes in the SUVmax.   An 
increase in the SUV has been described at the beginning of RT in 6 patients with 
metastatic papillary carcinoma of the thyroid. The 
18FDG avidity increased by 65 
to 89% after 6Gy and did not start to decline until after 30Gy [2]. Four patients 
reported in the study from this chapter had the SUV increased by 4.02 to 13.73% 
in the primary, and by 5.93 to 7.46% in three LNs within the same patient (no 
increase in the SUVmax within the primary). This is the mostly likely reason 
why  there  was  no  significant  reduction  in  the  SUVmax  within  the  primary 
volume at 8 to 18Gy.  
 
A single study in 16 patients with SCCHN assessed the change in the FV at 4 
time points during CRT. These patients all received curative CRT to a total dose 
of 72Gy (30Gy in 15 fractions, once daily, 42Gy in 1.4Gy per fraction twice 
daily). They underwent an initial 
18FDG PET pre treatment followed by 3 further 
scans (end of the 1
st/ 2
nd (10 to 20Gy) week, 3
rd/4
th week (30 to 44Gy), and 5
th/6
th 
week (58 to 72Gy). The FV was delineated by a individual signal to background 
ratio algorithm with iterative background correction by automatic segmentation 
software (ROVER, Fa. ABX, Radeberg, Germany). The SUVmax within the 
ROI continuously reduced during radiation treatment (15.2g/ml to 6.4g/ml), but 
this reduction was only significant after 30Gy. This finding is consistent with the 
results in this chapter, and this study also found the SUVmax increased in some 
patients prior to 30Gy. Using this automatic delineation algorithm, the mean FV 
increased during RT by 94.97% from 9.4cm
3 to 17.9cm
3 [3].  
 
Only  this  iterative  algorithm  was  reported,  the  nodal  and  primary  FVs  were 
combined rather than presented separately, and  PET and CT modalities were 
acquired separately. Interestingly, this group concluded that SUVmax did not   201
affect  the  final  delineated  volume  for  this  delineation  method.  Adaptive 
algorithms, which use the SUVmax to calculate the edge defining threshold will 
automatically be influenced by the SUVmax within the FV under investigation. 
 
The differences in the results from this chapter between the SUVmax within the 
primary and LN FVs are likely to reflect the differences in glucose metabolism 
due  to  tumour  heterogenity.  For  example  small  LNs  with  an  organized 
surrounding vasculature are likely to have improved nutrient delivery, and so be 
in a faster phase of growth (increased glucose metabolism), and more susceptible 
to radiation induced DNA damage and cell death. Similarly the calculated dose 
required to reduce the glucose metabolism (and therefore the 
18FDG uptake) to 
zero was less for the LN than the primary FV. This may be because the primary 
FV was larger (for example: mean 23.55cm
3 at 30% of the SUVmax threshold, 
compared to a median LN volume of 4.25cm
3). The larger pre treatment primary 
FV may have had a larger proportion of connective tissue, fibrosis, and necrosis, 
which would minimally influence the change in size, and the glucose metabolism 
compared to the fraction of viable cells.  
 
4.4.3 Background Uptake of 
18Fluoro 2 deoxyglucose  
The  background  uptake  of 
18FDG  did  not  significantly  differ  with  increasing 
radiation dose when assessed by all methods. The background 
18FDG uptake was 
slightly higher when the reference region was delineated by the IAT.  
 
The  most  likely  reason  for  this  is  the  iterative  algorithm  used  to  assess  the 
background  SUV  uptake.    The  ROI  was  in  an  identical  position  for  the 
assessment at each threshold, and was not moved as the FVs were calculated. 
The threshold setting only was change and this was used to define the edge and 
calculate  the  parameters  within  the  defined  boundary  box  and  segmented 
volume. This method may though be more representative of the background SUV 
over a larger area due to changes in the SUVmean and max within the volume.  
 
The PETVCAR auto segmentation IAT algorithm used to calculate the FV is 
based  on  a  number  of  different  mathematical  operations.  These  operations 
subtract the ROI from the surrounding area. The segmentation and edge defining   202
techniques are based on a background symmetry algorithm in which the peak of 
intensity is detected within the pixel/voxel of the image, and this peak is assumed 
to be the dominant peak within the region as defined by the algorithm. The slope 
of  the  peak  is  then  used  to  calculate  the  volume.  This  is  dependent  on  the 
SUVmean, which in turn is dependent on the tumour volume.  
 
In  areas  with  generalised  low level  background  uptake  of 
18FDG,  the  edge 
definition is difficult because the peak of the slope is too small to define the edge 
of the volume, therefore the algorithm will grow the volume until the volume 
edge reaches the defining boundary box.  
 
Figure 4.28a and b illustrate this phenomenon. Figure 4.28a indicates the peak of 
18FDG uptake within the ROI (blue arrow), and the slope used to define the edge 
(red arrow). The red line at the base of the peak is the FV. The final delineated 
FV is oval in shape with a red edge. The higher 
18FDG uptake is dark grey within 
this. This corresponds to the area within the peak, and is segmented from the 
black boundary box. The distance between the peak and the edge of the slope 
used to define the volume is indicated within the final delineated volume as a 
circle with a cross in the centre.    
 
Figure 4.28b indicates the peak of the slope is smaller. The software algorithm 
cannot  differentiate  the  numerous  small  peaks  of  uptake  intensity  from  the 
slightly higher uptake of the dominant peak. For example smaller voxel peaks 
may have an SUV of 1.7bwg/ml, and the dominant peak 1.72bwg/ml. The auto 
segmented defined volume is the entire boundary box in red, with the oval lower 
intensity  pale  grey  uptake  of 
18FDG  in  the  centre  has  not  been  successfully 
segmented from the background uptake. 
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Figure 4.28a and b: The definition of the functional volume by the individualised adaptive 
threshold method. Well defined volume a), and poorly defined volume b) 
 
 
Figure 4.29 illustrates the calculation of the edge of the FV defined by the IAT. 
The edge is defined when the gradient of the slope (red circle with red cross) 
changes. The vector (weighting) factor is automatically set to 0.5 for this point. 
This is between the peak 
18FDG uptake (blue arrow and circle with blue cross) 
within the defined boundary box, and the point of the slope when the gradient is 
zero (indicated by the violet circle with a central violet cross). The change in 
gradient  and  slope  steepness  between  the  maximum  and  minimum  voxels  of 
SUV uptake is illustrated by the dotted arrows that extend from the peak to the 
base of the slope. The edge of the boundary box, and the background uptake of 
18FDG are indicated by thick black arrows. 
b 
 
a 
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Figure  4.29:  Edge  definition  by  the  individualised  adaptive  threshold  according  to  the 
gradient of the slope  
 
This is in contrast to the other two methods were the threshold is defined by the 
user  of  the  software,  and  the  contents  of  the  defined  volume  are  calculated. 
Therefore areas with a low SUVmax may be defined as falsely large because of 
the difficulty in edge definition by the software. This may account for the lack of 
correlation  of  the  FV  defined  by  the  IAT  with  the  radiation  dose,  despite  a 
negative correlation of radiation dose with the SUVmax. 
 
4.4.4 Inflammation and Background 
18Fluoro 2 deoxyglucose Uptake  
Low  levels  of 
18FDG  uptake  occur  in  a  number  of  situations  including 
inflammation. During RT to the HN, inflammation develops within the tumour 
and the surrounding normal tissue.  
 
In  a  human  adenocarcinoma  ovarian  cancer  cell  line irradiated  with  a  single 
30Gy fraction, the basal uptake of 
18FDG was 9.77 times greater in the irradiated 
than  the  non irradiated  group  up  to  12  days  after  irradiation.  This  occurred 
despite  a  reduction  in  the  number  of  viable  cells.  When  compared  with  the 
uptake of 
3H thymidine (indicator of DNA synthesis), the basal uptake was up to 
948% greater in cells with increased DNA synthesis after irradiation [1]. This 
suggests that the increased uptake of 
18FDG is due to increased DNA repair, 
Edge of 
Boundary 
box 
Background 
18FDG 
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synthesis, and cell re population. Mononuclear white cells may infiltrate the area 
as part of an inflammatory reaction to degrade apoptotic cells.  
 
The normal tissue reaction to RT depends on the tissue type and the rate of 
delivered radiation dose. Apoptotic cell death occurs at the time of mitosis when 
cells  attempt  to  divide  after  radiation  delivery.  Epithelial  cells  may  start  to 
repopulate 8 days after radiation with a cell turnover time of 24 hours [4]. This 
early response to radiation is due to the stem cell turnover time in the tissue of 
interest.  An  inflammatory  reaction  and  leukocyte  infiltration  of  the irradiated 
tissue accompanies this due to a signalling cascade of cytokines. In patients with 
HN cancer after 30 to 60Gy of RT, the macrophage infiltration was found to be 
consistent with this inflammatory response [5]. 
 
The  background  uptake  of 
18FDG  during  RT  was  found  to  increase  within 
macrophages  associated  with  radiation induced  mucositis  [6].  The  risk  of 
confluent mucositis of the oral mucosa after 65 to 70Gy is 50% [7]. In mice, 
18FDG accumulated within granulation tissue and in macrophages at the necrotic 
tumour  rim  after  irradiation.  Dual  tracer  auto radiography  with 
3H thymidine 
indicated DNA synthesis and cell re population occurred in the same regions as 
increased glucose utilisation [8].   
 
The SUV within the vertebra of 163 lymphoma patients with no known bone 
marrow infiltration was assessed on 
18FDG PET after colony stimulating factor 
injections. The SUV increased by 2.37g/ml up to 90 days after the injections, and 
was greatest 0 to 7 days later [9]. This uptake was due to the mobilisation of 
marrow stem cells, and further suggests that activated leukocytes increase 
18FDG 
uptake. 
 
The increased uptake of 
18FDG can continue after RT has completed making 
scan assessment difficult especially when salvage surgery for residual disease is 
to  be  considered.  The  SUVmax  ranged  from  2.5  to  7.0g/ml  in  patients  with 
SCCHN  who  underwent  salvage  surgery  after  concurrent  chemotherapy  with 
IMRT, and had histologically proven residual disease. The SUV was 3.9g/ml in   206
those with no evidence of residual disease [10]. This SUV overlap between the 
two groups was due to post treatment residual inflammation. 
 
An  SUV  of  3.0g/ml  is  a  common  fixed  criteria  for  residual  disease  after 
treatment in patients with SCCHN. Ong et al [10], after applying this threshold to 
areas of increased 
18FDG uptake found the sensitivity was 66%, and specificity 
81%  for  the  detection  of  recurrent  disease  in  the  LN,  and  57%  and  84% 
respectively in the primary site. These values were greatest 12 weeks after the 
completion of treatment.  
 
Similarly, Andrade et al [11] reported in 28 patients with SCCHN imaged 4 to 
15.7 weeks after the completion of curative RT that the sensitivity was 76.9%, 
and specificity 93.3% for the detection of recurrent disease. The uptake of 
18FDG 
within  the  previously  irradiated  field  was  low  to  moderate  but  not  directly 
quantified. This suggested that the differentiation of normal tissue to residual 
tumour uptake continued to be difficult up to 12 weeks after the completion of 
curative RT/CRT. 
 
The placement of the reference region to define the background 
18FDG uptake is 
important.  Physiological  and  patient  related  factors  can  influence  this  [12]. 
Anxious  patients  may  tense  their  neck  muscles,  and  this  will  increase  the 
background  SUV  within  the  SCM  muscle.  Physiological  uptake  can  also  be 
noted in the larynx if the patient talks from injection to imaging, and would be 
especially problematic if the primary site was within the vocal cord.  
 
All  of  the  factors  discussed  have  the  potential  of  making  the  tumour  edge 
definition difficult, but the method of delineation is vitally important.  This is 
because 
18FDG uptake in the normal tissue may be increased to the same level as 
that within the tumour, and result in the greatest difficulty in edge definition 
towards the end of RT treatment. The use of an SUVCO threshold set above the 
background uptake will exclude this from the calculated FV. The lowest SUVCO 
threshold was greater than the background uptake in the results from this chapter, 
and this method therefore was less susceptible to changes in background uptake 
of 
18FDG.   207
Interestingly, the background 
18FDG uptake during RT did not correlated with 
RT dose, but did increase during the study when calculated by the IAT method.  
This  may  be  because  of  the  small  patient  numbers  (1  reference  region  to 
calculate  the  background  SUV  per  patient),  or  the  adaptive  algorithm.  The 
placement  of  multiple  ROI  within  the  muscle  rather  than  1  may  have  been 
appropriate, as well as the assessment of uptake within regions of pharyngeal 
mucositis. For this to be accurate the patient’s imaging and clinical examination 
during RT treatment would need to have been assessed by the same person. This 
was not possible because the FVs were delineated after study completion. The 
mucositis is often at a peak after the completion of treatment, and in this study 
there was no imaging at this time point. 
 
4.4.5 Delineated Functional Volume 
The  pre treatment  delineated  FV  varied  between  the thresholds  and  methods.  
The 40, 45, and 50% of SUVmax volumes were smaller than those delineated by 
other thresholds. The mean primary FV delineated by the 3.5bwg/ml SUVCO 
threshold was within 0.40cm
3 of the volume delineated by the 30% threshold of 
the SUVmax, and the IAT. This is shown in the histogram in figure 4.30. 
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Figure  4.30:  The  mean  pre treatment  primary  functional  volume  delineated  at  each 
threshold for all the investigated methods  
 
 
There  was  a  14.30cm
3  (40.92%)  reduction  in  volume  between  the  2.5  and 
4.0bwg/ml SUVCO, and 12.60cm
3 (36.47%) between the 30% and the 50% of 
the SUVmax thresholds.  
 
The primary FV delineated at the 30% of the SUVmax, IAT, and 2.5bwg/ml 
SUVCO thresholds were within 0.15cm
3 of each other at the start of treatment. 
The other LN volumes delineated by the 3.0 to 4.0bwg/ml SUVCO thresholds 
were  all  smaller  than  the  volume  delineated  by  the  50%  of  the  SUVmax 
threshold. 
 
The  pre treatment  LN  FVs  delineated  by  all  the  thresholds  of  the  SUVCO 
method were smaller than those delineated by any PTSUVmax, or IAT method. 
There  was  only  a  0.15cm
3  difference  between  the  pre treatment  LN  FV 
delineated by  the 2.5bwg/ml (2.65cm
3), 50% of the SUVmax (2.70cm
3), and 
individualised adaptive (2.80cm
3) thresholds. 
 
Both  the  LN  and  the  primary  FV  were  significantly  reduced  between  the 
delineating thresholds when compared to the minimum threshold of 2.5bwg/ml,   209
and 30% of the SUVmax. When the LN FV delineated by the 35% threshold of 
the SUVmax was compared with the 30% threshold this was not the case. This 
non significant result was because the defining edge was similar. The median 
difference in the SUV used to define the edge was 0.05 to 0.30bwg/ml between 
30 to 35% at each imaging point, compared to 0.60 to 1.15bwg/ml at 30 to 50% 
at  each  imaging  point.  There  was  minimal  volume  change  between  the 
thresholds. For example the median pre treatment defined LN FV at the 30% of 
the  SUVmax  threshold  was  4.25cm
3  (IQR  5.90cm
3),  and  at  35%  this  was 
4.20cm
3 (IQR 4.70cm
3). 
 
The LN and primary FV delineated by the SUVCO thresholds were significantly 
reduced  at  36  to  50Gy,  and  66Gy  compared  to  0Gy,  which  mirrored  the 
reduction in the SUVmax. This was most significant at 3.0bwg/ml for both FVs. 
This was confirmed by a negative correlation of the defined volume with the 
increase in radiation dose. The volume change was dependent on the SUVmax 
within these volumes delineated by this method, and the SUVmax was positively 
correlated with the defined FV by this method. 
 
The delineated FV was linked to the SUVmax within the volume and this was 
dependent  on  the  method  of  delineation.  There  was  a  negative  correlation 
between  the  radiation  dose  and  the  SUVmax  in  the  FVs  delineated  by  all 
methods.  But  the  FV  did  not  correlate  with  the  SUVmax  within  the  volume 
defined  by  the  PTSUVmax.  This  was  confirmed  by  the  significant  positive 
correlation  between  the  FV  delineated  by  the  SUVCO  thresholds  and  the 
SUVmax. One study found no association between these two variables in FVs 
delineated  by  an  adaptive  algorithm  in  patients  with  SCCHN  [3].  The  IAT 
defined primary FV used in this chapter did not correlate with the SUVmax, and 
only weakly with the LN FV. 
 
The differences in FV between the thresholds will impact on dose escalation 
techniques. Higher thresholds that contour smaller volumes have the possibility 
of greater normal tissue sparing and increased escalated dose delivery. However, 
the  SUV  is  not  able  to  differentiate  pathological  SCCHN  according  to 
histological grade, and so a low SUV does not exclude SCC, it only indicates that   210
that particular area of tissue has a low rate of glucose metabolism. Therefore the 
main  disadvantage  of  the  SUVCO  thresholds  is  the  potential  exclusion  of 
cancerous tissue, as the SUV within the ROI is not taken into consideration in the 
threshold method. 
 
The calculated theoretical dose required to reduce the primary FV to zero by the 
SUVCO method was 84 to 110Gy, and 58 to 68Gy for the LN volume. The 
greater the SUVmax, the larger the SUVCO defined FV will be. Larger volumes 
require  larger  doses  of  radiation  to  sterilise  them,  but  interestingly  the  dose 
calculated here for the LN volume for the SUVCO thresholds of 2.5, 3.0, and 
3.5bwg/ml  is  less  than  the  standard  macroscopic  dose  used  in  current  RT 
regimes.  This  is  purely  due  to  the  size  of  the  defined  volume  because  the 
theoretical dose required to reduce the LN FV to zero when defined by the IAT 
method was 80Gy.  
 
The SLR model however cannot account for intra tumoural biological changes 
and  the  development  of  resistant  sub populations  of  clonogenic  cells  during 
treatment. A lower SUV may also indicate cell cycle dormancy, which would 
need to be confirmed by  proliferation markers, and mean that these volumes 
would be more likely to cause loco regional failure.  
 
The phenomenon of the increased primary and LN FV after 36Gy when defined 
by the thresholds of the percentage of the SUVmax despite a reduction in the 
SUVmax  after  these  dose  points  is  interesting.  The  primary  and  LN  FV 
delineated  by  this  method  were  susceptible  to  changes  in  background  SUV 
uptake.  
 
The LN FVs delineated by the IAT method were significantly reduced at 36 to 
50Gy  and  66Gy  compared  to  the  pre treatment  volume,  but  there  was  no 
significant correlation of dose and FV on regression modelling. There was also 
no significant reduction in the primary volume during treatment by this method. 
Neither volume correlated with radiation dose.  
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Unfortunately  the  PETVCAR  software  did  not  have  the  facility  to  overlay 
structure  sets  containing  the  FV  defined  either  by  different  thresholds  or  by 
different  methods  within  an  image  from  single  or  multiple  time  points.  The 
assessment  of  correspondence  between  the  volumes  defined  by  the  different 
thresholds and methods could therefore not be performed.  
 
The  correspondence  between  volumes  has  been  evaluated  in  a  study  of  78 
patients with stage II to IV SCCHN. Four separate segmentation methods (visual 
interpretation, SUVCO [2.5g/ml], PTSUVmax [40% and 50%], and an adaptive 
threshold  (used  by  Daisne  et  al  [13]))  were  reviewed.  Patients  underwent 
separate CT and 
18FDG PET imaging 0 to 10 days prior to the start of RT. The 
image sets were co registered by an iterative algorithm. The 
18FDG PET volumes 
delineated by the 50% of the SUVmax, and the signal to background ratio based 
thresholds over lapped, and had greatest correspondence compared to volumes 
defined  by  the  other  methods  [14].  The  FV  defined  by  the  2.5g/ml  SUVCO 
threshold was at least 300cm
3 greater than those defined by the other methods 
(mean volume: visual interpretation 21.5cm
3, 40% of the SUVmax 16.5cm
3, 50% 
of the SUVmax 10.5cm
3, adaptive threshold 11.2cm
3) [14]. Similar to Daisne et 
al  [15],  this  group  also  reported  that  the  PET  volume  extended  outside  the 
volume defined on conventional CT imaging. The volume difference noted when 
the SUVCO threshold was used was not corroborated by the results from this 
chapter.   
 
Greco et al [16] in 2008 compared similar 
18FDG CT PET defined FV in 12 
patients with SCCHN prior to the start of RT by visual interpretation, 50% of the 
SUVmax, 2.5g/ml SUVCO threshold, and an iterative segmentation algorithm. 
These volumes were compared to those defined on the CT RT planning scan. 
There was no significant difference between the 2.5g/ml SUVCO volumes and 
the CT volume (mean 60.0ml and 75.5ml respectively). The volume defined by 
the PTSUVmax was 77.74%, and the iterative volume 25% smaller than the CT 
volume.  
 
Volume differences between thresholds may result from imaging related factors. 
In  6  patients  with  SCCHN,  FVs  were  defined  by  a  50%  threshold  of  the   212
SUVmax prior to the delivery of IMRT, and were outside the CT defined GTV 
by 0 to 72% [17]. 
 
The separate acquisition of PET and CT imaging in delineation studies can lead 
to mis registration of image sets, and suggest no overlap or an overlap between 
the volumes. These volume differences can result from partial volume effects, 
patient movement during imaging of the PET component, differences in image 
resolution, and user defined differences for example window level setting [17]. 
 
PET  volumes  defined  in  8  patients  with  SCCHN  were  compared  with  the 
delineation  of 
18FDG  filled  spheres  within  a  cylindrical  phantom  [18].    The 
information  gained  from  this  process  was  applied  to  the  volumes  defined  in 
patients. Two thresholds (42% and 50% of the SUVmax) were used. The post 
reconstruction smoothing of the PET images affected the final FV. This was 
associated with a loss of signal, which reduced the SUVmax and was associated 
with  smaller  FVs.  Signal  loss  also  occurred  when  a  wide  filter  was  used  to 
smooth the ROI. The contoured 
18FDG PET volumes were boosted to 77Gy for 
the 50% volume, and 72Gy for the 42% volume. The boost dose was different 
because the tumour volume at 42% of the SUVmax was 111.0cm
3, and at 50% of 
the  SUVmax  this  was  37.0cm
3.  The  total  radiation  dose  received  by  normal 
structures especially the cord and mandible remained the same. 
 
The imaging and CT PET guided FV used for RT planning should be reviewed 
in  conjunction  with  an  experienced  Nuclear  Medicine  Physician  and  Clinical 
Oncologist  and  the  FV  modulated  depending  on  extension.  Extension  of  the 
volume  into  normal  tissue  may  be  due  to  the  chosen  threshold,  or  local 
infiltration of metabolically active disease. Unusual uptake on the attenuation 
and  non attenuation  corrected  images  may  be  secondary  to  artefacts  and 
physiological  variants.    Extreme  variations  in  volume  definition  may  reflect 
inaccuracies in co registration, calibration, and ROI placement when automated 
algorithms are used. 
 
Geets  et  al  [19]  reported  10  patients  with  pharyngo laryngeal  cancer  who 
underwent 7 weeks of CRT. Prior to treatment CT, MRI, static and dynamic PET   213
imaging were undertaken, and at the mean prescribed dose of 14, 25, 35, and 
45Gy. PET volumes were delineated by the automatic gradient based method, 
and TVs on other imaging modalities were delineated by visual interpretation. 
The  PET  TVs  were  reduced  by  15  to  40%  during  treatment,  and  were 
significantly  smaller  than  those  defined  on  CT.  However,  there  was  no 
significant difference between the volumes defined by CT or MRI. 
 
The primary and LN FVs vastly differ accordingly to the delineation method, 
threshold,  and  the  radiation  dose  received.  Daisne  et  al  [15]  pathologically 
validated the 
18FDG positive ROI within laryngeal macroscopic specimens. The 
PET volumes when auto segmented by an iterative algorithm based on the signal 
to background ratio [13], were the most representative of the pathological true 
volume compared to CT and MRI defined volumes.  
 
Pathological validation is required to assess if the imaging is representative of the 
in vivo  biological  process  under  investigation.  Further  information  may  be 
gained by using H+E, IHC, and cytogenetic information for example. The 
18FDG 
PET FV most closely represents the pathological volume, but cannot fully define 
it. If the wrong threshold and delineation method are chosen to define the RT 
volume, then a geographical miss may occur, causing an increased risk of loco 
regional recurrence. 
 
With increasing radiation dose, other factors are also important if 
18FDG PET 
FVs are to be used for adaptive RT planning. Partial volume effects and edge 
definition  are  complicated  by  reduction  in  tumour  volume,  changes  in  the 
patient’s weight, oedema associated with inflammation, and organ position.  
 
Non rigid  methods  of  image  registration  aim  to  overcome  these  problems 
associated with deformity, and may help the accuracy of adaptive RT planning.  
Twelve  deformable  registration  methods  have  been  assessed  for  this  use  in 
patients  with  SCCHN  [20].  Registration  methods  that  incorporated  local 
smoothing  algorithms  provided  the  greatest  benefit  to  the  co registration  of 
image  sets  at  different  time  points  during  RT.  The  PETVCAR  software  co   214
registered images according to rigid methods, which had the potential to increase 
the volume delineated. 
 
TVs in patients with SCCHN have been defined prior to RT with an SUVCO 
threshold  of  2.5bwg/ml,  the  PTSUVmax  of  40%  and  50%,  and  an  adaptive 
threshold. The results are shown in table 4.19 and have been compared with 
those from this chapter. The adaptive and SUVCO thresholds are different, but 
between the 50% and 40% thresholds the volumes delineated were very similar, 
with a 35.97% reduction between the thresholded volumes reported by Schinagl 
[14], and 32.32% from the results of this chapter.  
 
Table 4.19: Delineation volumes compared from UCLH and the reported study by Schinagl 
et al 
Threshold   
SUV  Cut 
Off 
2.5bwg/ml 
(cm
3) 
40%  of  the 
SUVmax 
(cm
3) 
50%  of  the 
SUVmax 
(cm
3) 
Adaptive 
(cm
3) 
Schinagl  >300.0  16.40  10.50  11.20 
UCLH Patients  34.95  16.18  10.95  23.95 
 
 
This illustrates the similarities and differences of volume definition depending on 
the  threshold  used.  However  the  patient  population,  and  adaptive  threshold 
calculations are different. The extremely large volume gained by the use of the 
SUVCO threshold suggests that background uptake of 
18FDG within the HN is 
varied. PETVCAR may have been able to segment the background from tumour 
18FDG uptake better at this threshold. 
 
It  is  interesting  that  the  primary  FV  delineated  by  the  IAT  in  the  8  patients 
investigated  in  this  chapter  did  not  show  a  significant  reduction  during  RT, 
where as the LN volume did. This may have been due to the smaller number of 
FV investigated within the study. The macroscopic primary and LN FV were   215
within the higher radiation dose field. The effect of confluent mucositis within 
the pharyngeal mucosa may have had a greater impact on these volumes, but 
such  mucositis  would  have  been  absent  within  the  deep  tissues  of  the  neck. 
Hentschel  et  al  in  2009  [3]  reported  that  adaptive  threshold  defined  FVs 
increased in size with increased radiation dose, and did not correlate with the 
SUVmax.  The  IAT  method  was  dependent  on  the  difference  between  the 
SUVmax and SUVmean within the ROI, as well as the background SUV. Small 
differences in the SUVmax and mean would potentially reduce the ability of the 
software  to  auto segment  and  delineate  tumour  volume  from  the  background 
18FDG uptake.  
 
It  would  be  prudent  to  repeat  the  delineation  in  a  prospective  study  using 
PETVCAR,  and  compare  the  volumes  delineated  by  the  IAT  to  those  on  a 
phantom with differing levels of known 
18FDG activity. The true phantom and 
patient volumes could then be correlated and the differences assessed.  
 
The results from this chapter suggest a number of dosimetric implications. The 
SUVCO  threshold  is  potentially  of  greater  benefit  for  dose  escalated  FV 
definition during RT. 
 
The IAT delineation method may be more beneficial from the start of treatment 
rather than planning a potentially larger volume delineated by this method during 
treatment for use in dose escalation studies. Larger PET FVs delineated have less 
possibility of dose escalation due to the larger amount of normal tissue that may 
be irradiated as a consequence. 
 
Tissue sparing has been shown to be possible when RT treatment is re planned 
using  the  smaller  PET  defined  TV  [21]  with  no  increase  in  spinal  cord  or 
brainstem doses [18]. However, the microscopic dose to the prophylactic areas 
will  not  change.    During  RT  also  organs  such  as  the  parotid  glands  move 
medially and enter the high dose volume contributing to late morbidity. 
 
Madani et al [22] reported 41 patients with SCCHN treated to two dose escalated 
levels by an IMRT SIB technique (total dose of 72.5Gy, 2.5Gy per fraction, and   216
77.5Gy, 3.0Gy per fraction) for 10 fractions. The PET volume was defined on a 
pre RT 
18FDG  PET  using  an  automatic  segmentation  algorithm  based  on  the 
signal to background ratio. For PET volumes greater than 10cm
3, the central 
10cm
3  with  the  highest  SUVmax  received  IMRT  dose  escalation  at  3Gy  per 
fraction, and the remaining volume was escalated to 2.5Gy per fraction. The dose 
limiting toxicity was not reached in this study. One patient experienced Grade 4 
skin  toxicity  at  59.6Gy.  The  commonest  acute  toxicities  were  dysphagia  and 
mucositis, with fibrosis and dysphagia being the commonest late ones.  These 
results should be interpreted with caution. The follow up was only 1 year with a 
median  survival  in  this  group  of  14  months,  and  no  statistically  significant 
differences were found for acute or late toxicity, or the one year disease specific 
survival.  
 
Further studies are required to assess the optimal time of imaging, and optimal 
method for dose escalation. It may also be possible to dose escalate both the 
primary and LN volumes to a different final dose either using the IAT based on 
the risk of the individual ROI according to the SUVmax within it or the SUVCO 
threshold. 
 
The  advantage  of  the  IAT,  and  the  PTSUVmax  methods  over  the  SUVCO 
method is the lack of the absolute threshold. For example an SUVCO threshold 
would not define a FV if the SUVmax was less than the threshold. However the 
other two methods take the individual SUVmax within the ROI into account 
during the delineation process.  
 
The  argument  for  the  use  of  the  SUVCO  is  the  demarcation  of  benign  and 
malignant  disease  by  the  reporting  clinician.  Each  tumour  ROI  has  its  own 
biological phenotype that is distinct from another region within the patient. Its 
use therefore is controversial for 
18FDG PET FV delineation prior to the start of 
treatment. We have however demonstrated that this method is influenced less by 
the background uptake of 
18FDG and therefore is more applicable to use during 
RT for dose escalation strategies.  
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Indeed no primary ROI had an SUV of less than or equal to 2.5bwg/ml either 
prior to the start or during RT. Also no LN ROI had a SUV less than or equal to 
2.5bwg/ml before the start of RT. From 36Gy the SUVmax within the LN FVs 
did  in  some  patients  fall  below  this  value  indicating  reduced  intra tumoural 
glucose metabolism. 
 
4.4.6 The SUV used to Define the Edge of the Functional Volume  
The  results  from  this  chapter  have  shown  that  the  FVs  delineated  by  the 
PTSUVmax increased after 36Gy and continued to increase up to the completion 
of treatment. The method of volume delineation for the IAT and the potential 
pitfalls of an SUV within the ROI that is similar to the background uptake of 
18FDG have been discussed.  
 
The underlying cause for this increased volume after 36Gy in both the primary 
and  LN  FV  is  because  the 
18FDG  uptake  is  the  same  as  or  less  than  the 
background  uptake.  This  effect  is  less  evident  at  higher  thresholds.  The 
PETVCAR  software  cannot  then  differentiate  tumour  and  background 
18FDG 
uptake, and the entire boundary box rather than any tumour present inside it is 
delineated.  
 
Table 4.20 shows the calculated ratio of the SUV used to define the edge (mean 
primary, median LN) and the background SUV. This table shows that at 0Gy, 
and 8 to 18Gy the ratio in both volumes is greater than 1.0. However at 66Gy this 
ratio especially at the lower thresholds was less than 1.0 for the LN FV (the 
tumour was iso intense or hypo intense compared to the background uptake). 
This indicates the difficulty experienced by the software in defining the SUV 
uptake within the ROI from background uptake, resulting in the larger volumes 
from 36 to 66Gy. 
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Table 4.20: The calculated tumour edge to background ratios for the primary and lymph 
functional volumes delineated by the percentage threshold of the SUVmax  
Tumour to Background Ratio  Threshold 
0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Primary  3.24  3.01  1.89  1.45  30% 
Lymph  ode  1.73  1.42  0.83  0.70 
Primary  3.79  3.52  2.18  1.71  35% 
 ode  2.00  1.61  1.00  0.82 
Primary  4.27  4.04  2.50  1.96  40% 
Lymph  ode  2.31  1.83  1.12  0.97 
Primary  4.83  4.53  2.80  2.23  45% 
Lymph  ode  2.50  2.11  1.24  1.03 
Primary  5.40  5.06  3.16  2.47  50% 
Lymph  ode  2.88  2.33  1.36  1.17 
 
 
This has been confirmed by Daisne et al [13] who found FVs delineated by the 
PTSUVmax  were  more  susceptible  to  lower  tumour  to  background  ratios,  
especially when less than 1.5 [19]. 
 
Other studies in SCC cervix suggested that the PTSUVmax method required a 
tumour to background ratio of greater than 10 to effectively delineate the PET 
volume prior to definitive RT [23]. The results from this chapter and also from 
Schinagl [14] have not supported this finding. This may be due to differences in 
tumour biology at different anatomical sites. 
 
The  inherent  assumption  of  all  the  automatic  delineation  methods  is  that  the 
background  SUV  uptake  is  homogenous  across  the  patient,  and  therefore 
representative.  Heterogenous  background  uptake  is  likely  to  occur,  and  the 
method of delineation is then dependent on the placement by the user of the ROI 
to  define  this  uptake.  One  method  to  overcome  this  is  to  take  a  number  of 
background  values  of 
18FDG  uptake  that  are  representative  of  the  area  to  be 
treated.   219
4.4.7 Imaging Protocol 
The study was designed to image patients during radical RT or CRT at four time 
points 0, 10, 44, and 66Gy. These time points were selected because the curative 
RT  for  these  patients  at  UCLH  is  to  a  total  dose  of  66Gy  conventionally 
delivered. 
 
The  first  two  imaging  points  corresponded  to  the  treatment  of  microscopic 
disease during Phase I. The third imaging point was selected because this was 
when the second phase of RT treatment started. The last imaging point was the 
completion of treatment. This time point was chosen because if 
18FDG avid areas 
were still present with  a high SUV, then this  would have suggested that the 
metabolic response to RT had been small and loco regional recurrence was likely 
at  this  site.  This  final  volume  could  then  be  assessed  and  voxel  based  dose 
escalation strategies applied. Although it could be argued that volume delineation 
at  this  time  point  is  too  late  for  adaptive  treatment  strategies.  It  has  been 
important to view the response at 66Gy in relation to the delineation method, and 
has indicated that adaptive CT PET guided dose escalation strategies should be 
imaged between 36 to 50Gy. 
 
The study did not incorporate CT PET in the follow up of patients after they 
completed  treatment.  Future  studies  using  dose  escalation  techniques  should 
incorporate this to assess 
18FDG uptake, and the effectiveness of dose escalation 
on loco regional control.  
 
Further  CT PET  imaging  should  be  undertaken  at  a  minimum  of  4  months 
following completion [24], but also at 6, 12 and 24 months after treatment. This 
is because recurrence is commonest during the first 2 years after treatment.  
 
The PETVCAR software that has been used to delineate the FVs in this chapter 
and would allow the post treatment imaging to be co registered with the pre 
treatment imaging and the delineated volumes propagated as bookmarks to the 
same  location  on  the  subsequent  scans.  The  volumes  could  then  be  directly 
measured  for  loco regional  control  and  other  parameters  such  as  SUVmax 
correlated with this.    220
4.4.8 Collaboration 
All delineation methods need to be validated within departments (on individual 
CT PET scanners), and between departments for collaborative studies using PET 
radio nuclides.  Collaboration  would  provide  greater  patient  recruitment  and 
increased  validity  of  results.  Phantom  calibrations  are  required  to  assess  the 
accuracy of edge delineation techniques to aid comparability. This is because the 
delineation methods are dependent on the internal hard and software calibration 
factors of the individual camera. 
 
The advantage of the PETVCAR software although not commercially available 
yet within the UK, is that it does provide a standardised method for delineation 
which is transferable between institutions once availability is increased. A major 
criticism of PET studies to date is that patient numbers are small, but also the 
automatic  delineation  algorithms  are  made  and  adapted  in house  limiting  the 
transferability and reproducibility of data. This minimises collaboration between 
centres especially when adaptive thresholding methods are used.  
 
The other advantage is the dual purpose for reporting and response assessment of 
CT PET  imaging  with 
18FDG  and  other  radio nuclides  with  the  PETVCAR 
software.  This  indicates  the  cost effectiveness  of  purchasing  this  software, 
especially  as  it  is  used  in  conjunction  with  the  Advantage  Workstation  for 
Windows  software  that  is  commercially  available  and  used  by  PET  Centres 
across the UK. 
 
4.4.9 Possible Strategies for Dose Escalation 
The concept of the biological target volume derived from functional imaging, 
and its potential use to guide and sculpt increased radiation dose delivery was 
first proposed in 2000 by Clifton Ling [25]. 
 
Dose escalation strategies may be by a number of different methods including: 
boost towards the end or after completion of RT (high dose rate brachytherapy, 
IMRT, or intensity modulated arc therapy (IMAT), modulation of dose per voxel 
depending on the SUV within it, particle beam therapy with protons (Intensity 
Modulated  Proton  Therapy),  or  stereotactic  radiation).  Alternatively,  the   221
escalated dose may be incorporated from the start of treatment by photons or 
particle  therapy.  Currently  the  optimal  dose  escalation  method  is  still  being 
debated. Proton therapy is currently not available within the UK, and stereotactic 
RT facilities are limited. IMRT and less commonly IMAT are the most available 
within RT centres. 
 
Dose escalated IMRT or IMAT may be delivered by two techniques: either SIB 
to the CT PET FV from the start or at a time point during RT treatment, or 
voxel based  dose  painting.  The  SIB  technique  has  the  potential  for  the  most 
widespread use as this may be implemented on current software used to plan 
IMRT  within  departments,  and  in  centres  with  no  experience  of  PET  based 
planning. Voxel based dose painting requires dynamic PET data to allow 4D 
dose modulation, and is limited by the spatial resolution of the PET voxel. This 
can produce partial volume effects, and the need for dynamic imaging protocols 
are required for this technique. 
 
Further studies are required to assess the effect of dose escalation on normal 
tissue [18,22,26], function, loco regional and survival outcome, but initial studies 
are promising. 
 
4.4.10 Other Applications of CT PET Guided Adaptive Radiotherapy 
Adaptive PET guided strategies will undoubtedly lead to improvements in loco 
regional control and survival. However, these improvements are of most benefit 
when functional outcome in not compromised. 
 
18FDG CT PET may be used to potentially predict the response of normal tissue 
to irradiation, and therefore guide dose escalation strategies.  
 
For example a study in patients with NSCLC, found the development of acute 
radiation  pneumonitis  could  potentially  be  predicted  by  the 
18FDG  uptake  in 
irradiated lung during RT. The mean SUV when the mean lung dose was greater 
than 10Gy was 2.66g/ml after 40 to 49Gy compared to 1.89g/ml at 40 to 49Gy 
when the mean lung dose was less than 10Gy [27]. A similar increased risk of 
radiation induced pnuemonitis had been reported in patients with oesophageal   222
cancer  [28,29].  The  implication  of  this  is  not  only  to  predict  normal  tissue 
reaction but also to guide dose escalation strategies. Patients who have a lower 
SUV in normal lung during RT may have a greater possibility of a dose escalated 
boost without increasing the risk of radiation induced pneumonitis. 
 
This has the potential to be extrapolated to normal tissue within the HN such as 
the constrictor muscles of the pharynx, and parotid glands. 
18FDG guided CT 
PET FVs can then be dose escalated, and may also guide dose delivery to avoid 
normal tissue with a higher background 
18FDG uptake that may be at greater risk 
of late radiation induced damage. 
 
4.5 Conclusions 
 
Early studies using 
18FDG PET in SCCHN reported the potential benefit to all 
patients  who  underwent  RT  planning  but  especially  those  with  T3  and  T4 
primary tumours, and N2 and N3 nodal disease [30]. Out of the published studies 
which evaluated the clinical impact of 
18FDG PET on TV definition, imaging on 
combined  machines  was  uncommon,  and  different  thresholds  using  differing 
delineation methods at multiple time points during a course of curative RT in this 
group of patients was rare (no more than two threshold usually 40 and 50% of 
the SUVmax from same method were compared at baseline). 
 
The  results  from  this  study  suggest  that  the  volume  delineated  during  RT  is 
strongly  dependent  on  both  the  threshold,  and  method  used  to  delineate  the 
18FDG positive FV. The background uptake of 
18FDG within the HN has less 
impact on the FVs defined by the SUVCO method and may be of greater benefit 
when use to guided dose escalated RT during treatment. However there was a 
significant impact of this background uptake especially on volumes delineated by 
the PTSUVmax and the IAT method. 
 
The SUVmax influences the FV when delineated by the SUVCO method, but 
this  relationship  is  less  clear cut  when  volumes  are  defined  according  to  the   223
PTSUVmax and the IAT methods, as other factors such as radiation induced 
mucositis have an increasingly important role. 
 
There is no clear consensus as to which method is best from the published data 
both  in  SCCHN  and  NSCLC.  There  is  though  a  move  towards  the  use  of 
adaptive  algorithms  for  volume  delineation  at  the  start  of  RT  although  these 
methods have little benefit during RT. 
 
The  SUVCO  method  may  prove  on  larger  studies  to  be  best  at  delineating 
volumes to allow adaptive RT planning with IMRT. Even this though requires 
significant  software  availability  to  allow  auto contouring  of  normal  tissue 
structures to aid the planning process.  Regardless of which method is used either 
between or within institutions, a flexible, and close working relationship with the 
Nuclear  Medicine  (and  CT PET  Centre)  is  required  to  aid  delineation  and 
maximise the benefit of 
18FDG CT PET imaging in the RT planning process of 
patients with SCCHN. 
 
Future assessment of dose escalation to 
18FDG CT PET guided FV depends on a 
number of factors most importantly: the delineation method, threshold for FV 
delineation, time point of functional imaging, time point of dose escalation (for 
example simultaneous integrated boost delivered through IMRT from the start of 
treatment, voxel based dose painting with dose modulation at a given time point 
to “boost” the metabolically active FV), the method of dose escalation (IMRT, 
RapidArc, CyberKnife, Particle therapy), as well as intra tumoural factors such 
as size, and SUV. Collaborative approaches between institutions are required to 
improve  PET  based  RT  planning,  as  well  as  attempting  to  standardise  the 
software used for volume definition. Ultimately in combination PET guided TV 
delineation has the potential to improve outcome in patients with SCCHN.   224
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Chapter 5 
 
Hypoxic Imaging in Squamous Cell Carcinoma of 
the Head and  eck with 
64Cu ATSM 
 
5.1 Material and Methods 
 
5.1.1 Patient Recruitment 
Patients  were  recruited  according  to  the  eligibility  criteria  in  table  5.1  from 
UCLH.  
 
Table 5.1: Inclusion and exclusion criteria 
Inclusion Criteria  Exclusion Criteria 
Primary surgical resection for locally 
advanced SCCHN 
 
Impaired  renal  function  (serum 
creatinine greater than 200) 
Histo pathological  or  cytological 
confirmation of SCCHN 
Severely impaired liver function 
Age 50 years or older  Urinary or faecal incontinence 
ECOG Performance Status 0 to 2  Uncontrolled psychiatric disturbance 
Life  expectancy  greater  than  12 
weeks 
ECOG performance status greater than 3  
 
Adequate organ function 
Absence of other major concomitant 
illness 
Second primary tumour within the HN to 
be  treated  by  modality  other  than 
primary surgery 
 
 
Eligible patients were identified at the multi disciplinary team meeting and all 
relevant investigations reviewed. Patients were recruited in the Ear, Nose and 
Throat,  and  Oral  and  Maxillo Facial  clinics,  and  given  verbal  and  written   229
information concerning trial participation. Recruitment was according to GCP 
guidelines. Written consent was obtained from all patients prior to participation.  
 
Patients could withdraw from the study on request, or were withdrawn if there 
was  non compliance,  significant  patient  co morbidity,  inter current  illness,  or 
difficulty with the production of 
64Cu ATSM at St Thomas’ Hospital. 
 
5.1.2 Trial Arm Allocation 
Patients were allocated to 3D dynamic CT PET imaging of the HN only, 3D 
dynamic CT PET of the HN followed by DCE CT, and 3D dynamic CT PET, 
DCE CT with delayed static CT PET 18 to 24 hours after the injection of 
64Cu 
ATSM.  
 
5.1.3 
64Cu ATSM Production at St Thomas’ Hospital 
64Cu ATSM was produced and purified according to McCarthy et al [14, 15] to 
good manufacturing practice standards, by Dr Rowena Paul at the Clinical PET 
Centre, Guy’s and St Thomas’ Hospital, London.  
 
In summary 
64Ni was electroplated onto a gold target. The electroplated target 
was loaded and rotated into the line of the cyclotron (CTI RDS 112 11MeV 
model, positive ion machine). The target was bombarded with 11MeV protons 
for  5  to  8  hours  for  batches  of  1GBq  depending  on  the  activity  required. 
Operating parameters during irradiation were: beam current 20 to 30µA +/  5µA. 
 
(28,64) Ni + proton → (29,64) Cu + neutron   [
64Ni(p,n)
64Cu] 
 
Eluting with hydrochloric acid purified the 
64Cu to produce 
64CuCl2. Purified 
H2ATSM  was  dissolved  in  dimethyl sulphoxide,  and  added  to  the 
64CuCl2  to 
produce 
64Cu ATSM. This was then Sep –Pak conditioned, purified with ethanol, 
and combined with ascorbic acid to a concentration of 1mg of ascorbic acid per 
ml of 
64Cu ATSM solution.  
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This  solution  was  chemically  stable  for  over  24  hours,  and  the  addition  of 
ascorbic acid prevented radio lysis. Quality assurance procedures including pH 
analysis and isotope identity testing were then completed prior to the release of 
the radio nuclide for clinical use. 
 
Appendix 4 contains the production process of 
64Cu ATSM in detail. 
 
5.1.4 Administration of 
64Cu ATSM 
The 
64Cu ATSM was transported from St Thomas’ Hospital to UCLH in a lead 
container.  The  activity  in  MBq  was  calculated  and  calibrated  on  arrival  by 
Physicist  Dr  J  Dickson  at  UCLH  and  stored  until  required  (1Bq  =  1 
disintegration  per  second).  This  activity  was  compared  to  the  activity  on  the 
quality assurance certification. The patient’s height (cm) and weight (Kg) were 
recorded,  and  details  re confirmed.  The 
64Cu ATSM  was  drawn up  by  the 
Superintendent Radiographer (Miss Caroline Townsend), immediately prior to 
the start of imaging, into a 5ml sterile syringe encased in a lead syringe holder.  
 
Patients were positioned supine, with their arms by their sides. Their head was 
placed in the head holder on the couch of the CT PET machine and secured in 
place with a Velcro attachment. A scout CT of the HN was undertaken to ensure 
the patient was in the correct position to encompass the entire ROI.  
 
The patient then underwent the defined CT HN. The couch was then advanced 
into the PET section of the scanner. The 
64Cu ATSM was intra venously injected 
into a cannula in the patient’s forearm, and the dynamic imaging started at the 
time of injection. 
 
5.1.5 Imaging Protocols 
Patients underwent all imaging on the GE Discovery DVCT 64 CT PET machine 
(64 slice combination volumetric CT and PET imager). The Nuclear Medicine 
Department staff completed all imaging procedures. The imaging protocols, and 
radiation exposure are illustrated in table 5.2a to c. Only the protocols used for 
the patients enrolled have been included.  
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Table 5.2a: Acquisition protocol for the immediate 3D dynamic Head and  eck CT PET 
Parameter  Acquisition  
CT  Scout 120 kVp, 10mA 
CT 140 kVp, 80 mA, 0.8s, Pitch 1.75 
CT slice thickness 3.75mm  
PET  3D, 1 hour List Mode Dynamic 
Frames : 30 x 2 sec, 12 x 10 sec, 6 x 20 sec,  
5 x 60 sec, 10 x 300 sec   
PET Reconstruction  Iterative (3D OSEM) 
20 subsets, 2 iterations 
Post Filter 6.00mm Full Width Half Maximum 
Slice Thickness 3.27mm 
Reconstruction diameter 70cm 
Radiation Exposure  PET: 21.6mSv (based on a dose of 600MBq of 
64Cu 
ATSM)  
CT: 3.4mSv 
Total: 25.0mSv 
 
 
 
Table 5.2b: Acquisition protocol for the 3D static Head and  eck CT PET 18 to 24 hours 
after 
64Cu ATSM injection 
Parameter  Acquisition  
CT  Scout 120 kVp, 10mA 
CT 140 kVp, 80 mA, 0.8s, Pitch 1.75 
CT Slices 3.75mm  
PET  3D for 20 Minutes single static random frame 
3D for 40 Minutes single static random frame 
Both protocols are imaged in List Mode to help 
assess image quality.    232
PET Reconstruction  3D Iterative (OSEM) 
Filtered back projection 
20 subsets, 2 iterations 
Post Filter 6.00mm Full Width Half Maximum 
Slice Thickness 3.27mm 
Reconstruction diameter 70cm 
Radiation Exposure  Immediate dynamic CT PET: 25.0mSv 
Late static CT PET: 3.4mSv 
Total: 28.4mSv 
 
 
The DCE CT was started after completion of the CT PET. First, the 4cm region 
within  the  tumour  was  chosen  in  conjunction  with  the  Nuclear  Medicine 
Consultant (Dr I Kayani), and the scan extent programmed into the software. A 
50ml sterile saline (0.9%) intra venous infusion (4ml/sec) was administered to 
assess and ensure venous patency. Finally, 50ml of Omnipaque 350 (4ml/sec) 
was remotely administered, and the dynamic CT obtained 35 seconds after this. 
Table 5.2c illustrates the acquisition protocol for the DCE  CT. 
 
Table 5.2c: Acquisition protocol for the dynamic contrast enhanced CT  
Parameter  Acquisition  
CT  Scout 120 kVp, 10mA 
Scan Delay (after contrast): 35 seconds 
CT: 100 kVp, 100 mA, Axial 1.0s,  
Duration: 60 seconds 
8 images per rotation, 1 second scan, inter scan delay 
of 2.5 seconds and 5mm collimation of detectors 
Reconstruction: 5mm (Standard), diameter of the 
field of view 50cm  
Radiation Exposure  8.9mSv 
Immediate CT PET and DCE CT: Total: 33.9mSv 
Immediate CT PET, DCE CT, and late imaging at 18 
to 24 hours: Total 37.3mSv   233
5.1.6 Administration of Pimonidazole 
Pimonidazole  (Hypoxyprobe
TM,  NPI  Inc.,  Masschusettes,  USA)  was 
administered to all patients intra venously at least 16 hours prior to surgery. The 
freeze dried product was stored at 4°C in the Pharmacy Department of UCLH, 
and supplied (Natural Pharmacia International, Inc., Massachusetts, USA) in 1g 
vials.  
 
The  vial  was  brought  to  room  temperature  by  warming  in  the  hands,  and 
reconstituted in 10ml of sterile 0.9% normal saline (concentration of 0.1g/ml). 
Pimonidazole was administered at a dose of 0.5g/m
2 in 100ml of 0.9% normal 
saline over 20 minutes, via a light protective infusion set and filter. The dose was 
capped at a BSA of 2.0m
2, and the BSA calculated according to the equation 
below. 
 
BSA (m²) = ([Height(cm) x Weight(kg) ]/ 3600 )
½ [1]  
 
5.1.7 Time of Surgery 
Surgical teams and theatre staff were informed of each recruited patient. Patients 
underwent  a  general  anaesthetic,  and  were  positioned  on  the  operating  table 
according to the preparation for the surgical procedure to be carried out. 
 
Photographs were taken intra operatively, using a Cannon G9 Powershot (12.1 
mega  pixel,  product  code  2082B001)  camera,  to  aid  orientation  and  co 
registration of the histological specimen with the CT PET. The specimen was 
sutured onto a plastic template if required, to aid orientation by the reporting 
Pathologist. Figure 5.1 illustrates the template. 
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Figure 5.1: Surgical template for neck dissection specimens  
 
The surgeon indicated critical margins, and identified general territories of nodal 
groups with sutures. Additional macroscopic specimens were sent in separate 
pots  to  the  Pathology  Department  depending  on  the  intra operative  findings. 
Surgical surfaces were inked to aid orientation and co registration with CT PET 
data if there were no defining features. India inks were used on discussion with 
the Pathology Department, and were standard colours for mastectomy specimens. 
These  were:  red  (superior  margin),  green  (inferior),  medial  (yellow),  blue 
(anterior), black (posterior), and lateral (no ink). Prior to inking, the surgical 
surface was wiped dry with 100% alcohol by volume.  
 
All specimens were placed in specimen pots containing 10% neutral buffered 
formalin with the volume of fixative ten times the volume of the tissue.  
 
Specimens were immediately taken to the Nuclear Medicine Department, once 
they were signed out from theatre. The specimen was removed from the pot, 
placed on a tray, and a CT scan undertaken on the same CT PET machine the 
patient was scanned on to aid the co registration process. Following this, the 
specimen  was  returned  to  the  specimen  pot,  taken  directly  to  the  Pathology   235
Department, signed in, and immediately reviewed by the Duty Pathologist. The 
specimen remained in 10% neutral buffered formalin for a minimum to 24 to 
48hrs prior to macroscopic dissection. 
 
Initially a CT PET scan was planned of the specimen. However because of the 
timing of surgery, the specimen would needed to be scanned for a minimum of 
12  hours  (depending  on  residual  activity)  over  night.  This  was  not  possible 
because the specimen needed to be logged into Pathology Reception the same 
day as the procedure according to local Standard Operating Procedures.  
 
5.1.8 Preparation of Macroscopic Specimen Following Formalin Fixation 
Macroscopic examination was according to the Royal College of Pathologists 
and undertaken by Dr Amrita Jay (Consultant Pathologist) at UCLH. 
 
The specimen was removed from the specimen pot, further photographs taken, 
and  diagrams  annotated  to  aid  future  specimen  orientation.    Specimens  were 
orientated, inspected, and dimensions recorded.  
 
For ND specimens, surrounding structures were reviewed from the outer aspect, 
and the internal jugular vein was identified on the deep aspect to aid orientation. 
Lymph  nodes  were  identified  by  inspection  and  palpation  to  the  appropriate 
anatomical level. Each discrete node was dissected out with the attached peri 
capsular adipose tissue by scalpel. Larger nodes were bisected through the hilum 
or  sliced  according  to  the  plane  of  orientation.  The  extent  of  extra capsular 
spread was assessed by further dissection along the nodal capsular edge, together 
with the peri nodal tissues. Small or flat nodes were processed whole. Tissue was 
placed in cassettes prior to automated wax embedding.  
 
Laryngeal specimens were macroscopically reviewed, and sectioned through the 
posterior wall in the cranio caudal direction to expose the mucosal surface. The 
specimen was then placed in formic acid for a minimum of 5 days depending on 
the extent of calcification. After this the larynx was either sectioned  using a 
scalpel into axial rings or longitudinally. Figure 5.2a to c illustrates the fresh   236
laryngeal  sample  intra operatively  a),  the  sample  after  formalin  fixation  and 
posterior dissection b), and finally after axial dissection c). The area of squamous 
cell cancer is visible on each axial section as a creamy pale area indicated by the 
arrow. 
 
  
 
 
 
Figure 5.2a and b: Fresh macroscopic larynx a) and formalin fixed larynx b) 
 
Tumour ulcer 
on mucosal 
surface 
a 
b   237
 
Figure 5.2 c: Formalin fixed axially sectioned larynx  
 
5.1.9 Preparation of the Microscopic Specimen 
The formalin fixed dissected specimen was processed automatically overnight 
within the Pathology Department. In summary, first graded alcohols were used to 
dehydrate the specimen. The alcohol was cleared with xylene. The specimen was 
infiltrated and embedded with liquid paraffin wax, and cooled. An example of 
the fixed wax embedded tissue is shown in figure 5.3. The arrow indicates the 
area of SCC. 
 
   
Figure 5..3: Wax embedded laryngeal specimen 
Creamy pale 
squamous cell 
cancer 
c 
Creamy pale 
squamous cell 
cancer   238
The specimen block was cut into 4µm thick sections using a microtome. Tissue 
slices were floated on a water bath, and then captured on a glass slide and baked 
in an oven at 56°C for 30minutes. The resulting slides were H+E stained. The 
Medical  Laboratory  Scientific  Officers  within  the  Pathology  Department 
completed this process. Dr A Jay then reported the H+E stained specimen. 
 
5.1.9 Immuno Histochemical Staining of Specimens 
The IHC staining procedure was similar for all antigens. It has been explained for 
pimonidazole only. Antibody dilutions, and any deviations from this process are 
indicated for each IHC stain. 
 
5.1.9.1 Pimonidazole  
Pimonidazole  adducts  were  detected  by  a  two step  immuno histochemical 
procedure  using  a  primary  fluorescein  (FITC) conjugated  mouse  monoclonal 
antibody  (Mab)  directed  against  the  pimonidazole  protein  adducts  and  a 
secondary mouse anti FITC Mab conjugated to horseradish peroxidase. Human 
bladder  SCC  was  used  as  a  control,  and  had  previously  stained  positive  for 
pimonidazole. 
 
Four micron wax embedded sections were dewaxed in xylene for five minutes, 
and  then  rehydrated  through  graded  alcohols  (100,  90,  and  70%)  to  water. 
Antigen retrieval was then performed. The slides were placed in a bath of 10mM 
citric acid pH 6.0 and boiled for 8 minutes using an 800W microwave oven 
(2450MHz Panasonic NN 6453BBPQ). The volume of fluid was topped up to its 
original level if it had evaporated to maintain the pH. The slides were left to 
stand for 20 minutes at room temperature and then washed in running tap water. 
 
Slides  were  rinsed  in  Tris  Buffered  Saline  (TBS)  (Dako  A3536),  and  Dako 
Peroxidase block was applied for 5 minutes. They were then rinsed with TBS, 
and Dako protein block (DakoCytomation Ely Cambs X0909) was applied for 5 
minutes.  The  excess  was  removed,  and  hypoxyprobe 1  antibody  (Chemicon 
Europe Ltd Hamps HP2 100) applied diluted in 1 in 100 in antibody dilutent 
(Dako Catenation S2022) for 60 minutes.   239
Slides  were  washed  for  3  minutes  in  TBS,  and  covered  in  Anti fluorescein 
isothiocyanate  (Anti FITC)  Mab  (Chemicon  Europe  Ltd)  diluted  1  in  100  in 
Dako antibody dilutent (Envision 
TM HRP Rabbit polymer Dako K4010) for 30 
minutes. Slides were washed again for 3 minutes in TBS, and then covered in 
3,3’ diaminobenzidine DAB substrate (DakoCytomation K3467) for 5 minutes. 
Slides  were  rinsed  with  TBS,  washed  under  running  tap  water,  and  counter 
stained with Meyer’s haematoxylin (Surgipath Europe Ltd Peterborough UK Cat 
No 01582E) for 10 to 60 seconds. The slides were washed again in running tap 
water, dehydrated through graded alcohols, cleared in xylene, and mounted in 
DPX (Surgipath Europe Ltd 08600E). 
 
5.1.9.2 GLUT1 
The  GLUT1  antibody  (Abcam  40084)  was  diluted  to  1  in  200  in  antibody 
dilutent and applied for 60 minutes. Then Envision 
TM HRP Rabbit polymer was 
applied  for  30  minutes  followed  by  washing  in  TBS  for  3  minutes.  DAB 
substrate was then applied for 5 minutes followed by a further TBS wash and 
counter staining with Meyer’s haematoxylin. The control was germinal centres of 
reactive lymphoid tissue. 
 
5.1.9.3 CAIX 
Antigen  retrieval  did  not  require  microwave  heating.  The  CAIX  antibody 
(Professor  Pastorek,  University  of  Bratislava)  was  applied  diluted  to  a 
concentration of 1 in 50. Following this the process was the same as GLUT1 
staining. The control tissue was bladder SCC. 
 
5.1.9.4 HIF 1a 
The  HIF1a  antibody  (Abcam,  ab8366)  was  applied  diluted  to  a  1  in  8000 
concentration. Following this the process was the same as GLUT1 staining. The 
control was human bladder SCC. 
 
5.1.9.5 Modifications to Slide Preparation 
During the process of antigen retrieval, tissue would lift off the slide due to the 
boiling process, shown in figure 5.4 a) H+E and b) the GLUT1 stained slide. 
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Figure 5.4a and b: Haematoxylin and eosin stained specimen from patient 1 a), and GLUT1 
immuno histochemical stained specimen with folded tissue secondary to antigen retrieval 
 
 
To overcome this recurrent problem, glass slides were coated in vector bond 
(Vector Laboratories, USA, SP 1800) prior to tissue capture, and the slides and 
tissue where then heated overnight at 56°C. 
 
5.1.9.5.1 Vector Bonding Slides 
Clean glass slides were placed in metal racks, rinsed in water, and soaked in 
acetone for 5 minutes.  Vector bond (7ml) was mixed with 350ml of acetone and 
stirred  for  5  minutes.  The  acetone  cleaned  glass  slides  were  placed  in  this 
solution for 5 minutes. Excess reagent was removed by dipping the slides in 
deionised water. The slides were air dried at room temperature, and stored until 
required. 
 
5.1.9.6 Haematoxylin and Eosin Staining 
Although  H+E  slides  were  prepared  for  diagnostic  purposes,  these  were  not 
removed from the Pathology Department.  
 
Slides  were  dewaxed  through  xylene,  followed  by  graded  alcohols  to  water, 
stained in Meyer’s haematoxylin for 5 minutes, and rinsed in running water. 
Slides were then immersed in 70% alcohol for 10 seconds, followed by counter 
b  a 
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staining for 2 minutes in eosin (Surgipath Europe Ltd, Peterborough, UK 01600) 
and  further  washed  in  tap  water.  The  stained  tissue  was  dehydrated  through 
graded alcohol, cleared in xylene and mounted in DPX. 
 
5.10 Digitisation of Immuno Histochemical Slides 
All specimen slides were digitised into an ICS image format by mounting on a 
Nikon  eclipse  TE2000 E  microscope.  A  JVC  colour  camera  using  software 
designed at the Gray Cancer Institute, Mount Vernon Cancer Centre, Northwood 
Middlesex was used at the Guy’s Hospital Campus of Kings College, London.   
 
Slides once cleaned of dust and debris were placed face down on the slide mount 
within the microscope. The settings were: projection x 40 (x 4 objective lens and 
x 10 eye piece), shutter speed 1/30sec, white balance to manual, and the shading 
was turned off. 
 
The background was corrected for both black and whites averages to compensate 
for debris on the lens and colour changes on the slide. The light source was 
blocked, and the black average taken. The white average was from a clean area 
of the slide next to the edge of the specimen. 
 
X and Y co ordinates defined the ROI. The focal plane was defined by three x 
and y co ordinates randomly selected by the computer, accounting for changes in 
thickness of the specimen. If the computer chose a position on the slide with no 
specimen,  then  the  co ordinates  were  altered  to  ensure  that  the  focal  plane 
included tissue. 
 
Images  were  taken  using  a  computer controlled  motorised  microscope  stage 
according to the defined co ordinates. An overlap of 10% ensured all areas of the 
specimen were imaged. 
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Once the individual ICS images were acquired, they were stitched together using 
Image  Stitching  software  designed  at  the  Gray  Cancer  Institute.  The  image 
overlap was removed during this process. The final image was stored in a tiff file 
format.  
 
The  information  within  the  image  was  stored  as  an  8 bit  format.  The  value 
ranged from 0 to 255 for each red, green and blue colour. Total colour absence 
gave a value of 0, and total saturation a value of 255. This quantified the colour 
in each image. 
 
5.1.11 Linear Unmixing and Calculation of the Hypoxic Fraction 
Using the TRI2 software developed at the Gray Cancer Institute, the intensity 
and percentage of the IHC staining was assessed by a linear unmixing process, 
which  separated  the  brown  horseradish  peroxidase  stain  from  the  other 
background colours within the tissue. 
 
The  digitised  image  was  re sampled  to  between  50  to  100%  of  the  standard 
format otherwise the software could not deal with the size of the tiff file. The 
ROI was outlined to include all the histological area. Necrosis, connective tissue, 
stroma, and acellular regions [2,3] were excluded. The mask generated from this 
process  was  reviewed  and  edited  accordingly.  Positively  stained  cells  were 
identified under the microscope, and reference colours were selected both for 
this, and the background haematoxylin. The H+E stained sections were reviewed 
at the HN multi disciplinary team meeting at UCLH, and the tumour containing 
areas noted. At the time of linear unmixing, the H+E section was recalled and 
reviewed next to the IHC image to further aid delineation. Concerns regarding 
the tumour delineation were discussed with the Dr A Jay. 
 
Reference maps where generated through the linear unmixing process separating 
the brown (horseradish peroxidase), and blue (haematoxylin) colours within the 
stained tissue.   
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The  positively  stained  brown  IHC  image  was  processed  further.  A  colour 
intensity histogram was generated following re application of the mask to the 
excluded region and the total area calculated through histogram normalisation. 
Upper  and  lower  limits  were  altered  to  exclude  non specific  staining  due  to 
artefact and background. The stained area was noted, and used to calculate the 
hypoxic  fraction.  Analysis  of colour intensity  through computer software has 
been reported by other groups [4,5].  
 
Figure 5.5 a to d illustrates this process. Figure 5.5.a the IHC stained specimen 
for pimonidazole with no staining within the necrotic region, b) with the ROI 
masked in green, c) with the unmixed brown image (pre threshold) with the mask 
applied in red, and d) the final unmixed thresholded stain for pimonidazole. 
 
 
   
Figure 5.5a and b: The immuno histochemically stained specimen with pimonidazole from 
patient 1 a), and the image with mask applied b) 
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Figure  5.5c  and  d:  The  unmixed  pre thresholded  image  c)  and  the  final  thresholded 
unmixed image for pimonidazole staining d) 
 
The equation used to calculate the area hypoxic fraction is shown. 
 
 
Hypoxic fraction   =           Thresholded stained area       x 100 
                                                  Total stained area  
 
 
5.1.12 Grid Calculation of the Hypoxic Fraction and Correlation between 
Hypoxic Markers 
The thresholded linear unmixed image was then further assessed to calculate the 
hypoxic  fraction  to  corroborate  the  first  method.  Hypoxic  stains  are  positive 
when  the  pO2  is  less  than  10mmHg.  Negative  staining  acted  as  an  internal 
control.  
 
The linear unmixed images were orientated using Adobe Photoshop Elements 8. 
Then the image was loaded into the TRI2 software, resampled and binned. The 
images were re aligned (if required), and scaled to ensure that the size of each 
stained  specimen  corresponded.  A  10  x  10  (whole  mount)  or  a  6  x  6  grid 
(standard histological sized slides) was placed over each image, and the grids 
linked so that adjustment occurred in unison. The edge of the grid was placed 
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against the edge of the specimen, and the grid size was adjusted to encompass the 
image. The percentage staining was calculated within each grid as well as the 
mean intensity of staining. Only grids 100% encompassed within the specimen 
were used rather than grids that crossed the edge of the specimen.  Pimonidazole 
was compared and correlated with GLUT1, CAIX, and HIF1a, as well as GLUT1 
with CAIX, and HIF1a, and CAIX with HIF1a. Figure 5.6 a to d illustrates this 
process.  
 
   
   
Figure 5.6a to d: The unmixed and thresholded immuno histochemical stained specimen for 
patient 1 for pimonidazole a), the corresponding grayscale image with grid placement b), 
the unmixed, thresholded image for GLUT1 c), and the corresponding grayscale image d) 
 
a  b 
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Figure  5.6  a)  illustrates  the  aligned  unmixed  and  thresholded  stain  for 
pimonidazole  a),  the  image  converted  to  grayscale  b)  with  a  10  x  10  grid 
placement. Figure 5.6c) aligned unmixed and thresholded GLUT1 stained image, 
and d) the corresponding grayscale image with grid placement for one of the wax 
embedded blocks from patient 1. 
 
5.1.13 Time Activity Calculation 
The  uptake  of 
64Cu ATSM  in  Bq/ml  was  calculated  using  the  Xeleris  (GE 
Healthcare  Medical  Systems,  WI,  USA)  software  in  the  Nuclear  Medicine 
Department.  
 
The  patient  data  was  retrieved  from  optical  archive,  and  imported  into  the 
software. The 3D PET AC data set was selected. The images were summed by 
location to plot the uptake of 
64Cu ATSM with time. The window was adjusted 
to  view  the  uptake.  The  tumour,  necrosis,  IL  and  CL  salivary  glands 
(submandibular, +/  parotids), carotid artery, posterior neck, and the CL SCM 
were outlined as ROI. The plot icon was selected, and a text file created for the 
uptake  of 
64Cu ATSM  within  each  ROI  for  each  image  frame.  The  screen 
capture showing the ROI panel on the left and colour outlined ROI on each frame 
in the top right of the image is shown in figure 5.7. 
 
   
Figure 5.7: The screen capture from the Xeleris software indicating the delineation panel 
and outlined regions of interest 
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5.1.14 Tumour Ratio Calculation 
This uptake of 
64Cu ATSM was reviewed over time. The first 5 minutes after 
injection indicated fluctuant uptake, and from 5 to 60 minutes this stabilised and 
plateaued. Figure 5.8 illustrates the fused coronal CT PET frame at 1 minute 
after injection with activity in the bilateral vasculature of the neck. 
 
 
Figure  5.8:  Fused  coronal  CT PET  frame  at  1  minute  with 
64Cu ATSM  activity  in  the 
bilateral vasculature of the neck  
 
Tumour ratios were calculated at 5 to 20 minutes and 40 to 60 minutes for the 
dynamic list modes image sets. The 18 hour uptake ratio was calculated for the 
entire 1 hour imaging as the frames were acquired statically and could not be re 
binned. 
 
The image sets were again retrieved for each patient from optical archive, and 
transferred to the Xeleris Workstation. The PET AC frames were loaded, and 
those of interest were selected. For example: 5, 6, 7, 8, 9, 10 and 15 minutes 
frames for the 5 to 20 minute images, and 40, 45, 50 and 55 minute frames for 
the 40 to 60 minutes images.  
 
The selected PET frames were loaded into the Xeleris Dynamic PET application. 
The images were summed by time, saved and re archived. Next, the data sets 
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Healthcare Medical Systems, WI, USA) along with the CT HN. These data sets 
were  loaded  into  the  PET/CT  Review  application  of  this  software.  This  was 
because the Xeleris software was required to re bin the required frames, and 
Advantage Workstation software allowed the ratio calculation per axial image. 
 
The CT, PET, and fused images were reviewed in the axial, coronal and sagital 
planes, slice by slice. The images were thresholded to remove the saturation and 
aid delineation of the ROI. The display icon was selected, and a sphere drawn 
and placed within the ROI.  Each sphere was edited to ensure that it did not 
extend outside the ROI. The maximum value within the sphere was noted. This 
process was repeated for each slice. The minimum sphere size of 97mm
3 was 
used in the carotid artery. This is shown in figure 5.9 with the spheres numbered 
and delineated in red in the coronal a), and axial b) planes. The numbers on the 
image correspond to the sequential placement of each ROI to calculate the ratio 
 
         
Figure  5.9:  The  coronal  a),  and  axial  b)  image  of  the  fused  CT PET  with  the  spheres 
sequentially numbered and delineated in red 
 
 
Following this, the ratio was calculated for each point on each axial image, and 
then averaged. This method produced a more representative indication of 
64Cu 
ATSM  uptake  because  each  axial  slice  was  reviewed  rather  than  the  whole 
volume as a single ROI. 
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5.1.15  Correlation  of  Immuno Histochemical  Staining  with 
64Cu ATSM 
Uptake 
The IHC unmixed and thresholded images were aligned and a grid correlation 
undertaken to assess the mean grayscale intensity in each image. 
 
The fused CT PET, and  IHC unmixed thresholded images were converted to 
grayscale using Adobe Photoshop Elements 8. The fused CT PET image was 
used rather than the PET alone because this provided anatomical information so 
the uptake within the tumour ROI of 
64Cu ATSM could be accurately delineated. 
The grayscale conversions ensured that the same intensity score was used for 
each image.  
 
The information gained during the pathological dissection was reviewed. The 
specimen  size  was  noted  along  with  the  dimensions  of  the  macroscopic 
specimen.  The  distance  from  the  edge  of  the  tumour    (anterior  to  posterior, 
superior  to  inferior,  and  medial  to  lateral)  to  the  cut  surface  at  the  time  of 
dissection  was  evaluated.  The  reconstructed  CT PET  slices  were  3.27mm  in 
thickness, and each CT PET image was reviewed to ensure the CT PET slice 
visually  corresponded  to  the  fresh  and  formalin  fixed  specimen.  Then  the 
appropriate  CT PET  image  was  selected,  which  corresponded  with  the  IHC 
specimen. 
 
The images  (CT PET and unmixed thresholded IHC) were aligned and loaded 
into the TRI2 software. Any further alignment (rotation, size scaling) to ensure 
that the images were the same size was done at this stage.  Next a 10 x 10 (whole 
mount)  or  a  6  x  6  grid  (standard  histological  slides)  was  placed  onto  the 
corresponding images. The grid was adjusted so the edge of the grid was on the 
edge of the CT PET volume or IHC image. The mean intensity per grid was 
calculated by the TRI2 software and exported into an excel spreadsheet. Only the 
grids that were 100% inside the ROI were used in the analysis. 
 
Next  the  mean  intensities  gained  were  at  opposite  ends  of  the  grayscale 
spectrum. The IHC image intensity was inverted (255   mean intensity) for each 
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normal  tissue  when  imaged  by  CT.  The  grids  containing  normal  tissue  were 
reviewed, and for example if the mean intensity in the grid was 80, then 80 was 
subtracted from the mean grid intensity to ensure that the measured value only 
represented 
64Cu ATSM uptake. 
 
This process was repeated for each IHC stained specimen from each block for 
each patient, as well as for each stain on the CT PET images at 5 to 20 minutes, 
40 to 60 minutes, and at 18 hours after 
64Cu ATSM injection. Figure 5.10a and b 
illustrates the grid placement on the grayscale IHC image of pimonidazole a), 
and grayscale fused CT PET image at 40 to 60 minutes b). The threshold has 
been adjusted on the pimonidazole image for reproduction purposes. 
 
      
Figure 5.10a and b: Pimonidazole stained grayscale image with grid placement (10 X 10) a), 
and the grayscale fused CT PET image at 40 to 60 minutes b) 
 
 
5.1.15 DCE CT Parameter Calculation 
Two  separate  software  packages  were  used  within  the  Nuclear  Medicine 
Department for analysis of the DCE CT data. 
 
5.1.15.1 WinFun 
Firstly, WinFun (Cambridge Computed Imaging, Bourne, UK) is a validated [6] 
functional image analysis software package for Windows. This is based on the 
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information from time density data from  a single location DCE CT sequence 
through  a  pre determined  ROI.  The  tissue  perfusion  is  determined  from  the 
maximum  gradient  of  the  tissue  time density  curve  divided  by  the  peak 
enhancement within an arterial vessel. Data is gained from the curve because 
changes  in  the  CT  x ray  beam  attenuation  reflect  changes  in  the  iodinated 
contrast concentration in the ROI with time. A calibration factor can be added to 
the algorithm within the software (from phantom studies) and is related to the 
iodine concentration within the contrast and the attenuation within the CT PET 
camera [7]. 
 
All 88 DCE CT images for the ROI were loaded into the software. There were 8 
image sets, each with 11 frames that represented the 4cm scanned section (0.5cm 
per  image  set).  The  pre contrast  to  post contrast  frames  were  reviewed  and 
selected so that the images were all from the same axial slice. Using the DICOM 
(Digital Imaging and Communications in Medicine) 3.0 protocol the unwanted 
images were deleted.  
 
The first pre contrast frame was selected. The images were then reviewed within 
that 8 frame set to assess for mis selection of pre, peri and post contrast images 
due to patient movement. The tumour and IL carotid artery were delineated on 
the contrast containing image. The arterial ROI allowed the calculation of the 
AIF, and so the maximum enhancement within the tumour. The process icon box 
was selected, and the window width was set at 400, and window level at 40. The 
software calculated the dynamic parameters of: AIF, CP, BV and perfusion. The 
CP was calculated by Patlak analysis. This process was repeated to analyse all 11 
frames. 
 
5.1.15.2 Advantage WorkStation for Windows  
Secondly,  the  CT  perfusion  4  application  was  used  on  the  Advantage 
Workstation.    This  application  has  previously  been  validated  in  DCE CT 
perfusion  studies  in  patients  with  SCCHN  [8]  and  uses  a  deconvolution 
algorithm. Deconvolution techniques in SCCHN are the most widely used to 
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output and the possible delay in the passage of intra venous bolus contrast in the 
vascular pathways above the aorta. This software defined the following terms: 
 
BF:  
The volume flow rate of blood through the vasculature in the define ROI. This 
was calculated as BV/MTT. 
 
BV:    
The volume of blood within the vasculature of the ROI that flowed and did not 
stagnate. This was calculated by the area under the tissue enhancement curve 
divided by the area under the arterial enhancement curve. 
 
MTT: 
The average time taken by the blood to traverse the vasculature from the arterial 
to the venous end of the bed. This was calculated from the deconvolution of the 
arterial and tissue enhancement curves. 
 
Permeability Surface Area/Capillary Permeability: 
Total surface area of capillary endothelium in a unit mass of tissue representing 
the total diffusional flux across all capillaries (=1 –BF[In(1 E)], E is the fraction 
of contrast that leaks into the extra vascular space from the intra vascular space 
(extraction fraction)). 
 
The DCE CT was selected and loaded into the application. The body tumour 
protocol selected, and the HU set at  50 to 150. The ROI was drawn over the IL 
carotid artery, ensuring the boundary was within the vessel wall, and the ROI 
locked. The last pre and post contrast images were selected and then computed 
by the software. The tumour ROI was drawn on each axial image. The software 
numbered the ROI from 3 to 10 from superior to inferior. The BF, PS, MTT, BV 
parameters were automatically calculated by the software. 
 
5.1.16 Correlation of Perfusion with 
64Cu ATSM Uptake 
The axial CT PET fused images were reviewed, and saved for patient 5 at 5 to 20 
minutes, 40 to 60 minutes, and at 18 hours after 
64Cu ATSM injection. The ROI   253
outlined using the Advantage GE Healthcare CT Perfusion 4 software was also 
reviewed, and the corresponding axial CT PET and BF images selected. 
 
Using Adobe Photoshop Elements 8, the images were converted to grayscale, 
and assessed for alignment, as before. The images were converted to grayscale to 
allow the uptake of 
64Cu ATSM, and perfusion to be assessed for mean intensity 
because otherwise the correlation would not have been representative due to the 
different  colour  scales  used  (Blue  perfusion,  and  rainbow  for  CT PET).  The 
grayscale perfusion and corresponding CT PET axial images were loaded into 
the TRI2 software. Alignment was re assessed, and images scaled and rotated to 
correspond if required. A 10 x 10 grid was placed over each image with the 
edges of the grid aligned to the edges of the ROI. As before the mean intensity of 
the grayscale was assessed per grid for each image. 
 
Figure 5.11a to f illustrate this process. Figure 5.11a and b show the fused CT 
PET, and corresponding grayscale axial images for ROI 5 from patient 5. Figure 
5.11c  and  d  illustrate  the  blood  flow  for  this  ROI  and  the  corresponding 
grayscale image. Figures 5.11e and f illustrate the aligned grayscale blood flow 
and fused CT PET images with a 10 x 10 grid placement for analysis of the mean 
grayscale intensity.  
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Figure 5.11a to f: Aligned axial fused CT PET a), corresponding grayscale b), blood flow c), 
corresponding grayscale image d), grayscale blood flow image aligned with grid e), and 
grayscale CT PET image aligned with grid f) and of ROI 5  
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5.1.16 Hypoxic Volume Calculation on CT PET 
The  use  of  SUV  as  a  semi quantitative  measure  of  uptake  has  only  been 
validated in 
18FDG clinical imaging. The hypoxic FV has been calculated as a 
tumour to muscle, tumour to background, and tumour to blood ratio.  
 
Currently four clinical studies have used of these ratios. These include tumour to 
muscle ratios greater than or equal to 2 (CL SCM) [12], greater than or equal to 
3.0 (SCM) [13], greater than or equal to 3.5 (gluteal) ratio [14], or greater than or 
equal to 2.6 (internal pelvis) [15].  
 
5.1.17 Hypoxic Functional Volume Delineation 
The  hypoxic  FV  was  delineated  from  the  calculated  tumour  to  muscle, 
background, and blood ratios. The CT HN and the summed PET images at 5 to 
20 and 40 to 60 minutes, and those from the late imaging where selected and 
individually loaded into the single visit application of the PETVCAR software. A 
bookmark was placed in the ROI as previously described in Chapter 4, and the 
threshold was individually calculated from the values gained from the CL SCM, 
carotid artery and posterior neck. This ensured that the FV was delineated and 
calculated according to a ratio of 2.0, 2.5, 3.0, 3.5, and 4.0. This thresholding 
process was repeated for each ratio value. 
 
5.2 Statistical Analysis 
 
The distribution of the data was measured for normality by the Shapiro Wilks 
test. 
 
The  tumour  ratios  on  each  axial  slice  were  normally  distributed,  and  were 
compared at 40 to 60 minutes, and 18 hours post 
64Cu ATSM injection to 5 to 20 
minutes using the paired t test. 
 
All  the  other  data  was  not  normally  distributed  and  was  assessed  by  non 
parametric methods. The uptake of 
64Cu ATSM within the tumour ROI and other   256
ROIs  measured  during  dynamic  acquisition  according  to  time  on  the  Xeleris 
workstation was directly compared by the WCSRT.  
 
The percentage staining of pimonidazole, GLUT1, CAIX, and HIF1a per grid 
was  assessed  by  the  WCSRT  to  evaluate  the  differences  between  percentage 
staining, and Kendall’s correlation co efficient to investigate the presence and 
strength of a relationship between two variables.  
 
The mean grayscale intensity in each grid measured on the aligned CT PET and 
DCE CT axial images, and the IHC unmixed stained specimens and CT PET 
images as 5 to 20 minutes, 40 to 60 minutes and at 18 hours after 
64Cu ATSM 
injection were evaluated by the WCSRT, and Kendall’s correlation co efficient.   257
5.3 Results 
 
5.3.1 Patient Characteristics 
Forty four patients were screened, and six patients consented. Table 5.3 shows 
the patient characteristics and table 5.4 the presenting symptoms, smoking and 
alcohol history.  
 
Patients 3 and 6 highlighted in blue did not enter the study. Patient 3 could not be 
imaged because the cyclotron at St Thomas’ Hospital flooded preventing isotope 
production. Patient 6 failed on two occasions because initially the target did not 
move into the beam of the cyclotron, and then the isotope failed post production 
quality assurance due to radio lysis. Patient 2 indicated in violet was only imaged 
for 25 minutes. 
 
Table 5.3: Patient characteristics
  
Patient  Age  Gender  Primary 
Site 
T M 
Classification 
Planned Surgery 
1  65  Female  Unknown  Tx N2b M0  Modified right 
radical Neck 
dissection 
2  73  Male  Transglottic  T4 N2c M0  Laryngectomy and 
nodal sampling 
3  62  Male  Transglottic  T4 N0 M0  Laryngectomy 
4  63  Male  Transglottic  T4 N0 M0  Laryngectomy 
5  54  Male  Unknown  Tx N3 M0  Modified right 
radical Neck 
dissection 
6  63  Male  Transglottic  T4 N0 M0  Laryngectomy 
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Table 5.4: The presenting symptoms, smoking and alcohol history  
Patient  Presenting Symptoms  Pack  
Year  
History 
Units 
of 
Alcohol  
Per  
Week 
1  Right neck mass for 2 months  50  0  
2  3 months hoarse voice and local discomfort  120  10  
3  Shortness of breath, stridor and 3 months hoarse 
voice 
80  0  
4  6 months hoarse voice  23  10  
5  Right neck mass for 3 months  50  10  
6  4 months hoarse voice and shortness of breath  68  20  
 
 
5.3.2 Protocol Adherence 
 
5.3.2.1 Imaging 
Out of the 4 patients imaged, patient 1, 4, and 5 completed the imaging protocol 
as planned.  
 
Patient 1:  1 hour 3D dynamic CT PET only 
 
Patient 4:  1 hour 3D dynamic CT PET, followed by a DCE CT 
 
Patient 5:    1 hour 3D dynamic CT PET followed by a DCE CT, and 
late  static  1 hour  CT PET  18hours  after 
64Cu ATSM 
injection 
 
Patient  2  was  unable  to  tolerate  lying  on  the  scanner  couch  because  of 
longstanding lumbar spondylosis, and the development of claustrophobia. The 
scanning protocol was terminated 25 minutes after injection. This patient was 
imaged 24 hours after injection with analgesia.   259
All  patients  were  injected  with  505  to  595MBq  of 
64Cu ATSM.  Following 
injection the syringe was placed under a Geiger counter and the residual activity 
within the syringe calculated by the Superintendent Radiographer. This was 12.9 
to 18.6MBq. There were no adverse reactions with 
64Cu ATSM. Late imaging 
was completed 18hours after injection of 
64Cu ATSM, and was the first imaging 
appointment of the day within the department. 
 
5.3.2.2 Pimonidazole Administration 
All patients received 0.5g/m
2 of pimonidazole intravenously a minimum of 18 
hours prior to surgery with no adverse reactions. 
 
5.3.2.3 Pathological Review 
The specimens from all patients underwent standard pathological assessment by 
a single pathologist in 3 cases. The specimen was reviewed by the Pathologist 
and macroscopic dissection guided by the primary site and the appearance. For 
example to establish the presence of extra capsular spread.  
 
Figure 5.12a to d illustrates a specimen from patient 1. Figure 5.12a shows the 
formalin fixed  inked  macroscopic  specimen  on  the  surgical  template,  with  a 
visible gelatinous area of necrosis within the matted LN.  The specimen was 
dissected cranio caudally in the coronal plane. Figure 5.12b shows the specimen 
after this dissection process in plastic cassettes prior to wax embedding, and c) 
the  final  processed  wax  embedded  tissue  blocks.  Arrows  indicate  areas  of 
necrosis and SCC within the specimen. 
   260
                   
         
         
Figure 5.12a to c: The macroscopic pathological dissection of the specimen from patient 1. 
a) formalin fixed, b) dissected, and c) wax embedded specimen 
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5.3.3  Uptake  of 
64Cu ATSM  Within  Regions  of  Interest  During  Dynamic 
Imaging  
The uptake of 
64Cu ATSM within the tumour was assessed as well as in the CL 
SCM, posterior neck (post neck), the CL carotid artery, and the salivary glands  
(CL and IL). In patients 1 and 5, this has also been expressed in relation to the 
uptake of 
64Cu ATSM in the regions of necrosis within the tumour. 
 
Unfortunately due to the premature termination of imaging for patient 2, uptake 
was not able to be assessed in this format, and could only be expressed as a ratio 
at 5 to 20minutes after injection. This was because after 5 minutes of imaging 
when the patient developed back pain, and Dr Kayani decided to statically image 
the patient instead. 
  
The maximum tumour uptake of 
64Cu ATSM peaked at 30 seconds and ranged 
between 1,207,190 and 1,914,251Bq/ml. This compared to the peak in the carotid 
artery of activity between 2,424,634 and 6,427,844Bq/ml. The maximum activity 
in  the  CL  SCM  was  between  430,758  and  531,687Bq/ml  at  1 minute  after 
injection. The maximum activity within the posterior neck was between 295,997 
and 668,346Bq/ml at 1 minute. Similarly, the maximum activity within the CL 
salivary glands was 378, 219 and 817,097Bq/ml, and 592,680 to 919,363Bq/ml 
in the IL salivary glands at 1 minute. Within areas of intra tumoural necrosis the 
maximum activity was between 506,632 and 616,086Bq/ml at 1 minute. In all 
patients the maximum activity within these regions had plateaued at 5 minutes 
after  the  injection  of 
64Cu ATSM.  Table  18  in  Appendix  1  indicates  the 
maximum  activity  of 
64Cu ATSM  with  time  between  0  and  60  minutes  after 
injection. 
 
Figures 5.13a to e illustrate the time activity curves for patient 1. Figure 5.13a) 
illustrates the activity in tumour and necrotic regions, tumour and the CL SCM 
b),  tumour  and  the  carotid  artery  c),  tumour  and  the  posterior  neck  d),  and 
tumour and the CL and IL salivary glands e). The time activity curves of patients 
4 and 5 are in figures 16 and 17 of Appendix 2.The uptake within the tumour 
(Bq/ml)  has  been  expressed  as  a  line  graph  with  the  corresponding  standard   262
deviation  at  each  image  frame  during  the  1 hour  dynamic  imaging  process 
immediately following the injection of 
64Cu ATSM.  
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Figure 5.13a: Uptake of 
64Cu ATSM within the tumour and intra tumoural necrotic region 
of patient 1 
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Figure  5.13b:  Uptake  of 
64Cu ATSM  within  the  tumour  and  contra lateral 
sternocleidomastoid muscle of patient 1   263
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Figure  5.13c:  Uptake  of 
64Cu ATSM  within  the  tumour  and  within  the  contra lateral 
carotid artery of patient 1 
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Figure 5.13d: Uptake of 
64Cu ATSM within the tumour and posterior neck of patient 1 
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Figure 5.13e: Uptake of 
64Cu ATSM within the tumour and salivary glands of patient 1 
 
 
The tumour uptake ranged at 5 to 60 minutes between 228,291 to 425,795 Bq/ml, 
with the greatest activity in the tumour from patient 1. 
 
The uptake of 
64Cu ATSM was significantly greater in the tumour between each 
frame for the posterior neck (p=0.004, median difference 75,116Bq/ml, 95% CI 
182,335 to 146,2311Bq/ml), intra tumoural necrotic region (p=0.0002, median 
difference 87,828Bq/ml, 95% CI 47,277 to 117,851Bq/ml), and the CL salivary 
glands  (p=0.017,  median  difference  74,771Bq/ml,  95%  CI  9,452  to  126,393 
Bq/ml). There was no significant difference in the uptake between the tumour 
and IL salivary glands, carotid artery, and contra lateral SCM. 
 
5.3.4 Tumour Ratios 
The tumour ratio of 
64Cu ATSM uptake was calculated within each axial CT 
PET slice and other regions of interest at 5 to 20 minutes, 40 to 60 minutes, and 
18 hours after injection. The range of values for each patient across the ROI are 
illustrated in table 5.5a to c for 5 to 20 minutes, 40 to 60 minutes and the 18 hour 
time  points  respectively.  Tumour  to  muscle  represents  the  tumour  uptake   265
compared to that within the CL SCM, tumour to blood compares the uptake to 
that within the carotid artery, and the tumour to background compares the uptake 
of 
64Cu ATSM to that within the posterior neck. 
 
Table  5.5a:  The  ratio  of 
64Cu ATSM  uptake  compared  to  that  within  other  regions  of 
interest 5 to 20 minutes after injection  
Range of Ratios  Patient 
Tumour 
to 
Muscle 
Tumour 
to 
Blood 
Tumour to 
Background 
Tumour 
to 
 ecrosis 
Tumour 
to CL 
Salivary 
Gland 
Tumour 
to IL 
Salivary 
Gland 
1  2.39  to 
5.22 
1.57  to 
3.68 
2.08 to 4.38  3.13  to 
3.33 
1.17  to 
1.38 
1.14  to 
1.65 
2  2.32  to 
7.82 
2.55  to 
4.97 
3.06 to 7.02     1.76  to 
2.57 
1.76  to 
2.66 
4  1.80  to 
6.10 
1.35  to 
5.23 
2.16 to 6.88     1.72  to 
2.30 
1.79  to 
2.82 
5  1.62  to 
3.40 
1.24  to 
2.95 
1.86 to 4.64  2.43  to 
2.92 
0.95  to 
1.33 
0.91  to 
1.39 
 
 
In all patients, the tumour uptake was greater than the uptake in the CL SCM 
muscle, blood, posterior neck and necrosis at 5 to 20 minutes, 40 to 60 minutes, 
and 18 hours after 
64Cu ATSM injection.  
 
The ratio of 
64Cu ATSM uptake within the intra tumoural necrotic region was 
also compared to the uptake within the CL SCM, carotid artery and posterior 
neck at the three points of interest. At 5 to 20 minutes the intra tumoural necrosis 
to CL SCM uptake ratio was 0.94 to 1.29, the necrosis to blood ratio was 0.67 to 
1.10, and the necrosis to background ratio was 0.94 to 1.25.  
 
For all the patients combined at 5 to 20 minutes the mean tumour to muscle ratio 
was 2.98 (SEM 0.19), the mean tumour to blood ratio was 2.32 (SEM 0.16), and   266
the mean tumour to background ratio was 3.22 (SEM 0.19). The mean tumour to 
IL salivary gland ratio was 1.68 (SEM 0.12), the tumour to CL salivary gland 
ratio  was  1.61  (SEM  0.10),  and  the  mean  tumour  to  intra tumoural  necrotic 
region ratio was 2.88 (SEM 0.12). 
 
Table  5.5b:  The  ratio  of 
64Cu ATSM  uptake  compared  to  that  within  other  regions  of 
interest 40 to 60 minutes after injection  
Ratio  Patient 
Tumour 
to 
Muscle 
Tumour 
to 
Blood 
Tumour to 
Background 
Tumour 
to 
 ecrosis 
Tumour 
to CL 
Salivary 
Gland 
Tumour 
to IL 
Salivary 
Gland 
1  3.64  to 
6.48 
2.08  to 
5.38 
2.67 to 5.71  3.56  to 
5.73 
1.31  to 
1.83 
1.66  to 
2.03 
2                   
4  2.93  to 
3.94 
2.44  to 
3.94 
2.65 to 3.15     1.51  to 
2.16 
1.47  to 
2.16 
5  2.13  to 
2.78 
2.13  to 
2.93 
3.08 to 4.78  2.60  to 
2.67 
0.50  to 
2.01 
1.34  to 
2.10 
 
 
The dash line indicates no imaging at that time point available to calculate the 
ratio. 
 
The ratio of 
64Cu ATSM uptake within the intra tumoural necrotic regions at 40 
to 60 minutes post injection was 0.97 to 1.31 when compared to the uptake in the 
CL SCM, 0.667 to 1.10 compared to the blood within the carotid artery, and 0.70 
to 1.38 when compared to the uptake within the posterior neck. 
 
The  mean  tumour  to  muscle  ratio  for  all  the  patients  combined  at  40  to  60 
minutes  was  4.02  (SEM  0.30),  tumour  to  blood  was  3.24  (SEM  0.23),  and 
tumour to background was 3.84 (SEM 0.22). The mean complied tumour to IL 
salivary gland ratio was 1.73 (SEM 0.06), and the ratio with the CL salivary   267
gland was 1.66 (SEM 0.10), while the mean ratio to the intra tumoural necrotic 
region was 4.21 (SEM 0.44). 
 
Table  5.5c:  The  ratio  of 
64Cu ATSM  uptake  compared  to  that  within  other  regions  of 
interest 18 hours after injection  
Ratio  Patient 
Tumour 
to 
Muscle 
Tumour 
to 
Blood 
Tumour to 
Background 
Tumour 
to 
 ecrosis 
Tumour 
to CL 
Salivary 
Gland 
Tumour 
to IL 
Salivary 
Gland 
1                   
2  3.30  to 
6.75 
2.33  to 
5.07 
3.50 to 7.00    2.02  to 
3.03 
2.32  to 
3.75 
4                   
5  3.33  to 
6.56 
1.67  to 
5.46 
3.33 to 6.61  4.91  to 
6.54 
2.00  to 
3.42 
1.89  to 
3.22 
 
 
The mean ratio for tumour to muscle for the two patients was 4.73 (SEM 0.39), 
tumour to blood was 3.35 (SEM 0.32), tumour to background 5.06 (SEM 0.48).  
 
Table 5.6 illustrates the p values, mean difference and 95% CI for the paired t 
test for the ratios at 40 to 60 minutes compared to 5 to 20 minutes a), late 18 hour 
imaging compared to 5 to 20 minutes, and late imaging compared to 40 to 60 
minutes c).  
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Table 5.6a: Statistical results for the paired t test comparing the uptake ratio at 40 to 60 
minutes to the ratio at 5 to 20 minutes 
Ratio  p value  Mean  
Difference  
95% CI 
Tumour to muscle  0.001  1.10  0.66 to 1.55 
Tumour to blood  0.003  1.02  0.47 to 1.45 
Tumour to background  0.004  0.70  0.20 to 1.20 
Tumour to necrosis  0.004  2.22  1.42 to 3.01 
Tumour to CL salivary gland  0.287   0.07   0.33 to +0.19 
Tumour to IL salivary gland  0.214   0.12   0.41 to +0.18 
 
 
There was a significant increase in the ratios at 40 to 60 minutes compared to 5 
to 20 minutes. This was most significant for the tumour to muscle ratio. However 
there was no significant difference when the tumour to salivary gland ratio was 
compared. 
 
Table 5.6b: Statistical results for the paired t test comparing the uptake ratio at 18 hours 
after injection to the ratio at 5 to 20 minutes 
Ratio  p value  Mean  
difference 
95% CI 
Tumour to muscle  0.001  0.91  1.02 to 2.45 
Tumour to blood  0.004  0.99  0.36 to 1.32 
Tumour to background  0.001  1.86  1.06 to 2.67 
Tumour to necrosis  0.001  2.46  1.87 to 3.05 
Tumour to CL salivary gland  0.001  0.87  0.55 to 1.19 
Tumour to IL gland  0.008  1.02  0.51 to 1.53 
 
 
There  was  a  significant  increase  in  the  tumour  ratio  18  hours  after  injection 
compared to 5 to 20 minutes for all the regions investigated, although this was 
most significant for the tumour to muscle, tumour to necrosis, and tumour to CL 
salivary gland regions.   269
Table 5.6c: Statistical results for the paired t test comparing the uptake ratio 18 hours after 
injection compared to 40 to 60 minutes 
Ratio  p value  Mean  
difference 
95% CI 
Tumour to muscle  0.070  0.63   0.23 to +1.49 
Tumour to blood  0.477  0.02   0.74 to +0.79 
Tumour to background  0.015  1.16  0.25 to 2.02 
Tumour to necrosis  0.055  0.91   0.26 to +2.08 
Tumour to CL salivary gland  0.001  0.84  0.56 to 1.13 
Tumour to IL salivary gland  0.001  1.03  0.69 to 1.38 
 
 
There was a significant mean difference in the ratios between each axial slice for 
tumour to background, and tumour to salivary glands only. The difference in 
uptake with time is illustrated on the coronal fused CT PET images from patient 
5 in figure 5.14a) at 5 to 20 minutes, b) at 40 to 60 minutes and c) 18 hours after 
injection. Uptake is heterogeneous, and minimal uptake is seen within the region 
of necrosis. However the reduction in uptake within the salivary glands can be 
visualised with time. 
 
 
 
Figure 5.14 a: The uptake of 
64Cu ATSM within the tumour, salivary glands, and necrotic 
regions at 5 to 20 minutes  
a 
 ecrosis 
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Figure 5.14 b and c: The uptake of 
64Cu ATSM within the tumour, salivary glands, and 
necrotic regions at 40 to 60 minutes b) and 18 hours after injection c) 
 
 
5.3.4.1 Other Ratios 
Abnormal uptake of 
64Cu ATSM was noted in 2 patients. 
 
5.3.4.1.1 Mandible 
The uptake of 
64Cu ATSM was noted in the body of the left mandible in patient 
2. This is shown at 5 to 20 minutes and at 18 hours after injection in figure 5.15a 
and b respectively, and the corresponding uptake on 
18FDG CT PET 24 hours 
after 
64Cu ATSM injection c). The tumour to mandible uptake ratio at 5 to 20 
minutes was 0.87 to 1.44. The ratio was 3.39 to 4.15 when the uptake in the 
mandible was compared to the CL SCM, 2.71 to 3.66 compared to the blood, and 
3.02 to 3.93 when compared to the uptake in the posterior neck. 
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When this patient was imaged at 18 hours after the injection of 
64Cu ATSM the 
ratio with the muscle had reduced to 1.08 to 1.00, and that with the blood had 
reduced to 0.52 to 0.67, and that with the background had also reduced to 0.71 to 
1.17. The tumour to mandible uptake had increased with a ratio of 5.63 to 6.26. 
18FDG CT PET showed no FDG uptake within the region.  
 
 
 
Figure 5.15a to c: Fused CT PET axial image with increased 
64Cu ATSM uptake within the 
left mandible at 5 to 20 minutes a), reduced uptake at 18 hours after injection b), and no 
uptake on 
18FDG CT PET c) 
 
 
5.3.4.1.2 Right Shoulder 
Increased uptake of 
64Cu ATSM was noted in the right shoulder of patient 4. The 
ratio of 
64Cu ATSM uptake within the tumour and the right shoulder was 2.13 to 
2.57 at 5 to 20 minutes. The ratio of uptake during this time period within the 
a  b 
c   272
right shoulder was 2.66 to 3.42 when compared to that in the CL SCM, 1.55 to 
2.50 compared to the blood within the carotid artery, and 2.43 to 2.73 when 
compared to the uptake within the posterior neck.  
 
At 40 to 60 minutes the tumour to right shoulder ratio was 1.401. The ratio to the 
uptake in the CL SCM was 2.63, the blood was 2.10, and to the background was 
1.86. The change in 
64Cu ATSM uptake with time in this region is shown in 
figure 5.16a) at 5 to 20 minutes and b) at 40 to 60 minutes after injection. 
 
 
   
 
             
Figure 5.16a and b: The increased uptake of 
64Cu ATSM within the right shoulder at 5 to 
20 minutes a), and 40 to 60 minutes after injection b) 
 
 
5.3.5 Hypoxic Fraction 
Figures 5.17a to d show the wax embedded specimen a), and corresponding H+E 
staining b), and IHC pimonidazole staining c), and the corresponding fused CT 
PET image d).  In figure 5.17a the necrotic region is indicated with an arrow and 
a 
b   273
appears white. Creamy yellow SCC replaces the entire node, and skeletal muscle 
appears  dark  brown  at  the  bottom  of  the  specimen.  These  regions  are  both 
indicated by arrows. 
 
 
   
 
Figure 5.17a and b: The wax embedded tissue specimen a), and haematoxylin and eosin 
stained section from the corresponding wax block b) 
  
Figure 5.17b illustrates intense nuclear staining (haematoxylin – purple) within 
the tumour (arrowed). The eosin counter stain (pink) highlights this and also is 
positive for striated skeletal muscle. This stains gives a colloid appearance for 
the region of necrosis. 
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Figure  5.17c  and  d:  The  pimonidazole  staining  for  the  corresponding  wax  block  a)  for 
patient 1, and the CT PET fused image d) 
 
 
Figure  5.17c  shows  the  positive  pimonidazole  adduct  staining  (brown 
horseradish  peroxidase)  within  the  specimen.  There  was  no  pimonidazole 
staining  within  the  corresponding  area  of  necrosis.  There  is  generalised 
pimonidazole staining across the specimen, rather than focal staining suggesting 
the  entire  volume  of  tumour  has  a  pO2  less  than  10mmHg.  Figure  5.17d) 
indicates the tumour uptake and retention at 40 to 60 minutes of 
64Cu ATSM. 
There is a clear demarcation between reduced uptake within the necrotic region 
and tumour uptake. Pimonidazole staining and 
64Cu ATSM uptake and retention 
are absent in corresponding areas.  
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5.3.5.1 Calculated Hypoxic Area 
Table 5.7 illustrates the mean thresholded hypoxic fractional area for each IHC 
stain. The values for each specimen block were combined to gain the mean.  
 
Table 5.7: Mean hypoxic area fraction per block calculated from the linear unmixed image  
Patient  Hypoxic  
Immuno histochemical 
Stain 
Hypoxic  
Fractional  
Area (%) 
Pimonidazole  34.75 
GLUT1  29.22 
CAIX  10.90 
1 
(2 Tissue Blocks) 
HIF1a  8.54 
Pimonidazole  28.78 
GLUT1  34.33 
CAIX  21.44 
2 
(4 Tissue Blocks) 
HIF1a  11.56 
Pimonidazole  33.73 
GLUT1  36.78 
CAIX  31.01 
4 
(5 Tissue Blocks) 
HIF1a  20.59 
Pimonidazole  38.38 
GLUT1  56.26 
CAIX  22.78 
5 
(4 Tissue Blocks) 
HIF1a  15.91 
 
 
The mean hypoxic fraction for the combined patients was: pimonidazole 33.82%, 
GLUT1 43.85%, CAIX 23.01%, and HIF1a 14.39%. 
 
5.3.5.2 Calculated Percentage Staining per Grid  
Table 5.8a shows the median percentage staining per grid for each hypoxia IHC 
stain and the IQR for the combined specimen blocks for each patient, and table 
5.8b shows the data combined for all 4 patients.   276
Table 5.8a: Median percentage immuno histochemical staining within each grid for each 
patient and the corresponding inter quartile range 
Patient  Stain  Median  
Percentage 
Staining 
per Grid 
25
th 
Centile 
(%) 
75
th 
Centile 
(%) 
Inter 
quartile 
range 
(%) 
Range 
(%) 
Pimonidazole  44.58  28.37  59.92  31.55  6.31 to 
84.87 
GLUT1  49.26  31.35  53.71  27.36  6.35 to 
87.26 
CAIX  26.20  15.28  38.06  22.78  0.83 to 
70.35 
1 
HIF1a  8.348  3.65  15.21  11.56  0.70 to 
65.04 
Pimonidazole  35.19  14.81  48.64  33.83  1.02 to 
87.00 
GLUT1  46.01  25.12  63.93  38.81  3.06 to 
90.28 
CAIX  27.59  13.21  48.08  34.87  0.25 to 
98.43 
2 
HIF1a  11.96  3.41  23.70  20.29  0.11 to 
79.32 
Pimonidazole  54.26  29.44  71.43  41.98  1.29 to 
97.68 
GLUT1  58.78  34.24  74.51  40.27  5.72 to 
100.0 
CAIX  47.21  26.79  68.93  42.14  2.14 to 
99.51 
4 
HIF1a  22.69  10.00  36.54  26.54  0.00 to 
90.00 
5  Pimonidazole  27.72  15.42  40.91  25.48  1.03 to 
78.40   277
GLUT1  58.09  39.02  74.09  35.07  2.00 to 
97.98 
CAIX  10.20  3.85  28.28  24.43  0.00 to 
93.16 
 
HIF1a  14.48  4.28  28.38  24.09  0.00 to 
87.29 
 
 
Table 5.8b: Median percentage immuno histochemical staining within each grid and the 
corresponding inter quartile range for all the patients combined 
Stain  Median  
Percentage 
Staining per 
Grid 
25
th 
Centile 
(%) 
75
th 
Centile 
(%) 
Inter 
quartile 
range (%) 
Range 
(%) 
Pimonidazole  38.19  22.38  80.83  58.46  1.02  to 
100.00 
GLUT1  54.43  33.40  72.06  38.66  2.00  to 
100.00 
CAIX  24.06  8.35  48.08  39.73  0.00  to 
90.00 
HIF1a  14.12  4.32  28.32  24.00  0.00  to 
90.00 
 
 
The two methods used have produced similar results for the hypoxic fraction 
calculation and corroborate the findings. 
 
5.3.6 Immuno Histochemistry Correlation 
There  was  a  significant  positive  correlation  for  pimonidazole  staining  with 
GLUT1 (p<0.0001, correlation co efficient 0.450, 95% CI 0.437 to 0.583), CAIX 
(p<0.0001, correlation co efficient 0.584, 95% CI 0.535 to 0.629), and HIF1a  
(p0.001, correlation co efficient 0.297, 95% CI 0.231 to 0.360), when the IHC 
specimens were aligned and correlated for the area stained per grid and combined   278
for  all  the  blocks  for  all  4  patients.  On  an  individual  basis,  the  positive 
correlation was greatest for patient 4 for pimonidazole and GLUT1 (p<0.0001, 
correlation co efficient 0.708, 95% CI 0.640 to 0.765), pimonidazole and CAIX 
(p<0.0001,  correlation  co efficient  0.695,  95%  CI  0.623  to  0.754),  and 
pimonidazole and HIF1a (p<0.0001, correlation co efficient 0.475, 95% CI 0.371 
to 0.506). 
 
There was also a significant positive correlation when GLUT1, CAIX and HIF1a 
were  aligned  and  correlated  with  each  other  and  this  is  shown  in  table  5.9. 
However this is correlation was much weaker, especially for GLUT1 and HIF1a. 
 
Table 5.9: The correlation of GLUT1, CAIX and HIF1a immuno histochemical stains of all 
block from the 4 patients  
Correlated Stain  p value  Correlation 
Co Efficient 
95% CI 
GLUT1 and 
CAIX 
0.001  0.423  0.36 to 0.43 
GLUT1 and 
HIF1a 
0.02  0.107  0.04 to 0.18 
CAIX and HIF1a  0.001  0.237  0.13 to 0.23 
 
 
An example of the correlation between pimonidazole and GLUT1 is illustrated in 
figures 5.18 with the line of best fit drawn in green. Each circle represents an 
individual grid within the specimen. 
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Figure 5.18: Relationship between pimonidazole and GLUT1 staining per grid 
 
There was a significant difference in the percentage of staining within each grid 
when  the  stains  were  compared  to  each  other  using  the  WCSRT  and  this  is 
shown  in  table  5.10.  There  was  significantly  less  pimonidazole  staining 
compared  to  GLUT1,  and  significantly  greater  staining  of:  pimonidazole 
compared  to  CAIX  and  HIF1a,  GLUT1  compared  to  CAIX  and  HIF1a,  and 
CAIX compared to HIF1a within the specimens. 
 
Table 5.10: Difference in percentage staining per correlated grid  
Correlated Stain  p value  Median 
Difference (%) 
95% CI 
Pimonidazole 
and GLUT1 
<0.0001   10.19   12.09 to  8.34 
Pimonidazole 
and CAIX 
<0.0001  +7.08  +5.40 to +8.76 
Pimonidazole 
and HIF1a  
<0.0001  +17.41  +15.60 to +19.23 
GLUT1 and 
CAIX 
<0.0001  +19.75  +17.59 to +21.88   280
GLUT1 and 
HIF1a 
<0.0001  +24.73  +22.18 to +27.21 
CAIX and HIF1a  0.0002  +2.94  +1.27 to +4.73 
 
 
5.3.7 Physiological Dynamic Contrast Enhanced CT Parameters 
Two patients underwent DCE CT after the immediate CT PET (Patient 4 and 5). 
Only the data from patient 5 was used because patient 4 swallowed and raised 
their shoulders during the imaging acquisition. The resulted in the streak artefact 
on the CT images shown in figure 5.19 directly through the tumour ROI. The 
artefact was due to the attenuation of the x ray  beam through bone and soft 
tissue. The tumour is outlined in green, and the carotid artery on the IL side of 
the tumour has a red circle within it. An arrow indicates the area of hypo dense 
streak artefact. 
 
 
Figure 5.19: Axial CT of patient 4 with the streak artefact through the tumour region of 
interest 
 
Only 7 images out of 11 did not contain streak artefact and could be analysed. 
There  were  abnormal  parameters  in  these  images  of  44.62HU  maximum 
enhancement,  1ml/min/ml  perfusion,  69.11%  CP  and  8.19%  BV  which  were 
+181 
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falsely  high  for  patient  4.  The  tissue  enhancement  by  contrast  was  directly 
related to the streak artefact and beam attenuation. 
 
Table 5.11 illustrates the AIF, maximum enhancement in HU, perfusion, CP, and 
BV for each delineated ROI using the WinFun software for patient 5. Each ROI 
indicated  corresponds  to  the  frame  number  in  consecutive  order  from  the 
superior to inferior aspect of the tumour region. Region 9 represents the necrotic 
region within the most inferior ROI, 10 the CL SCM, 11 the CL sub mandibular 
gland, and 12 the scalene muscle in the posterior neck 
 
Table 5.11: Physiological parameters within the region of interest calculated by the WinFun 
software 
Region 
of 
Interest 
Arterial 
Input 
Function 
(HU) 
Maximum 
Enhancement 
(HU) 
Perfusion 
(ml/min/ml) 
Capillary 
Permeability 
(%/min) 
Blood 
Volume 
(%) 
1  214.89  25.47  0.78  21.47  2.73 
2  196.00  27.88  0.82  20.41  2.55 
3  194.50  26.95  0.75  25.87  1.60 
4  210.50  26.76  0.56  21.11  1.68 
5  206.50  26.74  0.58  22.68  1.28 
6  212.82  22.89  0.51  19.13  1.03 
7  217.08  25.47  0.44  19.53  0.90 
8  212.64  18.15  0.38  12.99  0.80 
9  218.80  3.57  0.11  3.46  0.25 
10  196.00  6.75  0.31  6.17  0.60 
11  196.00  23.48  0.63  25.39  3.66 
12  196.00  5.56  0.28  3.36  0.60 
 
 
The maximum enhancement within the necrotic region was 85.74% less than the 
combined maximum enhancement of ROI 1 to 7. This reduction was 73.04% in   282
the CL SCM, 6.23% within the CL submandibular gland, and 77.79% in the 
posterior neck.  
 
The perfusion within the necrotic region was 78.21% less than that within the 
combined tumour ROI, and 39.22%, and 45.09% less within the CL SCM and 
posterior  neck.  The  perfusion  within  the  submandibular  gland  was  23.53% 
greater than the tumour perfusion.  
 
The CP within the necrotic region was 83.04% less than that within the tumour. 
This compared with a 69.21% reduction in the CL SCM and 83.23% within the 
posterior neck. The CP within the salivary gland was also 26.69% greater than 
that within the tumour. 
 
The BV within the necrotic region was 84.08% less that that within the tumour, 
and 61.78% less within the CL SCM and posterior neck. However the BV within 
the CL submandibular gland was 133.12% greater than that within the tumour. 
 
Figure 5.20 a to c illustrates ROI 3 delineated by the WinFun software. Arrows 
indicate  the  tumour  ROI  delineated  in  red  and  the  carotid  artery  in  green. 
Contrast is present within the carotid artery and appears white. The scale is in 
HU.  Image  b  shows  the  maximum  enhancement  following  contrast 
administration which is colour mapped, and image c the CP in %/min. 
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Figure  5.20a  to  c:  Delineated  region  of  interest  a),  maximum  enhancement  b),  and 
permeability c) using the WinFun software 
 
Table 5.12 illustrates the physiological parameters defined by the CT Perfusion 4 
GE  Healthcare  software.  The  mean  value  for  the  ROI  is  shown.  Region  1 
represents the carotid artery, and region 9a necrosis within ROI 9. The other 
indicated ROI are in consecutive order from the superior to inferior aspect of the 
tumour  region.  Regions  10,  11,  and  12  represent  the  CL  SCM,  CL  sub 
mandibular gland, and scalene muscle of the posterior neck respectively. The 
values for ROI 9 are lower than the other tumour values because this contained 
the necrotic region and lowered all the calculated parameters. 
 
c 
b   284
Table 5.12: Physiological parameters within the region of interest calculated by the CT 
Perfusion 4 GE Healthcare software 
Region  of 
Interest 
Blood Flow 
(ml/min/100g) 
Blood 
Volume 
(ml/100g) 
Mean 
Transit Time 
(seconds) 
Permeability 
Surface Area 
(ml/min/100g) 
1 (Artery)  1000  65.70  1.94  0.00 
2  186.86  6.38  2.30  4.68 
3  169.52  5.69  2.18  9.81 
4  168.51  5.52  2.01  10.84 
5  159.23  5.67  2.54  9.75 
6  172.71  5.89  2.22  6.31 
7  142.45  5.02  2.49  5.04 
8  114.60  4.45  3.72  8.45 
9  129.90  4.54  3.01  2.78 
9a ( ecrosis)  15.04  0.80  11.26  0.61 
10  
(CL SCM) 
14.18  1.54  4.94  1.25 
11 
(CL Salivary 
Gland) 
87.02  6.15  5.20  0.64 
12 
(Posterior 
 eck) 
7.75  0.38  8.69  0.71 
 
 
The  mean  perfusion  values  across  the  tumour  ROI  were:  BF  155.47 
ml/min/100g, BV 5.40ml/100g, MTT 2.56 seconds, and PS 7.21 ml/min/100g. 
 
The mean BF within the necrotic region was 90.32% less than the maximum BF 
within the combined tumour ROI. The CL SCM muscle BF value was 90.88% of 
that within the tumour, the CL submandibular gland was 44.03% and posterior 
neck was 95.01% of that within the tumour.  
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The mean BV within the necrotic region was 85.17% less than that within the 
tumour.  The  BV  within  the  CL  SCM,  and  posterior  neck  was  71.45%  and 
92.96% less than that within the tumour respectively, and the CL submandibular 
gland was 13.97% greater then the tumour.  
 
The  maximum  MTT  was  341.18%  greater  in  the  necrotic  region  than  in  the 
tumour. This was 93.12%, 103.28%, and 239.72% greater in the CL SCM, CL 
submandibular gland, and posterior neck respectively.  
 
The maximum PS was 90.71% less in the region of necrosis than in the tumour, 
and 82.66%, 91.12%, and 90.15% less in the CL SCM, CL submandibular gland, 
and posterior neck respectively than the tumour. 
 
Figure 5.21 illustrates the corresponding axial images for ROI 9 defined by the 
GE Healthcare software. Figure 5.21a) is the DCE CT axial image, b) the BF, c) 
the BV, d) the MTT and e) the corresponding PS for the axial image. Purple 
arrows indicate the hypo dense region of necrosis within the ROI, and contrast 
within the carotid artery in figure 5.21a). 
   
 
 
In Figure 5.21b) BF across the image is low, but is greater within the ROI than 
the surrounding muscle. There is no BF within the necrotic region compared to 
a 
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the surrounding tumour. The carotid artery due to the high velocity of BF is 
bright red with values of 1000ml/min. An arrow indicates the submandibular 
gland and BF within this region is similar to that within the tumour region. 
 
 
 
The arrows in figure 5.21c) indicates the right carotid artery, region of necrosis, 
and tumour. The BV within the arterial vessel is greatest. The rim of tumour has 
a higher BV than the central area of necrosis. Similarly, the submandibular gland 
has a BV greater than the tumour. 
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Figure 5.21d) illustrates the colour map for the MTT. The MTT is fastest through 
the tumour region, and is slowest within the area of necrosis. The MTT within 
the submandibular gland is slower than that within the tumour. 
 
 
 
Lastly Figure 5.21e) illustrates the PS. This is heterogeneous across the tumour 
region. The arrow indicates the lower PS within the region of necrosis. 
 
 
Figure 5.21a to e: Axial images for region of interest 9 defined by the CT Perfusion 4 GE 
Healthcare software. The colour maps are: dynamic contrast enhanced CT a), blood flow 
b), blood volume c), mean transit time d), and permeability surface area e) 
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 5.3.8 Correlation of Blood Flow and 
64Cu ATSM Uptake 
There was a significant median difference between the grayscale intensity for BF 
measured by the DCE CT and 
64Cu ATSM uptake within the tumour region at 5 
to 20 minutes (p<0.0001, median difference 63.30, 95% CI 56.24 to 62.30), 40 to 
60 minutes (p<0.0001, median difference 48.53, 95% CI 46.37 to 50.66), and at 
18 hours (p<0.0001, median difference 54.71, 95% CI 53.05 to 56.28) after 
64Cu 
ATSM  injection.  This  showed  that  the 
64Cu ATSM  uptake  was  significantly 
greater than the BF within the region.  
 
At  5  to  20,  40  to  60  minutes  and  late  imaging  of  18  hours  there  was  no 
significant correlation between these two variables within the tumour region.  
 
However  when  the  necrotic  region  was  analysed  separately,  there  was  no 
significant correlation at 5 to 20 minutes, but there was a positive correlation at 
40 to 60 minutes (p=0.001, correlation co efficient 0.343, 95% CI 0.25 to 0.43) 
and at 18 hours post injection (p=0.001, correlation co efficient 0.288, 95% CI 
0.18 to 0.40). The correlation was weaker at 18 hours post injection compared to 
40 to 60 minutes. This showed that in necrotic regions when there was no BF 
there was minimal or no 
64Cu ATSM uptake. 
 
5.3.9 Correlation of Immuno Histochemistry and 
64Cu ATSM Uptake  
There was a significant correlation of pimonidazole, GLUT1, CAIX, and HIF1a  
IHC staining with the uptake and retention of 
64Cu ATSM at 5 to 20 minutes, 40 
to 60 minutes, and at 18 hours after injection for the combined grid data (all 
blocks for all patients). Table 5.13 illustrates these results. 
 
The correlation was most significant, and the co efficient strongest for GLUT1 at 
5 to 20 minutes, pimonidazole at 40 to 60 minutes, and HIF1a 18 hours after the 
injection of 
64Cu ATSM. 
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Table 5.13: The correlation between the hypoxic immuno histochemical staining and the 
64Cu ATSM uptake and retention 
Time  
after 
injection 
Stain  p value  Correlation  Co 
efficient  
95% CI 
Pimonidazole  <0.0001  0.513  0.45 to 0.57 
GLUT1  <0.0001  0.527  0.45 to 0.59 
CAIX  <0.0001  0.452  0.37 to 0.52 
5  to  20 
minutes 
HIF1a  0.001  0.363  0.28 to 0.44 
Pimonidazole  <0.0001  0.606  0.54 to 0.66 
GLUT1  0.001  0.225  0.12 to 0.33 
CAIX  0.01  0.122  0.04 to 0.20 
40  to  60 
minutes 
HIF1a  0.01  0.120  0.12 to 0.28 
Pimonidazole  <0.0001  0.504  0.41 to 0.59 
GLUT1  0.001  0.391  0.28 to 0.49 
CAIX  <0.0001  0.471  0.41 to 0.53 
18 hours 
HIF1a  <0.0001  0.538   0.48 to 0.60 
 
  
Figure 5.22a to c illustrate the spread of the data for the mean grayscale intensity 
of pimonidazole compared to the mean grayscale intensity of 
64Cu ATSM uptake 
on the fused CT PET images at 5 to 20 minutes, 40 to 60 minutes, and at 18 
hours after the injection of 
64Cu ATSM. The line of best fit is drawn in green. 
Again each circle represents an individual correlated grid. 
   290
0 30 60 90 120
0
30
60
90
120
Mean Cu-ATSM grayscale intensity per grid
Mean pimonidazole grayscale intensity per grid
 
Figure  5.22a:  The  mean  grayscale  intensity  of  pimonidazole  staining  and 
64Cu ATSM 
uptake at 5 to 20 minutes after injection 
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Figure  5.22b:  The  mean  grayscale  intensity  of  pimonidazole  staining  and 
64Cu ATSM 
uptake at 40 to 60 minutes after injection   291
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Figure  5.22c:  The  mean  grayscale  intensity  of  pimonidazole  staining  and 
64Cu ATSM 
uptake at 18 hours after injection 
 
5.3.10 Hypoxic Functional Volume Delineation 
The  hypoxic  FV  was  delineated  and  calculated  according  to  the  tumour  to 
muscle, tumour to blood and tumour to background ratios using the PETVCAR 
software.   
 
Figures 5.23 illustrates the delineated FVs according to the tumour to muscle 
ratios of: 2.0, 2.5, 3.0, 3.5, and 4.0 at 5 to 20 minutes, 40 to 60 minutes and 18 
hours  after 
64Cu ATSM  injection  for  patient  5  as  an  example.  As  previously 
shown,  as  the  ratios  increased  with  increasing  time  after  injection  of 
64Cu 
ATSM, and the defined FV increased accordingly. 
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Figure 5.23: 
64Cu ATSM defined hypoxic functional volume for patient 5 according to the 
tumour to muscle ratio 
 
Figure 18 a to c in Appendix 2 illustrates these defined hypoxic FV according to 
the tumour to muscle ratio for the other patients. 
 
Figure 5.24a and b illustrates the changes in FV delineated for patient 4 when 
defined by the tumour to muscle ratio of 2.5. The FV is delineated in green 
surrounded by a green boundary box. The red box indicates the reference region 
in the SCM muscle. The delineated hypoxic FV is greater at 40 to 60 minutes 
than at 5 to 20 minutes after injection. 
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Figure 5.24a and b: The delineated hypoxic functional volume and the reference region at 5 
to 20 minutes a) and 40 to 60 minutes b) after the injection of 
64Cu ATSM 
 
 
Table 5.14 indicates the actual hypoxic FV delineated for each tumour to muscle 
ratio. The hypoxic FV reduced as the defining ratio increased, and the volumes 
increased with time after the injection of 
64Cu ATSM. 
 
At  5  to  20  minutes  there  was  a  50.96%  to  100%  reduction  between  the  FV 
delineated by the 2.5 ratio, and that at the 4.0 ratio. This reduction was 53.27% to 
97.03% at 40 to 60 minutes, and 59.83% to 63.5% 18 hours after injection. 
a 
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Table 5.14: The hypoxic functional volume defined by the tumour to muscle ratio after the 
injection of 
64Cu ATSM 
Hypoxic  Functional  Volume  (cm
3)  Defined  by  the 
Tumour to Muscle Ratio 
Patient 
2.0 
 
2.5  3.0  3.5  4.0 
5  to  20 
minutes 
51.8  43.5  34.6  30.6  25.4  1 
40 to 60 
minutes 
61.2  49.1  40.9  36.4  32.6 
5  to  20 
minutes 
25.9  19.8  15.9  11.2  9.5  2 
Late  28.5  21.0  15.6  12.3  10.4 
5  to  20 
minutes 
3.1  1.2  0.0  0.0  0.0  4 
40 to 60 
minutes 
10.0  6.6  2.6  1.1  0.3 
5  to  20 
minutes 
32.3  19.8  5.1  3.5  0 
40 to 60 
minutes 
47.5  34.1  22.6  17.1  10.3 
5 
Late  60.5  43.6  33.4  28.9  24.3 
 
 
The  hypoxic  FV  defined  according  to  the  tumour  to  blood,  and  tumour  to 
background ratios were smaller than those defined by the tumour to muscle ratio 
and are shown in table 5.15 and 5.16 respectively. Similarly the volumes defined 
reduced with each increase in the defining ratio. 
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Table 5.15: The hypoxic functional volume defined by the tumour to blood ratio after the 
injection of 
64Cu ATSM 
Hypoxic  Functional  Volume  (cm
3)  Defined  by  the 
Tumour to Blood Ratio 
Patient 
2.0 
 
2.5  3.0  3.5  4.0 
5  to  20 
minutes 
25.4  19.2  13.5  4.4  1.1  1 
40 to 60 
minutes 
40.9  21.9  8.1  4.6  2.6 
5  to  20 
minutes 
22.1  15.9  11.2  8  5.7  2 
Late  15.6  9.9  7.0  4.6  3.2 
5  to  20 
minutes 
1.6  0.0  0.0  0.0  0.0  4 
40 to 60 
minutes 
7.3  3.5  1.4  1.3  0.0 
5  to  20 
minutes 
23.4  5.1  3.5  0.0  0.0 
40 to 60 
minutes 
30.1  17.1  4.9  1.2  0.0 
5 
Late  35.7  26.3  21.7  13.9  6.2 
 
 
The percentage reduction in the FV defined by the tumour to blood ratio of 2.5 
and  4.0  at  5  to  20  minutes  was  74.21%  to  100%.  At  40  to  60  minutes  this 
reduction was 93.64% to 100%, and at 18 hours after injection this was 79.47% 
to 82.63%. 
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Table 5.16: The hypoxic functional volume defined by the tumour to background ratio after 
the injection of 
64Cu ATSM 
Hypoxic  Functional  Volume  (cm
3)  Defined  by  the 
Tumour to Background Ratio 
Patient 
2.0 
 
2.5  3.0  3.5  4.0 
5  to  20 
minutes 
43.5  34.6  25.4  19.2  13.5  1 
40 to 60 
minutes 
49.1  40.9  21.9  8.1  1.4 
5  to  20 
minutes 
26.7  22.1  18.1  14.0  10.8  2 
Late  23.3  16.9  13.2  11.0  8.8 
5  to  20 
minutes 
4.5  1.6  0.5  0.0  0.0  4 
40 to 60 
minutes 
7.3  3.5  1.4  0.3  0.0 
5  to  20 
minutes 
47.7  32.3  19.8  10.2  3.0 
40 to 60 
minutes 
47.5  34.1  22.6  17.1  10.3 
5 
Late  60.5  43.6  33.4  28.9  24.3 
  
 
Lastly,  the  FV  delineated  by  the  tumour  to  background  ratio  at  2.5  and  4.0 
reduced by 59.55% to 100%. At 40 to 60 minutes this reduction was 78.31 to 
100%, and at 18 hours after injection this was 37.76% to 59.83%. 
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5.4 Discussion 
 
The  uptake  of 
64Cu ATSM  significantly  increased  with  time  after  injection 
within the tumour compared to other ROI such as the CL SCM. Hypoxia IHC 
staining  for  pimonidazole  was  generalised  across  the  tumour  volume,  and 
correlated with the other endogenous stains. The uptake and retention of 
64Cu 
ATSM on the fused CT PET images at 5 to 20 minutes, 40 to 60 minutes and 18 
hours after injection significantly correlated with all IHC hypoxia markers. There 
was no correlation on each axial image when this uptake was compared to BF. 
The hypoxic FV was greatest when defined by the tumour to muscle ratio, and 
reduced as the defining ratio increased. 
 
These results suggest that 
64Cu ATSM is retained within hypoxic tumour regions 
after injection, and may potentially act as a surrogate hypoxic radio nuclide in 
CT PET imaging. 
 
5.4.1 Uptake of 
64Cu ATSM on 3D Dynamic Imaging 
The activity of 
64Cu ATSM peaked within the arterial vessel at 30 seconds to 1 
minute  after  injection.  This  was  associated  with  the  bolus  injection  of 
64Cu 
ATSM into the venous network. It is assumed that during the first 5 minutes after 
injection, 
64Cu ATSM  moved  from  the  intra vascular  to  intra cellular 
compartment, and may have equilibrated with the intra cellular copper pool.  
 
In  EMT6  tumour  bearing  mice,  and  rat  xenograft  models, 
64Cu ATSM  was 
rapidly cleared from the blood pool within 5 minutes, and remained up to 4 hours 
after injection, at 2.22% to 7.88% of the injected dose [16,17]. This data from 
arterial sampling has the advantage of allowing the rate constant calculation for 
the transfer of the radio nuclide between compartments.  
 
In patients with NSCLC the organ residence time was calculated by an analytical 
integration method, and standardised for a 70Kg adult male. Arterial samples 
were also taken prior to 
64Cu ATSM injection, and then at 5, 15, 30, 60, and 90 
minutes. The activity at 5 minutes within the arterial blood pool was 12%, and at   298
90 minutes this had reduced to 8% of the injected dose. The calculated residence 
time within the blood pool was 1.25 +/  0.37 hours [18]. 
 
The detected activity of 
64Cu ATSM in the results from the chapter plateaued 
within all regions between 5 to 60 minutes after injection on dynamic image 
assessment. This gave a global evaluation of uptake over the ROI. Delineation of 
these ROI was on the PET only image and was open to error because of the lack 
of CT anatomical data to clearly define the edge of the region.  
 
The analysis of blood samples was possible within the study protocol due to the 
debate  in  the  literature  over  the  intra cellular  retention  pattern  both  of 
64Cu 
ATSM, 
64Cu, and the ATSM ligand. However, due to poor patient accrual blood 
samples were not taken. This was then planned for patients recruited at the Guy’ 
site. The venous samples would have been taken at 0, 2, 4, 6, 8, 10, 20, 30, 40, 
50, and 60 minutes after 
64Cu ATSM injection. Sample analysis would be able to 
calculate the percentage of the injected activity within the blood pool at later 
time points such as: 4, 6, 12, and 24 hours. The disadvantage of this sampling 
was patient inconvenience, potentially limiting compliance within the study.  
 
5.4.1.1 
64Cu ATSM uptake within the Salivary Glands 
Uptake was noted in the salivary glands at 5 to 20, 40 to 60 minutes and at 18 
hours  after 
64Cu ATSM  injection.  This  was  unusual  and  unexpected.  There 
currently is no published data on the bio distribution of any Cu isotope within the 
salivary gland.  The uptake of 
64Cu ATSM within the salivary glands may be a 
combination of incorporation into the copper intra cellular pool, utilisation in 
normal salivary function, and a correlation with the injected dose. 
 
In the rat SCCVII tumour model 
64Cu ATSM uptake was noted in the fronto 
nasal  sinus,  abdomen,  and  nasal  cavity  [19].  The  salivary  glands  arise  from 
ectodermal mesenchyme, and may impact 
64Cu ATSM uptake within the salivary 
glands.  Human  foetal  studies  have  suggested  increased  CAIX  expression 
continues into adult life in areas containing adult stem cells originating from 
embryonic coelom and mesenchyme  [20].   
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Pimonidazole  and  misonidazole  positively  stain  the intra lobular  ducts  of  the 
parotid gland on IHC [21,22]. This may be related to a lower pO2 and high levels 
of  NADH  reductase  within  the  major  and  minor  salivary  glands.  Under 
conditions of acute hypoxia, salivary flow increases in patients [23], and the 
serum amylase is also raised [24]. This will promote electron reduction of nitro 
imidazoles to a pimonidazole adduct for example. 
 
The normal copper retention and metabolism within the salivary glands may be 
implicated in the increased uptake of 
64Cu ATSM. A positive correlation exists 
between  the  amount  of  copper  within  the  saliva  and  plasma  [25].  This  may 
suggest a large bolus of radio nuclide in the blood increased the copper content 
within the salivary glands.  
 
Copper binds to salivary amylase at two metal binding sites [26], and is found in 
high  concentrations  within  the  rat  submandibular  gland  in  copper  containing 
super oxide  dismutase  [27].  Also  Menkes  protein  (copper  export  pump)  is 
located within acinar cells, further suggesting a role for copper secretion within 
the saliva [28].  
 
This interesting phenomenon could be further explored by correlating the uptake 
of 
64Cu ATSM in the blood with that in saliva samples after injection. Whole 
body CT PET imaging was planned within the study reported in this chapter but 
not undertaken due to poor patient accrual. It would be important to incorporate 
this  into  further  studies  using  copper  isotopes  to assess  the  whole  body  bio 
distribution of Cu ATSM. 
 
5.4.2 Uptake of 
64Cu ATSM According to the Calculated Tumour Ratios 
The Xeleris software was used to calculate the dynamic uptake of 
64Cu ATSM 
within a whole region. The disadvantage of this was that the activity could not be 
calculated for static images because dynamic data was required per frame, and 
that the activity was calculated over the entire ROI rather than per axial slice.  
 
SUV has been validated as a semi quantitative tool for uptake assessment of 
18FDG, but this cannot be used in uptake evaluation of other radio nuclides. The   300
ratios were calculated to represent the uptake within the tumour compared to 
other ROI. The uptake within the shoulder of patient 4 and mandible of patient 2 
could not be calculated by the Xeleris software because the uptake could not be 
cleared visualised on the PET only image.  
 
An important point is the tumour ratios are significantly different at  5 to 20 
minutes  and  40  to  60  minutes  compared  to  the  uptake  activity  measured  on 
dynamic  imaging.  The  measurement  methods  and  software  applications  are 
different therefore it is difficult to compare these results, and the differences in 
uptake and retention assessed by the Xeleris software are difficult to appreciate.  
 
5.4.2.1 Tumour to Muscle Ratio 
The calculated ratios have allowed the uptake of 
64Cu ATSM to be quantified in 
relation to normal tissue. These results are similar to those in animals were the 
uptake of 
64Cu ATSM was 4 times greater than or equal to normal tissue [16,29].  
 
The  data  suggested  the  retention  of 
64Cu ATSM  increased  with  time  after 
injection. The statistical difference in the tumour to muscle ratio was greatest at 
40  to  60  minutes  rather  than  18  hours  after  injection  when  compared  to  the 
uptake at 5 to 20 minutes. Even though only two patients were imaged 18 hours 
after injection there was still a significant difference in these ratios at this time 
point within each axial image. This variation suggests that hypoxia selectivity 
increases with time, and this may be due to the incorporation of 
64Cu ATSM into 
the intra cellular copper pools. Also as the retention within the tumour increases, 
the ratio will increase accordingly. The long half life of 
64Cu ATSM has enabled 
these differences to be seen. In NSCLC patients [18], tissue retention was greater 
than 8 hours in organs such as the liver when computer generated. Prolonged 
blood sampling and kinetic analysis would allow further evaluation of this. 
 
In the published clinical studies, tumour to muscle ratio’s have varied in patients 
with rectal cancer between 1.0 and 3.7 [15], in NSCLC between 1.2 to 4.8 [13], 
and in cervical cancer between 1.2 to 12.3 [14]. All these patients were imaged 
with 
60Cu ATSM, and these ratios corresponded to the uptake in the summed 
images at 30 to 60 minutes after injection.    301
5.4.2.2 Tumour to Blood Ratio 
The  mean  tumour  to  blood  ratio  at  5  to  20  minutes  was  only  2.32,  but  it 
significantly  increased  to  3.24  at  40  to  60  minutes,  and  3.35  at  18  hours 
compared to this initial time point. On closer inspection the lowest ratio at 5 to 
20 minutes was 1.57. It would be assumed that initial difference between these 
two regions should have been  greater. This may  indicate that 
64Cu ATSM is 
rapidly and non selectively distributed after injection, producing a reduction in 
the activity within the intra vascular compartment. This may be followed by  a 
more selective retention pattern. The time activity also showed that there was 
minimal difference initially with time. As the uptake within the tumour increases, 
and the uptake within the blood reduces due to the t1/2, metabolism and excretion. 
This leads to an increase in the calculated ratio. 
 
5.4.2.3 Tumour to Background Ratio 
Similarly, the tumour to background ratio significantly increased with time after 
injection. The uptake within the scalene muscle compared to the CL SCM was 
not appreciably different. Although the difference was greatest at 18 hours with 
only two patients imaged at this time point further studies are required to assess 
if  this  is  true  or  not.  The  mechanism  of  uptake  and  retention  within  the 
background  is  likely  to  be  similar  to  that  within  the  muscle  as  previously 
discussed due to the incorporation into the intra cellular Cu pool. 
 
5.4.2.4 Tumour to  ecrosis Ratio 
The increased uptake in the tumour compared to regions of necrosis suggests 
hypoxic but viable tissue is required for the retention of 
64Cu ATSM. In necrotic 
tissue the uncoupling of oxidative phosphorylation inhibits the uptake of Cu 
ATSM due to the lack of functioning mitochondria. In dogs, 24hour imaging 
after the injection of 
64Cu ATSM showed no Cu ATSM in necrotic regions in 
this canine myocardial perfusion model [30 32]. The examples shown in this 
chapter corroborated this by the lack of IHC pimonidazole staining and 
64Cu 
ATSM uptake in the same necrotic regions. The uptake and retention of 
64Cu 
ATSM was lower within the intra tumoural necrotic regions than the surrounding 
normal tissue for example CL SCM. Even though a region is necrotic, uptake at   302
the periphery may lead to partial volume effects, which increase the uptake noted 
within the necrotic region on CT PET imaging. 
 
5.4.2.5 
64Cu ATSM Uptake in Other Sites 
 
5.4.2.5.1 Mandible and Right Shoulder 
Abnormal uptake was noted within the mandible of patient 2 and the shoulder of 
patient 4. The tumour to ROI ratio was greater at 18 hours compared to 5 to 20 
minutes in patient 2. This suggested an initial non selective uptake and wash out 
of 
64Cu ATSM in these regions with time.  However, in patient 4 this uptake 
increased at 40 to 60 minutes in the shoulder because the calculated ratio reduced 
with time. In both patients the uptake within the ROI was greater than that in the 
CL SCM, blood, and posterior neck.  The changes in the tumour to blood and 
background ratios for both patients also reflected these findings. 
 
This  may  suggest  that 
64Cu ATSM  was  retained  due  to  a  hypoxia  related 
mechanism or copper dependent physiological pathway.  
 
Copper ions are pro or anti oxidant depending on intra cellular conditions. For 
example ions catalyse the conversion of superoxide to hydrogen peroxide and 
hydroxyl radicals leading to oxidative DNA damage [33]. Alternatively, they can 
act as an anti oxidant through Cu/Zinc superoxide dismutase and free radical 
production is reduced. Raised C reactive protein has been positively correlated 
with the serum copper concentrations in patients [34]. Ceruloplasmin, is the main 
copper  transport  protein  within  the  blood,  and  an  acute  phase  protein. 
Inflammatory  conditions,  and  infections  for  example  are  associated  with  an 
increased level of this protein, and increased copper concentrations within the 
blood [35,36].  
 
Both of the patients in this study had inflammatory conditions. Patient 2 had 
undergone  a  dental  extraction  2  weeks  prior  to  imaging,  and  patient  4  was 
diagnosed with an inflammatory peripheral neuropathy of unknown cause. The 
increased 
64Cu ATSM uptake in both sites may be secondary to inflammation.   303
Dental extraction may be associated reactive inflammatory change within the 
tooth socket and even resolving local hypoxia.  
 
Metallothioneins bind heavy metals including copper, and mop up hydroxyl free 
radicals.  The  greater  the  percentage  of  metallothioneins  present  within  the 
tumour, the poorer the outcome and reduced survival in SCC of the oral cavity 
when treated by surgery and PORT [37]. This is due to reduced free radical 
double stranded DNA damage by ionising radiation. Increased metallothionein 
expression has been positively correlated with the progression of oral cavity SCC 
[38]. 
64Cu ATSM  uptake  may  also  be  associated  with  the  increased 
metallothionein  expression  in  areas  of  inflammation  through  the  increased 
regional copper carrying and utilisation capacity.  
 
Lastly,  in  conditions  of  peripheral  nerve  demyelination,  associated  with 
inflammatory neuropathy, copper uptake and lipid oxidation within the nervous 
system precedes demyelination [39]. In human prostate cancer cell lines treated 
with a fatty acid synthase inhibitor, the retention of 
64Cu ATSM was positively 
correlated with the inhibition of fatty acid synthase [40]. Patient 4 was diagnosed 
with a demyelinating inflammatory disease, and this may have been associated 
with the increased uptake of 
64Cu ATSM within the right shoulder. 
 
5.4.2.5.2 Salivary Glands 
The tumour to salivary gland ratio was only significantly increased at 18 hours 
when compared to 5 to 20 minutes and not at 40 to 60 minutes. This suggests the 
salivary gland uptake and retention reduces with time after the injection of 
64Cu 
ATSM. The involvement of copper within the salivary glands has previously 
been discussed (section 5.4.1.1) and the increased ratio may be associated with 
the increased retention within the tumour that is more evident at the later time 
period. 
 
5.4.2.6 Uptake and Retention Pattern of 
64Cu ATSM 
Previous dual tracer studies have demonstrated the uptake of 
64Cu ATSM was 
heterogeneous compared to the homogeneous pattern of 
18FDG [30,32]. 
18FDG 
imaging  was  not  incorporated  into  the  study  due  to  excess  radiation  dose   304
exposure and the risk of a radiation induced cancers. Two patients did however 
have an 
18FDG examination up to 4 weeks prior to the 
64Cu ATSM imaging as 
part of their diagnostic investigations for carcinoma of unknown primary. The 
18FDG  image  acquisition  was  not  in  the  same  position  as  the 
64Cu ATSM 
imaging,  and  therefore  has  not  been  directly  correlated.  In  these  patients  the 
18FDG uptake was intense and homogeneous. 
 
Figure 5.25 a) illustrates the 40 to 60 minute axial immediate 3D dynamic 
64Cu 
ATSM CT PET image, and b) the corresponding 
18FDG CT PET axial image. 
There  was  intense 
18FDG  avidity  across  the  tumour  (SUVmax  31.2bwg/ml) 
compared to a maximum tumour to muscle ratio of 3.755 in patient 5. The uptake 
of 
64Cu ATSM is in the outer rim of tissue and an area of necrosis has developed 
within the centre of the region between the imaging points.  Uptake is also noted 
in the bilateral submandibular glands. Intense 
18FDG avidity is seen within the 
base of the tonsils due to prior biopsy.  
 
 
a 
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Figure 5.25a and b: The axial images of 
64Cu ATSM a), and 
18FDG b) representing the 
uptake differences of the two radio nuclides 
 
5.4.3 Immuno Histochemical Hypoxic Fraction 
The median hypoxic fractions for pimonidazole (38.194%), GLUT1 (54.43%), 
CAIX  (24.06%),  and  HIF1a  (14.12%)  from  this  chapter  are  consistent  with 
previously  published  data  for  example  pimonidazole  0  to  79%  [2,3,5,41 51].  
Such IHC techniques are highly likely (70 to 90%) to be within 0.1% of the true 
labelled fraction on IHC [52]. 
 
The hypoxic fraction calculated from the median staining per grid was slightly 
higher than the total stained area calculation method. Percentage and intensity 
staining were assessed because the timing of surgery was unpredictable. Patients 
were  allocated the start of the operating list but this changed because of the 
emergency  procedures,  and  unforeseen  circumstances.  This  can  affect  the 
intensity of pimonidazole adduct detection.  
 
The intensity of the staining is also dependent on the antibody dilution, method 
of  staining,  pO2  gradient  within  the  tumour,  the  absolute  amount  of  bound 
antigen/pimonidaozle, and the kinetics and clearance of pimonidazole [41]. The 
fraction of HIF1a was at the lower end of the spectrum in this study at 14.12%. 
The dilution used was 1 in 8,000, because more concentrated dilutions saturated 
b 
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the  specimen  with  excess  non specific  binding.  Alternatively  there  may  have 
been minimal up regulation of HIF1a expression depending on the intra tumoural 
hypoxia. HIF1a up regulation occurs at higher pO2 levels than are required for 
pimonidazole binding [51]. Necrosis with the specimens suggests an increasingly 
hypoxic environment. 
 
The linear unmixing and thresholding method of IHC staining is user dependent. 
The TRI2 software was set to ensure the colour range was the same for each 
patient, and  each block was  reviewed to  assess the positive and  non specific 
staining. By increasing the lower staining threshold this potentially reduced the 
sensitivity, as some cells that stained positive would have been excluded.  
 
There were a number of problems with the IHC staining process discussed in the 
section  5.1  that  potentially  affected  the  antigen  retrieval  due  to  antigen 
degradation. Factors include: delayed fixation that can lead to antigen proteolysis 
and increased non specific antibody binding, prolonged fixation (greater than 48 
hours) which increases the hydroxymethylene crossbridge formation and reduces 
the staining intensity, impure graded alcohols and xylene can produce inadequate 
tissue dehydration [53]. These factors may have influenced the hypoxic fraction 
calculation because the laryngeal specimens were fixed for a minimum of 5 to 7 
days  or  longer,  and  there  may  have  been  impurities  in  the  system  during 
automated  processing.  Also,  the  day  of  surgery  was  a  Thursday,  and  so  the 
earliest macroscopic dissection occurred 90 hours later on the Monday. 
 
Most importantly, this study did not interfere with the pathological diagnosis 
from the surgical specimen or patient treatment. Sampling a single large node 
prior to fixation or taking the central slice through a fresh laryngeal specimen 
would have enabled auto radiography to occur but jeopardised the pathological 
diagnosis  with  regard  to  tumour  invasion  into  surrounding  tissue,  and  extra 
capsular nodal extension. Auto radiography would have corroborated the uptake 
and retention of 
64Cu ATSM [54].     307
5.4.4 Correlation of Immuno Histochemical Hypoxic Fractions 
All the endogenous markers of hypoxia positively correlated with pimonidazole, 
as well as GLUT1 with CAIX and HIF1a, and CAIX with HIF1a. Published 
studies  have  found  similar  correlations.    For  pimonidazole  and  CAIX  the 
correlation is strongest at distances greater than 100 m from the blood vessel 
[44].  This  is  in  agreement  with  Koukourakis  et  al  [48]  who  reported  CAIX 
positivity was greatest in low micro vessel density areas. CAIX positivity was 
also  greatest  in  regions  of  pimonidazole  adduct  formation,  as  CAIX  up 
regulation is initiated by the HIF1a activation of the CAIX promoter region on 
the hypoxia response element [55]. CAIX and HIF1a expression in patients with 
SCCHN are associated with a poorer outcome when co expressed [49].  
 
Pimonidazole co localised with HIF1a but this correlation was weaker. HIF1a is 
mainly a nuclear stain, were as pimonidazole adducts are detected within the 
entire cell. Pimonidazole staining increases  with increasing distance  from the 
blood vessel and peaks at 80 to 100 m, and HIF1a at 40 to 50 m, reflecting the 
differing oxygen dependencies [5]. GLUT1 expression was correlated in SCC of 
the cervix with pimonidazole and CAIX [46].  In transitional carcinoma of the 
bladder, pimonidazole staining positively correlated with GLUT1, CAIX, and 
CAIX and GLUT1 with each other [47]. 
 
These  results  suggest  that  the  intra tumoural  oxygen  gradients  accounted  for 
differences in antigen detection. The correlation reported from the results in this 
chapter between pimonidazole and GLUT1 would suggest that the tumours are 
hypoxic, with an increased rate of glucose metabolism. This may promote a more 
aggressive tumour that may be more likely to locally recur because of radio 
resistance and genotypic changes. 
 
5.4.5  Haemo dynamic  Parameters  Assessed  by  Dynamic  Contrast 
Enhanced Computed Tomography 
It is difficult to draw any conclusions from the single patient in this chapter. The 
perfusion parameters from patient 5 are within the range of the current published 
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5.4.5.1 WinFun Software 
Perfusion data in 9 patients with breast cancer assessed by the WinFun software 
has  been  published  [56].  This  indicated  that  the  mean  tumour  perfusion  was 
0.41ml/min/ml (range 0.19 to 0.59ml/min/ml), and the mean CP was 15.0%/min 
(range 9 to 30%/min). The perfusion parameters gained from patient 5 using the 
WinFun  software  are  in  concordance  with  the  data  from  these  breast  cancer 
patients. The perfusion is slightly higher and this can occur if the arterial input 
function is underestimated. This method is highly dependent on cardiac output, 
and delay in the passage of contrast through the vasculature within the neck will 
affect the results. This could be overcome by standardising the values for cardiac 
output.  
 
5.4.5.2 GE Healthcare Software 
A number of studies have investigated DCE CT perfusion parameters in patients 
with SCCHN using the CT Perfusion application from GE Healthcare [8,9,57 
60]. The published data is summarised in table 5.17.  
 
Table 5.17: Perfusion parameters in patients with squamous cell carcinoma of the head and 
neck  from  DCE CT  images  measured  using  the  CT  Perfusion  application  from  GE 
Healthcare  
Region  of 
interest 
Blood Flow 
(ml/min/100g) 
Blood 
Volume 
(ml/100g) 
Mean 
Transit Time 
(seconds) 
Permeability 
Surface Area 
(ml/min/100g) 
Primary  and 
Metastatic 
Lymph  ode  
54.6 to 105.9 
[1.7 to 226.9] 
3.75 to 44.0 
[0.5 to 12.3] 
3.3 to 9.01 
[3.4 to 17.1 
13.33 to 23.2 
[0.1 to 39.1] 
CL SCM  4.3 to 16.4 
[4.03 to 10.1] 
1.4 to 1.95 
[0.58 to 0.7] 
5.5 to 15.97 
 [4.37 to 5.1] 
 
1.01 to 5.4 
[1.42 to 4.0] 
 
CL  Salivary 
Gland 
51.7 
[39.7] 
4.2 
[1.9] 
8.2 
[4.1] 
37.9 
[12.6] 
Posterior 
 eck 
4.7 to 10.67 
[2.7 to 7.06] 
1.1 to 1.14 
[0.6 to 0.67] 
13.27 to 20.8 
[5.32 to 6.8] 
1.22 to 6.5 
[0.81 to 5.3] 
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The range of mean values is shown with the standard deviation in brackets. In 
these  studies  the  para spinal  muscles  were  used  to  assess  the  uptake  in  the 
posterior neck.  
 
BV is difficult to measure in SCCHN because the surface mucosal epithelium is 
well  perfused.  This  increases  the  BV  within  the  ROI  [9]  as  it  is  difficult  to 
exclude the mucosa from the final calculated volume. 
 
Longer  MTT  within  tumours  is  associated  with  high  interstitial  pressure  and 
blood flow through the region. The leaky endothelium allows the contrast to 
extrasavate  and  blood  to  pool  within  the  region.  Deconvolution  algorithms 
include the intra vascular and extra vascular spaces in the calculation, preventing 
over estimation. The prolongation of the MTT is also related to the presence of 
necrosis, which increases the BV and so the MTT [8,58]. 
 
The CL SCM, and posterior neck have lower BF, BV, and PS, but longer MTT 
than tumour regions. The salivary glands had a greater PS and a longer MTT. 
This  has  been  confirmed  by  a  single  study  [9].  Salivary  glands  have  been 
excluded from all other published analyses but are specifically reviewed in this 
chapter because of the uptake of 
64Cu ATSM within the region. It is uncertain 
why the salivary glands have such different values compared to other normal 
tissue, but there is an overlap with the BV in these and tumour regions. 
 
Perfusion parameters vary throughout the ROI as shown in patient 5 and are 
heterogeneous  depending  also  on  the  presence  of  necrotic  regions.  Necrotic 
regions must be excluded from the tumour calculation to gain a reliable result. 
BF, and so perfusion are dynamic and only reflect the intra tumoural changes at 
the time of imaging. The results gained from the ROI from this patient were 
assumed to be representative of the entire tumour volume, but variation is present 
on each axial image. 
 
Serial imaging is required to assess changes with time. Potentially the dual use of 
62Cu ATSM and PTSM may allow this in future studies. Movement artefact will 
still be a problem on DCE CT imaging especially in the base of tongue and   310
larynx due to swallowing and respiration, and the attenuation of the x ray beam 
in regions of dense bone such as the clavicle and shoulders [9,60]. These both 
produce poor tissue enhancement curves. 
 
5.4.6 Correlation of
 64Cu ATSM Uptake and Blood Flow 
Two  studies  have  been  published  which  correlate  perfusion  in  ischaemic 
myocardial animal models with Cu ATSM.  
 
Fujibayashi compared 
62Cu ATSM uptake with 
201Thallium. In areas of very low 
perfusion, 
62Cu ATSM  uptake  was  low.  In  perfused  but  hypoxic  areas, 
myocardium 
201Thallium  uptake  was  low  and 
62Cu ATSM  uptake  was  high. 
Auto radiographic studies have shown 
64Cu ATSM uptake is greatest in areas 
with a low micro vessel density [32].  
 
Secondly,  in  rats  the  uptake  of 
64Cu ATSM  and 
11C  labelled  acetate  was 
assessed. 
11C labelled acetate has previously been reported to be proportional to 
BF [61]. There was a negative correlation between the two PET radio nuclides. 
In areas of low BF, there was no uptake of 
64Cu ATSM, when the BF was less 
than 20% [62].  
 
Overall these suggest that BF is required to deliver the tracer to the hypoxic 
region, and accumulation selectively occurs in hypoxic but perfused regions [63]. 
 
There was no correlation of 
64Cu ATSM uptake at 5 to 20 minutes, 40 to 60 
minutes or at 18 hours after injection with the BF on the DCE CT for patient 5.  
No correlation of BF within the tumour is encouraging but not conclusive. The 
DCE CT data is most representative of the 40 to 60 minute 
64Cu ATSM uptake. 
Ideally multiple DCE CT scans would be undertaken in future to assess changes 
in blood flow and 
64Cu ATSM uptake with time. 
 
The mean grayscale intensities for BF versus 
64Cu ATSM uptake were: 0.0 to 
29.74 vs. 0.0 to 79.21 at 5 to 20 minutes, 0.0 to 30.55 vs. 3.93 to 98.77 at 40 to 
60 minutes, and 0.0 to 28.50 vs. 4.202 to 121.98 at 18 hours after injection. 
These raw mean intensity values suggest the uptake of 
64Cu ATSM was greater   311
than the BF through the ROI within the tumour. Larger patient numbers would 
have allowed conclusions to be drawn from the perfusion results in this chapter.  
Further studies may conclude a negative or positive correlation depending on the 
tumour or necrotic region. 
 
5.4.7  Correlation  of 
64Cu ATSM  Uptake  and  Hypoxic  Immuno 
Histochemical Staining  
There was a positive correlation of all exogenous and endogenous markers of 
hypoxia with the uptake of 
64Cu ATSM at 5 to 20, 40 to 60 minutes and 18 hours 
after  the  injection.  This  was  greatest  for  GLUT1  at  5  to  20  minutes, 
pimonidazole at 40 to 60 minutes, and HIF1a at 18 hours.  
 
The  expression  of  endogenous  markers  of  hypoxia  will  depend  on  the  intra 
tumoural pO2. The  IHC expression is also most representative of the  18hour 
imaging point and chronic hypoxia. Pimonidazole forms adducts when the pO2 is 
less than 10mmHg, but 
64Cu ATSM may preferentially bind at lower O2 tensions 
and  in  conditions  of  anoxia,  which  would  account  for  its  heterogeneous 
distribution.  
 
Human and animal studies have assessed the IHC correlation of hypoxia markers 
with 
64Cu ATSM uptake. Correlation was dependent on the tumour model. The 
hypoxic  distribution  of 
64Cu ATSM  on  auto radiography  was  positively 
correlated with EF5, pimonidazole and CAIX expression in the mammary and 9L 
gliomas models only [64].  SCC models have suggested the positive correlation 
of Cu ATSM uptake with pimonidazole that was not dependent on the time after 
injection.  The  vascular  marker  Hoechst  33342  negatively  correlated  with 
pimonidazole binding [54]. In the SCCVII murine tumour model, the positive 
pimonidazole  fraction  was  36.0%  +/   7%.  The  uptake  of 
64Cu ATSM  and 
pimonidazole binding was greatest when these animals were exposed to hypoxic 
conditions [19].   
 
Auto radiography was planned in the study protocol, but not undertaken. Large 
specimens require prolonged fixation, and decalcification of ossified cartilage or 
bone prior to macroscopic dissection for example. Detection by auto radiography   312
would not be possible on fixed specimens because no isotope activity would be 
detected (4 days post injection of 
64Cu ATSM is equivalent to 8 half lives and 
only 0.391% of the original injected activity would be present).  
 
The freshly sectioned tissue is required for auto radiography and would need to 
be stored carefully to ensure exuded fluid did not affect the distribution pattern. 
Sampling fresh unfixed specimens was a problem because tissue planes would be 
difficult to interpret. Whole laryngeal specimens are difficult to cut with a band 
saw when fresh, and tissue from a single matted LN infiltrated with SCC may 
compromise  formal  pathological  reporting  if  sectioned  for  auto radiography 
studies prior to this. 
 
The results from this chapter suggest 
64Cu ATSM is a potential surrogate marker 
of hypoxia. It may initially be non selectively distributed, but when it is within 
the intra cellular hypoxic environment it is irreversibly trapped and accumulates 
with increasing time after injection. The retention may be due to its incorporation 
into the intra cellular Cu pool. The correlation with pimonidazole may suggest 
that chronic hypoxia is imaged rather than acute hypoxia. However the lack of 
correlation of 
64Cu ATSM uptake and retention with BF in 1 patient has not been 
able to confirm or refute this. 
 
5.4.7.1 Correlation Inaccuracies  
 
5.4.7.1.1 Macroscopic Dissection and Tissue Processing 
After the dissected specimen has been wax embedded the Medical Laboratory 
Scientific Officers would cut the wax block to ensure that the full surface of the 
specimen was level to allow even microtome sectioning. The position of tissue 
within  the  wax  block  was  dependent  on  placement  and  movement  during 
automated processing. 
 
This  reduced  the  amount  of  tissue  available  for  IHC,  as  blocks  were  only 
received  after  full  pathological  diagnosis  was  completed.  Ideally  serial  tissue 
sections would allow correlation at multiple levels within the same block and   313
specimen. There was no opportunity for this given the type of cases recruited and 
storage of fixed specimens (incinerated 28 days after receipt). 
 
5.4.7.1.2 Alignment of tissue and imaging 
The correlation achieved was regional, rather than per cell or pixel. The stained 
section was 4 m in thickness compared to 3.27mm for the fused reconstructed 
CT PET, leading to spatial registration difficulties. Measurements taken at the 
time  of  surgery,  and  macroscopic  dissection  could  not  be  used  alone  for 
alignment and correlation when choosing the most appropriate CT PET slice. 
Visual inspection was most important as the specimens contracted during the 
fixation process. 
 
Shrinkage of HN specimens has been assessed in a number of studies. Tissue 
shrinkage immediately after excision from standardised mucosal specimens in 
dogs  was  between  3.0  to  4.8  mm  (20.9  to  38.3%)  prior  to  fixation.    After 
formalin fixation this was 0.3 to 1.4mm (32.4 to 48.8%), and a total shrinkage 
was 3.7 to 5.7mm (30.7 to 47.3%) for a 12mm long specimen. The variation in 
shrinkage was greatest for buccal mucosa and base of tongue specimens [65]. 
The vocal cords within laryngeal specimens shrank by 9 to 24% from excision to 
the immersion in 10% buffered formalin, and a further 0 to 14% after formalin 
fixation.  This  was  greatest  at  the  medial  and  free  edge  of  the  cord  [66].  In 
patients with SCCHN, the mean shrinkage between pre and post processing was 
up to 60% [67]. Specimens containing bone and cartilage shrank less.   
 
The volume shrinkage between excision and fixation was 19.05 to 38.46% for 
the ND samples, and 3.84 to 6.66% for the whole larynx specimens from patients 
reported in this chapter. There was a further 4.83 to 10.0% shrinkage during the 
paraffin  wax  embedment  for  the  LN  samples,  and  8.94  and  10.0%  for  the 
laryngeal samples.  
 
These factors all influence and reduce the accuracy of alignment and correlation.   314
5.4.7.1.3 Other Methods of Registration 
The  method  used  to  align  the  IHC  specimen  and  CT PET  in  this  study  was 
Adobe Photoshop, and the aligned grids were compared using the TRI2 software. 
This was the only method and software available for use within the department.  
 
Other  rigid  or  non rigid  registration  methods  have  been  reported  which  use 
complex mathematical algorithms. 
 
Rigid registration uses 6 degrees of freedom (3 translational points: x, y, z, and 3 
rotational points: roll, pitch and yaw). The two images are assumed to be objects 
and are rotated around these points in relation to one and other until they are 
aligned. This method can incorporate scale factors, affine registration, and partial 
correction for calibration differences. For example the co registration of CT and 
MRI images within the brain. 
 
Non rigid methods have improved on this technique due to changes in shape or 
anatomy. For example an element of stretching or warping is required to overlay 
and register one image with another (deformable transformation model). These 
models  take  account  of  changes  in  position,  structure,  and  size  during  the 
registration process [68].  
 
One of the most relevant methods of registration to this chapter was by Bois 
d’Aische et al [69]. This study developed the registration process used by Daisne 
et  al  [70].  This  used  a  non rigid  method  through  a  constrained  dense 
displacement field to account for changes in the histology image due to freezing, 
fixation, cryotoming and staining.  This model used elastic based deformation 
with a linear elastic regularisation constraint to optimise the registration. The 
thicker specimen sections used by the group aided this registration process.  
 
The availability of such registration methods would have increased the accuracy 
of registration and correlation in the results from this chapter. 
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5.4.8 Hypoxic Functional Volume Delineation 
The  hypoxic  FV  delineated  according  to  the  tumour  to  muscle,  blood  and 
background ratios increased at 40 to 60 minutes for patient 1, 4, and 5, and these 
volumes had increased further at 18hours after the injection of 
64Cu ATSM in 
patient 5 when compared to the volume at 5 to 20 minutes. However the FV 
delineated for patient 2 were similar at 5 to 20 minutes and at 18 hours after the 
administration of 
64Cu ATSM. The volumes defined reduced with each increase 
in the delineating tumour ratio above the baseline of 2.0. The tumour to muscle 
ratio produced the most statistically significant results and would suggest that 
this ratio should be used to aid the delineation of 
64Cu ATSM hypoxic FVs. 
 
These  results  are  interesting  given  the  implications  for  use  in  RT  planning. 
Firstly  the  time  point  of  imaging  is  extremely  important.  Although  only  4 
patients were imaged in this study, it does suggest that the uptake of 
64Cu ATSM 
at 40 to 60 minutes and at 18 hours after injection would be appropriate rather 
than at 5 to 20 minutes as these may be more representative of the true hypoxic 
volume  within  the  tumour.  It  would  be  interesting  to  assess  the  differences 
between these two time points in a larger study, and specifically evaluate how 
this affects both the final delineated volume, and the dose distribution to adjacent 
organs  at  risk  during  dose  escalation. 
64Cu ASTM  does  allow  this  flexibility 
given its half life. Other isotopes such as 
62Cu would allow this to be assessed 
immediately after administration, and also at other time points during treatment. 
The lower emitted radiation dose may allow imaging during RT in conjunction 
with Cu PTSM to assess hypoxia and perfusion using dual tracer kinetics.  
 
A study with 3 healthy human volunteers and 3 dogs, the time, and order of 
injected radio nuclides were assessed in a dual tracer study with Cu PTSM and 
Cu ATSM according to the generated time activity curves. Identification of the 
individual tracers was greatest when 
62Cu PTSM was injected first, followed by a 
time delay of 20 minutes before 
62Cu ATSM was injected. The total dynamic 
PET scan duration was 50 minutes  (30 minutes for assessment of ATSM) [71]. 
Such a study would also be feasible if 
18Fluoro 3' deoxy 3' thymidine was used 
as a dual tracer with 
64Cu ATSM to assess proliferation and hypoxia within the 
same  tumour, 
64Cu ATSM  would  need  to  be  injected  second  because  of  its   316
longer half life, and 
18Fluorine has a higher positron emission rate. The higher 
rate of emission would saturate the camera and prevent detection of the second 
radio nuclide. By delaying the administration of 
64Cu ATSM by 24 hours, 
18F 
activity would have been reduced by 8 half lives and so the two tracers could be 
identified separately. 
 
Given the paucity of data, the defining ratio should be between 2.6 and 3.5, as 
these have been used with other Cu ATSM isotope studies [13 15]. Higher ratios 
will  be  associated  with  smaller  volumes  and  will  be  more  amenable  to  dose 
escalation than for example a ratio of 2.0. 
 
The pimonidazole staining would suggest the entire tumour volume would need 
to be dose escalated by RT, as the antigen detection was generalised rather than 
localised. This ultimately suggests that in the 4 patients imaged with 
64Cu ATSM 
the majority of the tumour volume was hypoxic to less than 10mmHg, and at a 
greater risk of local recurrence. 
 
5.4.9 Patient Recruitment 
Patient recruitment was unfortunately poor. When the 
64Cu ATSM study was 
initially  developed,  recruitment  was  planned  at  two  sites.  Following  the 
favourable ethics opinion by NRES (National Research Ethics Service) in April 
2007. Local approval was sought at UCLH, and recruitment started in May 2008. 
There  was  a  13 month  period  while  the  study  was  set  up  and  sponsorship 
agreement negotiated. This delay was compounded by the need to produce 
64Cu 
ATSM to good manufacturing practice standards. 
 
Patient  recruitment  was  also  planned  at  Northwick  Park  Hospital.  The  site 
specific local approval for Northwick Park, and Mount Vernon Cancer Centre 
was sought (imaging at Mount Vernon, and surgery at Northwick Park). The 
application was submitted to Northwick Park in February 2008, and to date local 
approval has not been  given. Despite  a number of meetings, assurances, and 
negotiations with all the stakeholders, different issues were raised including: the 
sponsorship  and  indemnity  agreement  between  the  sponsor  UCLH,  Mount   317
Vernon  Cancer  Centre,  and  Northwick  Park  Hospital,  and  Pathology  Service 
requirements. These unfortunately could not be overcome. 
 
This impacted the potential patient recruitment. However to improve recruitment 
a substantial amendment was submitted to NRES to open Guy’s and St Thomas’ 
Hospital as a second site for the study. This request was submitted in December 
2008.  Recruitment  would  have  been  through  the  Oral  and  Maxillo Facial 
Surgical Department with imaging at the Clinical PET Centre at St Thomas’ 
Hospital. The advantages included on site production of 
64Cu ATSM. Following 
submission, and then study presentation to the local Research and Development 
board at Guy’s Hospital in April 2009, approval was only gained in October 
2009, 10 months later. Only one patient per month could have been recruited 
from this site because of the stipulation from the Environment Agency that no 
more than 600MBq of waste could be discharged into the environment. This 
quota included waste from other radio nuclides such as 
18FDG. No patients were 
recruited from this site because of time constraints but it is hoped that the study 
will  continue  to  recruit  at  Guy’s  and  St  Thomas’  Hospitals  over  the  coming 
months. 
 
At UCLH 44 patients were screened, and only 6 recruited into the study. Patients 
were screened as eligible from the MDT, but due to inter current illness and 
smoking related co morbidities their treatment  plan changed from  curative to 
palliative, or from surgery to RT or CRT. This was most commonly due to the 
individual’s fitness for surgery.  
 
Patients also were not able to participate even though willing because of other 
commitments within UCLH. For example appointments with the Clinical Nurse 
Specialist, Speech and Language team, and Dieticians in the days leading up to 
their planned surgical treatment. Patients approached were overwhelmed by their 
diagnosis, and had great difficulty coming to terms their planned treatment. This 
was especially the case for laryngectomy patients.  
 
A further substantial amendment was submitted to NRES for favourable opinion 
to provide a one page summary patient information leaflet for each study arm.   318
This aimed to reduce the information given to potential participants, and then 
those who were considering participation were given a full information sheet. 
These were submitted in June 2008, and final favourable opinion was granted 5 
months later. 
 
Eligible study patients were also lost to recruitment if they were brought to the 
MDT either a few days prior to their surgery, or close to a treatment target date 
[72,73]. 
 
The production of 
64Cu ATSM was a significant problem. Only one cyclotron 
and radio chemist produced the 
64Cu ATSM. Unfortunately this radio chemist 
was  abroad  between  May  and  September  2008,  with  no  replacement  for 
production.  Production  was  not  automated,  which  increased  the  radiation 
exposure  for  the  individual  limiting  the  amount  of  isotope  that  could  be 
produced. Two patients recruited could not be imaged. One because of burst 
copper piping within the cyclotron, which flooding the unit. The other patient 
could not be imaged because the nickel target did not move into the beam of the 
cyclotron. This patient’s surgery was then delayed, and they agreed to continue 
in the study. Unfortunately again the 
64Cu ATSM could not be released as it 
failed quality assurance testing. A minimum of 2 weeks notice was required for 
production, and this was not always possible as previously explained. 
 
Lastly, treatment has moved towards primary RT or CRT with surgery reserved 
for advanced disease, and at the time of recurrence for salvage. This change in 
practice impacted on recruitment. 
 
5.4.9.1 Eligibility Criteria for Patient Recruitment 
The age of patient recruitment was determined due to the emission of ionising 
electrons  during  electron  capture  (41%)  and  negatron  decay  (40%).  These 
electrons cause a cascade reaction and the production of auger electrons. These 
all have significant ionisation potential and damage DNA in areas of 
64Cu ATSM 
uptake.  
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The International Commission of Radiological Protection, published guidance in 
1991 [74](ICRP 60) on the risk of lifetime mortality from cancer, and updated 
their  guidance  in  2008  (ICRP  103)  [75].  The  ICRP  60  has  data  for  cancer 
mortality  between  1950  and  1987  based  on  survivors  from  the  atomic  bomb 
explosion in Japan in 1945. The later publication has incidence data for the 47 
years following this event.   
 
The ICRP 60 publication suggested the probability of death was 0.0921 at the 
age of 25  for men and 0.1178 for women per mSv of whole body radiation 
exposure, compared to 0.0258 for men, and 0.0275 for women per mSv at the 
age  of  75.  This  equated  to  an  increased  lifetime  risk  of  1.9763  per  10,000 
population (sex averaged, age at exposure) at 18 to 40 years of age. The ICRP 
103 publication suggested this figure was lower at 1.103 per 10,000 population 
per mSv for men and 1.242 per mSv for women per 10,000 population aged 
between 18 and 64 years of age.  
 
The probability of increased death due to radiation exposure from the imaging 
protocol was for example 3.435 for a 25 year old man compared to 0.962 for a 75 
year old man who underwent a dynamic immediate CT PET, DCE CT, and a late 
18 to 24 hour static CT PET.  
 
The  use  of 
60  and  62Cu ATSM  may  reduce  this  risk  given  the  higher  positron 
emission rate, and so lower doses could be injected. An on site cyclotron would 
be required for production of Cu isotopes with a short t1/2. 
 
A  substantial  amendment  submission  for  the  study  was  considered  to  allow 
recruitment of patients with recurrent disease who were to be treated by salvage 
surgery, and also patients between the age of 40 and 50. Unfortunately, this was 
not possible due to the time constrains on recruitment, and gaining favourable 
opinion from NRES. 
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5.5 Conclusions 
The  uptake  and  retention  of 
64Cu ATSM  was  assessed  in  four  patients  with 
SCCHN, and correlated in surgical specimens with exogenous and endogenous 
IHC surrogate markers of hypoxia in these patients. 
 
The uptake and retention of 
64Cu ATSM stabilised 5 minutes after injection, and 
then  increased  with  time  following  injection.  The  uptake  when  compared  to 
surrounding normal tissue was most significant at 40 to 60 minutes on each axial 
CT PET slice according to the tumour to muscle ratio. Increased uptake was seen 
in the salivary glands, and this may have been due to the physiological pathway 
of  copper  in  saliva.  Unusual  uptake  was  noted  in  the  mandible  and  right 
shoulder, which may have been secondary to inflammation.  
 
Perfusion imaging was only completed in one patient and the lack of correlation 
between 
64Cu ATSM uptake and retention and BF especially at 40 to 60 minutes 
cannot conclude no association. The haemo dynamic parameters assessed by the 
DCE CT were consistent with those from other published studies in SCCHN.  
 
The  hypoxic  antigen  detection  of  GLUT1  and  pimonidazole  had  the  most 
significant  positive  correlation.  CAIX  and  HIF1a  hypoxic  fractions  were 
significantly smaller than those define by the other two antigens.  
 
The  distribution  pattern  of  pimonidazole  and  the  other  antigens  positively 
correlated with the retention pattern of 
64Cu ATSM at 5 to 20 minutes, 40 to 60 
minutes, and 18 hours after injection. The most significant correlation of the 
uptake and retention of 
64Cu ATSM at 40 to 60 minutes was with pimonidazole. 
 
The hypoxic FV delineated by the tumour ratios increased with each increase in 
the ratio threshold. The volumes increased in size with time after injection of 
64Cu ATSM, and were largest when defined by the tumour to muscle ratio. 
 
These  results  are  encouraging  and  suggest  a  possibility  that 
64Cu ATSM 
retention  and  uptake  is hypoxia  selective  according  to  the  distribution of  the   321
hypoxic  IHC  antigens  investigated.  Further  validation  of 
64Cu ATSM  and 
investigation is warranted. In future, the FV delineated by this radio nuclide on 
CT PET imaging (if confirmed to be hypoxic in larger studies) may allow dose 
escalation strategies to be developed to improved loco regional control to these 
hypoxic radio resistant tumour volumes.   322
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Chapter 6 
 
Conclusions  from  CT PET  Studies  in  Squamous 
Cell Cancer in the Head and  eck 
 
The 5-year survival of patients treated for SCCHN continues at 35% even though 
significant  improvements  have  been  made  in  investigative  pathways  and 
treatment.  Poor  outcome  is  associated  with  the  development  of  treatment 
resistance in tumour stem cells. This resistance leads to loco-regional recurrence 
in 50% of patients regardless of the treatment they receive. 
 
The major contributing factors are increased intra-cellular glucose metabolism 
and hypoxia. These processes are non-invasively detected and visualised by CT-
PET imaging. These volumes may be targeted by dose escalated RT. Effective 
strategies  require  CT-PET  guided  TV  delineation  for  RT  planning,  using  a 
method  and  software  that  can  be  transferred  between  institutions  to  allow 
collaboration.  
 
The method of delineation must accurately reflect the intra-tumoural regional 
process  and  the  defined  volume.  Volume  definition  in  turn  will  guide  RT 
planning, dosimetry, and the delivered dose to these TVs and adjacent at risk 
organs during the delivery of dose escalated RT. 
 
6.1 Conclusions 
 
6.1.1 
18Fluoro 2 deoxyglucose Target Volume Delineation 
18FDG  is  the  commonest  radio-nuclide  used  in  clinical  practise,  and  is  a 
surrogate marker for glucose metabolism. The methods of 
18FDG TV delineation 
have been much debated in the literature in both NSCLC, and SCCHN.  
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Two fixed (SUVCO, and PTSUVmax), and 1 adaptive automatic TV delineation 
methods were investigated before, and at three time points during conventionally 
fractionated curative RT or CRT in patients with locally advanced SCCHN at 
UCLH, London using PETVCAR software provided by GE Healthcare.  
 
From these three methods, 10 thresholds were directly compared: SUVCO 2.5, 
3.0, 3.5, and 4.0bwg/ml; 30, 35, 40, 45, and 50% of the SUVmax; and an IAT 
based on the individual SUVmax, and mean within the ROI, and the background 
uptake of 
18FDG. Each CT-PET data set during treatment was automatically and 
individually co-registered to the pre-treatment imaging. Every 
18FDG avid ROI 
was selected and automatically defined.  
 
Twelve patients were recruited, 10 completed the imaging protocol, and 8 were 
analysed. Patients underwent a CT-PET of the HN 72 hours prior to the start of 
treatment, and then at 8 to 18Gy, 36 to 50Gy, and 66Gy. Eight primary, and 20 
LN avid 
18FDG regions were evaluated. 
 
6.6.1.1 SUV Cut Off 
The delineated FVs significantly reduced with radiation dose at 36 to 50Gy, and 
66Gy compared to the pre-treatment FV. This was most significant when the 
3.0bwg/ml SUVCO threshold defined the FV. The volumes were dependent on 
the threshold and significantly reduced at each imaging point when the 3.0, 3.5, 
and 4.0bwg/ml threshold defined volumes were compared to that defined by the 
2.5bwg/ml  threshold.  This  was  most  significant  when  the  FV  defined  at 
4.0bwg/ml was compared to that at 2.5bwg/ml. The theoretical radiation dose 
required to reduce these FVs to zero was between 84 and 152Gy for the primary, 
and 60 to 68Gy for the LN sites.  
 
The SUVmax within the FVs defined by the various SUVCO thresholds was also 
significantly reduced at the same dose points, and positively correlated with the 
size of the defined FV. There was no significant difference in the SUVmax at 
each  imaging  point  within  the  primary  FV  when  SUVCO  thresholds  were 
compared. However, within the LN FV, the SUVmax was significantly reduced 
at  each  imaging  point.  This  was  because  the  SUVmax  was  lower  in  these   334
volumes and therefore  more affected by the absolute SUVCO threshold. The 
theoretical radiation dose required to reduce the SUVmax to zero within these 
FVs was 112 to 128Gy for the primary, and 68 to 80Gy for the LNs. 
 
6.6.1.2 Percentage Threshold of the SUVmax 
The FVs defined at all thresholds by this method were not significantly reduced 
during treatment. There was a trend to an increase in volume, especially at the 
primary  site,  but  this  was  not  significant.  The  defined  FVs  did  significantly 
reduce at each imaging point when the volume was compared to that defined by 
the 30% threshold. 
 
The  SUVmax  was  significantly  reduced  in  the  same  manner  as  the  SUVCO 
threshold. There was no correlation between the defined FVs and the SUVmax 
by this method. The theoretical dose required to reduce the SUVmax to zero was 
128Gy for the primary, and 100Gy for the LN volumes.  
 
6.6.1.3 Individualised Adaptive threshold 
Similarly,  the  primary  FVs  delineated  by  this  method  were  not  significantly 
reduced during treatment, but the LN FVs were significantly reduced (although 
there was no correlation between the dose and delineated FV). 
 
The SUVmax within the primary volume was significantly reduced after 36 to 
50Gy, and in the LN volume after 8 to 18Gy.The RT dose required to reduce the 
theoretical SUVmax within the volume to zero was 112Gy for the primary, and 
80Gy for the LN sites.  
 
6.6.1.4 Background Uptake of 
18Fluoro-2-deoxyglucose 
The background uptake of 
18FDG did not significantly increase during treatment, 
and in all cases was below the SUVCO thresholds used to define the FV.  
 
The  FVs  defined  by  the  SUVCO  method  therefore  were  not  influenced  by 
background 
18FDG uptake, and radiation induced-inflammation for example was 
excluded from the final volume. 
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However, the background SUV significantly influenced the FVs defined by the 
PTSUVmax,  especially  after  36Gy.  The  calculated  SUV  used  to  define  the 
volume was dependent on the SUVmax within the ROI. During treatment the 
difference between this and the background SUV reduced especially within the 
LN FV at 66Gy. This suggested the increased volume towards the end of RT was 
purely due to the delineation method, threshold, and SUV within the ROI.  
 
The FV delineated by the IAT method was also dependent on the difference 
between the maximum and minimum SUV within the ROI. 
 
6.1.2 
64Cu ATSM Hypoxia Definition, and Target Volume Delineation 
Cu-ATSM  has  been  proposed  as  a  surrogate  marker  of  hypoxia  in  CT-PET 
imaging. The use of 
64Cu-ATSM allowed immediate and late imaging due to the 
prolonged  half-life  of  12.7  hours.    The  uptake  and  retention  pattern  has  not 
previously been validated with IHC hypoxic exogenous or endogenous antigens 
in  patients  with  SCCHN.  The  imaging  of  tumour  hypoxia,  and  the  resultant 
delineation of hypoxic FVs may potentially be incorporated into dose escalation 
strategies to over come hypoxic radio-resistance in the defined FV and reduce the 
rate of loco-regional failure. 
 
Six patients due to be treated by primary surgery with locally advanced SCCHN 
were recruited over 12 months from May 2008. Four patients were injected with 
505  to  595MBq  of 
64Cu-ATSM,  and  underwent  an  immediate  1  hour  3D 
dynamic CT-PET. Two patients were also imaged by a 1-hour 3D static CT-PET 
18 hours after injection, and by a DCE-CT after completion of dynamic imaging.  
 
Eighteen  hours  prior  to  surgery,  patients  received  0.5g/m
2  of  pimonidazole. 
Following surgery, the macroscopic specimen was orientated and dissected, and 
IHC  undertaken  on  the  wax  embedded  tissue  blocks  to  detect  pimonidazole 
adducts,  GLUT1,  CAIX  and  HIF1a  antigens  representative  of  intra-tumoural 
hypoxia.  The  uptake  and  retention  of 
64Cu-ATSM  was  assessed  at  5  to  20 
minutes, 40 to 60 minutes, and 18 hours after injection by the calculation of 
tumour to muscle, background and blood ratios. The IHC hypoxic fraction was 
defined after linear unmixing the colours of the digitised IHC specimen. These   336
and the fused corresponding CT-PET images were converted to grayscale and 
correlated with the uptake and retention of 
64Cu-ATSM on CT-PET imaging at 
these time points, and within a 4cm section of intra-tumoural BF. 
 
The tumour to muscle, blood and background ratios at 5 to 20 minutes, 40 to 60 
minutes and 18 hours after injection were used to define the FV at ratios of 2.0, 
2.5, 3.0, and 4.0 using the PETVCAR software.  
 
The uptake and retention of 
64Cu-ATSM within the tumour on each axial CT-
PET  image  significantly  increased  at  40  to  60  minutes  and  18  hours  after 
injection when compared to the uptake at 5 to 20 minutes within the tumour and 
normal tissue. This was most significant for the tumour to muscle ratio at 40 to 
60 minutes after injection. Initially at 5 to 20 minutes after injection, the activity 
within the blood was not hugely different to that within the tumour, suggesting 
initial non-selective uptake that becomes hypoxia selective with time.  
 
Interestingly there was significant uptake and retention within the salivary glands 
in all patients. This has not formerly been published, and may highlight the use 
of copper in salivary amylase secretion. Two other unusual sites of retention 
were noted within the mandible and right shoulder. In both cases these patients 
were  found  to  have  a  inflammatory  process.    The  role  of  copper  during 
inflammation and demyelination is recognised which may have accounted for 
this uptake pattern, and local hypoxia may also have been a contributing factor. 
 
The IHC hypoxic fraction was dependent on the detected antigen of interest and 
ranged between 14 and 54%. Pimonidazole positively correlated with CAIX, and 
HIF1a, and this was most significant with GLUT1. There was no difference in 
the method of hypoxic fraction calculation. 
 
On a grid by grid regional assessment, there was a significant positive correlation 
with the IHC exogenous and endogenous markers of hypoxia at 5 to 20 minutes, 
40 to 60 minutes and 18 hours after the injection of 
64Cu-ATSM. This was most 
significant when the pimonidazole adduct staining was compared with the uptake 
and retention of 
64Cu-ATSM at 40 to 60 minutes. Eighteen hours after injection,   337
HIF1a, and pimonidazole correlation with 
64Cu-ATSM uptake and retention were 
most significant, and this was the case for GLUT1 at 5 to 20 minutes. 
 
The perfusion parameters on DCE-CT from one patient were analysed. Although 
no conclusions can be drawn, there was no correlation of BF with the uptake of 
64Cu-ATSM  in  this  patient  when  images  were  converted  to  grayscale,  and 
corresponding grids correlated on each axial image of the ROI over a 4cm region 
of the tumour. 
 
The hypoxic FV defined at 5 to 20 minutes, 40 to 60 minutes and 18 hours after 
injection, were largest for the tumour to muscle ratio of 2.5, and then reduced as 
the ratio increased to 4.0. The FVs were also larger at 40 to 60 minutes and 18 
hours after injection compared to 5 to 20 minutes. The hypoxic FVs defined by 
the tumour to blood and tumour to background ratios were smaller than those 
defined by the tumour to muscle ratio. 
 
The  results  suggest  that 
64Cu-ATSM  does  image  hypoxia,  and  hypoxic  TV 
delineation is dependent on the time of imaging after injection, and the method of 
delineation. The distribution of pimonidazole adducts, and 
64Cu-ATSM would 
suggest that the entire tumour volume was hypoxic. This study also highlighted 
the  complexity,  and  feasibility  of  early  phase  study  design,  set  up,  and 
recruitment  in  CT-PET  imaging  and  the  potential  difficulty  this  can  pose  to 
researchers. 
 
6.2 Future Directions and Applications to Clinical Practice 
 
6.2.1 
18Fluoro 2 deoxyglucose CT PET Guided Target Volume Delineation 
18FDG  CT-PET  guided  RT  has  the  potential  to  sculpt,  optimise,  and  deliver 
escalated  radiation  dose  heterogeneously  across  a  defined  FV  [1]  without 
increasing normal tissue toxicity [2].  
 
Effective  dose  optimisation  and  escalation  strategies  require  a  collaborative 
approach to CT-PET research in RT planning, definition of the timing of imaging   338
during  treatment,  and  method  and  threshold  of  volume  delineation.  Dose 
escalation may adapt the dose to the shrinking FV during treatment. Alternatively 
an increased dose may be delivered across the pre-treatment defined FV through 
a SIB technique. Adaptive strategies may utilise this as well as the voxel based 
dose painting method.  
 
Tumour heterogeneity and gradients of increased glucose metabolism or hypoxia 
across the volume, allow dose optimisation through dose painting techniques. 
With 3D dynamic imaging, the dose can be modulated within a CT-PET voxel 
depending on the uptake of the radio-nuclide which acts as a surrogate for radio-
resistance. Dose adaptation and optimisation during RT also requires effective 
methods of auto-contouring normal tissue, and image registration to account for 
changes  in  anatomy  due  to  nutritional  deficiency,  oedema,  and  inflammation 
during the radiation treatment. 
 
6.2.1.1 Dose Escalation Study 
This study has indicated that FVs delineated by the SUVCO are less susceptible 
to  background 
18FDG  uptake,  and  thresholds  of  3.0,  3.5,  and  4.0bwg/ml  are 
significantly reduced during treatment.  
 
Dose escalation methods to 
18FDG CT-PET guided volumes could incorporate a 
SIB technique at the start of treatment or after 36Gy of RT with voxel based dose 
painting  through  IMRT.  Other  methods  would  be  IMAT,  or  stereo-tactic 
irradiation  of  residual  volumes  either  during  or  at  the  end  of  treatment.  The 
placement of fucidal markers may aid stereo-tactic delivery. 
 
Commercially available software such as PETVCAR, increase the possibility of 
widespread  CT-PET  guided  treatment  planning,  and  aid  collaboration  in 
delineation studies. 
 
RT  structure  sets  (RTSS)  were  created  after  FV  definition  using  an  SUVCO 
threshold of 3.0bwg/ml by PETVCAR in patients from the study reported in 
Chapter  4.  These  were  DICOM  compatible,  and  transferable  from  the  GE 
Advantage  Windows  Work  Station  to  Oncentra  Masterplan  (Nucletron,   339
Veenendaal,  The  Netherlands),  and  then  to  Aria  and Eclipse  IMRT  planning 
software (Varian Medical Systems Inc., Palo Alto, CA, USA).  
 
The potential of dose escalation was explored in four patients using a standard 7 
field IMRT technique. CT-PET RTSS and the reconstructed CT HN were used to 
retrospectively plan IMRT (65Gy in 30 fractions to high-risk disease, and 54Gy 
in 30 fractions to low-risk disease). IMRT was escalated in 5% increments of this 
standard  IMRT  high-risk  dose  to  the  CT-PET guided  volume  defined  by  the 
SUVCO threshold of 3.0bwg/ml. The equivalent dose in 2Gy per fraction, and 
the biological effective dose for each dose increment was calculated according to 
an α/β ratio of 10 for HN tumours. A SIB technique was used and planned from 
the start of treatment because dynamic imaging was not available to allow dose 
painting, and the aim was to demonstrate the possibility and guide future dose 
escalation studies.  
 
The dose to the biological TV was optimised during the RT process and a 3mm 
margin was created to expand this volume to a PTV. 
 
Figure  6.1  illustrates  the  standard  IMRT  colour  washed  plan  with  the  95% 
isodose shown.  
 
 
 
Figure 6.1: Colour washed axial image of standard Head and  eck IMRT plan 
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Figure 6.2a) indicates the 115% dose escalated plan. The CT-PET guided PTV 
was  planned  to  receive  74.5Gy  in  30  fractions,  and  the  CTV1  65Gy  in  30 
fractions. A colour wash thresholded to 62Gy has been applied. In Figure 6.2b) 
the 95% isodose for the CT-PET guided PTV of 70.78Gy has been applied to 
exclude regions that would have received a lower dose from the image. The CT-
PET defined PTV is indicated by an arrow. Three 
18FDG CT-PET guided FVs 
are present on the image, two LN regions, and a primary posterior third of tongue 
region. 
 
 
Figure  6.2a  and  b:  Dose  escalated 
18FDG  CT PET  guided  target  volume  with  lower 
threshold set at 62Gy a), and lower threshold at 70.78Gy  
 
This  planning  study  demonstrated  the  possibility  of  CT-PET  guided  dose 
escalation using commercially available software. In this example normal tissue 
constraints were not exceeded, and both primary and LN FV were escalated to 
the same dose.   
 
A prospective study would examine the feasibility of both SIB and voxel based 
dose painting methods of dose escalation. Dose distribution across the CT-PET 
guided FV, and adjacent normal tissue structures would be assessed.  
 
The  PETVCAR  software  would  allow  CT-PET  data  sets  to  be  co-registered 
before, during and after treatment and volumes reviewed according to areas of 
local recurrence and dose distribution within that volume. Recurrence would be 
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assessed voxel by voxel, and the dose received and SUVmax compared within 
that voxel. 
 
Within  this  study  design,  dose  levels  in  increments  of  5%  will  be  compared 
either to 65Gy in 30 fractions, or 70Gy in 35 fractions. Different FV within the 
patient  may  be  escalated  to  different  dose  levels  depending  on  the  level  of 
biological risk as shown by the theoretical dose required to reduce the SUVmax 
to zero in these two volumes.  
 
Assessment of acute and late toxicity would be required to ensure patient safety, 
by stopping dose escalation levels if for example laryngeal necrosis develops. 
Standard  and  dose  escalated  IMRT  continue  to  use  tissue  tolerance  data 
published nearly 20 years ago [3]. QUANTEC (Quantitative Analysis of Normal 
Tissue Effects in Clinic) will guide tolerance doses for RT techniques such as 
IMRT  that  deliver  a  bath  and  shower  radiation  dose.  The  normal  tissues  are 
bathed in low dose irradiation, and the targeted disease sites are showered with 
high  dose.  This  important  step  forward  will  allow  CT-PET  guided  dose 
escalation studies to assess the impact on normal tissue, and functional outcome, 
and correlate with improvements in loco-regional control.  
 
Normal  tissue 
18FDG  uptake  assessment  within  for  example  the  pharyngeal 
constrictor muscles would be important. Physiological uptake in these tissues 
during radiation will provide valuable information to predict functional outcome 
after treatment. 
18FDG uptake during treatment in normal tissues may also guide 
the total escalated dose. Increased uptake may suggest an increased likelihood of 
late toxicity, and so limit the total dose delivered. Alternatively reduced uptake 
may suggest a lower risk of toxicity, and a potential to escalate to higher doses. 
 
6.2.1.2 Dual Radio-nuclide Studies 
Tumour biology is complex and increased glucose metabolism and hypoxia may 
suggest a more aggressive phenotype [4].  
 
Dual radio-nuclide imaging with 
18FDG and for example Cu-ATSM would allow 
different intra-tumoural regions to be visualised and potentially dose optimised   342
and escalated by voxel based dose painting depending on the level of  radio-
resistance calculated from tumour probability models [5]. Such studies need to be 
able to identify each individual radio-nuclide, and will require a time interval 
between administration for example a minimum of 5 half-lives for 
18FDG or 24 
hours with this nuclide administered first and then Cu-ATSM. 
 
6.2.1.3 Phantom Validation Studies 
18FDG delineation methods are dependent on the calibration factors, hard and 
software of individual cameras. Collaborative studies would require individual 
centres to incorporate these into studies using commercially available software. 
 
Adaptive thresholding methods require such knowledge. Prior to dose escalation 
with the IAT, further validation is required to assess the effect in larger patients 
numbers  on  FV  delineation  during  RT.  This  should  then  be  correlated  in 
phantom  studies  with  the  true  phantom  edge,  and  that  defined  on  CT-PET 
imaging in patients by the algorithm. 
 
6.2.2 
64Cu ATSM Hypoxia Definition, and Target Volume Delineation 
The  results  reported  in  chapter  5  suggested  that 
64Cu-ATSM  was  a  potential 
surrogate  marker  of  hypoxia.  However  before  dose  escalation  studies  are 
contemplated to the defined hypoxic FV, further validation is required in larger 
patient numbers to confirm or refute these results. 
 
6.2.2.1 Patient Recruitment 
This study had originally planned to recruit 20 patients, and this would have 
provided more robust conclusions. Ideally patient recruitment will continue at 
UCLH  and  commence  at  Guy’s  and  St  Thomas’  Hospitals  NHS  Foundation 
Trust. Other imaging arms within the protocol can then be completed including 
whole  body  CT-PET  imaging,  and  venous  blood  sampling  to  give  further 
information on the uptake, retention pattern, and bio-distribution of 
64Cu-ATSM. 
Also the association of 
64Cu, and the ATSM ligand can be closely evaluated 
within the blood. 
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6.2.2.2 Registration of Imaging and Pathological Specimens 
Improved registration with non-rigid methods may allow the overlap between the 
CT-PET and digitised IHC image to be evaluated. Laser capture microscopy [6] 
on the IHC digitised images will allow antigen detection at a cellular level which 
may then be correlated with the retention of 
64Cu-ATSM within an individual 
voxel and provide more accurate spatial mapping of distribution. The hypoxia 
within the voxel would then be proportional to the number of hypoxic cells. This 
microscopy could also be used in conjunction with hypoxia metagene sequencing 
and  analysis  in  micro-array  studies  because  the  gene  sequence  could  be 
established  within  an  individual  voxel  provided  the  tissue  and  imaging  are 
accurately co-registered. 
 
6.2.2.3 Dual Radio-nuclide and Perfusion Imaging 
Dual  radio-nuclide  imaging  using  Cu-ATSM  and  PTSM,  for  hypoxia  and 
perfusion imaging or 
18Fluoro-3'-deoxy-3'-thymidine for proliferation will give 
further information into the complex intra-tumoural biology that is associated 
with loco-regional recurrence. Similarly, consideration will need to be given to 
the order and timing of administration of each radio-nuclide under investigation. 
 
Perfusion  within  tumour  and  normal  tissues  is  dynamic  and  temporal  intra-
regional  variation  occurs  [7].  Serial  imaging  with DCE-CT,  would  provide  a 
more representative map of these changes, and allow more extensive correlation 
with IHC hypoxic antigens, and 
64Cu-ATSM uptake and retention.  
 
6.2.2.4 Hypoxia Imaging with other Copper Isotopes 
Alternative isotopes with a shorter half-life, and a higher positron emission rate 
such as 
60, 61, and 62Cu will allow repeated imaging without exposing the patients to 
excessive radiation dose. They may also be incorporated into dual tracer studies. 
This will allow the imaging of chronic hypoxia, perfusion and reoxygenation 
during treatment to be correlated. 
 
6.2.2.5 Correlation of Imaging with Hypoxia Metagene Sequencing 
Once validated in larger numbers of patients, the uptake and retention of 
64Cu-
ATSM may be correlated with hypoxia metagene sequences to further determine   344
individual risk. This will allow loco-regional recurrence to be correlated with 
genotype and Cu-ATSM uptake. Multiple biopsy specimens of whole specimens 
will give the greatest opportunity to spatially  map the tumour unless used in 
conjunction with laser microscopy. 
 
6.2.2.6 Hypoxic Target Volume Delineation 
Hypoxic TV delineation for use in RT planning is vitally important and as shown 
is  dependent  on  the  method  of  delineation  and  threshold.  The  uptake  and 
retention of Cu-ATSM must be defined according to the time point after injection 
as well. This will depend on the Cu isotope used. Later imaging time points may 
be more representative of chronic hypoxia. As with perfusion, this process is 
dynamic, and delineation on multiple hypoxia image sets may provide a more 
representative map of spatial distribution and ensure all the hypoxic areas are 
included in the volume [8]. 
 
The delineation of the FV may then be further assessed in studies specifically to 
evaluate the benefit of using the tumour to muscle, blood or background ratios. 
The threshold selected should predict the true hypoxic volume, and so the risk of 
loco-regional recurrence. 
 
6.2.2.7 Dose Escalation to Hypoxic Functional Volumes 
After  this,  dose  escalation  studies  similar  to  those  using 
18FDG  may  be 
attempted. Serial imaging will evaluate the most representative imaging point of 
chronic  hypoxia.  Retention  studies  before  and  during  treatment  will  evaluate 
when adaptive RT should be commenced, and how it should be delivered, as 
reoxygenation with treatment will be visualised [9].  
 
Voxel  based  dose  painting  will  give  the  best  opportunity  to  modulate  and 
optimise dose based on the individual risk within the voxel for recurrence and so 
mirror the heterogeneous pattern of hypoxia [10,11]. 
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6.3 Conclusion 
CT-PET  guided  RT  planning,  dose  optimisation  and  escalation  to  both 
metabolically  active  and  hypoxic  FVs  requires  close  collaboration  with  the 
Nuclear  Medicine  Department,  and  other  institutions  to  provide  robust 
delineation techniques. Accurate delineation also depends on factors related to 
the radio-nuclide, and camera.  
 
The  detection,  visualisation,  and  delineation  of  FVs  must  represent  the  true 
pathological  volume,  and  validation  studies  with 
64Cu-ATSM  are  vitally 
important.  
 
Finally, the Clinical Oncologist must be confident when defining the CT-PET 
guided TVs for RT planning that the delineation method provides an accurate 
representation  of  the  process  under  investigation.  Dose  escalation  to  targeted 
areas of radio-resistance will then be effective, and have the greatest impact on 
loco-regional control. 
 
 
 
   346
6.3 References 
 
1.  Ling  CC,  Humm  J,  Larson  S,  et  al.  Towards  multidimensional 
radiotherapy (MD-CRT): biological imaging and biological conformality. 
Int J Radiat Oncol Biol Phys 2000;47:551-560 
2.  Madani  I,  Duthoy  W,  Derie  C,  et  al.  Positron  emission  tomography-
guided, focal-dose escalation using intensity-modulated radiotherapy for 
head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-135 
3.  Emami  B,  Lyman  J,  Brown  A,  et  al.  Tolerance  of  normal  tissue  to 
therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122 
4.  Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting 
by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-
300 
5.  Alber  M,  Paulsen  F,  Eschmann  SM,  Machulla  HJ.  On  biologically 
conformal boost dose optimization. Phys Med Biol 2003;48:N31-35 
6.  Curran  S,  McKay  JA,  McLeod  HL,  Murray  GI.  Laser  capture 
microscopy. Mol Pathol 2000;53:64-68 
7.  Bisdas S, Surlan-Popovic K, Didanovic V, Vogl TJ. Functional CT of 
squamous cell carcinoma in the head and neck: repeatability of tumor and 
muscle quantitative measurements, inter- and intra-observer agreement. 
Eur Radiol 2008;18:2241-2250 
8.  Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor 
distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J 
Radiat Oncol Biol Phys 2008;70:235-242 
9.  Thorwarth  D,  Eschmann  SM,  Paulsen  F,  Alber  M.  A  model  of 
reoxygenation dynamics of head-and-neck tumors based on serial 18F-  347
fluoromisonidazole  positron  emission  tomography  investigations.  Int  J 
Radiat Oncol Biol Phys 2007;68:515-521 
10.  Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting 
by numbers. Lancet Oncol 2005;6:112-117 
11.  Dirix  P,  Vandecaveye  V,  De  Keyzer  F,  et  al.  Dose  painting  in 
radiotherapy  for  head  and  neck  squamous  cell  carcinoma:  value  of 
repeated  functional  imaging  with  (18)F-FDG  PET,  (18)F-
fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-
enhanced MRI. J Nucl Med 2009;50:1020-1027 
 
   348
Appendix 1     Tables 
 
Chapter 4 
 
Table 1 
The simple linear regression correlation for the defined the primary functional 
volume by the SUV Cut Off thresholds and radiation dose  
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(cm
3) 
2.5  -0.274  0.135  -0.57 to -0.09 
3.0  -0.374  0.038  -0.64 to -0.02 
3.5  -0.438  0.014  -0.67 to -0.10 
4.0  -0.468  0.008  -0.71 to -0.14 
 
 
Table 2 
Simple linear regression results for the primary functional volume delineated 
by the percentage of the SUVmax method and dose 
 
Percentage 
Threshold  of  the 
SUVmax (%) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(cm
3) 
30  0.337  0.058  -0.01 to +0.61 
35  0.326  0.068  -0.03 to +0.61 
40  0.300   0.095  -0.05 to +0.59 
45  0.288  0.109  -0.07 to +0.80 
50  0.257  0.155  -0.10 to +0.57 
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Table 3 
The  mean  percentage,  actual  reduction,  p-values,  and  95%  confidence 
intervals for the lymph node functional volume delineated by the SUV Cut Off 
thresholds  at each imaging point  
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Imaging  
Point 
(Gy) 
 
Median 
Percentage 
Reduction 
 
Median 
Reduction 
(cm
3) 
p-value  95%  CI 
(cm
3) 
0  35.85  1.10  0.0001  0.60 - 2.00  
8 to 18  65.22  0.60  0.001  0.30 - 1.40  
36 to 50  87.50  0.65  0.002  0.20 - 1.00 
2.5 to 3.0 
66  -  0.20  0.007  0.00 - 0.45  
0  54.72  1.65  <0.0001  0.90 - 2.12 
8 to 18  91.30  1.08  <0.0001  0.40 - 2.20  
36 to 50  100.00  0.80  <0.0001  0.20 - 2.25  
2.5 to 3.5 
66  -  0.20  0.004  0.00 - 0.55  
0  69.81  1.90  <0.0001  1.10 - 3.90  
8 to 18  95.65  1.38  <0.0001  0.50 - 2.80 
36 to 50  100.00  0.85  <0.0001  0.20 - 2.80  
2.5 to 4.0 
66  -  0.20  0.004  0.00 - 0.55  
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Table 4 
The median percentage, actual change, p-values and 95% confidence intervals 
for  the  lymph  node  functional  volume  delineated  by  the  SUV  Cut  Off 
thresholds between the imaging points  
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Compared 
Imaging  
Points 
(Gy) 
 
Median 
Percentage 
change 
 
Median 
change 
(cm
3) 
p-value  95%  CI 
(cm
3) 
0 to  
8 18 
-56.60  +1.65  0.999  +0.65 to 
+3.25 
0 to  
36 50 
-84.91  -2.45  <0.0001  -5.30 to  
-1.15 
2.5 
0 to 66  -100.00  -3.38  <0.0001  -7.05 to  
-1.45 
0 to  
8 18 
-76.47  +0.90  0.999  +0.25 to 
+2.50 
0 to  
36 50 
-97.06  -1.85  <0.0001  -4.40 to  
-0.75 
3.0 
0 to 66  -100.00  -3.53  <0.0001  -5.90 to  
-0.25 
0 to  
8 18 
-91.66  +0.73  0.998  +0.20 to 
+2.35 
0 to  
36 50 
-100.00  -1.93  <0.0001  -4.00 to  
-0.45 
3.5 
0 to 66  -100.00  -2.00  0.0001  -4.95 to  
-0.45 
0 to  
8 18 
-93.75  +0.50  0.995  +0.05 to 
+2.1 
0 to  
36 50 
-100.00  -3.50  0.0002  -3.50 to  
-0.25 
4.0 
0 to 66  -100.00  -2.75  0.0002  -4.35 to  
-0.25   351
Table 5 
Simple linear regression results for the relationship between the lymph node 
functional volume delineated by the SUV Cut Off thresholds and radiation 
dose 
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(cm
3) 
2.5  -0.285  0.01  -0.48 to -0.07 
3.0  -0.291  0.009  -0.48 to -0.08 
3.5  -0.290  0.009  -0.48 to -0.08 
4.0  -0.287  0.009  -0.48 to -0.07 
 
 
Table 6 
The  median  percentage,  actual  reduction,  p-values,  and  95%  confidence 
intervals for the lymph node functional volume delineated by the percentage 
thresholds of the SUVmax at each imaging point  
 
Percentage 
Threshold  of 
the SUVmax 
(%) 
Imaging  
Point 
(Gy) 
 
Median 
Percentage 
Reduction 
 
Median 
Reduction 
(cm
3) 
p-value  95%  CI 
(cm
3) 
0  -1.18  +0.90  >0.999  +0.14 to 
+1.70 
8 to 18  -18.18  -0.05  0.3529  -1.05 to 
+0.55 
36 to 50  +1.12  +0.63  <0.999  +0.01 to 
+0.45 
30 to 35 
66  0.00  +0.20  0.999  +0.00 to 
+1.30   352
0  -10.59  -1.20  <0.0001  -3.10 to  
-0.70 
8 to 18  -26.14  -1.23  <0.0001  -2.45 to  
-0.60 
36 to 50  -11.11  -1.23  <0.0001  -2.50 to  
-0.25 
30 to 40 
66  -2.22  -0.40  0.0005  -2.55 to  
-0.50 
0  -25.06  -1.88  <0.0001  -3.60 to  
-1.10 
8 to 18  -34.09  -1.70  <0.0001  -3.90 to  
-0.55 
36 to 50  -23.86  -2.05  <0.0001  -3.90 to  
-0.55 
30 to 45 
66  -13.33  -0.73  <0.0001  -3.05 to  
-0.20 
0  -36.47  -2.55  <0.0001  -4.50 to  
-1.45 
8 to 18  -40.91  -2.23  <0.0001  -4.25 to  
-1.35 
36 to 50  -33.33  -2.63  <0.0001  -5.70 to  
-1.35 
30 to 50 
66  -24.44  -1.45  <0.0001  -4.30 to  
-0.60 
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Table 7 
The median percentage, actual change, p-values and 95% confidence intervals 
for the lymph node functional volumes delineated by the percentage thresholds 
of the SUVmax between the imaging points  
 
Percentage 
Threshold  of 
the SUVmax 
(%) 
Compared 
Imaging  
Points 
(Gy) 
 
Median 
Percentage 
Change 
 
Median 
Change 
(cm
3) 
p-value  95%  CI 
(cm
3) 
0 to  
8 18 
+2.44  +0.58  0.414  -6.67 to 
+5.52 
0 to  
36 50 
+17.35  +4.09  0.211  -7.26 to 
+15.44 
30 
0 to 66  +35.73  +25.53  0.065  -9.76 to 
+60.82 
0 to  
8 18 
+5.16  +0.99  0.355  -7.06 to 
+5.08 
0 to  
36 50 
+9.26  +1.78  0.321  -6.88 to 
+10.43 
35 
0 to 66  +133.49  +20.41  0.071  -8.79 to 
+49.61 
0 to  
8 18 
+3.54  +0.58  0.401  -5.81 to 
+4.66 
0 to  
36 50 
-6.34  -1.03  0.334  -6.43 to 
+4.38 
40 
0 to 66  +116.48  +14.89  0.078  -7.29 to 
+37.07 
0 to  
8 18 
+1.49  +0.20  0.453  -4.05 to 
+3.65 
45 
0 to  
36 50 
-13.70  -1.837  0.165  -6.00 to 
+2.33   354
  0 to 66  +111.43  +11.79  0.091  -7.01 to 
+30.58 
0 to  
8 18 
-0.12  +0.01  0.496  -3.17 to 
+3.20 
0 to  
36 50 
-22.49  -2.462  0.075  -6.064 to 
+1.139 
50 
0 to 66  +95.82  +8.19  0.101  -5.59 to 
21.96 
 
Table 8 
Simple  linear  regression  results  for  the  lymph  node  functional  volume 
delineated by the percentage thresholds of the SUVmax and radiation dose 
Percentage 
Threshold  of  the 
SUVmax (%) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(cm
3) 
30  +0.057  0.612  -0.16 to +0.27 
35  +0.073  0.519  -0.15 to +0.29 
40  +0.054  0.635  -0.17 to +0.27 
45  +0.073  0.515  -0.15 to +0.29 
50  +0.078  0.492  -0.14 to +0.30 
 
 
Table 9 
Simple linear regression results for the SUVmax within the primary functional 
volume delineated by the SUV Cut Off thresholds and radiation dose 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(bwg/ml) 
2.5  -0.447  0.012  -0.69 to -0.11 
3.0  -0.483  0.006  -0.72 to -0.16 
3.5  -0.435  0.014  -0.68 to -0.10 
4.0  -0.384  0.036  -0.65 to -0.03   355
Table 10 
The  median  percentage,  actual  reduction,  p-values,  and  95%  confidence 
intervals for the SUVmax within the lymph node functional volume delineated 
by the SUV Cut Off thresholds at each imaging point  
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Imaging  
Point 
(Gy) 
 
Median 
Percentage 
Reduction 
 
Median 
Reduction 
(bwg/ml) 
p-value  95%  CI 
(bwg/ml) 
0  0.00  0.00  0.790  * 
8 to 18  0.00  0.00  0.875  * 
36 to 50  -49.18  0.00  0.063  0.0 to + 1.35 
2.5 to 3.0 
66  0.00  0.00  0.895  * 
0  0.00  -0.65  0.016  -1.65 to 0.0 
8 to 18  -43.59  0.00  0.031  -1.40 to 0.0 
36 to 50  -100.00  -1.35  0.008  -1.65 to 0.0 
2.5 to 3.5 
66  -100.00  -1.45  0.031  -1.45 to 0.0 
0  0.00  -1.55  0.003  -1.75 to 0.0 
8 to 18  -100.00  0.00  0.003  -1.40 to 0.0 
36 to 50  -100.00  -1.35  0.007  -1.65 to 0.0 
2.5 to 4.0 
66  -100.00  -1.45  0.007  -1.75 to 0.0 
*  Indicates  no  CI  calculated  as  there  was  no  difference  between  the 
compared groups 
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Table 11 
The  median  percentage,  actual  reduction,  p-values  and  95%  confidence 
intervals for the SUVmax within the lymph node functional volume delineated 
by the SUV Cut Off thresholds between the imaging points 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Compared 
Imaging  
Points 
(Gy) 
 
Median 
Percentage 
Change 
 
Median 
change 
(bwg/ml) 
p-value  95%  CI 
(bwg/ml) 
0 to  
8 18 
+36.59  +2.1  0.999  +1.15 to 
+3.05  
0 to  
36 50 
-50.41  -4.05  <0.0001  -7.55 to  
-3.85 
2.5 
0 to 66  -100.00  -5.45  <0.0001  -7.55 to  
-3.85 
0 to  
8 18 
+36.59  +2.18  0.997  +1.20 to 
+3.35  
0 to  
36 50 
-74.80  -4.30  <0.0001  -5.70 to  
-3.10 
3.0 
0 to 66  -100.00  -5.68  <0.0001  -7.90 to 
 -3.75 
0 to  
8 18 
+29.26  +1.80  0.998  +0.20 to 
+3.05  
0 to  
36 50 
-100.00  -4.26  <0.0001  -5.80 to  
-2.55 
3.5 
0 to 66  -100.00  -5.55  <0.0001  -8.00 to  
-3.40 
0 to  
8 18 
+21.13  +1.30  0.991  +0.0 to 
+2.65  
0 to  
36 50 
-100.00  -3.60  0.0002  -3.60 to  
-5.80 
4.0 
0 to 66  -100.00  -5.55  0.0002  -8.20 to 
 -3.40   357
Table 12  
Simple  linear  regression  results  for  the  SUVmax  within  the  lymph  node 
functional volume delineated by the SUV Cut Off thresholds and radiation 
dose 
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(bwg/ml) 
2.5  -0.537  <0.0001  -0.64 to -0.36 
3.0  -0.517  <0.0001  -0.66 to -0.34 
3.5  -0.476  <0.0001  -0.63 to -0.29 
4.0  -0.476  <0.0001  -0.63 to -0.28 
 
 
Table 13 
The mean and standard error of the mean for the SUV used to define the 
primary  functional  volume  delineated  by  each  percentage  threshold  of  the 
SUVmax  
SUV (bwg/ml)    Percentage 
Threshold  of 
the SUVmax 
(%) 
0Gy  8 to 18Gy  36 to 50Gy  66Gy 
Mean  3.73  3.15  2.33  1.73  30 
  SEM  0.70  0.64  0.35  0.28 
Mean  4.34   3.70  2.70  2.01  35 
  SEM  0.81  0.74  0.41  0.33 
Mean  4.93  4.24  3.09  2.30  40 
SEM  0.94  0.86  0.46  0.38 
Mean  5.50  4.75  3.45  2.55  45 
SEM  1.05  0.96  0.53  0.42 
Mean  6.20  5.31  3.88  2.90  50 
SEM  1.17  1.07  0.59  0.46 
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Table 14 
The mean increase, p-values, and 95% confidence intervals for the SUV used 
to  define  the  primary  functional  volume  at  each  imaging  point  by  the 
percentage thresholds of the SUVmax  
 
Percentage 
Threshold  of  the 
SUVmax 
(%) 
Mean Increase 
(bwg/ml) 
p-value  95% CI  
(bwg/ml) 
0  0.62  0.001  0.35 to 0.89 
8 to 18  0.54  0.001  0.30 to 0.78 
36 to 50  0.36  0.0004  0.21 to 0.51 
30  to 
35 
66  0.29  0.0004  0.17 to 0.41 
0  1.20  0.0008  0.62 to 0.18 
8 to 18  1.09  0.0008  0.57 to 1.60 
36 to 50  0.76  0.0003  0.48 to 1.04 
30  to 
40 
66  0.58  0.0003  0.34 to 0.81 
0  1.83  0.0007  0.99 to 2.67 
8 to 18  1.60  0.0008  0.85 to 2.35 
36 to 50  1.12  0.0002  0.69 to 1.55 
30  to 
45 
66  0.88   0.0001  0.57 to 1.18 
0  2.48  0.0006  1.35 to 3.61 
8 to 18  2.15  0.0007  1.15 to 3.16 
36 to 50  1.56  0.0002  0.99 to 2.13 
30  to 
50 
66  1.16  0.0002  0.73 to 1.60 
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Table 15 
The median increase, p-values, and 95% confidence intervals for the SUV used 
to  define  the  lymph  node  functional  volume  at  each  imaging  point  by  the 
percentage thresholds of the SUVmax  
 
Percentage 
Threshold  of  the 
SUVmax 
(%) 
Mean  Increase 
(bwg/ml) 
p-value  95% CI  
(bwg/ml) 
0  0.35  <0.0001  0.20 to 0.49 
8 to 18  0.30  <0.0001  0.20 to 0.40  
36 to 50  0.20  <0.0001  0.15 to 0.25  
30  to 
35 
66  0.10   <0.0001  0.10 to 0.15  
0  0.70  <0.0001  0.45 to 0.95 
8 to 18  0.55  <0.0001  0.40 to 0.80 
36 to 50  0.35  <0.0001  0.25 to 0.50 
30  to 
40 
66  0.25  <0.0001  0.20 to 0.30 
0  1.05  <0.0001  0.70 to 1.40 
8 to 18  0.80  <0.0001  0.55 to 1.50 
36 to 50  0.55  <0.0001  0.40 to 0.70 
30  to 
45 
66  0.35  <0.0001  0.30 to 0.45 
0  1.50  <0.0001  0.95 to 1.95 
8 to 18  1.05  <0.0001  0.65 to 1.55 
36 to 50  0.75  <0.0001  0.55 to 0.95 
30  to 
50 
66  0.50  <0.0001  0.40 to 0.65 
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Table 16 
Simple linear regression relationship between the SUVmax and the primary 
functional volume delineated by the SUV Cut Off thresholds 
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(bwg/ml) 
2.5  0.618  0.0002  0.34 to 0.80 
3.0  0.718  <0.0001  0.49 to 0.86 
3.5  0.749  <0.0001  0.53 to 0.87 
4.0  0.780  <0.0001  0.59 to 0.89 
 
 
Table 17 
Simple  linear  regression  relationship  between  the  SUVmax  and  the  lymph 
node functional volume delineated by the SUV Cut Off thresholds 
 
SUV  Cut  Off 
Threshold 
(bwg/ml) 
Correlation  
Co-efficient 
p-value  95%  Confidence 
Interval 
(bwg/ml) 
2.5  0.633  <0.0001  0.48 to 0.75 
3.0  0.631  <0.0001  0.48 to 0.75 
3.5  0.632  <0.0001  0.48 to 0.75 
4.0  0.627  <0.0001  0.47 to 0.74 
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Table 18 
The range of activity of 
64Cu-ATSM with time after injection 
 
Time in minutes  Region of interest  Maximum
  
64Cu-ATSM  
Activity (Bq/ml) 
Tumour  0 
 ecrosis  0 
CL SCM  0 
Carotid  0 
Posterior  eck  0 
IL Salivary gland  0 
0 
CL Salivary gland  0 
Tumour  1,207190 to 1,914,251 
 ecrosis  407,086 to 509,500 
CL SCM  222,093 to 602,272 
Carotid  2,524,364 to 6,427,844 
Posterior  eck  248,720 to 668,346 
IL Salivary gland  505,133 to 701,623 
0.5 
CL Salivary gland  222,093 to 969,980 
Tumour  802,635 to 952,490 
 ecrosis  506,632 to 616,632 
CL SCM  430,758 to 531,687 
Carotid  463,499 to 934,858 
Posterior  eck  295,997 to 536,123 
IL Salivary gland  592,680 to 919,363 
1  
CL Salivary gland  378,219 to 817,097 
Tumour  472078 to 528834 
 ecrosis  295,921 to 332,470 
5 
CL SCM  235,522 to 365,885   362
Carotid  350,185 to 390,944 
Posterior  eck  218,572 to 488,606 
IL Salivary gland  383,724 to 384,385 
 
CL Salivary gland  293,257 to 449,352 
Tumour  342,589 to 394,509 
 ecrosis  213,397 to 29,3397 
CL SCM  188,005 to 281608 
Carotid  277,875 to 290,935 
Posterior  eck  213,776 to 332,624 
IL Salivary gland  237,757 to 326,410 
10 
CL Salivary gland  272,016 to 375,880 
Tumour  228,291 to 408,949 
 ecrosis  95,034 to 102,034 
CL SCM  136,355 to 201,087 
Carotid  148,684 to 202,467 
Posterior  eck  139,776 to 200,642 
IL Salivary gland  192,535 to 240,687 
60 
CL Salivary gland  191,850 to 238,621 
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Appendix 2     Figures 
 
Chapter 4 
 
Figures 1a to c 
The negative correlation of the primary functional volume delineated by the 
SUV Cut Off thresholds of 2.5bwg/ml a), 3.0bwg/ml b), and 3.5bwg/ml c) and 
radiation dose 
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Figures 2a to d 
The simple linear regression of the primary functional volume delineated by 
the percentage of the SUVmax thresholds of 35% a), 40% b), 45% c, and 50% 
d) and radiation dose 
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Figure 3 
The simple linear regression relationship between the delivered radiation dose 
and the primary functional volume delineated by the individualised adaptive 
threshold  
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Figures 4a to c 
The box and whisker plots of the lymph node functional volumes delineated by 
the SUV Cut Off thresholds of 3.0bwg/ml a), 3.5bwg/m b), and 4.0bwg/ml c) 
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Figures 5a to c 
The negative correlation of the lymph node functional volume delineated by 
the SUV Cut Off thresholds of 2.5bwg/ml a), 3.0bwg/ml b), and 3.5bwg/ml c), 
and 4.0bwg/ml d) and radiation dose 
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Figures 6a to d 
The box and whisker plots of the lymph node functional volumes delineated by 
the percentage thresholds of the SUVmax 30% a), 35% b), 40% c), and 50% d) 
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Figures 7a to d 
The simple linear regression of the lymph node functional volume delineated 
by the percentage of the SUVmax thresholds of 30% a), 35% b), 40 c), 45% d), 
and 50% e) 
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Figure 8 a to c 
The  negative  correlation  between  SUVmax  within  the  primary  functional 
volume delineated by the SUV Cut Off thresholds of 2.5bwg/ml a), 3.5bwg/ml 
b), and 4.0bwg/ml c) and the radiation dose 
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Figure 9a to c 
The box and whisker plots of the SUVmax within the lymph node functional 
volumes delineated by the SUV Cut Off thresholds of 2.5bwg/ml a), 3.5bwg/ml 
b), and 4.0bwg/ml c) 
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Figure 10a to c 
The negative correlation between the lymph node functional volume delineated 
by the SUV Cut Off thresholds of 3.0bwg/ml a), 3.5bwg/ml b), and 4.0bwg/ml c) 
and radiation dose 
 
0 20 40 60 80
0
4
8
12
16
SUVmax (bwg/ml)
Dose (Gy)
 
 
 
0 20 40 60 80
0
4
8
12
16
SUVmax (bwg/ml)
Dose (Gy)
 
 
 
a) 3.0bwg/ml 
b) 3.5bwg/ml   380
0 20 40 60 80
0
4
8
12
16
SUVmax (bwg/ml)
Dose (Gy)
 
 
 
Figure 11 
The  negative  correlation  between  the  SUVmax  within  the  lymph  node 
functional  volume  delineated  by  the  percentage  of  the  SUVmax  and  the 
radiation dose 
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Figure 12 
The  SUVmax  within  the  lymph  node  functional  volume  delineated  by  the 
individualised adaptive threshold  
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Figure 13 
Simple  linear  regression  between  the  SUVmax  within  the  lymph  node 
functional volume delineated by the individualised adaptive threshold and the 
radiation dose 
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Figure 14 a to c 
The positive correlation between the primary functional volume delineated by 
the SUV Cut Off thresholds of 2.5bwg/ml a), 3.5bwg/ml b), and 4.0bwg/ml c), 
and the SUVmax within the volume 
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Figure 15 a to d 
The positive correlation between the lymph node functional volume delineated 
by the SUV Cut Off thresholds of 2.5bwg/ml a), 3.0bwg/ml b), 3.5bwg/ml c), 
and 4.0bwg/ml d), and the SUVmax within the volume 
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Chapter 5 
Figure 16 a to d 
The uptake of 
64Cu ATSM within the tumour in patient 4 compared to other 
regions of interest. Contra lateral SCM a), carotid artery b), posterior neck c), 
and salivary glands d) 
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Figure 17 a to d 
The uptake of 
64Cu ATSM within the tumour in patient 5 compared to other 
regions  of  interest.   ecrosis  a),  contra lateral  SCM  b),  carotid  artery  c), 
posterior neck d), and salivary glands e) 
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Figure 18 a to c 
The  defined  hypoxic  functional  volumes  in  patient  1  a),  2  b),  and  4  c) 
according to the tumour to muscle ratio 
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Appendix 3     Equations 
 
Chapter 4 
 
Equations 1 to 3 
Simple linear regression modelling for the relationship between the radiation 
dose  and  the  primary  functional  volume  delineated  by  the  SUV  Cut  Off 
thresholds 
 
1. SUV Cut Off 2.5bwg/ml: FV (cm
3) =  -0.226Dose(Gy) + 34.273  
 
2. SUV Cut Off 3.0bwg/ml: FV (cm
3) =  -0.250Dose(Gy) + 27.490 
 
3. SUV Cut Off 3.5bwg/ml: FV (cm
3) =  -0.256Dose(Gy) + 23.284  
 
 
Equations 4 to 7 
Simple linear regression modelling for the relationship between the radiation 
dose  and  the  primary  functional  volume  delineated  by  the  percentage 
thresholds of the SUVmax  
 
4. 35% of the SUVmax:  FV (cm
3) =  0.271Dose(Gy) + 17.049 
 
5. 40% of the SUVmax:  FV (cm
3) =  0.191Dose(Gy) + 14.205 
 
6. 45% of the SUVmax:  FV (cm
3) =  0.150Dose(Gy) + 11.569 
 
7. 50% of the SUVmax:  FV (cm
3) =  0.101Dose(Gy) + 9.421 
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Equations 8 to 10 
Simple linear regression modelling for the relationship between the radiation 
dose and the lymph node functional volume delineated by the SUV Cut Off 
thresholds 
 
8. SUV Cut Off 2.5bwg/ml:   FV (cm
3) =  -0.107Dose(Gy) + 7.121 
 
9. SUV Cut Off 3.5bwg/ml:   FV (cm
3) =  -0.077Dose(Gy) + 4.552 
 
10. SUV Cut Off 4.0bwg/ml:  FV (cm
3) =  -0.067Dose(Gy) + 3.855 
 
Equations 11 to 14 
Simple linear regression modelling for the relationship between the radiation 
dose  and  the  lymph  node  functional  volume  delineated  by  the  percentage 
thresholds of the SUVmax  
 
11. 35% of the SUVmax:  FV (cm
3) =  0.036Dose(Gy) + 7.616 
 
12. 40% of the SUVmax:  FV (cm
3) =  0.022Dose(Gy) + 6.688 
 
13. 45% of the SUVmax:  FV (cm
3) =  0.025Dose(Gy) + 5.495 
 
14. 50% of the SUVmax:  FV (cm
3) =  0.023Dose(Gy) + 4.527 
 
Equations 15 to 17 
Simple linear regression modelling for the relationship between the radiation 
dose and the SUVmax within the primary functional volume delineated by the 
SUV Cut Off thresholds 
 
15. SUV Cut Off 2.5bwg/ml:   
SUVmax (bwg/ml)  =  -0.093Dose(Gy) + 11.848 
 
16. SUV Cut Off 3.5bwg/ml:   
SUVmax (bwg/ml)   =  -0.096Dose(Gy) + 11.683   395
17. SUV Cut Off 4.0bwg/ml:   
SUVmax (bwg/ml)  =  -0.094Dose(Gy) + 11.279 
 
Equations 18 to 20 
Simple linear regression modelling for the relationship between the radiation 
dose and the SUVmax within the lymph node functional volume delineated by 
the SUV Cut Off thresholds 
 
18. SUV Cut Off 3.0bwg/ml:   
SUVmax (bwg/ml)   =  -0.085Dose(Gy) + 6.264 
 
19. SUV Cut Off 3.5bwg/ml:   
SUVmax (bwg/ml)   =  -0.082Dose(Gy) + 5.728 
 
20. SUV Cut Off 4.0bwg/ml:   
SUVmax (bwg/ml)  =  -0.083Dose(Gy) + 5.583 
 
Equations 21 to 23 
Simple linear regression modelling for the relationship between the SUVmax 
and the primary functional volume delineated by the SUV Cut Off thersholds 
 
21. SUV Cut Off 2.5bwg/ml:   
FV (cm
3) =  2.461SUVmax(bwg/ml) + 5.157 
 
22. SUV Cut Off 3.5bwg/ml:   
FV (cm
3) =  1.961SUVmax(bwg/ml) -1.321 
 
23. SUV Cut Off 4.0bwg/ml:   
FV (cm
3) =  1.704SUVmax(bwg/ml) -1.457 
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Equations 24 to 26 
Simple linear regression modelling for the relationship between the SUVmax 
and  the  lymph  node  functional  volume  delineated  by  the  SUV  Cut  Off 
thresholds 
 
24. SUV Cut Off 2.5bwg/ml:   
FV (cm
3) =  1.536SUVmax(bwg/ml) - 2.464 
 
25. SUV Cut Off 3.5bwg/ml:   
FV (cm
3) =  0.973SUVmax(bwg/ml) - 0.936 
 
26. SUV Cut Off 4.0bwg/ml:   
FV (cm
3) =  0.834SUVmax(bwg/ml) - 0.723 
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Appendix 4    
64Cu ATSM Production 
 
4.1  Preparation of 
64 i Solution 
64Ni was transferred onto a weighing boat with a gold spatula, and placed in a 
50ml  beaker.  Ten  millilitres  of  high  purity  concentrated  nitric  acid  was 
transferred to the beaker via disposable pipette, along with the same quantity of 
deionised water. The solution was stirred, heated and evaporated to a green film 
under a stream of air. High purity concentrated nitric acid (6ml) was added to the 
beaker, heated again and evaporated to a green film. High purity sulphuric acid 
(20  drops)  was  added  once  cooled,  and  then  10ml  of  deionised  water.  The 
solution was reheated to near dryness. Once cooled this was transferred to a 
volumetric flask, and made up with deionised water. 
 
4.2 Electroplating of the Target 
Teflon plating spacers and plating glass tubes were soaked in 50% hydrochloric 
acid, and rinsed with deionised water. Platinum electrodes and the gold bullet for 
electroplating were cleaned with 6 molar(M) hydrochloric acid. The bullet was 
rinsed with deionised water, oven dried, cooled, and weighed. The plating cell 
was then assembled. 
 
Ammonium hydroxide was added to the 
64Ni solution to achieve a pH of 9.0. 
Ammonium sulphate was added equal to 0.1g of target. The solution was then 
transferred to the plating cells. The gold bullet was electroplated for a minimum 
of 12 hours at 3 volts, at a revolution speed of 1 revolution per second. When 
completed, the nickel solution was discarded. The gold bullet was removed from 
the teflon spacer, rinsed with deionised water, and oven dried. The dry weight of 
the target was noted. 
 
4.3 Production of the H2ATSM Ligand  
4 methyl 3 thiosemicarbazide was dissolved in 50ml of 5% acetic acid solution, 
and heated to 60°C with constant stirring.  The solution was filtered and any 
undissolved material removed. Over the next 45 minutes, 2,3 butanedione was 
added  drop  wise  to  achieve  a  1:2  stoichiometry  with  4 methyl 3   398
thiosemicarbazone. The H2ATSM (yellow air stable solid) precipitated out, and 
the mixture was stirred for an additional 30 minutes at 60°C. The solution was 
filtered (Buchner filter funnel and flask connected to a vacuum pump), and the 
crude  H2ATSM  washed  in  two  50ml  aliquots  of  deionised  water,  two  50ml 
aliquots of methanol, and two 50ml aliquots of diethyl ether, and then vacuum 
dried at 75°C overnight.  
 
The  crude  H2ATSM  was  suspended  in  dichloromethane  to  re crystallise,  and 
heated to 40°C for 30 minutes. Dimethylsulfoxide was added drop wise. The 
solution was cooled after the solid complex had dissolved. Methanol was added 
until the H2ATSM precipitated. The solution was filtered while hot, and then 
refrigerated  overnight.  Any  undissolved  material  was  collected  and  dried 
overnight at 75°C. 
 
The  solution  was  then  re filtered,  and  washed  with  two  50ml  aliquots  of 
deionised water, two 50ml aliquots of methanol, and two 50ml aliquots of diethyl 
ether, and then vacuum dried for 1 hour. 
 
The purified H2ATSM was characterised by elemental analysis, nuclear magnetic 
resonance (
1H and 
13C) and mass spectroscopy (molecular ion peak m/z = 2601). 
 
4.4 
64Copper Production and Purification 
After the gold bullet target was electroplated, it was loaded and rotated into the 
line  of  the  cyclotron  (CTI  RDS  112  11MeV  model,  positive  ion  machine). 
Operating parameters during irradiation were: beam current 20 to 30µA +/  5 
µA. Irradiation times of 5 to 8 hours for batches of 1GBq were used. The cold 
finger was inserted into the back of the bullet. The bombardment parameters 
were determined according to the required 
64Cu activity, and the proton beam 
was switched on. On completion, the cold finger was removed, and the bullet 
was rotated out of the line of the beam. The bullet was removed and placed in a 
lead pot. The copper production is shown in the equation. 
 
(28,64) Ni + proton → (29,64) Cu + neutron   [
64Ni(p,n)
64Cu]   399
4.5 Purification of the Isotope 
Before the bullet was processed, the Bio Rad column and vials were prepared. 
The column and tap were washed with deionised water, followed by a small 
volume of 6M hydrochloric acid. Bio Rad AG 1X8 resin (2.5g) was added to 
10ml of deionised water, decanted and repeated, ensuring the resin did not dry 
out during the process. Ten millilitres of 9M hydrochloric acid was added, and 
stirred until a slurry formed. The resin slurry was transferred to the column, and 
allowed  to  settle.  The  excess  hydrochloric  acid  was  drained,  and  more  resin 
added  to  produce  a  stationary  phase  6  to  8cm  in  length.  Fifteen  vials  were 
labelled to receive the elution aliquots. The hot finger was assembled and the GE 
detector set up to measure the spectrum. 
 
The unloaded bullet was placed in a 30ml syringe, and then in capintec (settings: 
chamber 1, calibration 015, isotope other) and the activity level recorded. The 
bullet was then placed on the hot finger, and a few drops of 6M hydrochloric acid 
added,  and  then  evaporated  at  90°C.  This  was  repeated  3  times  with  9M 
hydrochloric  acid.  The  elutent  within  the  column  was  drained  to  ensure  the 
elutent meniscus just touched the top of the resin bed. The residue from the bullet 
was dissolved using 9M hydrochloric acid, and then loaded into the column. This 
was repeated three times. The bullet was then removed from the hot finger to the 
lead pot, and the activity measured.  
 
The column tap was opened, and the column eluted into vial 1, until the solvent 
meniscus touched the top of the resin bed. Five millilitres of 9M hydrochloric 
acid was added to the column, and eluted into vial 1. The activity measured and 
spectral  analysis  performed.  Twenty  millilitres  of  6M  hydrochloric  acid  was 
added to the column, and 5mls of elutent collected into vials 2 to 5. This was 
repeated with 5ml of 0.5M hydrochloric acid, and 1ml elutent volumes were 
collected  until  the  majority  of  the  radio activity  was  removed.  Characteristic 
64Cu  peaks  were  visualised  at  511  and  1345KeV.  The  vials  with  the  highest 
64CuCl2 activity were combined, and used to radio label the ligand. 
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4.6 Preparation of 
64Cu ATSM 
 
4.6.1 Radio-labelling of ATSM 
One milligram of H2ATSM was dissolved in 1ml of dimethyl sulphoxide, and 
10µl of this ATSM/dimethyl sulphoxide was added to the 
64CuCl2. Once agitated 
the mixture was allowed to stand for 2 to 5 minutes at room temperature. The 
64Cu ATSM  containing  solution  was  then  transferred  to  the  conditioned  C18 
SepPak Light cartridge 
 
4.6.2 C18 Sep-Pak Conditioning 
Five millilitres of sterile ethanol was passed through the C18 Sep Pak cartridge, 
followed by 5ml of deionised sterilised water, and the cartridge air dried. 
 
4.6.3 Purification of 
64Cu-ATSM 
Ten milligrams of ascorbic acid was dissolved in 1ml of sterile saline. The 
64Cu 
ATSM was transferred to a sterile 30ml syringe connected to the C18 Sep Pak 
cartridge via a 3 way tap. The solution was pushed through the Sep Pak. Ten 
millilitres of sterile water was pushed through the cartridge, and repeated twice. 
The 
64Cu ATSM bound to the Sep Pak was eluted with 2ml of sterile ethanol and 
collected in fractions of 0.2ml. The activity was measured, and the fractions with 
the greatest activities combined. The dissolved ascorbic acid was combined with 
the 
64Cu ATSM  fractions  to  a  final  volume  of  1mg/ml  ascorbic  acid.  The 
solution  was  diluted  with  at  least  20  times  the  ethanol  volume  with  sodium 
chloride for injection (0.9%) BP. The 
64Cu ATSM was then filtered through a 
Millipore (0.2µm sterile membrane) filter using a shielded syringe, followed by 
5ml of sterile saline. This procedure was carried in the isolator. 
 
4.6.4 Quality Assurance 
 Ten millilitres of ethanol was placed in the TLC tank, and 0.2ml of 
64Cu ATSM 
was removed from the final vial for quality assurance, and 1ul was placed on a 
TLC plate. The plate was dried with compressed air, and placed in the tank. 
When the solvent front was 1cm away from the top of the plate, it was removed 
and dried. The TLC plate was placed in the TLC scanner, and a tab placed half   401
way through the plate width. Measurements were taken for 2 minutes with the 
gas turned on. 
 
4.6.5 pH Analysis 
One drop of the 
64Cu ATSM sample was placed on a pH strip, and the colour 
compared to the scale on the dispenser cartridge. 
 
4.6.7 Isotope Identity Testing 
The sterile vial containing 
64Cu ATSM was placed in front of the GE detector 
and activity recorded for 240 seconds. 
 
4.6.8 Chemical Stability of the Isotope 
64Cu ATSM  was  unstable  with  time  as  an  ethanol/saline  solution.  The  purity 
remained  greater  than  99.9%  (gamma ray  spectroscopy).  However,  radio 
chemical  purity  (radio TLC)  was  unreliable  and  often  less  than  95%  after  3 
hours.  Ascorbic  acid  as  a  10mg/ml  solution  was  added  to  produce  1mg  of 
ascorbic acid per ml of 
64Cu ATSM solution to prevent radio lysis. The solution 
was then stable for over 24 hours. 
 